

Draft NTP Research Report on the CLARITY-BPA Core Study: A Perinatal and Chronic Extended-Dose-Range Study of Bisphenol A in Rats

Research Report 9
National Toxicology Program

February 2018

NOTICE

This DRAFT Research Report is distributed solely for the purpose of predissemination peer review under the applicable information quality guidelines. It has not been formally disseminated by the NTP. It does not represent and should not be construed to represent NTP determination or policy.

National Toxicology Program
Public Health Service
U.S. Department of Health and Human Services
ISSN: 2473-4756

Official citation: National Toxicology Program. 2018. *Draft NTP Research Report on the CLARITY-BPA Core Study: A Perinatal and Chronic Extended-Dose-Range Study of Bisphenol A in Rats*. NTP RR 9. Research Triangle Park, NC. National Toxicology Program. (9): 1-249.

Foreword

This study was carried out under the auspices of the National Toxicology Program (NTP) as part of the Consortium Linking Academic and Regulatory Insights on Bisphenol A Toxicity (CLARITY-BPA), a consortium-based research program between the National Institute of Environmental Health Sciences (NIEHS) of the National Institutes of Health (NIH) and the National Center for Toxicological Research (NCTR) of the US Food and Drug Administration (FDA).

The aim of the CLARITY-BPA program was to bridge guideline-compliant research conducted at the FDA with hypothesis-based research investigations conducted by academia on the toxicity of bisphenol A (BPA). A detailed description of the CLARITY-BPA program is covered in Heindel and co-authors (<https://www.ncbi.nlm.nih.gov/pubmed/26232693>).

The CLARITY-BPA research program has two components: 1) A “core” guideline-compliant chronic study conducted at NCTR according to FDA Good Laboratory Practice (GLP) regulations (2-year perinatal only or chronic BPA exposure, including perinatal), and 2) CLARITY-BPA grantee studies of various health endpoints, conducted by NIEHS-funded researchers at academic institutions using animals born to the same exposed pregnant rats as the core GLP study.

This NTP research report only covers the core study and includes the narrative, tables, and figures reported in the GLP report. The core study GLP report had 34 appendices, which are listed in Appendix A and referred to as Supplemental Appendices throughout this report. The original GLP report for the core study is on file at NCTR.

The interpretation of biological and toxicological responses described in this report is based only on the results of the core GLP study. Integration of these data with other data from the grantee-studies conducted as part of the CLARITY-BPA research program or extrapolation of the results to other species, including characterization of hazards and risks to humans, is outside of the scope of this report.

The core GLP study was designed to characterize and evaluate the toxicologic potential of BPA following perinatal only or chronic exposure in rats under the conditions of a chronic, extended-dose response design. The core GLP study was designed by NCTR and NIEHS scientists with substantial input from the CLARITY-BPA consortium members.

This study was funded via an interagency agreement between FDA and NIEHS. The study’s conduct and progress were monitored by the Toxicology Study Selection and Review Committee (composed of representatives from NCTR, other FDA product centers, and NIEHS, ad hoc members of other federal government agencies, and academia), the CLARITY-BPA Steering Committee, and the CLARITY-BPA External Scientific Panel.

Animal care and use were in accordance with the Public Health Service Policy on Humane Care and Use of Animals. The core GLP study is subjected to retrospective quality assurance audits before being presented for public review.

Table of Contents

Foreword.....	ii
Figures.....	vi
Tables.....	vii
About This Report.....	xii
Peer Review	xvii
Abstract.....	xix
Background.....	1
Animal Model	2
Rationale for Dose Selection for BPA and the Reference Estrogen, EE ₂	3
Materials and Methods.....	6
Procurement and Characterization of Bisphenol A	6
Preparation and Analysis of Dose Formulations	7
Administration of Dose Formulations and Vehicle	8
Diet Assessment: Nutrients and Contaminants, including Background BPA	9
Assessment of Background BPA in Study Materials Other than Diet.....	11
Animal Source and Microbiological Surveillance	12
Animal Welfare.....	13
Study Design.....	13
Animal Maintenance, Breeding, Randomized Allocation to Study, and Dosing	14
Animal Identification	17
Data Collected in Interim and Terminal Sacrifice Animals.....	17
In-Life Data Collection	17
Clinical Chemistry and Hematology, Interim Sacrifice Animals	18
Sperm Evaluations, Interim Sacrifice Animals.....	20
Organ Weights and Histopathology.....	21
Statistical Methods.....	23
Survival Analyses (Supplemental Appendices XX, XXI, and XXII).....	24
Body Weight Analyses (Supplemental Appendices XVII, XXIII, XXIV, and XXV).....	24
Implantation Sites and Litter Parameters (Supplemental Appendices XVIII and XIX)	26
Analyses of Vaginal Opening, Vaginal Cytology, and Onset of Aberrant Estrous Cycles (Supplemental Appendices XXVI-XXVIII)	26
Organ Weight Analyses (Supplemental Appendix XXX)	28
Clinical Chemistry and Hematology Analyses (Supplemental Appendix XXIX)	28
Sperm Parameter Analyses (Supplemental Appendix XXXI).....	29
Analyses of Non-Neoplastic and Neoplastic Lesions, Interim and Terminal Sacrifice (Supplemental Appendices XXXIII and XXXIV)	29
Sensitivity Analyses.....	31
Quality Assurance.....	32
Results.....	33
Gestational Body Weight, Fetal Implantation, and Litter Parameters	33

Survival, Prewaning and Postweaning Study Phases.....	33
Survival in Prewaning Animals	33
Females	33
Males.....	33
Interim Sacrifice Animals: Postweaning Survival.....	34
Females, Continuous-Dose Arm.....	34
Females, Stop-Dose Arm.....	34
Males, Continuous-Dose Arm	34
Males, Stop-Dose Arm	34
Survival, Postweaning in Terminal Sacrifice Animals.....	35
Females, Continuous-Dose Arm.....	35
Females, Stop-Dose Arm.....	35
Males, Continuous-Dose Arm	36
Males, Stop-Dose Arm	36
Body Weights.....	37
Body Weights in Prewaning Animals	37
Females	37
Males.....	37
Body Weights in Interim and Terminal Sacrifice Animals	37
Females, Continuous-Dose BPA and EE ₂	37
Females, Stop-Dose BPA	38
Males, Continuous-Dose BPA and EE ₂	38
Males, Stop-Dose BPA	39
Vaginal Opening	39
Vaginal Cytology – Estrous Cycle Analysis at Approximately 16 Weeks of Age.....	39
Continuous-Dose Arm	39
Stop-Dose Arm	40
Vaginal Cytology – Onset of Aberrant Estrous Cycles in Aging Animals.....	40
Continuous-Dose Arm	40
Stop-Dose Arm	41
Hematology Endpoints in Interim Sacrifice Animals.....	41
Females, Continuous-Dose Arm.....	41
Females, Stop-Dose Arm	42
Males, Continuous-Dose Arm	42
Males, Stop-Dose Arm.....	42
Serum Clinical Chemistry Endpoints in Interim Sacrifice Animals.....	43
Females, Continuous-Dose Arm.....	43
Females, Stop-Dose Arm	43
Males, Continuous-Dose Arm	43
Males, Stop-Dose Arm.....	44
Organ Weights in Interim Sacrifice Animals.....	44
Females, Continuous-Dose Arm.....	44
Females, Stop-Dose Arm	45
Males, Continuous-Dose Arm	45
Males, Stop-Dose Arm.....	46
Sperm Analysis, Interim Sacrifice Animals.....	46

CLARITY-BPA Core Study, NTP RR 9

Histopathology.....	46
Females.....	47
Mammary gland, neoplastic lesions.....	47
Mammary gland, non-neoplastic lesions.....	48
Uterus, neoplastic lesions.....	49
Uterus, non-neoplastic lesions.....	50
Ovary, non-neoplastic lesions.....	52
Vagina, non-neoplastic lesions.....	53
Pituitary, non-neoplastic lesions.....	54
Heart, non-neoplastic lesions.....	55
Kidney, non-neoplastic lesions.....	56
Liver, non-neoplastic lesions.....	57
Thyroid, non-neoplastic lesions.....	58
Males.....	59
Epididymis, non-neoplastic lesions.....	59
Dorsal/Lateral and ventral prostate, neoplastic and non-neoplastic lesions.....	60
Pituitary, non-neoplastic lesions.....	61
Thyroid, non-neoplastic lesions.....	62
Parathyroid, non-neoplastic lesions.....	62
Kidney, non-neoplastic lesions.....	63
Liver, non-neoplastic lesions.....	63
Discussion.....	66
References.....	75
Appendix A List of Supplemental Appendices.....	A-1

Figures

Figure 1. Scheme for Chronic BPA Toxicity Study Design	81
Figure 2. Kaplan-Meier Survival Curve for Terminal Sacrifice Female BPA Continuous-Dose Arm (Weeks 4-104). See Table 18 for data analysis results.	81
Figure 3. Kaplan-Meier Survival Curve for Terminal Sacrifice Female EE ₂ Continuous-Dose Arm (Weeks 4-104). See Table 18 for data analysis results.	82
Figure 4. Kaplan-Meier Survival Curve for Terminal Sacrifice Female BPA Stop-Dose Arm (Week 4-104). See Table 19 for data analysis results.	83
Figure 5. Kaplan-Meier Survival Curve for Terminal Sacrifice Male BPA Continuous-Dose Arm (Weeks 4-104). See Table 20 for data analysis results.	84
Figure 6. Kaplan-Meier Survival Curve for Terminal Sacrifice Male EE ₂ Continuous-Dose Arm (Weeks 4-104). See Table 20 for data analysis results.	85
Figure 7. Kaplan-Meier Survival Curve for Terminal Sacrifice Male BPA Stop-Dose Arm (Week 4-104). See Table 21 for data analysis results.	86
Figure 8. Body Weight for Interim Sacrifice Female BPA Continuous-Dose Arm. Data tabulated in Table 24.	87
Figure 9. Body Weight for Interim Sacrifice Female EE ₂ Continuous-Dose Arm. Data tabulated in Table 24.	88
Figure 10. Body Weight for Terminal Sacrifice Female BPA Continuous-Dose Arm. Data tabulated in Table 25.	89
Figure 11. Body Weight for Terminal Sacrifice Female EE ₂ Continuous-Dose Arm. Data tabulated in Table 25.	90
Figure 12. Body Weight for Interim Sacrifice Female BPA Stop-Dose Arm. Data tabulated in Table 26.	91
Figure 13. Body Weight for Terminal Sacrifice Female BPA Stop-Dose Arm. Data tabulated in Table 27.	92
Figure 14. Body Weight for Interim Sacrifice Male BPA Continuous-Dose Arm. Data tabulated in Table 28.	93
Figure 15. Body Weight for Interim Sacrifice Male EE ₂ Continuous-Dose Arm. Data tabulated in Table 28.	94
Figure 16. Body Weight for Terminal Sacrifice Male BPA Continuous-Dose Arm. Data tabulated in Table 29.	95
Figure 17. Body Weight for Terminal Sacrifice Male EE ₂ Continuous-Dose Arm. Data tabulated in Table 29.	96
Figure 18. Body Weight for Interim Sacrifice Male BPA Stop-Dose Arm. Data tabulated in Table 30.	97
Figure 19. Body Weight for Terminal Sacrifice Male BPA Stop-Dose Arm. Data tabulated in Table 31.	98
Figure 20. Kaplan-Meier Time to Aberrant Cycling Curve for BPA Continuous-Dose Arm. See Table 36 for data analysis results.	99
Figure 21. Kaplan-Meier Time to Aberrant Cycling Curve for EE ₂ Continuous-Dose Arm. See Table 36 for data analysis results.	100
Figure 22. Kaplan-Meier Time to Aberrant Cycling Curve for BPA Stop-Dose Arm. See Table 37 for data analysis results.	101

Tables

Table 1. Summary of Endpoints Evaluated and Statistically Significant Treatment Effects of BPA and EE ₂ Relative to Vehicle Controls	xxvi
Table 2. Experimental Design and Materials and Methods in the Two-Year Chronic Gavage Toxicology Study of Bisphenol A (NCTR E0219001), Including Interim (One-Year) Assessment	102
Table 3. Numbers of F ₀ Breeding Pairs Assigned to Study	105
Table 4. Number of Litters Produced Per Mating	105
Table 5. Number of Litters Contributing Pups to Interim and/or Terminal Assessments	105
Table 6. Number of Male and Female Pups Represented in Interim (1-Year) Sacrifice from Each Mating, Continuous-Dose	106
Table 7. Number of Male and Female Pups Represented in Interim (1 Year) Sacrifice from Each Mating, Stop-Dose	106
Table 8. Number of Male and Female Pups Represented in Terminal (2 Year) Sacrifice from Each Mating, Continuous-Dose	107
Table 9. Number of Male and Female Pups Represented in Terminal (2 Year) Sacrifice from Each Mating, Stop-Dose	107
Table 10. Dam Body Weights from Time of Mating to Parturition in Vehicle, BPA, and EE ₂ Dose Groups (Mean ± S.E.M.)	108
Table 11. Implantation Sites And Litter Parameters For Vehicle, BPA, And EE ₂ Dose Groups (Mean ± S.E.M)	109
Table 12. Survival of Female Pups from PND 1 to Weaning in the Vehicle, BPA, and EE ₂ Dose Groups	111
Table 13. Survival of Male Pups from PND 1 to Weaning in the Vehicle, BPA, and EE ₂ Dose Groups	112
Table 14. Survival of Female Pups from Weaning to Interim (1 Year) Sacrifice in the Continuous Vehicle, BPA, and EE ₂ Dose Groups	113
Table 15. Survival of Female Pups from Weaning to Interim (1 Year) Sacrifice in the Stop-Dose Vehicle and BPA Groups	114
Table 16. Survival of Male Pups from Weaning to Interim (1 Year) Sacrifice in the Continuous Vehicle, BPA, and EE ₂ Dose Groups	115
Table 17. Survival of Male Pups from Weaning to Interim (1 Year) Sacrifice in the Stop-Dose Vehicle and BPA Groups	116
Table 18. Survival of Female Pups from Weaning to Terminal (2 Year) Sacrifice in the Continuous Vehicle, BPA, and EE ₂ Dose Groups	117
Table 19. Survival of Female Pups from Weaning to Terminal (2 Year) Sacrifice in the Stop-Dose Vehicle and BPA Groups	118
Table 20. Survival of Male Pups from Weaning to Terminal (2 Year) Sacrifice in the Continuous Vehicle, BPA, and EE ₂ Dose Groups	119
Table 21. Survival of Male Pups from Weaning to Terminal (2 Year) Sacrifice in the Stop-Dose Vehicle and BPA Groups	120
Table 22. Prewean Body Weights (g) of Female Pups in the Vehicle, BPA, and EE ₂ Dose Groups (Mean ± S.E.M.)	121
Table 23. Prewean Body Weights (g) of Male Pups in the Vehicle, BPA, and EE ₂ Dose Groups (Mean ± S.E.M.)	122

Table 24. Female Postwean Body Weights (g), Vehicle, BPA, and EE ₂ Continuous-Dose, Interim (1 Year) Sacrifice (Mean ± S.E.M.)	123
Table 25. Female Postwean Body Weights (g), Vehicle, BPA, and EE ₂ Continuous-Dose, Terminal (2 Year) Sacrifice (Mean ± S.E.M.).....	124
Table 26. Female Postwean Body Weights (g), Vehicle and BPA Stop-Dose, Interim (1 Year) Sacrifice (Mean ± S.E.M.).....	126
Table 27. Female Postwean Body Weights (g), Vehicle and BPA Stop-Dose, Terminal (2 Year) Sacrifice (Mean ± S.E.M.).....	127
Table 28. Male Postwean Body Weights (g), Vehicle, BPA, and EE ₂ Continuous-Dose, Interim (1 Year) Sacrifice (Mean ± S.E.M.)	129
Table 29. Male Postwean Body Weights (g), Vehicle, BPA, And EE ₂ Continuous-Dose, Terminal (2 Year) Sacrifice (Mean ± S.E.M.).....	130
Table 30. Male Postwean Body Weights (g), Vehicle and BPA Stop-Dose, Interim (1 Year) Sacrifice (Mean ± S.E.M.).....	132
Table 31. Male Postwean Body Weights (g), Vehicle and BPA Stop-Dose, Terminal (2 Years) Sacrifice (Mean ± S.E.M.).....	133
Table 32. Vaginal Opening, Age and Body Weight (Means ± S.E.M.) at Occurrence, Vehicle, BPA, and EE ₂ Continuous-Dose.....	135
Table 33. Vaginal Opening, Age and Body Weight (Means ± S.E.M.) at Occurrence, Vehicle and BPA Stop-Dose	135
Table 34. Estrous Cycle Analysis, Vehicle, BPA, and EE ₂ Continuous-Dose	136
Table 35. Estrous Cycle Analysis, Vehicle and BPA Stop-Dose	137
Table 36. Time to Onset of Aberrant Estrous Cycles in Vehicle, BPA, and EE ₂ Continuous-Dose Groups	138
Table 37. Time to Onset of Aberrant Estrous Cycles in Vehicle and BPA Stop-Dose Groups	139
Table 38. Female Hematology, Vehicle, BPA, and EE ₂ Continuous-Dose, Interim Sacrifice (Mean ± S.E.M.).....	140
Table 39. Female Hematology, Vehicle and BPA Stop-Dose, Interim Sacrifice (Mean ± S.E.M.).....	141
Table 40. Male Hematology, Vehicle, BPA, and EE ₂ Continuous-Dose, Interim Sacrifice (Mean ± S.E.M.).....	142
Table 41. Male Hematology, Vehicle and BPA Stop-Dose, Interim Sacrifice (Mean ± S.E.M.).....	143
Table 42. Female Clinical Chemistry, Vehicle, BPA, and EE ₂ Continuous-Dose, Interim Sacrifice (Mean ± S.E.M.).....	144
Table 43. Female Clinical Chemistry, Vehicle and BPA Stop-Dose, Interim Sacrifice (Mean ± S.E.M.).....	145
Table 44. Male Clinical Chemistry, Vehicle, BPA, and EE ₂ Continuous-Dose, Interim Sacrifice (Mean ± S.E.M.).....	146
Table 45. Male Clinical Chemistry, Vehicle and BPA Stop-Dose, Interim Sacrifice (Mean ± S.E.M.)	147
Table 46. Female Organ Weights, Vehicle, BPA, and EE ₂ Continuous-Dose, Interim Sacrifice (Mean ± S.E.M.).....	148
Table 47. Female Organ Weights, Vehicle and BPA Stop-Dose, Interim Sacrifice (Mean ± S.E.M.)	150

Table 48. Male Organ Weights, Vehicle, BPA, and EE ₂ Continuous-Dose, Interim Sacrifice (Mean ± S.E.M.).....	152
Table 49. Male Organ Weights, Vehicle and BPA Stop-Dose, Interim Sacrifice (Mean ± S.E.M.).....	154
Table 50. Sperm Analysis, Vehicle, BPA, and EE ₂ Continuous-Dose, Interim Sacrifice (Mean ± S.E.M.).....	156
Table 51. Sperm Analysis, Vehicle and BPA Stop-Dose, Interim Sacrifice (Mean ± S.E.M.).....	157
Table 52. Neoplastic Lesions in the Mammary Gland of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA	158
Table 53. Neoplastic Lesions in the Mammary Gland of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE ₂	160
Table 54. Neoplastic Lesions in the Mammary Gland of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA	161
Table 55. Non-Neoplastic Lesions in the Mammary Gland of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA	162
Table 56. Non-Neoplastic Lesions in the Mammary Gland of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE ₂	164
Table 57. Non-Neoplastic Lesions in the Mammary Gland of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA	165
Table 58. Neoplastic Lesions in the Uterus of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA	166
Table 59. Neoplastic Lesions in the Uterus of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE ₂	166
Table 60. Neoplastic Lesions in the Uterus of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA	167
Table 61. Non-Neoplastic Lesions in the Uterus of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA	168
Table 62. Non-Neoplastic Lesions in the Uterus of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE ₂	170
Table 63. Non-Neoplastic Lesions in the Uterus of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA	171
Table 64. Non-Neoplastic Lesions in the Ovary of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA	172
Table 65. Non-Neoplastic Lesions in the Ovary of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE ₂	173
Table 66. Non-Neoplastic Lesions in the Ovary of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA	174
Table 67. Non-Neoplastic Lesions in the Vagina of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA	175
Table 68. Non-Neoplastic Lesions in the Vagina of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE ₂	176
Table 69. Non-Neoplastic Lesions in the Vagina of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA	177
Table 70. Non-Neoplastic Lesions in the Pituitary of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA	178

Table 71. Non-Neoplastic Lesions in the Pituitary of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE ₂	179
Table 72. Non-Neoplastic Lesions in the Pituitary of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA	180
Table 73. Non-Neoplastic Lesions in the Heart of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA	181
Table 74. Non-Neoplastic Lesions in the Heart of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE ₂	182
Table 75. Non-Neoplastic Lesions in the Heart of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA	183
Table 76. Non-Neoplastic Lesions in the Kidney of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA	184
Table 77. Non-Neoplastic Lesions in the Kidney of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE ₂	185
Table 78. Non-Neoplastic Lesions in the Kidney of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA	186
Table 79. Non-Neoplastic Lesions in the Liver of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA	187
Table 80. Non-Neoplastic Lesions in the Liver of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE ₂	188
Table 81. Non-Neoplastic Lesions in the Liver of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA	189
Table 82. Non-Neoplastic Lesions in the Thyroid of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA	190
Table 83. Non-Neoplastic Lesions in the Thyroid of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE ₂	191
Table 84. Non-Neoplastic Lesions in the Thyroid of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA	192
Table 85. Non-Neoplastic Lesions in the Epididymis of Interim and Terminal Sacrifice Male Rats: Continuous-Dose BPA	193
Table 86. Non-Neoplastic Lesions in the Epididymis of Interim and Terminal Sacrifice Male Rats: Continuous-Dose EE ₂	194
Table 87. Non-Neoplastic Lesions in the Epididymis of Interim and Terminal Sacrifice Male Rats: Stop-Dose BPA.....	195
Table 88. Non-Neoplastic Lesions in the Dorsal/Lateral Prostate of Interim and Terminal Sacrifice Male Rats: Continuous-Dose BPA.....	196
Table 89. Non-Neoplastic Lesions in the Dorsal/Lateral Prostate of Interim and Terminal Sacrifice Male Rats: Continuous-Dose EE ₂	197
Table 90. Non-Neoplastic Lesions in the Dorsal/Lateral Prostate of Interim and Terminal Sacrifice Male Rats: Stop-Dose BPA.....	198
Table 91. Neoplastic Lesions in the Ventral Prostate of Interim and Terminal Sacrifice Male Rats: Continuous-Dose BPA.....	199
Table 92. Neoplastic Lesions in the Ventral Prostate of Interim and Terminal Sacrifice Male Rats: Continuous-Dose EE ₂	199
Table 93. Neoplastic Lesions in the Ventral Prostate of Interim and Terminal Sacrifice Male Rats: Stop-Dose BPA.....	200

Table 94. Non-Neoplastic Lesions in the Ventral Prostate of Interim and Terminal Sacrifice Male Rats: Continuous-Dose BPA.....	201
Table 95. Non-Neoplastic Lesions in the Ventral Prostate of Interim and Terminal Sacrifice Male Rats: Continuous-Dose EE ₂	202
Table 96. Non-Neoplastic Lesions in the Ventral Prostate of Interim and Terminal Sacrifice Male Rats: Stop-Dose BPA.....	203
Table 97. Non-Neoplastic Lesions in the Pituitary of Interim and Terminal Sacrifice Male Rats: Continuous-Dose BPA	204
Table 98. Non-Neoplastic Lesions in the Pituitary of Interim and Terminal Sacrifice Male Rats: Continuous-Dose EE ₂	204
Table 99. Non-Neoplastic Lesions in the Pituitary of Interim and Terminal Sacrifice Male Rats: Stop-Dose BPA	205
Table 100. Non-Neoplastic Lesions in the Thyroid of Interim and Terminal Sacrifice Male Rats: Continuous-Dose BPA	206
Table 101. Non-Neoplastic Lesions in the Thyroid of Interim and Terminal Sacrifice Male Rats: Continuous-Dose EE ₂	207
Table 102. Non-Neoplastic Lesions in the Thyroid of Interim and Terminal Sacrifice Male Rats: Stop-Dose BPA.....	208
Table 103. Non-Neoplastic Lesions in the Parathyroid Gland of Interim and Terminal Sacrifice Male Rats: Continuous BPA	209
Table 104. Non-Neoplastic Lesions in the Parathyroid Gland of Interim and Terminal Sacrifice Male Rats: Continuous-Dose EE ₂	209
Table 105. Non-Neoplastic Lesions in the Parathyroid Gland of Interim and Terminal Sacrifice Male Rats: Stop-Dose BPA.....	210
Table 106. Non-Neoplastic Lesions in the Kidney of Interim and Terminal Sacrifice Male Rats: Continuous-Dose BPA	210
Table 107. Non-Neoplastic Lesions in the Kidney of Interim and Terminal Sacrifice Male Rats: Continuous-Dose EE ₂	210
Table 108. Non-Neoplastic Lesions in the Kidney of Interim and Terminal Sacrifice Male Rats: Stop-Dose BPA	211
Table 109. Non-Neoplastic Lesions in the Liver of Interim and Terminal Sacrifice Male Rats: Continuous-Dose BPA	212
Table 110. Non-Neoplastic Lesions in the Liver of Interim and Terminal Sacrifice Male Rats: Continuous-Dose EE ₂	213
Table 111. Non-Neoplastic Lesions in the Liver of Interim and Terminal Sacrifice Male Rats: Stop-Dose BPA	214

About This Report

Author

National Toxicology Program¹

¹National Institute of Environmental Health Sciences, Division of the National Toxicology Program, Research Triangle Park, NC, USA

Collaborators

K. Barry Delclos, Luísa Camacho, Sherry M. Lewis, Michelle M. Vanlandingham, Frederick A. Beland, Matthew S. Bryant, Kathy A. Carroll, Robert P. Felton, Gonçalo Gamboa da Costa, Paul C. Howard, Greg R. Olson, Ralph Patton, Nigel J. Walker

Study conduct, evaluation and reporting of findings

National Center for Toxicological Research, US Food and Drug Administration

K. Barry Delclos, Ph.D., Principal Investigator
Luísa Camacho, Ph.D., Co-Principal Investigator
Sherry M. Lewis, Ph.D., Co-Principal Investigator (now retired)
Michelle M. Vanlandingham, Co-Principal Investigator
Frederick A. Beland, Ph.D.
Matthew S. Bryant, Ph.D.
Kathy A. Carroll
Robert P. Felton, M.S.
Gonçalo Gamboa da Costa, Ph.D.
Paul C. Howard, Ph.D. (now retired)

Toxicologic Pathology Associates

Greg R. Olson, D.V.M., Ph.D.
Ralph Patton, B.S.

National Institute of Environmental Health Sciences

Nigel J. Walker, Ph.D.

Contributors

National Center for Toxicological Research

Microbiology surveillance and diagnostics

Sung-Guk Kim, Ph.D.
Christine V. Summage-West, B.S.
Lillie M. Sims, B.S.
Roger S. Steel, B.S.

Chemical analysis and dose certifications

Matthew S. Bryant, Ph.D.
F. Michelle McLellan, M.S.
Gonçalo Gamboa da Costa, Ph.D.
Kellie A. Woodling, Ph.D.
Mani Chidambaram, Ph.D.

Computer support

Kathy A. Carroll
Patricia Shores

Quality assurance

Joe M. Fowler, B.S.
Russell D. Smith, B.S.

Statistical support

Robert P. Felton, M.S.
Beth E. Juliar*, M.S. (now retired)
Mackean P. Maisha, M.S.

*Beth E. Juliar, M.Sc. did much of the analysis of non-histopathology data from this study. She retired from NCTR prior to the completion of the report.

*Veterinary services**

Jeff Carraway, D.V.M, M.S. (now retired)
Neera Gopee, D.V.M., Ph.D. (now at the Office of Laboratory Animal Welfare, National Institutes of Health)
Pamela Mack, D.V.M., M.S.

*During the in-life portion of the study, Dr. Jeff Carraway and Dr. Neera Gopee were the veterinarians involved in the study. Dr. Pamela Mack became Director of Veterinary Services after the in-life portion of the study was completed.

Priority One Services

Diet and dose preparation, animal care

Mark Moore, B.S.
Andy Matson, B.S.
Florene Lewis
Felita Reynolds

Toxicologic Pathology Associates

Histopathology and clinical chemistry evaluations and reporting

Greg R. Olson, D.V.M., Ph.D., Study Pathologist
Kelly J. Davis, D.V.M.
Ralph E. Patton, B.S.
Alan R. Warbritton
Kristie L. Voris-Acuff
Lisa P. Wiley, B.S.
Betty P. Raiford, B.S.
William M. Witt, D.V.M., Ph.D.

NTP Pathology Working Group

Evaluated pathology findings

Erin Quist, D.V.M., M.S.

Experimental Pathology Laboratories, Inc.

Greg R. Olson, D.V.M., Ph.D.

Toxicologic Pathology Associates

Thomas J. Steinbach, D.V.M.

Experimental Pathology Laboratories, Inc.

David Malarkey, D.V.M., Ph.D.

National Institute of Environmental Health Sciences

Kelly J. Davis, D.V.M.

Toxicologic Pathology Associates

Darlene Dixon, D.V.M., Ph.D.

National Institute of Environmental Health Sciences

Steven Mog, D.V.M.

Center for Food Safety and Applied Nutrition, US Food and Drug Administration

Susan A. Elmore, M.S., D.V.M.

National Institute of Environmental Health Sciences

Jerry F. Hardisty, D.V.M.

Experimental Pathology Laboratories, Inc.

Karen S. Regan, D.V.M.

National Institute of Environmental Health Sciences

National Institute of Environmental Health Sciences

Oversight for data management

Jennifer M. Fostel, Ph.D.

ICF

Prepared NTP Research Report from the NCTR GLP report

Jeanne Luh, Ph.D.

Natalie Blanton, M.P.H.

Penelope Kellar, M.S.

Kate Helmick, M.P.H.

Cara Peyser, B.S.

ASRC Vistronix

Provided support for data management and reporting

Jamie F. Moose, M.S.

Carolyn R. Martini, B.S.

Isabel A. Lea, Ph.D.

Marcus A. Jackson, M.S.

1 **National Institute of Environmental Health Sciences/National Center for Toxicological**
2 **Research Interagency Agreement Project Officers**

3 *Provided oversight and coordination of all Interagency Agreement aspects of the CLARITY-BPA*
4 *research program*

5 Nigel J. Walker, Ph.D.

6 National Institute of Environmental Health Sciences

7 Gonçalo Gamboa da Costa, Ph.D.*

8 National Center for Toxicological Research

9 Paul C. Howard, Ph.D. (now retired)

10 National Center for Toxicological Research

11 *Dr. Gonçalo Gamboa da Costa became the FDA Interagency Agreement Project Officer after the in-life portion of
12 the study was complete.

13 **Consortium Linking Academic and Regulatory Insights on Bisphenol A Toxicity**
14 **(CLARITY-BPA)**

15 *Participating members of the consortium involved in design of the core study and monitoring of*
16 *study progress.*

17 K. Barry Delclos, Ph.D.

18 National Center for Toxicological Research

19 Luísa Camacho, Ph.D.

20 National Center for Toxicological Research

21 Paul C. Howard, Ph.D. (now retired)

22 National Center for Toxicological Research

23 Gonçalo Gamboa da Costa, Ph.D.

24 National Center for Toxicological Research

25 Jason Aungst, Ph.D.

26 Center for Food Safety and Applied Nutrition, US Food and Drug Administration

27 Nigel J. Walker, Ph.D.

28 National Institute of Environmental Health Sciences

29 John R. Bucher, Ph.D.

30 National Institute of Environmental Health Sciences

31 Jerry J. Heindel, Ph.D. (now retired)

32 National Institute of Environmental Health Sciences

33 Thaddeus T. Schug, Ph.D.

34 National Institute of Environmental Health Sciences

35 Retha R. Newbold, M.S.

36 National Institute of Environmental Health Sciences

37 Scott M. Belcher, Ph.D.

38 North Carolina State University

39 Nira Ben-Jonathan, Ph.D.

40 University of Cincinnati

41 Kim Boekelheide, M.D., Ph.D.

42 Brown University

43 Jodi A. Flaws, Ph.D.

44 University of Illinois at Urbana-Champaign

45 Nestor Gonzalez-Cadavid, Ph.D.

1 University of California, Los Angeles
2 Andrew S. Greenberg, M.D.
3 Tufts University
4 Shuk-Mei Ho, Ph.D.
5 University of Cincinnati
6 Norbert E. Kaminski, Ph.D.
7 Michigan State University
8 Heather B. Patisaul, Ph.D.
9 North Carolina State University
10 Gail S. Prins, Ph.D.
11 University of Illinois at Chicago
12 Cheryl S. Rosenfeld, D.V.M., Ph.D.
13 University of Missouri
14 Ana M. Soto, M.D.
15 Tufts University
16 Frederick S. vom Saal, Ph.D.
17 University of Missouri
18 R. Thomas Zoeller, Ph.D.
19 University of Massachusetts, Amherst

20 **CLARITY-BPA External Scientific Panel**

21 *Provided input and guidance on CLARITY-BPA research program's progress*

22 Daniel A. Casciano, Ph.D.
23 University of Arkansas at Little Rock
24 Michael A. Gallo, Ph.D.
25 Rutgers University
26 Martin A. Philbert, Ph.D.
27 University of Michigan

1

Peer Review

2

Peer Reviewers

1 **Publication Details**

2 Publisher: National Toxicology Program

3 Publishing Location: Research Triangle Park, NC

4 ISSN: 2473-4756

5 DOI:

6 Report Series: NTP Research Report Series

7 Report Series Number: 9

Abstract

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Bisphenol A (BPA, CAS #80-05-7) is a high-production-volume industrial chemical used as a monomer for polycarbonate plastics and epoxy resins that have broad applications in consumer products, including storage containers for foods and beverages and medical devices. The potential toxicity resulting from chronic exposure to BPA as an indirect food additive is the concern addressed in this study.

This study is part of the Consortium Linking Academic and Regulatory Insights on Bisphenol A Toxicity (CLARITY-BPA); a research program between the NIEHS and the National Center for Toxicological Research (NCTR) of the FDA, developed to bridge guideline-compliant research conducted at the FDA with hypothesis-based research investigations conducted by academia on the toxicity of bisphenol A (BPA). The CLARITY-BPA research program has two components: 1) A “core” guideline-compliant chronic study conducted at NCTR according to FDA Good Laboratory Practice (GLP) regulations and 2) studies of various health endpoints, conducted by NIEHS-funded researchers at academic institutions using animals born to the same exposed pregnant rats as the core GLP study. This current research report only covers data from the “core” guideline-compliant chronic study.

The toxicity of BPA administered by oral gavage from gestation day (GD) 6 through the start of labor and then directly to pups from postnatal day (PND) 1 (day of birth = PND 0) until termination at one year or two years was examined in Sprague-Dawley rats from the National Center for Toxicological Research (NCTR) breeding colony (Sprague-Dawley/CD23/NctrBR). BPA doses were 2.5, 25, 250, 2,500, and 25,000 µg/kg body weight (bw)/day. A vehicle (0.3% carboxymethylcellulose (CMC)) control group was also included. In addition to animals that were dosed daily throughout the study, a stop-dose study arm was included with animals dosed

1 until PND 21 and then held without further treatment until termination to assess any effects that
2 were due to early exposure only. Because many of the effects of BPA reported in the literature
3 are associated with estrogen signaling pathways, two doses (0.05 and 0.5 µg/kg bw/day) of the
4 orally active estrogen ethinyl estradiol (EE₂) were also included in the continuous-dose arm. Rats
5 were obtained as weanlings from the NCTR breeding colony and placed under study conditions
6 (soy- and alfalfa-free diet (5K96, LabDiet, Purina Mills), polysulfone cages, hardwood chip
7 bedding, glass water bottles, and food-grade silicone stoppers) until mating. Study materials
8 were monitored for background BPA levels. Prior to mating to males that were not siblings or
9 first cousins, female rats were stratified by body weight and were randomized to treatment
10 groups to give approximately equivalent mean body weights in each group. Each morning after
11 pairing, females were examined for evidence of mating (presence of an *in situ* vaginal plug or
12 sperm-positive vaginal smear). Upon evidence of mating, the females were separated from the
13 males and individually housed; this day was considered gestation day GD 0. On GD 6, daily
14 dosing of the dam with BPA, EE₂, or vehicle began and was based on the body weight measured
15 immediately prior to the administration of these compounds. Direct gavage dosing of the pups
16 was started on PND 1, with the same dose and agent that was administered to their dams. At
17 weaning on PND 21, no more than one animal per sex per litter was assigned to the following
18 study arms: 1) continuous dosing to sacrifice at two years (terminal sacrifice, 46–50 animals per
19 sex per vehicle control or BPA treatment group and 26 animals per sex per EE₂ group); 2)
20 similar continuous dosing to sacrifice at one year (interim sacrifice, 20–26 animals per sex for all
21 groups); 3) no further treatment after PND 21 until sacrifice at two years (stop-dose terminal
22 sacrifice, 46–50 animals per sex per preweaning vehicle control or BPA group); and 4) no further
23 treatment after PND 21 until sacrifice at one year (stop-dose interim sacrifice, 20–26 animals per

1 sex for preweaning vehicle control and BPA groups). The stop-dose study arms for which
2 gavage dosing was not continued beyond weaning were included because of concern for the
3 potential of permanent effects induced by exposure to hormonally active compounds during
4 developmental stages. EE₂ treatments were not included in these stop-dose arms because of
5 resource constraints.

6 Data collected included body weights, litter parameters, age at vaginal opening, vaginal
7 cytology, clinical chemistry (interim sacrifice only), sperm parameters (interim sacrifice only),
8 organ weights (interim sacrifice only), and histopathology (both interim and terminal sacrifices).
9 Vaginal cytology data were collected for 14 consecutive days at approximately 16 weeks of age
10 from the same subset of females in the terminal sacrifice arm that had been monitored for vaginal
11 opening; these same animals were then monitored for five consecutive days monthly to estimate
12 the time at which they began having aberrant cycles.

13 Table 1 lists all non-histopathology endpoints analyzed and associated statistical findings. For
14 histopathology data, Table 1 only lists the endpoints where a statistically significant difference
15 was found by the primary statistical tests applied (Cochran-Armitage/Fisher's Exact Test for
16 interim sacrifice animals, Poly-3 test for terminal sacrifice animals). Results from all statistical
17 tests applied to the histopathology data, which further included Jonckheere-Terpstra/Shirley's
18 and Relative Treatment Effect tests, are included in the text of this abstract and in the report text
19 and tables. Statistically significant results are indicated regardless of biological significance.

20 There were few significant effects of BPA treatment in the in-life data collected. In the late
21 stages of the study (weeks 96–104), mean female body weights in the 250 µg BPA/kg bw/day
22 continuous-dose group were significantly higher than the mean vehicle control body weights. At
23 other stages of the study, there were few statistically significant body weight differences among

1 vehicle control and BPA dose groups. For clinical chemistry endpoints or organ weights, there
2 were few statistically significant effects of BPA treatment, continuous- or stop-dose, and it was
3 not clear that these were treatment-related.

4 In the stop-dose BPA study arm at two years, there was a statistically significant increase in the
5 incidence of female mammary gland adenocarcinoma (22% versus 6%; $p = 0.016$) or the
6 combination of adenoma and adenocarcinoma (24% versus 8%; $p = 0.018$) in the 2.5 μg BPA/kg
7 bw/day dose group. No increase in female mammary gland neoplasms was observed in the
8 continuous BPA dose arm at two years. Limited historical control data for this strain of rat in
9 experiments conducted at NCTR using the same diet show a background rate of 12–17% for
10 adenocarcinoma or adenoma in the female mammary gland at two years. There were no
11 significant treatment-related non-neoplastic lesions in the mammary gland of interim or terminal
12 sacrifice stop-dose BPA groups. In the interim and terminal BPA continuous dosing arm, there
13 was an increase in female mammary gland atypical foci at 2.5 μg BPA/kg bw/day (14% versus
14 0% and 15% versus 4% for the interim and terminal dose group animals, respectively). Limited
15 historical control data for this lesion in two-year old female control rats in experiments
16 conducted at NCTR using the same diet ranged from 11–37%. There was a significant trend
17 ($p = 0.037$) for uterine stromal polyps in the interim sacrifice animals in the continuous BPA
18 dose arm; this was not observed in the terminal sacrifice animals.

19 In the histopathological evaluations, there were many non-neoplastic lesions associated with
20 aging in this strain of rats in both males and females that were variable across control and BPA
21 treatment levels. In the stop-dose interim sacrifice BPA females, there was an increase in cystic
22 endometrial hyperplasia and squamous metaplasia in the uterus at 25,000 μg BPA/kg bw/day and
23 an increased trend and significant increase in follicular cysts in the ovary at 25,000 μg BPA/kg

1 bw/day. An increase in cystic endometrial hyperplasia was also noted at 2,500 and 25,000 μg
2 BPA/kg bw/day in the terminal stop-dose animals. Cardiomyopathy was increased in the stop-
3 dose BPA terminal sacrifice females at 2.5, 250, 2,500, and 25,000 μg BPA/kg bw/day, as
4 assessed by statistical tests that incorporated severity scores, although background incidence was
5 high at this age and differences across dose groups were minimal. In continuous-dose interim
6 females, uterine apoptosis and vaginal epithelial hyperplasia were elevated at 25,000 μg BPA/kg
7 bw/day. Vaginal epithelial hyperplasia was also increased in terminal continuous-dose BPA
8 animals at doses from 25 to 25,000 μg BPA/kg bw/day, with a similar response across each of
9 those dose levels.

10 There were no apparent BPA treatment-related neoplastic effects in stop-dose or continuous-dose
11 interim or terminal sacrifice males. There were also no apparent treatment-related non-neoplastic
12 effects in stop-dose interim sacrifice males; in terminal sacrifice stop-dose BPA males, an
13 increase of hyperplasia in the pars distalis of the pituitary at 25,000 μg BPA/kg bw/day was the
14 only effect noted. In continuous-dose interim sacrifice males, but not in continuous-dose terminal
15 sacrifice males, there was an increase in exfoliated germ cells and an increase in lymphocyte
16 infiltration in the epididymis at 25,000 μg BPA/kg bw/day. In the continuous-dose terminal
17 sacrifice males, hyperplasia of the pars distalis of the pituitary was increased at 25 and 25,000 μg
18 BPA/kg bw/day. Increases in dorsal/lateral prostate inflammation were variable across a high
19 background in both interim and terminal sacrifice animals, with variable increases across most
20 dose groups in the interim and terminal sacrifice animals.

21 In the EE₂ reference estrogen dose groups, there were multiple significant treatment-related
22 effects at the 0.5 $\mu\text{g}/\text{kg}$ bw/day exposure level in females. At the time of estrous cycle evaluation
23 at 16 weeks, more than 90% of the females in the 0.5 μg EE₂/kg bw/day dose group were

1 exhibiting prolonged estrus. At the interim sacrifice, mean weights of the adrenal glands, heart,
2 kidney, liver, and pituitary gland were higher in the 0.5 μg EE₂/kg bw/day dose group than the
3 vehicle control means. Ovarian/parametrial fat pad and ovary weights were significantly lower
4 than mean vehicle control weights in the high EE₂ dose group. At the interim sacrifice, lobular
5 hyperplasia and ductal dilatation were elevated in the mammary glands of the 0.5 μg EE₂/kg
6 bw/day dose group. Increases in apoptosis, cystic endometrial hyperplasia, and squamous
7 metaplasia were observed in the uterus of the high dose EE₂ females. Atrophy and cystic follicles
8 were increased in the ovaries, the incidence of vaginal hyperplasia was increased, and increases
9 in hyperplasia of the pars distalis and angiectasis were observed in the pituitary at 0.5 μg EE₂/kg
10 bw/day. The incidences of cardiomyopathy and nephropathy were also increased in the high dose
11 EE₂ females at one year. At terminal sacrifice, there was a significant increase in the incidence of
12 mammary gland adenocarcinomas in the 0.5 μg EE₂/kg bw/day dose group. There was a trend
13 toward increasing uterine metaplasia at two years, and the incidence of nephropathy was
14 increased at both the 0.05 and 0.5 μg EE₂/kg bw/day dose group.

15 Few statistically significant effects of EE₂ in males were observed. In the high dose EE₂ group,
16 there was an elevated incidence of lymphocyte infiltration observed in the epididymis in interim
17 sacrifice animals and an increase in hyperplasia in the pars distalis of the pituitary at two years.

18 In conclusion, in the CLARITY-BPA core study, BPA produced minimal effects that were
19 distinguishable from background in this study, particularly below 25,000 μg BPA/kg bw/day. In
20 contrast, the high EE₂ dose elicited several strong effects in females. Many of the statistically
21 significant BPA effects were not dose-responsive or occurred in only one dose group. There was
22 not a clear pattern of consistent responses in the stop-dose and continuous-dose study arms.

23 Although animals in the stop-dose and continuous-dose arms were handled differently and were

- 1 not statistically compared, in several cases statistically significant increases in lesion incidences
- 2 in BPA treatment groups relative to the vehicle control in one study arm were similar to the
- 3 vehicle control group in the other study arm. This suggests that these observed increases within a
- 4 given study arm were within the range of normal biological variation.

1 **Table 1. Summary of Endpoints Evaluated and Statistically Significant Treatment Effects of BPA**
 2 **and EE₂ Relative to Vehicle Controls^{a,b}**

Endpoint	Stop-Dose BPA	Continuous-Dose BPA	Continuous- Dose EE ₂
Gestational weight	NA	-	-
Implantation sites	NA	-	-
Litter size	NA	-	-
Sex ratio	NA	-	-
Litter weight	NA	-	-
Male group pup weight, PND 1	NA	-	-
Female group pup weight, PND 1	NA	-	-
Preweaning pup survival, male	NA	-	-
Preweaning pup survival, female	NA	-	↓ (0.05)
Preweaning pup body weight, male	NA	-	-
Preweaning pup body weight, female	NA	-	↓ (0.05)
			PND 4 & 7
Age at vaginal opening	-	-	-
Body weight at vaginal opening	Not analyzed ^c	-	-
Postweaning survival, male, 1 year	-	-	-
Postweaning survival, female, 1 year	-	-	-
Postweaning body weight, male, 1 year	-	-	-
Postweaning body weight, female, 1 year	-	-	-
Postweaning survival, male, 2 years	-	-	-
Postweaning survival, female, 2 years	-	-	-
Postweaning body weight, male, 2 years	↓ (T), wk 4	-	-
Postweaning body weight, female, 2 years	↓ (T), wk 4	↑ (250) wks 96 – 104	↑ (0.5) wks 4 and 8
Abnormal estrous cycles at 16 weeks of age	-	-	↑ (0.5)
Early onset of aberrant estrous cycles	↓ (2,500)	-	↑ (0.5)
Female organ weights, 1 year^d			
Adrenal gland	-	-	↑ (0.5) ^e
Fat pad, ovarian/parametrial	-	-	↓ (0.5)
Fat pad, retroperitoneal	-	- ^f	-
Heart	-	-	↑ (0.5)
Kidney	-	-	↑ (0.5) ^e
Liver	-	↑ (T)	↑ (0.5) ^e
Ovary	↓ (T) ^g	-	↓ (0.5) ^e
Pituitary gland	-	-	↑ (0.5) ^e
Spleen	-	-	-
Thymus	-	-	-
Thyroid gland	-	-	-
Uterus	-	-	-
Male organ weights, 1 year^d			
Adrenal gland	-	-	-
Epididymis	-	-	-
Fat pad, epididymal	-	-	-
Fat pad, retroperitoneal	-	-	-
Heart	-	-	-
Kidney	-	-	-
Liver	↑ (T)	↓ (2.5)	-
Pituitary gland	-	-	-

CLARITY-BPA Core Study, NTP RR 9

Endpoint	Stop-Dose BPA	Continuous-Dose BPA	Continuous- Dose EE ₂
Spleen	-	-	-
Testes	-	-	-
Thymus	-	-	-
Thyroid gland	-	-	-
Female hematology and clinical chemistry, 1 year			
Hemoglobin concentration	-	↑ (T)	-
Red blood cells	↑ (T)	-	-
% Reticulocytes	-	-	-
Packed cell volume	-	-	-
Mean corpuscular volume	-	-	-
Mean corpuscular hemoglobin	↓ (T)	-	-
Mean corpuscular hemoglobin concentration	-	↑ (25)	-
Platelets	-	↓ (25,000, T)	↓ (0.5)
White blood cells	-	-	-
Neutrophils	-	-	-
% Neutrophils	-	-	-
Lymphocytes	-	-	-
% Lymphocytes	-	-	-
Monocytes	-	↑ (T)	-
% Monocytes	-	-	-
Basophils	-	-	-
% Basophils	↑ (T)	-	-
Eosinophils	-	↓ (250)	↓ (0.5)
% Eosinophils	-	-	↓ (0.5)
Blood urea nitrogen (BUN)	-	-	-
Creatinine	-	-	-
Total protein	-	-	-
Albumin	(T) ^h	-	-
Alkaline phosphatase	-	↑ (250)	↑ (0.05)
Alanine aminotransferase	-	-	-
Aspartate aminotransferase	-	-	-
Sorbitol dehydrogenase	-	-	-
Gamma-glutamyl transferase	-	-	-
Total bile acids	-	-	-
Cholesterol	-	-	-
Glucose	-	-	-
Triglycerides	-	-	-
Insulin	-	-	-
Leptin	-	-	-
Triiodothyronine (T3)	-	-	-
Thyroxine (T4)	-	-	-
Thyroid-stimulating hormone (TSH)	-	-	↑ (0.5)
Male hematology, clinical chemistry, and sperm analyses, 1 year			
Hematocrit	-	↑ (T)	-
Hemoglobin concentration	-	↑ (25,000, T)	↑ (0.05)
Red blood cells	-	-	-
% Reticulocytes	-	-	-
Packed cell volume	-	↑ (T)	-
Mean corpuscular volume	-	↑ (T)	-
Mean corpuscular hemoglobin	-	↑ (T)	-

CLARITY-BPA Core Study, NTP RR 9

Endpoint	Stop-Dose BPA	Continuous-Dose BPA	Continuous- Dose EE ₂
Mean corpuscular hemoglobin concentration		-	-
Platelets		↓ (T)	-
White blood cells	-	-	-
Neutrophils	-	-	-
% Neutrophils	↓ (T)	-	-
Lymphocytes	-	-	-
% Lymphocytes	-	-	-
Monocytes	-	-	-
% Monocytes	-	-	-
Basophils	-	-	-
% Basophils	-	-	-
Eosinophils	-	-	-
% Eosinophils	-	↓ (250)	-
Blood urea nitrogen (BUN)	-	-	-
Creatinine	-	-	-
Total protein	↓ (25)	-	-
Albumin	-	(T) ^h	-
Alkaline phosphatase	-	-	-
Alanine aminotransferase	-	-	-
Aspartate aminotransferase	-	-	-
Sorbitol dehydrogenase	-	-	-
Gamma-glutamyl transferase	-	-	-
Total bile acids	↓ (25, T)	↓ (T)	-
Cholesterol	-	-	-
Glucose	-	-	-
Triglycerides	-	-	↑ (0.5)
Insulin	-	-	↓ (0.05)
Leptin	-	-	-
Troponin T	-	↑ (T)	-
T3	-	-	-
T4	↓ (T)	(T) ^h	-
TSH	-	-	-
Testicular spermatid head counts	-	-	-
Cauda sperm counts	-	-	-
Cauda sperm, % motility	-	-	-
Cauda sperm, abnormal	-	-	-
Females, neoplastic lesions, 1 year			
Uterus, stromal polyps	-	↑ (T)	-
Females, neoplastic lesions, 2 years			
Mammary gland, adenocarcinoma	↑ (2.5)	-	↑ (0.5, T)
Adrenal, medulla, pheochromocytoma, benign	-	-	↑ (T)
Thyroid gland, adenoma, C-cell	-	-	↑ (T)
Females, non-neoplastic lesions, 1 year^{i,j}			
Mammary gland, dilatation, duct	-	-	↑ (0.5, T)
Mammary gland, hyperplasia, lobular	-	-	↑ (0.5, T)
Mammary gland, galactocele	-	-	↑ (T)
Uterus, apoptosis	-	↑ (25,000, T)	↑ (0.5, T)
Uterus, hyperplasia, cystic, endometrium	-	-	↑ (0.5, T)

CLARITY-BPA Core Study, NTP RR 9

Endpoint	Stop-Dose BPA	Continuous-Dose BPA	Continuous- Dose EE ₂
Uterus, metaplasia, squamous	-	↑ (T)	↑ (0.5, T)
Ovary, atrophy	-	-	↑ (0.5, T)
Ovary, cyst, follicle	↑ (25,000, T)	-	↑ (0.5, T)
Ovary, cyst, bursa	-	-	↑(T)
Ovary, cyst, corpora lutea	-	↑ (T)	-
Ovary, depletion, corpora lutea	-	↑ (T)	↑ (0.5, T)
Ovary, hypertrophy, interstitial cell	-	↑ (T)	↑ (0.5, T)
Vagina, hyperplasia, epithelium	-	↑ (T)	↑ (0.5, T)
Vagina, mucification, epithelium	-	-	↑ (T)
Pituitary, angiectasis	-	-	↑ (T)
Heart, cardiomyopathy	-	-	↑ (0.5, T)
Kidney, mineralization	-	↑ (T)	-
Kidney, cyst, renal tubule	-	↑ (2.5)	↑ (0.05)
Kidney, nephropathy	-	-	↑ (0.5, T)
Liver, infiltration, mononuclear cells	↑ (2.5, 25,000)	-	-
Females, non-neoplastic lesions, 2 years^{i, k}			
Mammary gland, dilatation, duct	-	-	↑ (0.5, T)
Mammary gland, dilatation, alveolus	-	-	↑ (0.5, T)
Mammary gland, galactocele	-	-	↑ (T)
Ovary, cyst	-	-	↑ (T)
Ovary, cyst, bursa	-	-	↑ (T)
Uterus, dilatation, lumen	-	↑ (T)	-
Uterus, cyst, endometrium	-	-	↑ (T)
Uterus, hyperplasia, endometrium	-	-	↑ (0.05)
Uterus, metaplasia, squamous	-	-	↑(T)
Uterus, atrophy	-	-	↑ (0.5, T)
Vagina, hyperplasia, epithelium	-	↑ (25, 2,500, 25,000, T)	-
Vagina, degeneration, epithelium	-	↑ (2,500)	-
Pituitary, angiectasis	-	-	↑ (0.5, T)
Pituitary, hemorrhage	-	-	↑ (0.5, T)
Kidney, nephropathy	-	↑ (2.5)	↑ (T)
Kidney, cyst, renal tubule	↑ (2.5)	-	-
Kidney, cyst, cortex	-	-	↑ (0.05)
Liver, cystic degeneration	↑ (T)	-	-
Liver, basophilic focus	-	-	↑ (T)
Liver, vacuolization, cytoplasmic	-	-	↑ (0.05)
Thyroid, hyperplasia, follicular cells	-	-	↑ (0.05)
Thyroid, ultimobranchial cyst	↑ (250, 2,500)	-	↑ (T)
Thymus, atrophy	-	↑ (T)	-
Pancreas, hyperplasia, acinar cell	-	-	↑ (T)
Adrenal cortex, degeneration, cystic	-	-	↑ (0.5, T)
Adrenal cortex, pigmentation	-	-	↑ (T)
Bone marrow, hyperplasia, myeloid cell	-	-	↑ (T)
Spleen, pigmentation	-	-	↑ (0.5, T)
Brain stem, compression	-	-	↑ (0.5, T)
Brain stem, hemorrhage	-	-	↑ (0.5, T)
Males, neoplastic lesions, 1 year			

CLARITY-BPA Core Study, NTP RR 9

Endpoint	Stop-Dose BPA	Continuous-Dose BPA	Continuous-Dose EE ₂
None	-	-	-
Males, neoplastic lesions, 2 years			
Malignant lymphoma, systemic	↑ (T) ^l	-	-
Males, non-neoplastic lesions, 1 year^{i,j}			
Epididymis, exfoliated germ cells	-	↑ (25,000, T)	-
Epididymis, infiltration cellular, lymphocyte	-	↑ (25,000, T)	-
Liver, hepatodiaphragmatic nodule	-	↑ (2,500)	-
Liver, infiltration, mononuclear cells	-	↑ (250, 2,500)	↑ (0.05)
Liver, fatty change	-	-	↑ (T)
Spleen, hematopoietic cell proliferation	-	↑ (T)	-
Spleen, pigmentation	↑ (250, T)	-	-
Males, non-neoplastic, 2 years^{i,k}			
Dorsal/lateral prostate, suppurative inflammation	-	↑ (2.5)	-
Mammary gland, dilatation, alveolus	-	↑ (2.5)	-
Kidney, hyperplasia, transitional epithelium	↑ (T)	↑ (25)	-
Kidney, cyst, renal tubule	↑ (T)	↑ (250, 2,500)	↑ (0.05)
Pituitary gland, hyperplasia, pars distalis	↑ (25,000, T)	↑ (25,000, T)	↑ (0.5, T)
Pituitary, cyst, pars distalis	↑ (250)	↑ (T) (multilocular)	-
Thyroid gland, hyperplasia, C-cell	-	↑ (2,500, T)	↑ (0.05)
Parathyroid gland, hyperplasia	↑ (T)	↑ (25)	-
Pancreas, pigmentation	↑ (2.5)	-	-
Pancreas, polyarteritis	↑ (2,500, T)	-	-
Heart, cardiomyopathy	↑ (T)	-	-
Heart, metaplasia, osseus	-	-	↑ (T)
Adrenal medulla, hyperplasia	↑ (2,500, T)	-	-
Adrenal cortex, hypertrophy	-	-	↑ (0.05)
Testes, polyarteritis	↑ (2,500, T)	-	-
Bone marrow, hypocellularity	↑ (250, 25,000)	-	-
Spleen, hyperplasia, lymphoid	↑ (250, T)	-	-
Liver, angiectasis	-	↑ (2.5)	-
Liver, vacuolization, cytoplasmic	-	-	↑ (0.5, T)

1 ^aStatistically significant results are summarized without consideration of potential biological relevance, which is further discussed
2 in the text. Results for the sensitivity analyses that excluded a subset of animals (see text) are not included in this summary table.
3 NA, not applicable; ↑ or ↓, significant increase or decrease relative to controls at the exposure concentration (μg/kg bw/day)
4 indicated in parentheses; “-” = no significant treatment effect; “T” = trend.
5 ^bFor EE₂ dose groups, trend analyses were only conducted for the histopathology data.
6 ^cEndpoint was not analyzed since body weight at vaginal opening was not recorded for many pups.
7 ^dResults for organ weights adjusted for body weights are summarized in this table.
8 ^eAbsolute organ weight and organ weight adjusted for brain weight were also significantly different from vehicle control.
9 ^fAbsolute organ weight and organ weight adjusted for brain weight in the 2.5 μg BPA/kg bw/day dose group were significantly
10 higher than the vehicle control.
11 ^gThere were also significant dose trends for the absolute organ weight and organ weight adjusted for brain weight, and the 25,000
12 μg BPA/kg bw/day dose group was significantly lower than the vehicle control weight in both cases.
13 ^hStatistical analysis indicated a significant trend, but the nature of the trend is not evident from inspection of the data.
14 ⁱFor histopathology data, statistically significant effects in a negative, or potentially beneficial, direction relative to controls are
15 not included in this summary table, but are presented in the Supplemental Appendices and, in some cases, in the body of the
16 report. Some diagnoses included in the statistical tables (Supplemental Appendices XXXIII and XXXIV), such as stages of the

CLARITY-BPA Core Study, NTP RR 9

1 estrous cycle in females or changes noted that would not be considered of pathological significance (*e.g.*, tension lipodosis), are
2 not tabulated in this summary table.
3 ^jFor interim non-neoplastic lesions, only Cochran-Armitage with Fisher's exact (CAFE) test results are summarized in this table.
4 Results of additional statistical tests are presented and discussed in the text.
5 ^kFor terminal non-neoplastic lesions, only Poly-3 test results are summarized in this table. Results of additional statistical tests are
6 presented and discussed in the text.
7 ^lA significant trend for systemic lymphoma was noted in liver, bone marrow, spleen, kidney, and dorsal/lateral prostate. In
8 addition, the incidence in the dorsal/lateral prostate at 25,000 µg BPA/kg bw/day was significantly higher than the incidence in
9 vehicle control.

1 **Background**

2 Bisphenol A (BPA) is a high-production-volume industrial chemical that is used as a monomer
3 in the production of polycarbonate plastics and epoxy resins that have broad applications in
4 consumer products, including storage containers for foods and beverages and in medical devices.
5 BPA has undergone extensive toxicological evaluations in laboratories around the world, but the
6 conclusions derived from the aggregate results of the studies remain under debate. The current
7 safety assessments by the preponderance of international regulatory agencies conclude that BPA
8 at current exposure levels (upper 95th percentile of typical daily aggregate exposure <0.5 µg/kg
9 body weight (bw)/day) does not pose a risk to humans via dietary exposure^{20; 23; 55; 56}. In contrast,
10 others have concluded that the overall body of evidence from BPA investigations indicates that
11 BPA is likely to be a human health hazard^{21; 41; 61}. France has banned the use of BPA in food
12 contact materials based on the assessment of the French Agency for Food, Environmental Health
13 and Safety². The Office of Environmental Health Hazard Assessment of the California
14 Environmental Protection Agency has listed BPA as a reproductive toxicant under California's
15 Proposition 65³⁸.

16 The National Toxicology Program (NTP) previously assessed BPA in two-year dietary
17 administration studies in both sexes of F344 rats at feed concentrations of 1,000 and 2,000 ppm
18 (approximately 50,000 and 100,000 µg BPA/kg bw/day), in male B6C3F₁ mice at feed
19 concentrations of 1,000 and 5,000 ppm (approximately 150,000 and 750,000 µg BPA/kg
20 bw/day), and in female B6C3F₁ mice at feed concentrations of 5,000 and 10,000 ppm
21 (approximately 750,000 and 1,500,000 µg BPA/kg bw/day)³³. The NTP conclusions from these
22 studies were that there was no convincing evidence of carcinogenesis. The earlier NTP studies
23 did not address the current issues of toxicities resulting from developmental exposures at levels

1 closer to human exposure levels. Given the current public controversy, the NTP and the National
2 Institute of Environmental Health Sciences (NIEHS) Division of Extramural Research and
3 Training (DERT) agreed to fund a study that would involve exposures to a broad range of BPA
4 doses, include developmental exposure, and, in addition to evaluating endpoints typically used
5 for regulatory decision making, provide animals or tissues from this study to a group of NIEHS-
6 funded academic scientists to pursue hypothesis-driven studies in various organ systems. For
7 most of these studies, the academic scientists were provided by the Food and Drug
8 Administration (FDA)'s National Center for Toxicological Research (NCTR) with tissues or
9 serum from animals of various ages. The exceptions were behavioral and erectile dysfunction
10 studies, where staff from the academic laboratories conducted the studies with animals at NCTR
11 with the assistance of NCTR staff. Detailed descriptions of the general plan of this project,
12 termed the Consortium Linking Academic and Regulatory Insights on BPA Toxicity
13 (CLARITY-BPA), have been published^{24; 44}. This report focuses only on the description of the
14 core study conduct and results.

15 **Animal Model**

16 The animal model used in these studies was the Sprague-Dawley rat maintained at NCTR. This
17 colony had its origins in the late 1970s from Charles River Sprague-Dawley founders and has
18 been used in toxicology studies with hormonally active agents for over a decade at NCTR^{12-14; 29;}
19 ³⁴⁻³⁷. A comprehensive evaluation of the pharmacokinetics of BPA in this rat strain across life
20 stages has been conducted^{17; 19; 52}. Dietary ethinyl estradiol (EE₂) exposure studies in this strain^{13;}
21 ^{29; 36; 37} resulted in peak blood levels of EE₂ in adult animals below 10 pg/mL (30 pM) at the
22 highest dose tested (50 ppb dietary concentration, or approximately 4 and 5-6 µg/kg bw/day in
23 males and females, respectively)⁵¹. Stimulation of male mammary hyperplasia was observed at 2,

1 10, and 50 ppb dietary EE₂ at postnatal day (PND) 140, and effects on vaginal opening, body
2 weight gain, food efficiency, and estrous cyclicity were observed at the higher doses of 10 and
3 50 ppb, approximately 1 and 6 µg/kg bw/day, respectively. Similar, but not identical, effects
4 were observed with dietary genistein over a dose range of 5 to 500 ppm (approximately 300 to
5 50,000 µg/kg bw/day)¹³. Taken together with the more recent gavage BPA and EE₂ studies^{10; 14},
6 these data demonstrated the relative sensitivity of this rat strain to estrogenic compounds.

7 **Rationale for Dose Selection for BPA and the Reference** 8 **Estrogen, EE₂**

9 Prior to the design of this chronic toxicity study and the conception of the CLARITY-BPA
10 project, a subchronic study was conducted at NCTR using the same animal model and dosing
11 regimen used in the current chronic study¹⁴. BPA in 0.3% carboxymethylcellulose (CMC) was
12 administered by oral gavage to pregnant female Sprague-Dawley rats from gestation day (GD) 6
13 through the start of parturition, with seven equally spaced doses between 2.5 and 2,700 µg
14 BPA/kg bw/day. Two high doses of BPA (100,000 and 300,000 µg/kg bw/day) were added as
15 doses expected to produce adverse effects based on published guideline studies^{53; 54}, and vehicle
16 and naïve controls were included. Dams were not dosed after their litters were born, but pups
17 were directly dosed by oral gavage from PND 1 until termination (PND 90 ± 5). Pups were
18 directly dosed because of the demonstrated low transmission of BPA to pups via milk¹⁸. BPA
19 showed clearly adverse effects in F₁ females in the subchronic study at the highest doses of
20 100,000 and 300,000 µg BPA/kg bw/day. Statistically significant differences at lower doses were
21 few and sporadic and were judged not to provide evidence of BPA-induced toxicity¹⁴. There
22 were no BPA effects observed in the males.

1 The design of the CLARITY-BPA core study was discussed and finalized at a series of meetings
2 in late 2011 and early 2012. These meetings included NTP, NCTR, and FDA product center
3 representatives, as well as NIEHS-funded CLARITY-BPA grantees. It was proposed that,
4 because of the literature concerning permanent adverse effects resulting from developmental
5 exposures to hormonally active agents, the study would include groups of animals for which
6 exposure would terminate at weaning. For discussion of dose selection, a summary of data
7 obtained from the NCTR BPA subchronic study¹⁴ was presented and discussed. It was initially
8 agreed that a vehicle control and six log-spaced doses between 2.5 and 250,000 µg BPA/kg
9 bw/day would provide an adequate dose range from reasonably close to human exposure on the
10 low end to a dose expected to produce clear adverse effects at the high end. Serum measurements
11 of BPA across the postnatal life span of animals in the subchronic study¹⁰ showed that the high
12 dose of 300,000 µg BPA/kg bw/day gave rise to approximately 50 µM active aglycone in PND 4
13 animals and approximately 1 µM in PND 80 animals, which were clearly out of the range of
14 attainable human internal exposure from dietary sources, estimated to be in the low to sub-pM
15 range⁶⁰. There was general agreement that the current concern was restricted to a lower dose
16 range, below the previously reported no-observed-adverse-effect level in guideline-compliant
17 regulatory toxicity assays, which was 5,000 µg/kg bw/day^{53; 54}. The 250,000 µg BPA/kg bw/day
18 dose group would provide little additional information to influence regulatory action. A high
19 dose of 25,000 µg BPA/kg bw/day was viewed as providing an adequate margin of human
20 exposure, greater than 25,000-fold based on the aggregate human exposure estimates of <0.5 µg
21 BPA/kg bw/day mentioned above.

22 Much of the research on BPA, particularly early in the investigations of the potential toxicity of
23 low doses of BPA, focused on its estrogenic activity, although the involvement of mechanisms

1 other than classical estrogen receptors have been increasingly implicated in BPA actions^{1; 32; 57;}
2 ⁵⁸. Both doses of EE₂ used in the NCTR BPA subchronic study (0.5 and 5 µg EE₂/kg bw/day)
3 produced strong effects in female reproductive organs and on estrous cyclicity. In males, the low
4 dose of 0.5 µg/kg bw/day had little effect, with an increase in male mammary hyperplasia as the
5 only apparent effect at PND 90¹⁴. The 5 µg EE₂/kg bw/day dose also stimulated male mammary
6 gland hyperplasia at PND 90, and increased hyperplasia in the coagulating gland, increased
7 degeneration in the testicular germinal epithelium, and increased exfoliated germ cells and
8 hypospermia in the epididymis. Based on the observed effects in the subchronic study, two levels
9 of EE₂, one of which was lower than the low dose used in the subchronic study, were selected for
10 use in the current study to expand information on the sensitivity of the animal model to EE₂. In
11 the absence of data from this exposure model to guide the selection of the EE₂ lower dose, a 10-
12 fold lower dose was chosen. The CLARITY-BPA consortium consensus for the two doses of
13 EE₂ used in the current study was 0.05 and 0.5 µg/kg bw/day. Resource limitations would not
14 allow for the inclusion of stop-dose EE₂ groups. Likewise, while the NCTR BPA subchronic
15 study had included a naïve control group that was not gavaged, this extra group could not be
16 included in the chronic study. The responses of the naïve and vehicle control groups in the
17 NCTR subchronic study were similar¹⁴.

1 **Materials and Methods**

2 **Procurement and Characterization of Bisphenol A**

3 Bisphenol A (BPA, CAS #80-05-7, synonyms: 2,2-bis(4-hydroxyphenyl)propane;
4 4,4'-isopropylidenediphenol) was supplied by TCI America (Portland, OR; product #B0494) as
5 lot #6052012, with a purity assessment on the Certificate of Analysis by Battelle, Inc.
6 (Columbus, OH) of 99.9%. This lot of BPA (original lot designation AOHOK) was purchased by
7 the NTP in 2009 and was characterized for identity and purity by proton nuclear magnetic
8 resonance (NMR) and high performance liquid chromatography with photodiode array detection
9 (HPLC-PDA) at NCTR prior to the start of the BPA subchronic study (NCTR E0217601).
10 Battelle Laboratories extensively characterized this lot of BPA and reported the analysis to be
11 consistent with the manufacturer's stated purity of 99.9% (Bulk Chemical Limited Analysis
12 Report: Bisphenol A, Battelle Project No. G005430-DSU, October 29, 2010, which was included
13 as part of the NCTR Technical Report for E0217601, July 15, 2013). For the present study,
14 Battelle air milled this same lot of BPA prior to shipment to NCTR and provided a current
15 statement of purity. Purity assessment was conducted at NCTR prior to the study start, at
16 intervals during the study, and after study completion using the technique of HPLC-PDA
17 (spectral purity). A sample of the test article was subjected to HPLC separation at least in
18 triplicate and the PDA was scanned from 200 to 400 nm. A single major peak was obtained at
19 the expected HPLC retention time for BPA and showed 99-100% purity (Supplemental
20 Appendix VII)^a.

21 The reference estrogen test article ethinyl estradiol (EE₂, CAS #57-63-6, product #E4876, lot
22 #071M1492V) was purchased from Sigma-Aldrich Corporation (St. Louis, MO). The stated

^a Supplemental Appendices at: http://tools.niehs.nih.gov/cebs3/views/?action=main.dataReview&bin_id=3856

1 purity of the EE₂ was >98%. A sample of this test article was evaluated by HPLC with PDA and
2 electrospray mass spectrometry and found to contain a single peak that contained fragment ions
3 consistent with and matching a reference sample of EE₂ from Steraloids, Inc. (Newport, RI).
4 Analysis in the same manner as described for BPA showed purity >99% (Supplemental
5 Appendix VII).

6 CMC (sodium salt; product #C5013, lot #041M0105V) was obtained from Sigma-Aldrich (St.
7 Louis, MO). Aqueous CMC solutions were prepared for use as the vehicle for BPA and EE₂ by
8 the Diet Preparation Support Group at NCTR as described in Supplemental Appendix IX.

9 **Preparation and Analysis of Dose Formulations**

10 Dosing solutions or suspensions were prepared by the Diet Preparation Support Group at NCTR
11 (Supplemental Appendix IX). For BPA, the target concentrations of the dose preparations were
12 0.5, 5, 50, 500, and 5000 µg/mL 0.3% CMC for the 2.5, 25, 250, 2,500, and 25,000 µg/kg
13 bw/day dose groups, respectively. For EE₂, the target concentrations were 0.01 and 0.1 µg/mL
14 0.3% CMC for the 0.05 and 0.5 µg/kg bw/day dose groups, respectively. The two high BPA
15 dosing suspensions were mixed by directly adding BPA solid to the vehicle with sonication, and
16 the suspensions were stirred constantly. The three low BPA and the two EE₂ dosing solutions
17 were mixed by serial dilutions of stock solutions prepared and certified by the NCTR Chemistry
18 Support Group. Stabilities (± 10% of the target) of the low and high dose levels of both BPA and
19 EE₂ were established for up to 50 days. Homogeneity (± 10% of the target) of the high BPA
20 suspension and both EE₂ dosing solutions was established (Supplemental Appendix VII).

21 At the start of the study and approximately every 8–10 weeks over the course of the study, all
22 dose level preparations were assayed by the Chemistry Support Group prior to delivery to the
23 animal rooms and certified to be within 10% of the target concentration with a % CV of ≤ 10%.

1 In addition, at intervals spaced 4-7 months apart, BPA and EE₂ dosing preparations from the
2 animal rooms were assayed at the end of their use to verify the dose concentrations. One batch of
3 0.3% CMC vehicle was found to have a detectable concentration of BPA (0.11 µg/mL) that was
4 approximately 20% of the low BPA dose level (Table 13 in Supplemental Appendix VII). One
5 container of this batch of vehicle was used to dose 16 cages (31 animals; 6 males and 6 females
6 continuous-dose one-year sacrifice, and 9 males and 10 females continuous-dose two-year
7 sacrifice) of vehicle control animals ranging in age from PND 139 to PND 141 on a single day
8 before this batch of vehicle was discarded (Supplemental Appendix III, note to study file
9 October 13, 2017). Given the short half-life of BPA and age of the animals, the impact of this
10 event was considered minimal. All affected animals were from the first mating group. Thus,
11 these animals were excluded from the sensitivity analysis described in the Statistical Methods
12 section below. Following the detection of this contaminated batch of vehicle, all batches of
13 vehicle that had been previously used in the study and all subsequent batches of vehicle were
14 assayed and none contained BPA detectable above the analytical background.

15 **Administration of Dose Formulations and Vehicle**

16 Doses were administered by gavage with modified Hamilton Microlab® ML511C programmable
17 115 V pumps (Hamilton Co., Reno, NV). Dosing containers were constantly stirred and dose
18 volume calculation and dispensing were automated³¹. Four separate dosing stations were used in
19 each animal room: (1) vehicle control; (2) 2.5, 25, and 250 µg BPA/kg bw/day; (3) 2,500 and
20 25,000 µg BPA/kg bw/day; and (4) 0.05 and 0.5 µg EE₂/kg bw/day. Dosing was conducted from
21 the lowest to highest dose on any given pump and the Teflon tubing was flushed between dose
22 levels. Verification of the accuracy of dose delivery from these pumps had been demonstrated
23 for BPA dosing solutions ranging from 0.5 to 60,000 µg/mL 0.3% CMC and for 0.1 and 1 µg

1 EE₂/mL 0.3% CMC for the prior NCTR BPA subchronic study (NCTR E0217601); accuracy
2 was verified before the start of this study by chemical analysis for the low dose of EE₂, which
3 was 10-fold lower than the lowest dose used in the previous experiment (Table 8C in
4 Supplemental Appendix VII). Subsequently, the accuracy of liquid delivery from the pumps was
5 assessed every three months and established to be within 10% of the target volume
6 (Supplemental Appendix XI).

7 **Diet Assessment: Nutrients and Contaminants, including** 8 **Background BPA**

9 Pelleted rodent chow, verified casein diet 10 IF, irradiated, 5K96 (product #1810069, TestDiet,
10 Purina Mills, Richmond, IN) was the diet used in the study. The manufacturer provided analyses
11 for selected nutritive quality attributes (including protein, fat, crude fiber, calcium, phosphorous,
12 and vitamins A, B₁, and E) and contaminants (including nitrosamines, fumonisins, arsenic,
13 cadmium, lead, mercury, aflatoxins, organochlorine and organophosphate pesticides, butylated
14 hydroxyanisole, butylated hydroxytoluene, and tert-butyl hydroquinone). These analysis reports
15 are found in Supplemental Appendix XII.

16 On arrival at NCTR, each lot of diet used in the present study was sampled and assayed by the
17 Chemistry Support Group for background BPA and selected phyto- and myco-estrogens
18 (genistein, daidzein, coumestrol, and zearalenone). These results are found in Supplemental
19 Appendix VII. Low (ppb) background levels of BPA above the limit of blank (LOB) had
20 previously been reported in all lots of 5K96 diet used in the prior NCTR BPA subchronic study
21 and in other rodent diets^{9; 14} and a rejection limit of 5 ppb BPA in feed was set for both that and
22 the present study. Ten of the 11 lots of diet used in the present study contained detectable levels
23 of BPA, with an average (using 0 for the lot with no BPA detectable above the LOB) of 1.3 ± 0.9

1 (standard deviation, S.D.) ng/g diet (range 0-3.0). Based on estimates of food consumption
2 (Supplemental Appendix XIIIa and XIIIb) for interim and terminal sacrifice animals,
3 respectively, this resulted in an average consumption over the course of the study of
4 approximately 0.05-0.06 µg BPA/kg bw/day (2-2.5% of the lowest BPA dose tested) at the mean
5 dietary concentration of BPA and approximately 0.12-0.15 µg BPA/kg bw/day (5-6% of the
6 lowest BPA dose tested) at the maximum measured dietary concentration (calculations
7 summarized in Supplemental Appendix XIV). Since younger animals consume higher quantities
8 of food per unit of body weight, younger animals consumed higher background levels of dietary
9 BPA. For example, estimates of food consumption for the week after weaning (week 4) indicate
10 that the amount of BPA consumed per kg bw was approximately 2- to 3-fold higher than the
11 mean value calculated over the entire study (Supplemental Appendix XIV).

12 The 5K96 diet, which is low in soy-derived phytoestrogens, was selected to ensure a consistent
13 and low level of these phytoestrogens to minimize any impact on the endpoints measured in this
14 study. A goal of 2 ppm total genistein and daidzein was stated in the protocol based on our prior
15 experience with the isoflavone levels attainable in this diet. Although the diet manufacturer
16 indicated that the levels of isoflavones were less than 10 ppm in this diet (page 6 of
17 Supplemental Appendix IX), less than 2 ppm combined genistein and daidzein (measured after
18 hydrolysis of glucosides in the diet) was typical in studies conducted with this diet at NCTR¹⁰; 34-
19 ³⁷;9. Samples of each lot of diet were acid hydrolyzed to convert the glucosides of genistein and
20 daidzein to aglycones that were quantified using HPLC-electrospray ionization-multiple reaction
21 monitoring mass spectrometry. There was variation from lot to lot (Supplemental Appendix VII),
22 but values of genistein and daidzein reported over the course of the study were consistent with
23 the expectation of combined levels less than 2 ppm. After the study concluded and during the

1 preparation of the Chemistry Support Report, however, it was discovered that a calculation error
2 was made and that values of genistein and daidzein were 10-fold higher than those reported
3 during the study. The values reported during the study are reflected in the Diet Preparation
4 Report, Supplemental Appendix IX and the corrected values are found in the Chemistry Support
5 Report, Supplemental Appendix VII. Mean values for genistein and daidzein in the 11 diet lots
6 tested were 1.79 ± 1.94 (S.D.) and 1.66 ± 2.06 (S.D.) ppm, respectively. Although the values of
7 isoflavones in the diet were higher than anticipated based on prior experience with this diet^{10; 34-}
8 ^{37;9}, the measured levels are low relative to other commonly used chow diets that have been
9 reported to have values ranging from 100 to greater than 600 ppm^{6; 48-50}. The phytoestrogen
10 coumestrol and the mycoestrogen zearalenone were also measured in the diets used in the present
11 study. The protocol-established level of concern for these agents was 0.5 ppm. Two of the 11
12 diet lots tested were positive for coumestrol (0.05 and 0.08 ppm) and two lots were positive for
13 zearalenone (0.01 and 0.05 ppm) (Supplemental Appendix VII).

14 **Assessment of Background BPA in Study Materials Other than** 15 **Diet**

16 In addition to the dosing vehicle and diet, the rodent drinking water and extracts of animal cages
17 and bedding (hardwood chip and cellulose) were assayed for background BPA levels. These
18 results are reported in Supplemental Appendix VII. For the polysulfone cages (Ancare
19 Corporation, Bellmore, NY) used in this study, previous results from NCTR BPA subchronic
20 study (NCTR E0217601) indicated no BPA detectable above the analytical background (NCTR
21 Technical Report for E0217601, July 15, 2013). For the present study, three previously used
22 polysulfone cages and three newly purchased cages were extracted and the extracts confirmed to
23 have no detectable BPA above the analytical background. Similarly, all drinking water samples

1 and bedding extracts had BPA levels that were less than or close to the analytical limits of the
2 BPA assay.

3 **Animal Source and Microbiological Surveillance**

4 The NCTR Multigeneration Support System (MGSS), an operator-prompted database system,
5 was used to track the genealogy of all animals in the current study and to collect in-life animal
6 data. For the parental (F₀) generation, 600 male and 600 female weanling (circa PND 21)
7 Sprague-Dawley/CD23/NctrBR rats were obtained from the NCTR breeding colony in five
8 groups of 120 of each sex. While in the breeding colony, these F₀ breeders were maintained with
9 their dams under the standard conditions used in the NCTR colony (fed NIH-41 irradiated pellets
10 and housed in polycarbonate cages with hardwood chip bedding and water from polycarbonate
11 bottles). Once assigned to the study at weaning on PND 21, the F₀ breeders were fed pelleted
12 irradiated TestDiet 5K96 feed, housed two to three per cage in polysulfone cages with hardwood
13 chip bedding, and given water from glass water bottles with silicone stoppers. The rats were held
14 under these conditions until they were individually housed prior to mating for one to two weeks
15 for females, or for 48 hours for males. Animals were 10-15 weeks of age at mating. The animal
16 rooms, water, feed, and health of the animals were monitored during the study in accordance
17 with NCTR's Sentinel Animal Program; the results are reported in Supplemental Appendix VIII.
18 As noted in a protocol deviation (Supplemental Appendix II), one room was without a sentinel
19 for approximately the last month of the study as the sentinel animal had to be removed as
20 moribund. All 46 sentinel animals evaluated periodically over the course of the study were
21 determined to be free of pathogenic organisms.

1 **Animal Welfare**

2 Animal care and use were in accordance with the Public Health Service Policy on Humane Care
3 and Use of Animals (<https://grants.nih.gov/grants/olaw/references/phspolicylabanimals.pdf>). The
4 study was conducted in an animal facility accredited by the Association for the Assessment and
5 Accreditation of Laboratory Animal Care International. The study was approved by the NCTR
6 Animal Care and Use Committee and conducted in accordance with all relevant NIH and NTP
7 animal care and use policies and applicable federal, state, and local regulations and guidelines.
8 NCTR Veterinary Services Staff monitored the health of the animals throughout the study and
9 made recommendations as to the timing of animal removal from the study based on evident
10 distress or discomfort, decreased mobility, or inability to eat or drink. The Veterinary Staff also
11 recommended the transfer of a subset of animals with pododermatitis or ventral masses from
12 hardwood chip bedding that was irritating these lesions to Alpha Dri cellulose bedding
13 (Shepherd Specialty Papers, Watertown, TN; Supplemental Appendix II and Supplemental
14 Appendix XV, Animals transferred to Alpha Dri bedding).

15 **Study Design**

16 An interim sacrifice was conducted at one year of age (PND 365 ± 20) and the terminal sacrifice
17 was conducted at two years of age (PND 730 ± 20). A summary of the experimental design and
18 data collected is found in Table 2, and a scheme is shown in Figure 1. The study protocol and all
19 amendments are found in Supplemental Appendix I. Protocol deviations are included in
20 Supplemental Appendix II. Many of these deviations document missing data collections or
21 missed or under- or over-dosing of specific animals on specific days. Cases where missing data
22 affected data analyses are noted in the data summary tables and in the statistical report
23 appendices (Supplemental Appendices XVII-XXXI, XXXIII, and XXXIV).

1 An important component of this study, shown in Figure 1, was the provision of animals from the
2 core study to academic investigators for studies funded by NIEHS as part of the CLARITY-BPA
3 consortium^{24; 44}. Results from these academic grantee-conducted studies are not reported here,
4 but are or will be reported in the open literature. All the data collected by the academic grantees
5 as part of the CLARITY-BPA-funded studies will be made available to the public via the NTP
6 website (<https://ntp.niehs.nih.gov>) and in the NTP's Chemical Effects in Biological Systems
7 ([CEBS](#)) database^b. The allocation of animals to these studies did impact the allocation of animals
8 to the study reported here, particularly regarding adjustment of the sex distribution for PND 1
9 culling and the number of animals assigned to the interim sacrifice.

10 **Animal Maintenance, Breeding, Randomized Allocation to Study, and** 11 **Dosing**

12 Animals were housed in rooms with a 12-hour light cycle (lights on at 6 AM and off at 6 PM)
13 and 10 room air changes per hour. For all animals, cages were changed twice weekly. Glass
14 water bottles were changed weekly or as often as necessary to maintain a constant supply of
15 drinking water. Throughout the study, cage racks were changed every two weeks and cage
16 locations on those racks were rotated every two weeks. The study definition documents and start-
17 up memos that describe the cage and rack arrangements in the animal rooms are included as
18 Supplemental Appendices IV and V. Animal rooms were maintained at $23 \pm 3^{\circ}\text{C}$ and $50 \pm 20\%$
19 humidity and were monitored so that corrective action could be taken if values went outside
20 these limits. Summary temperature and humidity reports for all animal rooms are in
21 Supplemental Appendix X. In one case, a malfunction of a humidity sensor required movement
22 of animals to another animal room for approximately 11 weeks (Supplemental Appendix II).

^bhttp://tools.niehs.nih.gov/cebs3/views/?action=main.dataReview&bin_id=3856

1 Approximately two weeks prior to mating, female breeders were randomized to treatment
2 groups, stratified by body weight to produce approximately equivalent mean body weights in
3 each group. The weight ranking and pairing information provided by the NCTR Statistical
4 Support Group for each mating are in Supplemental Appendix VI. Male breeders were assigned
5 to breeding pairs with the stipulation that no sibling or first cousin mating was permitted. Rats
6 were mated at 10–14 weeks of age for females and 11–15 weeks of age for males. Females were
7 placed in solid-bottomed polysulfone cages with hardwood chip bedding with the assigned males
8 and were assessed daily for up to 10 days for sperm-positive vaginal smears or a copulation plug
9 that precluded a vaginal smear. In three cases, males intended for mating with females in BPA or
10 EE₂ dose groups died prior to mating and, in two of these cases, males from the vehicle control
11 group that had already been mated with control females were re-mated with these females (Table
12 3). Dams were separated from the males on the day of sperm/plug detection, which was
13 designated GD 0. If no sperm-positive vaginal smear or copulation plug was detected after 10
14 days, the pair was removed from the study and euthanized. Mating was conducted in five cohorts
15 spaced four weeks apart. The number of pairs assigned to treatment groups in each mating group
16 is shown in Table 3. While equivalent numbers of breeding pairs were assigned to the vehicle
17 control and all BPA dose groups in the first three cohorts, adjustments were made in the fourth
18 and fifth mating assignments based on the number of pups that had been allocated to the study
19 from the earlier matings. The numbers of litters produced in each dose group in each mating and
20 the number of litters contributing pups to the study are shown in Table 4 and Table 5,
21 respectively.

22 Daily gavage dosing of the dams began on GD 6 (GD 0 = sperm- or plug-positive day) and
23 continued until the initiation of parturition. Pups were not dosed on the day of birth (PND 0).

1 Pups without evident malformations were randomly culled to a maximum of five males and five
2 females on PND 1. While the post-culling sex ratio was generally balanced, the sex distribution
3 was skewed toward males later in the study because the hypothesis-driven studies conducted by
4 academic investigators required a culling strategy to provide more males than females. Litters
5 with fewer than 3 pups/sex and live litters born to dams earlier than GD 20 were excluded from
6 the core study, except in the cases of 3 females in the 25,000 µg/kg bw/day continuous BPA dose
7 group that came from litters that did not have 3 pups/sex (Supplemental Appendix II). Direct
8 gavage dosing of the pups started on PND 1 after the litter was culled. For animals younger than
9 PND 5, the gavage needle was inserted to the opening of the esophagus, but did not enter the
10 esophagus⁸. This dosing method for young pups had also been used in the BPA subchronic study
11 conducted at NCTR, where serum levels were measured after dosing in PND 4 animals
12 demonstrating the effectiveness of this dosing procedure^{10; 14}. Pups were weighed and dosed
13 daily until weaning at PND 21. After weaning, pups were housed two per cage and either
14 gavaged with vehicle, BPA, or EE₂ daily until termination (continuous-dose arm) or maintained
15 without further dosing (stop-dose arm).

16 At weaning, up to a maximum of three pups/sex/litter were assigned to the chronic study. Same-
17 sex littermates were not assigned to the same combination of study dose arm and time of
18 sacrifice. Twenty to 26 pups/sex/dose group were assigned to the one-year interim continuous-
19 dose assessment (Table 6); 19 to 22 pups/sex/dose group were assigned to the one-year interim
20 stop-dose assessment (Table 7); 46 to 50 pups/sex/BPA dose group/dose arm and 26
21 pups/sex/EE₂ dose group were assigned to the two-year study continuous-dose assessment (Table
22 8); and 46 to 50 pups/sex/BPA dose group/dose arm were assigned to the two-year study stop-
23 dose assessment (Table 9). The remaining pups from those litters with more than three same-sex

1 pups were assigned to the hypothesis-driven studies of academic investigators. The reason that
2 stop-dose EE₂ groups were not included in the study was solely a space and resource
3 consideration, given the number of animals that needed to be provided and housed for both this
4 study and the NIEHS-funded academic CLARITY grantee studies.

5 **Animal Identification**

6 Prior to mating, all F₀ females were identified with their unique cage number by tail tattoo
7 (Animal Identification and Marking Systems, Inc., Hornell, NY). F₁ pups were initially
8 numbered on their backs with an indelible marker after culling on PND 1 and then shortly
9 thereafter with a standard 4-paw tattoo pattern. The paw tattoo pattern and dam identification
10 number (cage number) provided unique identification for preweaning pups. Retained F₁ pups
11 were marked by tail tattoo with their unique identification number (cage number and an
12 additional digit to distinguish cage mates) after weaning on PND 21.

13 **Data Collected in Interim and Terminal Sacrifice Animals**

14 **In-Life Data Collection**

15 All activities conducted by animal care technicians in the animal rooms were monitored by the
16 MGSS. Morbidity/mortality checks were performed twice daily and clinical observations were
17 recorded weekly or when a significant clinical observation was noted. Starting at six months of
18 age, animals were palpated weekly to detect the presence and progress of tissue masses. Body
19 weights were obtained prior to dosing for dams from GD 6 through parturition and similarly for
20 the pups from PND 1, as described above. Feed consumption was measured weekly from the
21 start of dosing for approximately the next 13 weeks and monthly afterward. These data were not
22 analyzed beyond summary statistics that were used to estimate consumption of background
23 dietary BPA as a result of the low (<5 ppb) level of BPA in the feed (Supplemental Appendices

1 XIII a and b, XIV). On the day of birth, PND 0, the number of pups alive and dead was recorded.
2 On PND 1, the number of pups alive and dead, sex ratio, and live litter weight by sex were
3 determined prior to culling. Individual body weights for all retained pups were recorded daily
4 from PND 1 until weaning at PND 21. Animals in the continuous-dose arm were weighed daily
5 through PND 90 ± 3 and weekly thereafter. Weights of animals in the stop-dose arm were
6 recorded weekly after weaning.

7 All dams that were sperm- or plug-positive were euthanized after litters were weaned, on the
8 litter's day of birth if the litter had less than three pups/sex, or on GD 26 if no litter was
9 produced. The uterus was removed and stained with 10% ammonium sulfide for enumeration of
10 implantation sites.

11 Females (26 animals from 13 randomly selected cages per dose group per dose arm from the
12 two-year study arm) were monitored daily for vaginal opening from PND 22. Vaginal smears
13 were collected for 14 consecutive days from these same animals beginning at 16 ± 2 weeks of
14 age. One month after these vaginal smears were completed, the same animals had vaginal smears
15 collected for five consecutive days monthly until the animal did not show evidence of cycling,
16 that is, that showed three or more consecutive days of estrus (including estrus, estrus/diestrus, or
17 proestrus/estrus intermediate stages) or five consecutive days that did not include an estrus smear
18 for two consecutive months.

19 **Clinical Chemistry and Hematology, Interim Sacrifice Animals**

20 For the one-year interim sacrifice, food, but not water, was removed from cages on the evening
21 before the scheduled necropsy. Animals were anesthetized with gaseous carbon dioxide and
22 blood was collected from the retro-orbital sinus. Hematology and clinical chemistry endpoints
23 evaluated are listed in Table 2. All blood was collected into serum and

1 ethylenediaminetetraacetic acid (EDTA) tubes between 7:00 AM and 12:00 PM. Blood in the
2 serum tubes was allowed to clot and centrifuged at $1000 \times g$ for 10 minutes at room temperature.
3 The serum was removed and aliquoted into two tubes. One tube was used for immediate testing
4 (see below) and the other was frozen at -60°C until additional testing was performed. The EDTA
5 tube was used for hematology testing performed the same day as collection.

6 Clinical chemistry analyses were conducted on an Alfa Wassermann ALERA (West Caldwell,
7 NJ). Alfa Wassermann reagents were used to quantify glucose, alkaline phosphatase, alanine
8 aminotransferase, aspartate aminotransferase, γ -glutamyl transpeptidase, total protein, albumin,
9 cholesterol, triglycerides, blood urea nitrogen, and creatinine. Catachem (Bridgeport, CT)
10 reagents were used to quantify sorbitol dehydrogenase and total bile acids. All testing was
11 completed on the day of collection. The instrument was calibrated daily and two levels of
12 assayed controls were included in daily analyses as internal controls.

13 Rat-specific troponin I, troponin T (Life Diagnostics, West Chester, PA), and leptin (Millipore,
14 St. Charles, MO) were quantified using ELISA methods. The plates were read on an ELx800
15 Universal Microplate Reader (Bio-Tek, Winooski, VT). A standard curve was run with each
16 batch of samples and results were calculated by the instrument's software. Insulin,
17 triiodothyronine (T3), and thyroxine (T4) were quantified using Siemens (Los Angeles, CA) RIA
18 "Coat-a-Count" method and thyroid-stimulating hormone (TSH) with rat-specific TSH
19 radioimmune assay (Alpco, Salem, NH). The tubes were then counted on a Wizard2 gamma
20 counter (PerkinElmer, Shelton, CT). A standard curve was run with each batch of samples and
21 results were calculated by the instrument's software. Two levels of assayed controls were
22 included in daily analyses as internal controls.

1 Complete blood counts were determined on an Pentra 60 C+ analyzer (ABX, Irvine, CA).
2 Maintenance and calibration were done per the manufacturer's recommendations. Three levels of
3 assayed controls were included in daily analyses as internal controls. Packed cell volume (PCV)
4 analysis was performed by centrifugation in a CritSpin centrifuge (Beckman Coulter, Inc,
5 Indianapolis, IN) and PCV determined by manual read. For determining the percentage of
6 reticulocytes, 1,000 cells per animal were counted on slides prepared from blood collected in
7 EDTA tubes and stained with New Methylene Blue Reticulocyte Stain (Volu-Sol, Salt Lake
8 City, UT).

9 **Sperm Evaluations, Interim Sacrifice Animals**

10 For sperm motility assessment, the left epididymis was dissected from the testis and weighed. If
11 gross lesions or abnormalities were noted at necropsy with either the left testis or epididymis, the
12 right organ was used for motility studies and the left was sent for histology. The cauda section
13 was dissected and immediately placed in a petri dish containing 40 mL of a solution consisting of
14 1% bovine serum albumin dissolved in phosphate buffered saline. The solution was prewarmed
15 to a temperature of approximately 37°C. A minimum 2-minute period was allowed for the sperm
16 to swim out. Following the swim-out period, a sperm sample was obtained using an 80 µm deep
17 slide. The slide was immediately loaded into the prewarmed stage of the Hamilton Thorne IVOS
18 automated sperm analyzer. Five fields were automatically selected by the analyzer, and each
19 motion image was recorded and stored on an optical disk. The images were subsequently
20 analyzed and the percent motility determined for each animal. Two eosin-stained slides were also
21 prepared for each animal from the caudal epididymis suspension for evaluation of morphological
22 development; a minimum of 200 sperm cells/animal was examined.

1 After the motility and morphology samples were collected, the cauda was minced with scissors
2 and mixed. Approximately 1 mL of the suspension was placed in a prelabeled tube and frozen on
3 dry ice for subsequent determination of the total caudal sperm count. The left testis was weighed,
4 placed on dry ice, and stored frozen until evaluation for testicular spermatid head counts. Each
5 frozen epididymis suspension and testis was thawed. The tunic was removed from the testis, and
6 each testis was weighed and homogenized. The suspension was transferred to a vial containing a
7 dye (IDENT, bis-benzimide trihydrochloride, Hamilton Thorne, Inc., Beverly, MA) that uniquely
8 stains the head of sperm. A sample of the stained sperm was placed into a 20 µm deep glass slide
9 that was loaded into the analyzer. Twenty fields were automatically selected by the instrument
10 for each animal, and total sperm counts were determined. The counts were reported adjusted for
11 testis weight (million sperm/g tissue).

12 **Organ Weights and Histopathology**

13 All animals maintained on study after weaning that survived to the scheduled sacrifice dates or
14 were removed early as dead or moribund were subjected to a full necropsy. All gross lesions
15 were processed for histological evaluation. Selected organs were collected and weighed at the
16 interim sacrifice (Table 2). Organs were not weighed at the terminal sacrifice. Tissues not
17 specified for microscopic evaluation, which are listed in Table 2, were processed to paraffin
18 block and held for potential later evaluation. For tissues specified for evaluation by the study
19 pathologist (Table 2), tissues from all dose groups were evaluated for both the interim and
20 terminal sacrifice animals. Six step sections of each prostate were examined. The International
21 Harmonization of Nomenclature and Diagnostic Criteria (INHAND) guidelines
22 (<https://www.toxpath.org/inhand.asp>) were used as diagnostic criteria for the microscopic
23 evaluations. For the female reproductive tissues, mammary gland, and male reproductive tissues,

1 the diagnostic criteria outlined in Dixon et al. (2014), Rudmann et al. (2012), and Creasy et al.
2 (2012)^{16; 42;11}, respectively, were used. Approximately 9% of the animals in the study,
3 represented in all dose groups, were observed to have seizures over the course of the study,
4 mostly during handling procedures (*e.g.*, dosing, cage changes). The brains, spinal cords, and
5 peripheral nerves of these animals were examined by the study pathologist for any histological
6 abnormalities (Supplemental Appendix XXXII). Animals assigned to the two-year sacrifice were
7 not fasted, and no clinical chemistry, hematology, organ weights, or sperm evaluations were
8 conducted for these animals.

9 Upon completion of the microscopic evaluations, the data were entered into the NTP's
10 Toxicology Data Management System Enterprise. Slides, paraffin blocks, and residual wet
11 tissues were sent to the Block and Slide Laboratory for inventory, slide/block match, and wet
12 tissue audit. Individual animal data records and pathology tables were evaluated by an
13 independent quality assessment (QA) group, and QA pathologists evaluated selected
14 histopathology slides. The reviewed slides, along with the diagnoses made by the study
15 pathologist and QA pathologists, were reviewed by the Pathology Working Group (PWG). The
16 QA pathologists served as coordinators of the PWG. Representative histopathology slides
17 containing examples of lesions potentially related to chemical administration, examples of
18 disagreements in diagnoses between the laboratory and QA pathologists, or lesions of general
19 interest were presented by the coordinator to the PWG for review. While tissues from multiple
20 organ systems were selected by the QA pathologists for review by the PWG to allow evaluation
21 and confirmation of the broad spectrum of lesions observed in control and treatment groups,
22 female and male reproductive tissues were emphasized in the review. The PWG consisted of the
23 QA pathologists, the study pathologist, and other pathologists experienced in rodent

1 toxicological pathology. This group examined the tissues with no knowledge of dose groups.
2 When the PWG consensus differed from the opinion of the study pathologist, the diagnosis was
3 changed. Final diagnoses for reviewed lesions represent a consensus of the PWG.

4 **Statistical Methods**

5 The full statistical analysis reports, including detailed methods and *p*-values for each analysis,
6 including the omnibus tests, are found in Supplemental Appendices XVII-XXXI, XXXIII, and
7 XXXIV. The pairwise comparisons to the vehicle control and trend tests are the comparisons of
8 interest that are presented in the tables in this report. The statistical methodology for each
9 endpoint is summarized below. Statistical comparisons were conducted within sex and, for data
10 collected after weaning, within dosing arm (continuous-dose or stop-dose). For pairwise
11 comparisons, the five BPA dose groups were compared to the vehicle control group. Similarly,
12 the two EE₂ reference estrogen dose groups were compared to the vehicle control. Tests were
13 conducted at the 0.05 significance level and, in most cases, were two-sided. Exceptions were
14 one-sided tests for the pairwise comparisons of histopathology lesion incidence and severity to
15 vehicle controls and trend tests for abnormal estrous cycles. Although a *p*-value of <0.05 was
16 used to flag a result as significant, the actual *p*-values are included in some of the tables in this
17 report and in all the statistical report appendices (Supplemental Appendices XVII-XXXI,
18 XXXIII, and XXXIV) to aid in the further evaluation of the statistical and biological significance
19 of each result. Trend tests for treatment effect (either increased or decreased relative to vehicle
20 control) with increasing dose were conducted only for vehicle control and BPA treatment groups,
21 except for non-neoplastic and neoplastic lesions, where trend tests were also conducted within
22 the vehicle control and EE₂ groups. Because pups within litter and sex were assigned at weaning

1 to different dosing arms and sacrifice times, litter correlation was not a consideration for
2 endpoints evaluated after weaning in this study.

3 **Survival Analyses (Supplemental Appendices XX, XXI, and XXII)**

4 Animals with a disposition of dead or moribund were treated as uncensored observations, while
5 those reaching PND 21, one year, or two years were considered censored for the preweaning,
6 interim, and terminal survival analyses, respectively. To compare survival of treatment groups to
7 the control group, Cox proportional hazards regression analysis was performed. For the interim
8 sacrifice survival analysis, several groups had 100% survival. For this situation, a modified Cox
9 proportional hazards regression analysis was performed after adjusting the number of uncensored
10 observations by adding one for each treatment group and sex to allow estimability. Multiple
11 comparisons of treatments to the vehicle control group were adjusted using Holm's (step-down
12 Bonferroni) method.

13 **Body Weight Analyses (Supplemental Appendices XVII, XXIII, XXIV, and** 14 **XXV)**

15 Gestational weight at parturition was analyzed using analysis of covariance (ANOCOVA) with
16 terms for treatment group, dam weight at baseline, and litter size as covariates, and the
17 interaction between treatment and litter size. Data were collected at baseline on GD 0 or GD 1
18 prior to dosing and daily from GD 6 to parturition. Gestational weight at parturition was defined
19 as the last dam body weight prior to delivery. For preweaning pup body weight data, the analysis
20 was performed using contrasts within sex and PND. The experimental unit was the litter, and a
21 stratified one-way repeated measures, mixed model analysis of variance (ANOVA) was used to
22 test for treatment effect and to account for litter correlation assuming a compound symmetric
23 correlation structure. The cross-sectional analysis was performed on selected PNDs (1, 4, 7, 14,
24 and 21) so that the intra-litter correlation could be accounted for accurately.

1 For the interim sacrifice and terminal sacrifice post-weaning analyses, there were no littermates
2 among the males or females in any dose group within each dosing arm and sacrifice time, so
3 intra-litter correlation was not considered. Body weight data collected from four to 52 weeks
4 (interim sacrifice animals) or four to 104 weeks (terminal sacrifice animals) were analyzed using
5 the last weekly observation for each animal, with PND 21 defined as the first day of week four.
6 Although no formal comparisons were made between the continuous- and stop-dose study arms,
7 for females and males in both the interim and terminal sacrifice phases, the week 4 body weights
8 in the continuous-dose groups appeared to be higher than the week 4 body weights in the stop-
9 dose groups (compare Table 24 and Table 25 with Table 26 and Table 27 for females; compare
10 Table 28 and Table 29 with Table 30 and Table 31 for males). This apparent difference was an
11 artifact of the experimental design and the statistical analysis. After weaning, the continuous-
12 dose groups were weighed daily until PND 90, so that the last body weight of week 4 was PND
13 27. For the stop-dose groups, weekly body weights were taken after weaning, so the last body
14 weight recorded in week 4 was generally earlier than PND 27. Outliers were identified by
15 comparing observed body weight to predicted body weight using a five-point running median
16 smoother and nearest neighbor interpolation. A threshold for outlier exclusion was set at a
17 difference between observed and predicted weights greater than 35 g for both sexes in the
18 interim analysis, and 60 and 65 g for females and males, respectively, in the terminal analysis.
19 Lists of the outliers are found in Supplemental Appendices XXIV and XXV. Pairwise
20 comparisons of means were performed using contrasts within a two-way repeated measures,
21 mixed model ANOVA for females and males separately. Model terms were treatment group,
22 weeks, and the interaction. Within-group correlations were modeled using a heterogeneous first-
23 order autoregressive (ARH(1)) correlation structure that allows for correlated differences in

1 variability across time points. Pairwise comparisons of each treatment mean to the vehicle
2 control group mean were performed using contrasts with Dunnett's method of adjustment for
3 multiple comparisons.

4 **Implantation Sites and Litter Parameters (Supplemental Appendices XVIII**
5 **and XIX)**

6 Implantation site counts and litter weight data were analyzed using a one-way ANOVA and litter
7 mean pup weights were analyzed using contrasts within an ANOCOVA, with litter size as a
8 covariate, to test for treatment effect. Dunnett's test was used for comparisons to the vehicle
9 control group to adjust for multiple comparisons. Sex ratios of pups within litters were analyzed
10 for treatment effects using logistic regression. Pup counts (number alive, males, females, number
11 unsexed (*i.e.*, pups that could not be definitively assigned as male or female), and number born
12 dead) were analyzed using Poisson regression. For analyses of sex proportions and female and
13 male counts, unsexed pups were assigned either as male sex or female sex in separate runs with
14 comparable results (Supplemental Appendix XIX).

15 **Analyses of Vaginal Opening, Vaginal Cytology, and Onset of Aberrant**
16 **Estrous Cycles (Supplemental Appendices XXVI-XXVIII)**

17 Analyses of age and body weight at occurrence of vaginal opening were performed using
18 contrasts within a one-way ANOVA to test for treatment effect. Comparisons of dosed groups to
19 vehicle control for age and body weight were performed with Dunnett's method to adjust for
20 multiple comparisons.

21 Summary statistics were calculated for proportions of days spent in estrus, diestrus, and proestrus
22 for each animal and for estrous cycle length. Cycle length in days was defined from the first day
23 of estrus in one sequence of contiguous days to the first day of estrus in the following sequence

1 of stages. Cycles were considered censored if the last stage of data collection was either diestrus
2 or proestrus.

3 Analyses were conducted on proportions of animals with abnormal cycles. The endpoints
4 evaluated were any abnormal cycling, extended estrus, extended diestrus, and excessive
5 proestrus. Extended estrus was defined as three or more consecutive days of estrus; extended
6 diestrus was defined as four or more consecutive days of diestrus; and excessive proestrus was
7 defined as two or more consecutive days of proestrus in a cycle. For abnormal cycling defined by
8 animal, the Cochran-Armitage method for binomial proportions was used to evaluate the
9 pairwise differences in proportions. The two-sided p -value for the Fisher's exact test is reported
10 for comparisons of dosed groups to control, and the one-sided Cochran-Armitage trend test was
11 performed. Holm's (step-down Bonferroni) method was used to adjust for multiple pairwise
12 comparisons of dosed groups to control.

13 An accelerated failure time model assuming a lognormal distribution was used for onset of
14 aberrant cycling, which was defined as occurring at first swab date of two consecutive months of
15 aberrant estrous cycle data. An aberrant estrous cycle was defined as three or more consecutive
16 days of estrus or five consecutive days without estrus. The data for this endpoint contained left-,
17 right-, and interval-censored data, which can all be accommodated by the accelerated failure time
18 model used. Left censoring occurred because some animals had begun to show aberrant cycles
19 prior to the start of monitoring, while right censoring occurred because some animals died or
20 reached the end of the study without showing aberrant cycles. The intermittent nature of the data
21 collection, one 5-day period every month, makes it impossible to determine the exact time of
22 onset of aberrant cycles, so the data are interval censored. Multiple comparisons were adjusted

1 using Holm's (step-down Bonferroni) method for treatment group comparisons to the control
2 group.

3 **Organ Weight Analyses (Supplemental Appendix XXX)**

4 Statistical analyses were performed separately for the BPA study arms, stop-dose and
5 continuous-dose, and for the EE₂ continuous-dose arm in one-year interim sacrifice rats. Weights
6 of paired organs were analyzed as combined weight. ANOVA was performed for each sex and
7 organ to determine the effect of treatment on organ weight. ANOCOVA was performed to
8 determine the effect of treatment on organ weight adjusted for body weight at necropsy or brain
9 weight. Separate analyses were performed with each covariate. Comparisons of dosed groups
10 versus vehicle control were performed using Dunnett's method for adjusted contrasts. Tests of
11 trend, increasing treatment effect with increasing dose, were performed for the BPA and vehicle
12 control groups. Organ weight exclusions based on the observation of gross cysts or consideration
13 of statistical distributions are listed in Supplemental Appendix XXX.

14 **Clinical Chemistry and Hematology Analyses (Supplemental Appendix 15 XXIX)**

16 A non-parametric ANOVA method based on mid-ranks was used to evaluate the effect of
17 treatment on clinical chemistry and hematology assessments assuming an unstructured
18 covariance⁷. The average of the left and right ranks was used for ties. Dunnett's adjustment was
19 used for pairwise multiple comparisons relative to the control. Orthogonal contrasts were used to
20 test for trends over increasing BPA dose concentrations. Any measurements below the limit of
21 detection (LOD) were evaluated at half the LOD level.

1 Sperm Parameter Analyses (Supplemental Appendix XXXI)

2 Analysis of sperm morphology data was performed using a generalized linear model with a
3 Poisson distribution and a log link function. Each treatment was compared to the vehicle control
4 group, and adjustment for multiple comparisons was performed using Dunnett's method. Percent
5 sperm motility, testes sperm counts, and caudal sperm counts were analyzed using an ANOVA
6 model with Kenward-Roger estimated degrees of freedom²⁷. Each treatment was compared to the
7 control group, and adjustment for multiple comparisons was performed using Dunnett's method.
8 Tests of trends, increasing treatment effect with increasing dose, were performed for each
9 compound and dosing arm.

**10 Analyses of Non-Neoplastic and Neoplastic Lesions, Interim and Terminal
11 Sacrifice (Supplemental Appendices XXXIII and XXXIV)**

12 Microscopic findings were recorded in NTP's automated Toxicology Data Management System
13 Enterprise. For the statistical analyses of groups with 20–26 animals (all interim sacrifice groups
14 and EE₂ terminal sacrifice groups), any lesion present in at least two animals in any dose group
15 was included in the analyses. In groups with 46–50 animals (all terminal sacrifice vehicle control
16 and BPA groups), any lesion present in at least four animals in any dose group was included in
17 the analyses.

18 The NTP-preferred approach to assess neoplastic and non-neoplastic lesion prevalence is a
19 survival-adjusted quantal-response procedure (see description of Poly-3 test below) that modifies
20 the Cochran-Armitage linear trend test to take survival differences into account
21 (<https://ntp.niehs.nih.gov/testing/types/stats/index.html>). For neoplasm and non-neoplasm
22 incidence for interim sacrifice animals, where early removals or deaths were few, the Cochran-
23 Armitage test, without survival adjustment, was used to test for a linear dose trend, with the
24 Fisher's exact test used to compare dosed groups to the vehicle control. This combination of tests

1 is referred to as CAFE. For neoplasm and non-neoplasm incidence for terminal sacrifice animals,
2 the Poly-3 method of Bailer and Portier³, as modified by Bieler and Williams⁴, and the NIEHS
3 continuity-correction, discussed in Peddada and Kissling³⁹, was used to analyze age-adjusted
4 incidence for linear dose trend and for pairwise comparisons to the vehicle control. For both the
5 analysis of interim and terminal neoplasm and non-neoplasm incidences, tests were one-sided for
6 treatment comparisons to the vehicle control group with no adjustment for multiple comparisons
7 to the vehicle control, while the trend test was two-sided.

8 Lesion severities, ordinal scores provided by the Study Pathologist, were available for many of
9 the non-neoplastic lesions. Although these scores are more subjective than the lesion incidences,
10 statistical tests were run to include this additional information. The Jonckheere-Terpstra test^{46; 47}
11 was run to test for monotonic dose trends, followed by Shirley's test^{46; 59} to compare to controls.
12 This combination of tests is referred to as JT/SW, and it presumes a monotonic dose response.
13 One aspect of this study was to consider potential non-monotonic effects, which would be
14 detected by the pairwise comparisons. JT/SW is blind to this effect. Therefore, a test not
15 typically used in NTP studies, the nonparametric Relative Treatment Effects (RTE) method⁷ was
16 used to test for non-monotonic dose effects. While the results of the JT/SW and RTE tests are
17 presented in the summary tables and in the statistical appendices (Supplemental Appendices
18 XXXIII and XXXIV), the CAFE and Poly-3 tests are the primary tests to be considered both
19 because of the nature of the severity scores and, in the case of terminal sacrifice, because the
20 JT/SW and RTE tests are not mortality adjusted.

21 A subset of lesions is discussed and tabulated in the body of this report. Comprehensive
22 tabulations of all statistical results, including the JT/SW and RTE test results, for all lesions
23 diagnosed in the study are found in Supplemental Appendices XXXIII and XXXIV.

1 **Sensitivity Analyses**

2 In the present study, approximately 20% of the animals were housed for a short period early in
3 the study in the same room as animals dosed with 250,000 µg BPA/kg bw/day exclusively for a
4 CLARITY-BPA grantee study. These animals were potentially exposed to low levels of BPA,
5 leading to blood levels of BPA metabolites above the limit of detection and similar to those
6 resulting from the 2.5 µg BPA/kg bw/day dose²⁴ (Supplemental Appendix XVI). Animals co-
7 housed only with the high dose from the two-year study (25,000 µg BPA/kg bw/day) had no
8 detectable BPA metabolites in their blood²⁴. As a conservative approach to determine if this low-
9 level exposure to a subset of animals impacted the interpretation of study results, a sensitivity
10 analysis was conducted for each endpoint. In the sensitivity analysis, all animals that for any
11 portion of their lives were co-housed in the same room as the subset of animals treated with the
12 250,000 µg BPA/kg bw/day dose were excluded. Any significant effects found in the sensitivity
13 analysis that were not found in the analysis that included all animals are noted in data tables and
14 in the statistical appendices (Supplemental Appendices XVII-XXXI, XXXIII, and XXXIV).
15 Only those animals involved in or resulting from the first mating were co-housed at any point in
16 their lives with the animals dosed with 250,000 µg BPA/kg bw/day. Thus, the sensitivity
17 analyses that were conducted after exclusion of all animals in the first mating removed all
18 animals that potentially had exposure to BPA above that present in the diet. This included the
19 subset of animals that had received a single dose of contaminated vehicle as adults (see above
20 under “Preparation and Analysis of Dose Formulations” and Supplemental Appendix III, note to
21 study file October 13, 2017).

1 **Quality Assurance**

2 This study was conducted in compliance with the Food and Drug Administration (FDA) Good
3 Laboratory Practice for the conduct of nonclinical laboratory studies (United States Code of
4 Federal Regulations Title 21, Part 58). The Quality Assurance Unit at NCTR performed audits
5 and inspections of the protocols, procedures, data, and reports throughout the course of the study.
6 Separate audits covering completeness and accuracy of the pathology data, pathology specimens,
7 and final pathology tables, and a draft of this technical report were conducted. Audit procedures
8 and findings are on file at NCTR. The audit findings were reviewed and assessed by the NCTR
9 staff, and all comments were resolved or otherwise addressed either before or during the
10 preparation of the technical report. Raw data sheets from the study are archived by NCTR's
11 Record Management Unit. Histopathology samples collected during the study are stored in the
12 archives of Toxicologic Pathology Associates at NCTR. Backup computer data are maintained
13 by the Computer Support Group at the NCTR. All records and samples are stored in accordance
14 with Food and Drug Administration Good Laboratory Practice Regulations.

1 **Results**

2 **Gestational Body Weight, Fetal Implantation, and Litter** 3 **Parameters**

4 Dam body weights during pregnancy were not affected by BPA or EE₂ treatment (Table 10). The
5 number of implantation sites in mated dams did not differ across BPA or EE₂ treatment groups
6 and control groups, and treatment had no effect on litter size, sex ratio, litter weight by sex, or
7 mean pup weight at birth by sex (Table 11).

8 **Survival, Prewaning and Postweaning Study Phases**

9 **Survival in Prewaning Animals**

10 **Females**

11 The survival of female pups between PND 1 and PND 21 ranged from 91–95% in vehicle control
12 and BPA dose groups (Table 12). There were no significant BPA treatment effects. The survival
13 of female pups in the 0.05 and 0.5 µg EE₂/kg bw/day groups was 85% and 91%, respectively.
14 Survival in the lower EE₂ group was significantly lower than that in the vehicle control group.
15 The study protocol did not call for detailed evaluation of the cause of morbidity/death in pups
16 removed from the study prior to weaning.

17 **Males**

18 The survival of male pups between PND 1 and PND 21 ranged from 91–95% in vehicle control
19 and BPA dose groups (Table 13). There were no significant BPA treatment effects. The survival
20 of male pups in the 0.05 and 0.5 µg EE₂/kg bw/day groups was 90% and 95%, respectively, and
21 did not differ significantly from the vehicle control. The study protocol did not call for detailed
22 evaluation of the cause of morbidity/death in pups removed from the study prior to weaning.

1 **Interim Sacrifice Animals: Postweaning Survival**

2 **Females, Continuous-Dose Arm**

3 The survival of females dosed daily with vehicle or BPA until the scheduled one-year sacrifice
4 ranged from 91–100% and there were no treatment effects (Table 14). Over the same period, the
5 survival of females in the low and high EE₂ dose groups was 92 and 100%, respectively, and did
6 not differ from vehicle controls. Causes of morbidity/death in animals that did not survive to the
7 interim sacrifice, when known, are noted in footnotes to Table 14.

8 **Females, Stop-Dose Arm**

9 In the stop-dose study arm, there was 100% survival in all dose groups of females scheduled for
10 sacrifice at one year, except for the 25,000 µg BPA/kg bw/day dose group where survival was
11 91% (Table 15). There was no treatment effect. Causes of morbidity/death in animals that did not
12 survive to the interim sacrifice, when known, are noted in footnotes to Table 15.

13 **Males, Continuous-Dose Arm**

14 Survival of males dosed daily with vehicle or various BPA doses until the scheduled one-year
15 sacrifice ranged from 82–100%, with the lowest percent survival seen in the vehicle control
16 group (Table 16). There were no significant treatment effects on survival after this one-year
17 exposure. Over the same period, the survival of males in the low and high EE₂ dose groups was
18 85 and 88%, respectively, and did not differ significantly from vehicle controls. Causes of
19 morbidity/death in animals that did not survive to the interim sacrifice, when known, are noted in
20 footnotes to Table 16.

21 **Males, Stop-Dose Arm**

22 In the stop-dose study arm, there was 100% survival in males of all BPA dose groups sacrificed
23 at one year, with the exception of the 25 µg BPA/kg bw/day dose group where survival was 95%
24 (Table 17). There was no treatment effect. The cause of death in the one animal in the 25 µg

1 BPA/kg bw/day dose group that died early was uncertain (Supplemental Appendix XXXII,
2 Subappendix VI).

3 **Survival, Postweaning in Terminal Sacrifice Animals**

4 **Females, Continuous-Dose Arm**

5 The Kaplan-Meier survival curves for females dosed daily with the vehicle or BPA, or with the
6 vehicle or EE₂, until sacrifice at two years are shown in Figure 2 and Figure 3, respectively. Data
7 and analysis results are shown in Table 18. Survival at the end of the study in the BPA dose
8 groups ranged from 17–40%. Survival in the low and high EE₂ dose groups was 27 and 15%,
9 respectively. No significant treatment effects were seen for this chronic exposure to BPA or EE₂
10 at the doses administered. Most of the animals that did not survive until the terminal sacrifice
11 were removed as moribund between one and two years of age. Causes of death/morbidity are
12 listed in an appendix to the pathology report (Supplemental Appendix XXXII, Subappendix VI);
13 mammary gland fibroadenomas and pituitary adenomas accounted for most of the early
14 removals.

15 **Females, Stop-Dose Arm**

16 The Kaplan-Meier survival curves for females in the vehicle control or BPA two-year stop-dose
17 arm are shown in Figure 4. Data and analysis results are shown in Table 19. Survival at the end
18 of the study in the BPA dose groups ranged from 24-34%; survival in the vehicle control group
19 was 22%. There were no significant treatment effects in female rats after only gestational and
20 preweaning exposure to BPA. Most animals that did not survive until the terminal sacrifice were
21 removed as moribund between one and two years of age. Causes of death/morbidity are listed in
22 an appendix to the pathology report (Supplemental Appendix XXXII, Subappendix VI); as was
23 the case in the two-year continuous-dose arm females, mammary gland fibroadenomas and
24 pituitary adenomas accounted for most of the early removals.

1 Males, Continuous-Dose Arm

2 The Kaplan-Meier survival curves for males dosed daily with vehicle or BPA, or with vehicle or
3 EE₂, until sacrifice at two years are shown in Figure 5 and Figure 6, respectively. Data and
4 analysis results are shown in Table 20. Survival at the end of the study in the BPA dose groups
5 ranged from 24–35%. Survival in the low and high EE₂ dose groups was 35 and 46%,
6 respectively. There were no significant treatment effects. Most animals that did not survive until
7 the terminal sacrifice were removed as moribund between one and two years of age. Causes of
8 death/morbidity are listed in an appendix to the pathology report (Supplemental Appendix
9 XXXII, Subappendix VI). Many primary and contributory conditions in various organs were
10 diagnosed, with pituitary adenomas, nephropathy, preputial gland carcinoma, and malignant
11 lymphoma indicated as primary causes of death/morbidity in multiple animals across all dose
12 groups.

13 Males, Stop-Dose Arm

14 The Kaplan-Meier survival curves for males in the vehicle control or BPA two-year stop-dose
15 arm are shown in Figure 7. Data and analysis results are shown in Table 21. Survival at the end
16 of the study in the BPA dose groups ranged from 20–33% in comparison to the 34% survival
17 seen in the vehicle controls. There were no significant treatment effects. Most animals that did
18 not survive until the terminal sacrifice were removed as moribund between one and two years of
19 age. Causes of death/morbidity are listed in an appendix to the pathology report (Supplemental
20 Appendix XXXII, Subappendix VI) and were similar to those diagnosed for the continuous-dose
21 arm males.

1 **Body Weights**

2 **Body Weights in Prewaning Animals**

3 **Females**

4 Body weights on PNDs 1, 4, 7, 14, and 21 in female pups treated daily with vehicle, BPA, or EE₂
5 are shown in Table 22. There were no BPA treatment-related effects on female pup body weights
6 at these time points. On PNDs 4 and 7, the low EE₂ dose group females had significantly lower
7 mean body weight than vehicle controls, with body weights in the treated animals approximately
8 5% lower than controls on both days. At PND 4, both the 2.5 µg BPA/kg bw/day and the 0.05 µg
9 EE₂/bw/day dose groups had identical means and standard errors, but only the latter was
10 statistically significant, suggesting that the smaller sample size in that group contributed to this
11 marginal difference.

12 **Males**

13 Body weights on PNDs 1, 4, 7, 14, and 21 in male pups treated daily with vehicle, BPA, or EE₂
14 are shown in Table 23. There were no BPA or EE₂ treatment-related effects on male pup body
15 weights at these time points.

16 **Body Weights in Interim and Terminal Sacrifice Animals**

17 **Females, Continuous-Dose BPA and EE₂**

18 Body weights of females in the continuous vehicle control and BPA groups scheduled for the
19 interim sacrifice are shown in Figure 8 and Table 24. The data for the EE₂ groups are also
20 tabulated in Table 24 and are shown graphically in Figure 9. There were no significant
21 differences from the vehicle controls in any of the BPA or EE₂ dose groups. The mean body
22 weights in the 2.5 µg BPA/kg bw/day group in weeks 36–52 were 10–13% higher than vehicle
23 control means; however, these differences were not statistically significant.

1 Body weights of females in the continuous vehicle control, BPA, and EE₂ dose groups scheduled
2 for the terminal sacrifice are shown in Table 25 and in Figure 10 and Figure 11 for BPA and EE₂,
3 respectively. Mean body weights of females in the 250 µg BPA/kg bw/day dose group were
4 significantly higher by 16–18% than those of the vehicle control group for weeks 96–104. In this
5 same period, the mean body weights of females in the 2.5 and 25 µg BPA/kg bw/day dose
6 groups were 11–16% higher than those of vehicle controls, but these differences were not
7 significant. Animals in the 2.5 µg BPA/kg bw/day dose group did not have higher mean body
8 weights than vehicle controls in the earlier weeks noted above for interim sacrifice animals. In
9 the terminal sacrifice high EE₂ dose group, transiently higher (approximately 5%) mean body
10 weights were observed at 4 and 8 weeks. The same tendency in the high EE₂ dose group was
11 seen in the interim sacrifice animals at 4 and 8 weeks, although the differences in mean body
12 weights were not statistically significant.

13 **Females, Stop-Dose BPA**

14 Body weights of females in the vehicle control and BPA stop-dose groups scheduled for the
15 interim sacrifice are shown in Table 26 and Figure 12. There were no significant treatment
16 effects. In the stop-dose females scheduled for terminal sacrifice (Table 27 and Figure 13), there
17 was a significant decreasing trend at week 4, but no other treatment effects.

18 **Males, Continuous-Dose BPA and EE₂**

19 Body weights of the continuously dosed males in the vehicle control, BPA, and EE₂ groups for
20 interim and terminal sacrifices are shown in Table 28 and Table 29, respectively. The growth
21 curves for interim BPA and EE₂ dose groups are shown in Figure 14 and Figure 15, respectively,
22 and the growth curves for terminal BPA and EE₂ dose groups are shown in Figure 16 and Figure
23 17, respectively. There were no significant treatment effects for either compound, although

1 means were approximately 10% higher than vehicle control means in the 250 µg BPA/kg bw/day
2 dose group from weeks 92 through 104.

3 **Males, Stop-Dose BPA**

4 Mean body weights of the stop-dose arm vehicle control and BPA groups of male rats for interim
5 and terminal sacrifices are shown in Table 30 and Table 31 and graphically depicted in Figure 18
6 and Figure 19, respectively. The sole statistically significant treatment effect was a decreasing
7 dose trend at week 4 in the terminal sacrifice animals (Table 31).

8 **Vaginal Opening**

9 Female pups were evaluated for vaginal opening starting on PND 22. Mean age and body weight
10 at vaginal opening for continuous-dose vehicle control, BPA, and EE₂ dose groups are shown in
11 Table 32. There were no treatment-related effects on these endpoints for any dose of either
12 compound. For stop-dose vehicle control and BPA groups, mean age at vaginal opening is shown
13 in Table 33. No treatment effects were observed in the stop-dose BPA groups. Body weight at
14 vaginal opening could not be analyzed for the stop-dose animals because weight at vaginal
15 opening was not recorded for many of the animals due to a technical error (Supplemental
16 Appendix II, deviations 72–74). While no formal analysis was conducted comparing vehicle
17 controls in the continuous- and stop-dose arms, the mean vaginal opening date appears to be later
18 regardless of BPA treatment in the stop-dose groups.

19 **Vaginal Cytology – Estrous Cycle Analysis at Approximately 16** 20 **Weeks of Age**

21 **Continuous-Dose Arm**

22 Data and results of analysis of the 14 consecutive daily vaginal smears collected from animals in
23 the continuous-dose arm at 16 ± 2 weeks of age are summarized in Table 34. The individual

1 animal data are found in the statistical report in Supplemental Appendix XXVII. There were no
2 significant differences from the vehicle control among the continuous BPA dose groups. The
3 high EE₂ dose had a highly significant effect on the estrous cycle, with 96% of the animals
4 showing extended estrus as compared to 12% of the vehicle controls (Table 34). When all types
5 of abnormal cycles were considered, 100% of the high EE₂ dose group animals showed abnormal
6 cycles compared to 27% of the vehicle controls.

7 **Stop-Dose Arm**

8 There were no BPA treatment-related effects on the estrous cycle in the stop-dose animals (Table
9 35). The individual animal data are found in the statistical report in Supplemental Appendix
10 XXVII.

11 **Vaginal Cytology – Onset of Aberrant Estrous Cycles in Aging** 12 **Animals**

13 **Continuous-Dose Arm**

14 The time of onset of aberrant estrous cycles in aging females was estimated by evaluating five
15 consecutive vaginal smears every month (see Materials and Methods and legend to Table 36).
16 The data for the animals in the continuous-dose arm are summarized in Table 36, and the
17 complete statistical report is found in Supplemental Appendix XXVIII. The Kaplan-Meier
18 survival curves related to the onset of aberrant cycles for the continuous vehicle control and BPA
19 and vehicle control and EE₂ groups are shown in Figure 20 and Figure 21, respectively. There
20 was no treatment effect of BPA in the continuous-dose arm. None of the dose groups differed
21 significantly in the median onset time of 56.8 weeks in the vehicle control group. As expected
22 based on the previously mentioned analysis of estrous cycle data at 16 weeks, the onset of
23 aberrant cycles occurred significantly earlier in the 0.5 µg EE₂/kg bw/day dose group.

1 **Stop-Dose Arm**

2 The time of onset of aberrant estrous cycles in the stop-dose BPA females is shown in Table 37.

3 The Kaplan-Meier survival curves related to the onset of aberrant cycles for the stop-dose
4 vehicle control and BPA groups are shown in Figure 22, and the complete statistical report is
5 found in Supplemental Appendix XXVIII. The sole significant effect was a delay in the median
6 time of onset in the 2,500 µg BPA/kg bw/day dose group (57 weeks versus 42 weeks in vehicle
7 controls). While no formal analysis was conducted to compare the continuous-dose vehicle
8 control group with the stop-dose vehicle control group, the estimated median time of onset of
9 aberrant cycling appeared shorter in the stop-dose vehicle control group.

10 **Hematology Endpoints in Interim Sacrifice Animals**

11 **Females, Continuous-Dose Arm**

12 Hematology endpoints examined at the interim sacrifice in females dosed continuously with
13 BPA or EE₂ are shown in Table 38. Platelet counts were significantly lower (~10%) than vehicle
14 controls in the 25,000 µg BPA/kg bw/day dose group. Eosinophils were decreased (~25%) in the
15 250 µg BPA/kg bw/day dose group relative to the vehicle control group, and mean corpuscular
16 hemoglobin concentration was marginally higher (~1.4%) than vehicle controls in the 25 µg
17 BPA/kg bw/day dose group. There were significant trends over increasing levels of BPA dose
18 concentrations for hemoglobin concentration ($p = 0.023$), monocytes ($p = 0.045$), and platelet
19 counts ($p = 0.008$). In female rats continuously dosed with 0.5 µg EE₂/kg bw/day, lower
20 eosinophil counts (~25%), % eosinophils (~ 21%), and platelet counts (~8%) were observed.
21 Platelet counts were also lower by approximately 8% in the 0.05 µg EE₂/kg bw/day dose group
22 ($p = 0.054$).

1 Females, Stop-Dose Arm

2 Hematology endpoints examined at the interim sacrifice in stop-dose BPA female rats are shown
3 in Table 39. No statistically significant differences in values were observed in pairwise
4 comparisons between BPA dose groups and vehicle controls. Significant trends were noted for %
5 basophils ($p = 0.031$), mean corpuscular hemoglobin ($p = 0.013$), and red blood cells ($p = 0.044$).

6 Males, Continuous-Dose Arm

7 Hematology endpoints examined at the interim sacrifice in males dosed continuously with BPA
8 or EE₂ are shown in Table 40. Hemoglobin levels were significantly higher (~4%) in the 25,000
9 µg BPA/kg bw/day group and the percentage of eosinophils lower (~28%) in the 250 µg BPA/kg
10 bw/day group relative to vehicle controls. Significant trends were observed for hematocrit
11 ($p = 0.006$), hemoglobin concentration ($p = 0.016$), packed cell volume ($p = 0.008$), mean
12 corpuscular hemoglobin ($p = 0.018$), mean corpuscular hemoglobin volume ($p = 0.016$), and
13 platelet counts ($p = 0.011$). The sole observed statistically significant effect in the EE₂ groups
14 was an elevated hemoglobin concentration (~3%) relative to the vehicle control level in the 0.05
15 µg EE₂/kg bw/day group.

16 Males, Stop-Dose Arm

17 Hematology endpoints examined at the interim sacrifice in stop-dose BPA male rats are shown in
18 Table 41. No statistically significant effects were observed in pairwise comparisons between
19 BPA dose groups and vehicle controls. A significant trend for % neutrophils ($p = 0.045$) was
20 noted over the levels of BPA dose concentrations in the stop-dose arm.

1 **Serum Clinical Chemistry Endpoints in Interim Sacrifice Animals**

2 **Females, Continuous-Dose Arm**

3 Clinical chemistry endpoints examined at the interim sacrifice in females dosed continuously
4 with BPA or EE₂ are shown in Table 42. Alkaline phosphatase levels were significantly higher
5 (~31%) in the 250 µg BPA/kg bw/day group than levels in the vehicle control group, although
6 similar to those in the stop-dose vehicle control group (Table 43). Although mean levels of
7 alkaline phosphatase were higher than controls in most of the BPA groups, none of the others
8 were statistically significant. There were no other statistically significant treatment effects on
9 clinical chemistry endpoints in any continuous BPA dose group. The female rats in the
10 continuous 0.5 µg EE₂/kg bw/day dose group had higher (~38%) mean levels of TSH, while rats
11 in the 0.05 µg EE₂/kg bw/day dose group had higher (~24%) mean levels of alkaline phosphatase
12 than the vehicle control group. There were no EE₂ treatment effects on T3 or T4.

13 **Females, Stop-Dose Arm**

14 Clinical chemistry endpoints examined at the interim sacrifice in stop-dose BPA female rats are
15 shown in Table 43. No statistically significant differences were noted in pairwise comparisons
16 between stop-dose BPA-treated female rats and the vehicle controls. There was a significant
17 trend over levels of BPA dose concentrations for albumin ($p = 0.004$).

18 **Males, Continuous-Dose Arm**

19 Clinical chemistry endpoints examined at the interim sacrifice in males dosed continuously with
20 BPA or EE₂ are shown in Table 44. No statistically significant differences were noted in pairwise
21 comparisons between any BPA treatment group and vehicle controls. Significant trends were
22 noted for albumin ($p = 0.007$), T4 ($p = 0.002$), total bile acids ($p = 0.026$), and troponin T
23 ($p = 0.003$). For EE₂, mean insulin levels were significantly lower (~35%, $p = 0.047$) in the 0.05

1 $\mu\text{g EE}_2/\text{kg bw/day}$ dose group and mean triglyceride levels were significantly higher (~26%) in
2 the 0.5 $\mu\text{g EE}_2/\text{kg bw/day}$ dose group than those in vehicle controls.

3 **Males, Stop-Dose Arm**

4 Clinical chemistry endpoints examined at the interim sacrifice in stop-dose BPA male rats are
5 shown in Table 45. In the 25 $\mu\text{g BPA}/\text{kg bw/day}$ dose group, decreases in the mean levels of
6 total protein (~4%) and total bile acids (~31%) relative to vehicle controls were observed.

7 Significant trends were noted over the levels of BPA dose concentrations for T4 ($p = 0.046$) and
8 for total bile acids ($p = 0.024$).

9 **Organ Weights in Interim Sacrifice Animals**

10 **Females, Continuous-Dose Arm**

11 Summary statistics for organ weights collected from females in the continuous-dose BPA and
12 EE_2 dose groups are shown in Table 46. Organ weights were analyzed as absolute weights, and
13 relative weights with brain and body weight at necropsy as covariates. There were few sporadic
14 significant differences between BPA groups and the vehicle control group. In the 2.5 $\mu\text{g BPA}/\text{kg}$
15 bw/day dose group, the mean absolute retroperitoneal fat pad weight was significantly higher
16 (40%) than the mean weight in the vehicle control group. The brain weight-adjusted
17 retroperitoneal fat pad weight was similarly significantly greater than the vehicle control. The
18 mean retroperitoneal fat pad weight adjusted for body weight was higher (23%) than the vehicle
19 control group, but this was not a statistically significant difference. The only other significant
20 BPA treatment effect was a dose trend for liver adjusted for body weight.

21 Multiple organ weights were significantly affected by the 0.5 $\mu\text{g EE}_2/\text{kg bw/day}$ treatment. Mean
22 absolute adrenal weights, as well as adrenal weights adjusted for brain and body weights, were
23 increased by 27%, 28%, and 22%, respectively. Mean ovarian/parametrial fat pad weight was

1 decreased, with mean weight adjusted for body weight significantly decreased (~17%) relative to
2 the vehicle control group mean. Mean heart weight was also increased in the high EE₂ dose
3 group, with mean heart weight adjusted for body weight significantly increased (~6%) relative to
4 the vehicle control group mean. Mean absolute kidney weights, as well as kidney weights
5 adjusted for brain and body weights, were increased relative to the vehicle control mean by 15%,
6 16%, and 13%, respectively. Mean absolute liver weights, as well as liver weights adjusted for
7 brain and body weights, were increased relative to the vehicle control mean by 20%, 20%, and
8 18%, respectively. Mean absolute ovary weights, as well as ovary weights adjusted for brain and
9 body weights, were decreased relative to the vehicle control mean by 18%, 16%, and 15%,
10 respectively. Mean absolute pituitary weights, as well as pituitary weights adjusted for brain and
11 body weights, were increased by 31%, 32%, and 20%, respectively.

12 **Females, Stop-Dose Arm**

13 Summary statistics for organ weights collected from females in the BPA stop-dose groups are
14 shown in Table 47. There were significant dose trends for absolute ovary weight and ovary
15 weight adjusted for brain and body weight. The mean absolute ovary weight, as well as ovary
16 weight adjusted for brain weight, in the 25,000 µg BPA/kg bw/day dose group were significantly
17 lower than the vehicle control group by approximately 13% and 12%, respectively. Mean ovary
18 weight adjusted for body weight was also 9% lower than the controls, but this difference was not
19 statistically different.

20 **Males, Continuous-Dose Arm**

21 Summary statistics for organ weights collected from males in the continuous-dose BPA and EE₂
22 dose groups are shown in Table 48. The sole significant BPA treatment effect was a lower (~7%)

1 mean liver weight adjusted for body weight relative to the vehicle control in the 2.5 µg BPA/kg
2 bw/day dose group. There were no significant treatment effects of either EE₂ dose.

3 **Males, Stop-Dose Arm**

4 Summary statistics for organ weights collected from males in the BPA stop-dose groups are
5 shown in Table 49. The sole significant treatment effect was a significant dose trend for liver
6 weight adjusted for body weight.

7 **Sperm Analysis, Interim Sacrifice Animals**

8 Testicular spermatid head counts, caudal sperm counts, and caudal sperm motility and
9 morphology data are shown in Table 50 for continuous BPA and EE₂ dose groups and in Table
10 51 for BPA stop-dose groups. There were no significant treatment effects observed for either
11 compound.

12 **Histopathology**

13 The pathology report, which has tabulations of organs assessed and all lesions noted in all
14 animals in both the interim (one-year) and terminal (two-year) phases of the study, along with
15 the Study Pathologist's narrative report, is found in Supplemental Appendix XXXII. The few
16 neoplastic lesions that showed any statistically significant increased incidence for either BPA or
17 the reference estrogen, EE₂, are discussed below. As noted in the pathology narrative, many non-
18 neoplastic lesions common to aging animals in this strain of rat were found in both sexes at one-
19 and two-years of age. Incidences were highly variable across dose groups and BPA treatment
20 effects were not evident to the Study Pathologist. After the finalization of the pathology report,
21 statistical analyses, described in Materials and Methods, were conducted for any lesion that had
22 an incidence of two or more in the interim sacrifice animals or in the EE₂ terminal sacrifice
23 animals and four or more in the BPA-treated terminal sacrifice animals. All statistical results are

1 shown in Supplemental Appendix XXXIII for interim sacrifice animals and Supplemental
2 Appendix XXXIV for terminal sacrifice animals and selected lesions of interest with some
3 statistically significant increased incidences are discussed below. Lesions for which there was
4 lower incidence in treatment groups relative to vehicle controls are generally not discussed,
5 although a few of these cases are presented. For statistical analyses of microscopic lesions, one-
6 sided *p*-values with no correction for multiple comparisons are reported.

7 **Females**

8 Neoplastic lesions showing statistically significant differences in the BPA dose groups versus the
9 vehicle control group were limited to the female mammary gland and uterus. For EE₂, significant
10 dose trends were also noted in terminal sacrifice animals for benign pheochromocytoma in the
11 adrenal medulla and C-cell adenomas in the thyroid gland. In both cases, the incidence in the
12 high dose EE₂ group was 8% versus 0% in controls (Supplemental Appendix XXXII and
13 XXXIV).

14 **Mammary gland, neoplastic lesions**

15 Neoplastic lesions in the mammary glands of interim and terminal sacrifice females for
16 continuous BPA, continuous EE₂ and stop-dose BPA treatments are shown in Table 52, Table
17 53, and Table 54, respectively. Fibroadenomas are a common high-incidence lesion in this strain
18 of rats, and were observed in 4–25% of interim sacrifice females and 54–90% of terminal
19 sacrifice animals with no significant treatment effects. Fibroadenoma counts in each affected
20 animal were recorded and are found in an appendix to the pathology report (Supplemental
21 Appendix XXXII, Subappendix VII).

22 Adenocarcinomas and/or adenomas were observed in the continuous-dose BPA-treated animals
23 (Table 52). In interim sacrifice animals, there were no treatment-related increases in neoplasm

1 incidence, but both the 2.5 and 25 µg BPA/kg bw/day continuous-dose groups had single
2 adenocarcinomas in 22 animals examined (4% incidence). In the terminal sacrifice continuous-
3 dose vehicle control animals, 8% had adenocarcinoma and 12% had adenoma or
4 adenocarcinoma. In the continuous BPA dose groups, the incidence of adenocarcinoma varied
5 between 6 and 18%, and the incidence of adenocarcinoma or adenoma or adenocarcinoma varied
6 between 9 and 20%. None of these incidences were significant compared to the vehicle control
7 group.

8 In interim sacrifice animals, 2 of 26 animals (8% incidence) from the 0.05 µg EE₂/kg bw/day
9 dose group had adenocarcinomas (Table 53). For the continuous EE₂ treatment groups, there was
10 a significant dose trend ($p < 0.001$) and a significant increase in adenocarcinomas in the 0.5 µg
11 EE₂/kg bw/day dose group (38% versus 8%, $p < 0.001$).

12 Adenocarcinomas and/or adenomas were also observed in the terminal stop-dose females (Table
13 54). In the terminal sacrifice stop-dose females, vehicle controls had 6% animals with
14 adenocarcinomas and 8% with adenomas or adenocarcinomas. The 2.5 µg BPA/kg bw/day stop-
15 dose group had a significantly higher incidence of adenocarcinomas (22% versus 6%, $p = 0.016$)
16 or adenomas and adenocarcinomas combined (24% versus 8%, $p = 0.018$).

17 **Mammary gland, non-neoplastic lesions**

18 Non-neoplastic lesions in the mammary glands of interim and terminal sacrifice females for
19 continuous BPA and EE₂ and stop-dose BPA treatments are shown in Table 55, Table 56, and
20 Table 57, respectively.

21 In the continuous-dose BPA groups, in both the interim and terminal sacrifice females, the
22 incidences of atypical foci were higher in some treatment groups than in vehicle controls, and
23 this was significant (by the RTE test only) for the 2.5 µg BPA/kg bw/day dose group in both the

1 interim (14% versus 0%) and terminal (15% versus 4%) females (Table 55). In the interim
2 sacrifice animals, there was a significantly increased incidence (RTE test only) of ductal
3 dilatation (32% versus 9%) in the 25 µg BPA/kg bw/day dose group, but this was not the case in
4 the terminal sacrifice females, where the incidence in the dose group was decreased relative to
5 the vehicle controls (15% versus 30%).

6 In the continuous-dose EE₂ treatments, there were several significant trends and high dose
7 treatment effects observed by all statistical tests applied (Table 56). In both interim and terminal
8 animals, there was a significant trend and a significant pairwise comparison of the 0.5 µg EE₂/kg
9 bw/day dose group and vehicle control for ductal dilatation (85% versus 9%, interim; 81%
10 versus 30%, terminal). In interim sacrifice animals, there was a significant trend and a significant
11 pairwise comparison of the 0.5 µg EE₂/kg bw/day dose group and vehicle control for lobular
12 hyperplasia (88% versus 44%). In terminal sacrifice animals, there was a significant trend and a
13 significant pairwise comparison of the 0.5 µg EE₂/kg bw/day dose group and vehicle control for
14 alveolar dilatation (85% versus 18%).

15 In the stop-dose BPA treatments, there were no statistically significant increased lesion
16 incidences in BPA dose groups relative to vehicle controls, although multiple cases of decreased
17 incidences in BPA groups relative to vehicle were observed (Table 57).

18 **Uterus, neoplastic lesions**

19 Stromal polyps were found in interim and terminal females and their incidences are shown for
20 continuous BPA and EE₂ and stop-dose BPA in **Table 58**, Table 59, and Table 60, respectively.

21 There was a significant dose trend in the interim sacrifice females treated continuously with BPA
22 (**Table 58**). The incidence for the vehicle control group was 1/23 (4%) compared to 3/20 (15%)
23 for the 2,500 µg BPA/kg bw/day group and 3/24 (12%) for the 25,000 µg BPA/kg bw/day group,

1 but these differences were not statistically significant. This trend was not observed in the
2 terminal sacrifice animals.

3 There were no significant effects of continuous EE₂ treatment (Table 59).

4 In the stop-dose terminal females, the vehicle control incidence of stromal polyps was 14%, and
5 a negative trend was observed along with a reduced incidence in the 25,000 µg BPA/kg bw/day
6 dose group relative to the vehicle control (14% versus 2%, Table 60). There were no other
7 statistically significant neoplastic effects observed in interim or terminal sacrifice BPA
8 continuous or stop-dose treatments in the uterus.

9 **Uterus, non-neoplastic lesions**

10 Non-neoplastic lesions in the uteri of interim and terminal sacrifice females for continuous BPA
11 and EE₂ and stop-dose BPA treatments are shown in Table 61, Table 62, and Table 63,
12 respectively.

13 In interim sacrifice continuous-dose BPA females, there was a significant dose trend for
14 apoptosis in the luminal epithelial cells of the endometrium for all statistical analyses applied,
15 with the incidence in the 25,000 µg BPA/kg bw/day dose group significantly higher than the
16 vehicle controls (38% versus 9%, Table 61). Endometrial hyperplasia was significantly increased
17 in the interim continuous-dose 2.5 and 250 µg BPA/kg bw/day dose groups (RTE test only, 32%
18 versus 9% and 29% versus 9%, respectively). It should be noted that the incidence of
19 endometrial hyperplasia in the interim sacrifice stop-dose vehicle controls was 30% (Table 63).
20 There were also significant dose trends for squamous metaplasia and dilatation of the lumen in
21 the interim and terminal sacrifice continuous-dose BPA females, respectively, with no significant
22 pairwise comparisons for any dose group to vehicle controls (Table 61).

1 In the continuous EE₂-treated interim sacrifice females, there were increased trends and
2 significant pairwise comparisons of the 0.5 µg EE₂/kg bw/day dose group to the vehicle control
3 detected in all statistical tests applied for uterine apoptosis (69% versus 9%), cystic endometrial
4 hyperplasia (54% versus 22%), and squamous metaplasia (54% versus 4%) (Table 62). In the
5 terminal animals, a trend was detected for squamous metaplasia in both the Poly-3 and JT/SW
6 tests (incidences of 4%, 8%, and 15% in the vehicle control, low and high EE₂ dose groups,
7 respectively).

8 In the stop-dose females, the incidence of apoptosis in the 25,000 µg BPA/kg bw/day dose group
9 was higher than that in vehicle controls (27% versus 10%), but this difference was not
10 statistically significant (Table 63). In stop-dose BPA treated females, there was a significant
11 increase in cystic endometrial hyperplasia relative to vehicle controls in the 25,000 µg BPA/kg
12 bw/day dose group (32% versus 10%, JT/SW and RTE tests) at interim sacrifice, while in the
13 terminal sacrifice females there was a significant dose trend and the incidences in the 2,500 and
14 25,000 µg BPA/kg bw/day dose groups were significantly higher than that in the vehicle control
15 (57% and 52%, respectively, versus 37%). It should be noted that the vehicle control incidences
16 of cystic endometrial hyperplasia in the continuous-dose arm of the study were 22% in the
17 interim sacrifice animals and 60% in the terminal sacrifice animals (Table 61). Additional
18 statistically significant differences in BPA stop-dose interim sacrifice animals versus controls
19 were an increased incidence of squamous metaplasia in the 25,000 µg BPA/kg bw/day dose
20 group (JT/SW and RTE tests, 18% versus 0%) and an increased incidence of dilatation of the
21 lumen in the 250 µg BPA/kg bw/day dose group (RTE test only, 18% versus 5%) (Table 63).

1 Ovary, non-neoplastic lesions

2 Non-neoplastic lesions in the interim and terminal sacrifice animals for continuous BPA and EE₂
3 and stop-dose BPA are shown in Table 64, Table 65, and Table 66, respectively.

4 There were no statistically significant BPA treatment-related effects in the continuous-dose
5 terminal sacrifice females. Females in the interim sacrifice continuous BPA dose arm showed
6 significant dose trends for depletion of corpora lutea and interstitial cell hypertrophy (Table 64).

7 For interstitial cell hypertrophy, the 2,500 µg BPA/kg bw/day dose group was significantly
8 different from the vehicle control incidence (RTE test only, 40% versus 17%). The 25,000 µg
9 BPA/kg bw/day dose group had an incidence of 38% ($p = 0.068$).

10 In the ovaries of continuous EE₂-treated interim sacrifice females, there were significant dose
11 trends and significant pairwise comparisons of the 0.5 µg EE₂/kg bw/day dose group to the
12 vehicle control detected in all statistical tests applied for atrophy (100% versus 44%), follicular
13 cysts (100% versus 35%), depleted corpora lutea (100% versus 17%), and interstitial cell
14 hypertrophy (100% versus 17%) (Table 65). In the terminal sacrifice females, there was a 94%
15 incidence of ovarian atrophy in vehicle controls and 100% atrophy in the high EE₂ dose group,
16 with greater severity in the EE₂-treated group that was significantly greater than controls by both
17 tests that incorporate severity scores (JT/SW and RTE, $p < 0.001$ for both).

18 There were no statistically significant BPA treatment-related effects in the stop-dose terminal
19 sacrifice females. In the stop-dose BPA-treated interim sacrifice animals, there was a significant
20 dose trend ($p < 0.001$) for follicular cysts and the 25,000 µg BPA/kg bw/day dose group had a
21 higher incidence than vehicle controls (82% versus 25%) (Table 66). The 2,500 µg BPA/kg
22 bw/day dose group had an incidence of 55% ($p = 0.053$). There were no continuous-dose BPA
23 groups with significantly higher follicular cyst incidence than the vehicle controls (Table 64).

1 Vagina, non-neoplastic lesions

2 Non-neoplastic lesions in the vaginas of interim and terminal sacrifice females for continuous
3 BPA and EE₂ and stop-dose BPA are shown in Table 67, Table 68, and Table 69, respectively.
4 Statistically significant effects were observed in both the interim and terminal sacrifice BPA-
5 treated animals for epithelial hyperplasia for the continuous-dose arm (Table 67). For the interim
6 sacrifice animals, there was a significant dose trend (all statistical tests) and the 25,000 µg
7 BPA/kg bw/day dose group had a significantly higher incidence of hyperplasia than the vehicle
8 controls (JT/SW and RTE tests, 33% versus 13%). The incidence in the 2,500 µg BPA/kg
9 bw/day continuous-dose group was 30% ($p = 0.074$ and 0.067 for the JT/SW and RTE tests,
10 respectively). In the terminal sacrifice females, there was a significant dose trend (all statistical
11 tests) and significant pairwise comparisons to control for 25–25,000 µg BPA/kg bw/day dose
12 groups, although the response was similar across dose groups (incidences of 8% in vehicle
13 controls and 27%, 20%, 22%, and 26% for the 25, 250, 2,500, and 25,000 µg BPA/kg bw/day
14 dose groups, respectively). The Poly-3 and RTE tests were not significant for the 250 µg BPA/kg
15 bw/day dose group.

16 In the vaginas of females treated continuously with EE₂, statistically significant effects were
17 observed in the interim sacrifice animals, but not in terminal sacrifice animals. For all statistical
18 tests applied, there was a dose trend for epithelial hyperplasia and a significant pairwise
19 comparison for the 0.5 µg EE₂/kg bw/day dose group relative to vehicle control (77% versus
20 13%) (Table 68). There was also a trend toward increased epithelial mucification (all statistical
21 tests) and a significant pairwise comparison for the 0.5 µg EE₂/kg bw/day dose group relative to
22 vehicle control (69% versus 44%, JT/SW and RTE tests).

1 In the stop-dose arm, there were no statistically significant BPA effects in the interim or terminal
2 sacrifice females, although the incidence of epithelial hyperplasia was 27% in the 25,000 µg
3 BPA/kg bw/day dose group versus 10% in the vehicle control ($p = 0.064$) in the interim sacrifice
4 animals (Table 69).

5 **Pituitary, non-neoplastic lesions**

6 Non-neoplastic lesions in the pituitaries of interim and terminal sacrifice females for continuous
7 BPA and EE₂ and stop-dose BPA are shown in Table 70, Table 71, and Table 72, respectively.

8 There were no statistically significant treatment effects in the pituitaries of continuous BPA dose
9 arm interim or terminal sacrifice females (Table 70).

10 In the pituitaries of females treated continuously with EE₂, increased lesion incidences relative to
11 vehicle controls were observed in the interim and terminal sacrifice animals (Table 71). In the
12 interim sacrifice animals, there was a significant increasing trend for hyperplasia in the pars
13 distalis and a significant pairwise comparison for the 0.5 µg EE₂/kg bw/day dose group relative
14 to the high incidence in the vehicle control (96% versus 78%, JT/SW and RTE tests). There was
15 also a significant trend for angiectasis in the interim sacrifice females (all statistical tests) and a
16 significant pairwise comparison for the 0.5 µg EE₂/kg bw/day dose group relative to vehicle
17 control (23% versus 4%, JT/SW and RTE tests). Similar trends and pairwise comparisons of the
18 high EE₂ dose group to vehicle control were seen in the terminal sacrifice females (65% versus
19 20%, all statistical tests).

20 There were few statistically significant increased incidences over vehicle control in the stop-dose
21 BPA arm, all indicated only by the RTE test (Table 72). In the interim sacrifice females, there
22 was a slight increase in angiectasis (dilated vasculature) in the 2.5 µg BPA/kg bw/day stop-dose
23 group (9% versus 0%). In the stop-dose terminal sacrifice females, the incidence of hyperplasia

1 in the pars distalis was increased in the 2.5 and 25 µg BPA/kg bw/day stop-dose groups (64%
2 and 71%, respectively, versus 51%) (Table 72). In the terminal sacrifice continuous-dose
3 females, the incidences of the same lesion in the vehicle control, 2.5 and 25 µg BPA/kg bw/day
4 stop-dose groups were 54%, 46%, and 70%, respectively, with no statistically significant
5 comparisons (Table 70).

6 **Heart, non-neoplastic lesions**

7 Cardiomyopathy is a high-incidence background lesion in this rat strain, which increases with
8 aging in both sexes. The lower incidences in females than in males allowed for a better
9 evaluation of any potential treatment effects. Incidences and severity scores for cardiomyopathy
10 in interim and terminal sacrifice females for continuous BPA and EE₂ and stop-dose BPA are
11 shown in Table 73, Table 74, and Table 75, respectively.

12 There were no statistically significant positive effects observed in female rats dosed continuously
13 with BPA (Table 73). In the terminal sacrifice continuous-dose females, the vehicle control
14 incidence of cardiomyopathy was 70%, with a reduced incidence (52%) in the 25 µg BPA/kg
15 bw/day dose group.

16 In females dosed continuously with EE₂, all three statistical tests applied indicated a significant
17 dose trend and a significant increase in the incidence of cardiomyopathy in the 0.5 µg EE₂/kg
18 bw/day dose group relative to vehicle control (65% versus 30%) (Table 74). The JT/SW and
19 RTE tests also detected an increase in the terminal sacrifice females (85% in the 0.5 µg EE₂/kg
20 bw/day dose group versus 70% in the vehicle control group). The RTE test also indicated a
21 significant increasing trend in terminal sacrifice EE₂ females.

22 In stop-dose BPA animals, no effects were observed in interim sacrifice females (Table 75). In
23 terminal sacrifice stop-dose females, the statistical tests that incorporate severity scores (JT/SW

1 and RTE) detected a dose trend, and there were significant pairwise comparisons for 2.5, 250,
2 2,500, and 25,000 µg BPA/kg bw/day dose groups relative to the vehicle control (incidences of
3 74%, 74%, 70%, and 76%, respectively, versus 64%). Like the incidence rates, there was an
4 increase in severity scores in treated groups that was relatively constant across dose groups,
5 mostly due to increased numbers of lesions diagnosed as mild rather than minimal in those dose
6 groups.

7 **Kidney, non-neoplastic lesions**

8 Non-neoplastic lesions in the kidneys of interim and terminal sacrifice females for continuous
9 BPA and EE₂ and stop-dose BPA are shown in Table 76, Table 77, and Table 78, respectively.

10 The incidence of nephropathy was high and highly variable between continuous- and stop-dose
11 vehicle controls (continuous interim and terminal controls, 26% and 38% (Table 76),
12 respectively; stop-dose interim and terminal controls, 50% and 57% (Table 78), respectively).

13 For interim sacrifice females dosed continuously with BPA, the RTE test indicated an increased
14 incidence of nephropathy in the 25 and 2,500 µg BPA/kg bw/day dose groups relative to the
15 vehicle control (50% and 55%, respectively, versus 26%) (Table 76). In the terminal sacrifice
16 females in the continuous BPA dose arm, both the Poly-3 and RTE tests detected increased
17 incidences of nephropathy in the 2.5 µg BPA/kg bw/day group (58% versus 38%). In addition,
18 the JT/SW and RTE tests detected an increased incidence in the 25,000 µg BPA/kg bw/day dose
19 group relative to vehicle control (54% versus 38%). Additional statistically significant effects in
20 the continuous BPA dose groups in the interim sacrifice animals were an increase in renal
21 tubular cysts in the 2.5 µg BPA/kg bw/day group relative to vehicle controls (32% versus 0%,
22 CAFE test; the control incidence in stop-dose group was 20% (Table 78)) and an increased dose
23 trend (all statistical tests applied) of mineralization, with a greater incidence in the 25,000 µg

1 BPA/kg bw/day group relative to the vehicle control group (67% versus 48%, JT/SW and RTE
2 tests only).

3 In females dosed continuously with EE₂, statistically significant increased incidences of kidney
4 lesions relative to vehicle controls were also observed (Table 77). In interim sacrifice females, all
5 statistical tests applied indicated a dose trend and a significant pairwise comparison for the 0.5
6 µg EE₂/kg bw/day dose group relative to vehicle control for nephropathy (58% versus 26%).
7 This trend was also evident in the terminal sacrifice females (all statistical tests applied), and the
8 JT/SW and/or RTE tests indicated significantly increased incidences in both the low and high
9 EE₂ dose groups (54% and 58%, respectively, versus 38%). In the interim female 0.05 µg EE₂/kg
10 bw/day dose group, there was an increase in renal tubule cysts (19% versus 0%) and
11 mineralization (RTE test only, 65% versus 48%).

12 In terminal stop-dose females, renal tubular cysts were increased in the 2.5 µg BPA/kg bw/day
13 group relative to the vehicle control group (43% versus 21%) (Table 78).

14 **Liver, non-neoplastic lesions**

15 Non-neoplastic lesions in the livers of interim and terminal sacrifice females for continuous BPA
16 and EE₂ and stop-dose BPA are shown in Table 79, Table 80, and Table 81, respectively.

17 No statistically significant positive treatment-related effects were observed in continuous BPA or
18 EE₂ treatment groups (Table 79 and Table 80).

19 In the stop-dose BPA treatments in interim sacrifice females, mononuclear cell infiltration
20 showed an increased incidence in several dose groups that was statistically significant for the 2.5
21 (CAFE and RTE tests) and 25,000 µg BPA/kg bw/day stop-dose groups (all statistical tests
22 applied; 46% and 36%, respectively, versus 10%) (Table 81). In the terminal sacrifice females,

1 there was a trend toward an increased incidence of cystic degeneration (all statistical tests
2 applied) and significant pairwise comparisons (JT/SW and RTE tests) for 2,500 and 25,000 µg
3 BPA/kg bw/day stop-dose groups (16% and 15%, respectively, versus 4%).

4 **Thyroid, non-neoplastic lesions**

5 Non-neoplastic lesions in the thyroid glands of interim and terminal sacrifice females for
6 continuous BPA and EE₂ and stop-dose BPA are shown in Table 82, Table 83, and Table 84,
7 respectively.

8 In the continuous-dose BPA terminal sacrifice females, the sole significant effect was an
9 elevated incidence (RTE test only) of follicular cell hyperplasia in the 2.5 µg BPA/kg bw/day
10 dose group relative to the vehicle control (12% versus 2%) (Table 82). The vehicle control
11 incidence of follicular cell hyperplasia in the terminal sacrifice stop-dose vehicle control was 8%
12 (Table 84).

13 The only statistically significant effects in females treated continuously with EE₂ were an
14 elevation (Poly-3 and RTE tests) of the incidence of follicular cell hyperplasia in the 0.05 µg
15 EE₂/kg bw/day dose group relative to vehicle control (15% versus 2%) and an increasing trend
16 for ultimobranchial cysts in terminal sacrifice animals (Table 83).

17 In stop-dose BPA interim sacrifice females, the 2.5 µg BPA/kg bw/day stop-dose group had a
18 higher incidence of C-cell hyperplasia than controls (RTE test only; 73% versus 50%) (Table
19 84). In stop-dose BPA terminal sacrifice females, the incidence of ultimobranchial cysts was
20 elevated in the 250 and 2,500 µg BPA/kg bw/day stop-dose groups relative to vehicle controls
21 (19% and 22%, respectively, versus 4%) (Table 84).

1 Males

2 No statistically significant differences versus control were found regarding organ-specific
3 neoplasms in males in any BPA treatment group. There was an increased trend (*p*-values ranging
4 from 0.002 to 0.009) for systemic lymphoma that presented in multiple organs (liver,
5 dorsal/lateral prostate, bone marrow, spleen, and kidney) in terminal sacrifice animals of the
6 stop-dose BPA arm (Supplemental Appendix XXXII and XXXIV). The incidence of lymphoma
7 in the dorsal/lateral prostate was increased in the 25,000 µg BPA/kg bw/day stop-dose group
8 (9% versus 0%, Supplemental Appendix XXXIV). Selected neoplastic and non-neoplastic
9 lesions are presented below.

10 Epididymis, non-neoplastic lesions

11 Non-neoplastic lesions in the epididymides of interim and terminal sacrifice males for
12 continuous BPA and EE₂ and stop-dose BPA are shown in Table 85, Table 86, and Table 87,
13 respectively.

14 In the continuous-dose BPA interim sacrifice males, there were significant trends (all statistical
15 tests applied) for exfoliated germ cells and lymphocyte infiltration (Table 85). With both lesions,
16 the incidence in the 25,000 µg BPA/kg bw/day dose group was significantly higher than that in
17 the vehicle control group (all statistical tests applied; 27% versus 4% for exfoliated germ cells,
18 23% versus 0% for lymphocyte infiltration). There were no significant BPA treatment effects in
19 the terminal sacrifice males in the continuous BPA dose groups.

20 In males dosed continuously with EE₂, there were increased trends for lymphocyte infiltration in
21 interim (JT/SW and RTE tests) and terminal (RTE test only) sacrifice animals and significant
22 pairwise comparisons for the 0.5 µg EE₂/kg bw/day dose group relative to vehicle control (12%
23 versus 0% for interim animals, 38% versus 20% for terminal animals) (Table 86).

1 The sole statistically significant effect in the stop BPA dose males was an increase in exfoliated
2 germ cells in the 2.5 µg BPA/kg bw/day dose group (RTE test only; 15% versus 0%) (Table 87).

3 **Dorsal/Lateral and ventral prostate, neoplastic and non-neoplastic lesions**

4 Non-neoplastic lesions in the dorsal/lateral prostates of interim and terminal sacrifice males for
5 continuous BPA and EE₂ and stop-dose BPA are shown in Table 88, Table 89, and Table 90,
6 respectively.

7 There were statistically significant increased incidences relative to vehicle controls of
8 lymphocyte infiltration and suppurative inflammation in continuous-dose BPA groups, primarily
9 in the interim sacrifice males (Table 88). Lymphocyte infiltration was increased (RTE test only)
10 in the 2.5 µg BPA/kg bw/day dose group (46% versus 18%). The incidence of suppurative
11 inflammation was increased (RTE and/or JT/SW tests) over a high background (82% in vehicle
12 control) in the 2.5, 250, 2,500, and 25,000 µg BPA/kg bw/day dose groups (91%, 92%, 90%, and
13 86%, respectively) in interim sacrifice continuous-dose males (Table 88). The incidence of
14 suppurative inflammation was increased (Poly-3 test) in the 2.5 µg BPA/kg bw/day dose group
15 in terminal sacrifice animals (96% versus 82%; Table 88).

16 There were no statistically significant differences in lesion incidences in continuous-dose EE₂
17 (Table 89) or stop-dose BPA (Table 90) groups relative to their respective vehicle control group.

18 The incidences of ventral prostate adenomas in terminal sacrifice males were discussed in the
19 narrative pathology report (Supplemental Appendix XXXII) and are shown for continuous BPA
20 and EE₂ and stop-dose BPA in Table 91, Table 92, and Table 93, respectively. The continuous-
21 and stop-dose vehicle control incidences were 12% and 8%, respectively, and there were no
22 treatment-related differences in any exposure group relative to vehicle controls. Regarding non-
23 neoplastic lesions in the ventral prostate, lower incidences of suppurative inflammation were

1 seen in some continuous BPA (Table 94) or EE₂ (Table 95) treatment groups relative to the
2 vehicle control group.

3 **Pituitary, non-neoplastic lesions**

4 Non-neoplastic lesions in the pituitaries of interim and terminal sacrifice males for continuous
5 BPA and EE₂ and stop-dose BPA are shown in Table 97, Table 98, and Table 99, respectively.

6 There were no significant treatment effects in interim sacrifice animals in the continuous (Table
7 97) or stop-dose (Table 99) BPA arms or in the continuous EE₂ treatments (Table 98).

8 In terminal sacrifice males treated continuously with BPA, there was a significant dose trend (all
9 statistical tests applied) for hyperplasia in the pars distalis and a significant increase relative to
10 vehicle controls in the 25 µg BPA/kg bw/day dose group (RTE test only, 40% versus 23%) and
11 the 25,000 µg BPA/kg bw/day dose group (all statistical tests applied, incidence 42% versus
12 23%) (Table 97).

13 In males continuously dosed with EE₂, there was an increased trend (all statistical tests applied)
14 for pars distalis hyperplasia in terminal sacrifice animals and a significant pairwise comparison
15 for the 0.5 µg EE₂/kg bw/day dose group relative to vehicle control (50% versus 23%) (Table
16 98).

17 In stop-dose BPA terminal sacrifice males, the Poly-3 test indicated a significant dose trend for
18 pars distalis hyperplasia and a significant pairwise comparison between the 25,000 µg BPA/kg
19 bw/day dose group and vehicle controls (incidences, 44% versus 26%) (Table 99).

1 **Thyroid, non-neoplastic lesions**

2 Non-neoplastic lesions in the thyroid glands of interim and terminal sacrifice males for
3 continuous BPA and EE₂ and stop-dose BPA are shown in Table 100, Table 101, and Table 102,
4 respectively.

5 There were no statistically significant treatment effects in the thyroid gland of continuous-dose
6 interim sacrifice males (Table 100). In terminal sacrifice males continuously dosed with BPA,
7 there was a significant dose trend (Poly-3 test), and the 2,500 µg BPA/kg bw/day dose group had
8 a higher hyperplasia incidence than vehicle controls (Poly-3 and RTE tests, 46% versus 20%).
9 Follicular cell hyperplasia was increased at 25 µg BPA/kg bw/day relative to the vehicle control
10 group (19% versus 6%, RTE test only).

11 In males continuously dosed with EE₂, the incidence of C-cell hyperplasia was significantly
12 higher in the 0.05 µg EE₂/kg bw/day dose group relative to vehicle control (Poly-3 and RTE
13 tests, 48% versus 20%) (Table 101).

14 There were no statistically significant effects in the thyroid of stop-dose BPA interim or terminal
15 sacrifice males (Table 102)

16 **Parathyroid, non-neoplastic lesions**

17 Non-neoplastic lesions in the parathyroid glands of interim and terminal sacrifice males for
18 continuous BPA and EE₂ and stop-dose BPA are shown in Table 103, Table 104, and Table 105,
19 respectively.

20 Statistically significant treatment effects were seen in the terminal sacrifice animals, but not in
21 the interim sacrifice animals. In the males dosed continuously with BPA, the incidence of
22 hyperplasia in the parathyroid gland was increased at 25 µg BPA/kg bw/day (Poly-3 and RTE

1 tests, 49% versus 22%) and at 250 µg BPA/kg bw/day (RTE test only, 36% versus 22%) (Table
2 103).

3 In males continuously dosed with EE₂, there was a significant dose trend (JT/SW and RTE tests)
4 in parathyroid gland hyperplasia, and the incidence in the 0.5 µg EE₂/kg bw/day dose group was
5 significantly higher than in the vehicle control group (44% versus 22%) (Table 104).

6 In terminal sacrifice BPA stop-dose males, there was a significant dose trend (Poly-3 test) in the
7 incidence of parathyroid gland hyperplasia (Table 105).

8 **Kidney, non-neoplastic lesions**

9 Non-neoplastic lesions in the kidneys of interim and terminal sacrifice males for continuous BPA
10 and EE₂ and stop-dose BPA are shown in Table 106, Table 107, and Table 108, respectively.

11 Hyperplasia of the transitional epithelium of the kidney was significantly increased in terminal
12 sacrifice males relative to vehicle controls in the 25 µg BPA/kg bw/day dose group of the
13 continuous BPA dose arm (Poly-3 and RTE tests, 25% versus 6%) (Table 106).

14 In males continuously dosed with EE₂, there were no observed statistically significant effects in
15 the kidney (Table 107).

16 In the BPA stop-dose males in the terminal sacrifice arm, there was a significant dose trend for
17 hyperplasia of the transitional epithelium of the kidney (Poly-3 test) (Table 108). The only dose
18 group that had an apparent, although not statistically significant, increased incidence relative to
19 controls was the 2,500 µg BPA/kg bw/day dose group (40% versus 24%).

20 **Liver, non-neoplastic lesions**

21 Non-neoplastic lesions in the livers of interim and terminal sacrifice males for continuous BPA
22 and EE₂ and stop-dose BPA are shown in Table 109, Table 110, and Table 111, respectively.

1 In the livers of continuous BPA dose males, statistically significant pairwise comparisons to
2 vehicle controls were noted for fatty change, hepatodiaphragmatic nodules, and mononuclear cell
3 infiltration (Table 109). Two of 20 animals in the 25 µg BPA/kg bw/day interim sacrifice dose
4 group were diagnosed with fatty change; these were the only animals in the interim sacrifice
5 continuous BPA dose group diagnosed with this change, which was statistically significant by
6 the RTE test only. The diagnosis occurred in 4–17% of the terminal sacrifice continuous BPA
7 dose males (vehicle control incidence, 8%), but there was no significant treatment effect.

8 Stop-dose BPA interim sacrifice males had variable incidences (5–10%) of fatty liver diagnosed
9 in some dose groups, but none were significant and there were similar findings in the terminal
10 sacrifice stop-dose males (Table 111).

11 Fatty liver was also diagnosed in the interim sacrifice males treated continuously with EE₂, and
12 there was a significant dose trend (all tests) and a significantly higher incidence in the 0.5 µg
13 EE₂/kg bw/day dose group relative to vehicle control (15% versus 0 %, JT/SW and RTE tests
14 only) (Table 110). Overall, fatty liver appears to be a spontaneous background lesion and not a
15 biologically relevant treatment effect.

16 Hepatodiaphragmatic nodule, growth of the median lobe into the diaphragm, is a congenital
17 background lesion. As with fatty liver, there were variable incidences of this lesion diagnosed
18 across treatment groups in both interim and terminal sacrifice males for continuous and stop-
19 dose BPA and continuous-dose EE₂. In one case, there was a significantly higher incidence
20 (CAFE test) in the interim sacrifice 2,500 µg BPA/kg bw/day continuous-dose group relative to
21 control (21% versus 0%) (Table 109). As with fatty liver, this appears to be a spontaneous
22 background lesion and not a biologically relevant treatment effect.

1 Mononuclear cell infiltration was diagnosed in all dose groups in both interim and terminal
2 sacrifice groups for continuous- and stop-dose BPA and continuous-dose EE₂. Significant
3 increases over control were noted in multiple continuous BPA dose treatment groups (2.5, 250,
4 2,500, and 25,000 µg BPA /kg bw/day) relative to vehicle control in interim sacrifice males
5 (Table 109). The incidence rate of 23% in interim continuous-dose vehicle control (Table 109)
6 appears to be anomalous given the higher incidences in most interim continuous- and stop-dose
7 groups, including in the stop-dose vehicle controls (55% incidence, Table 111). Thus, this
8 apparent increase in mononuclear cell infiltration in continuous BPA dose groups is unlikely to
9 be treatment-related. There were no statistically significant treatment effects in terminal sacrifice
10 BPA-treated males. Mononuclear cell infiltration was increased relative to the vehicle controls in
11 the 0.05 µg EE₂/kg bw/day terminal sacrifice males (85% versus 70%, Table 110).

12

1 Discussion

2 BPA is a high-production-volume chemical to which there is ubiquitous sub-microgram/day
3 human exposure, primarily through the diet. A large body of data has been published on the
4 effects of BPA in *in vitro* and *in vivo* systems, including epidemiological studies investigating
5 the association of early life exposures to BPA with a variety of diseases^{5; 30; 40; 41; 45}. After
6 considering these data, the levels of exposure, and the extent of metabolic inactivation of BPA
7 upon ingestion, most international regulatory agencies have concluded that current non-
8 occupational BPA exposures do not pose a credible risk to humans. However, this conclusion is
9 not without controversy. Given the large body of data available on BPA and the level of human
10 exposure that is prompting the discussion, the present study was designed not as a high dose
11 hazard identification study, but rather to examine a broad dose range from reasonably close to
12 human dietary exposure levels to levels >25,000-fold higher than current estimated aggregate
13 non-occupational exposure.

14 The background diet analyses that were conducted for this study and for previous studies^{9; 14}
15 indicated that commercial rodent diets contain trace levels (low ppb) of BPA. The ingested levels
16 resulting from this dietary background did not lead to measurable levels of BPA or its
17 metabolites in blood or tissues, but the presence of this background places a lower limit on the
18 dose of BPA that can be tested. For the present study, a rejection level of 5 ppb BPA in the diet
19 was established. This level of dietary BPA would have resulted in ingestion of approximately
20 0.25 µg/kg bw/day, a 10-fold lower exposure, on a µg/kg bw/day basis, over the course of the
21 study than the exposure in the lowest chosen BPA dose group of 2.5 µg/kg bw/day. None of the
22 lots of diet used in the study had a background level of BPA ≥5 ppb.

1 Survival in the one-year phase of the study was 82–100%, and there were no effects of BPA on
2 survival of animals in either the one- or two-year phases of the study. However, $\geq 60\%$ of the
3 animals in the two-year phase of the study did not survive to the scheduled terminal sacrifice.
4 Most were removed as moribund for animal welfare considerations and provided a full set of
5 data for evaluation. The Poly-3 test applied for the analysis of the two-year pathology data is
6 adjusted for mortality.

7 Female body weights in the continuous 250 μg BPA/kg bw/day dose group were significantly
8 higher than the mean vehicle control body weights in the final months of the study. There were
9 no other statistically significant body weight differences in pairwise comparisons of BPA dose
10 groups to the vehicle controls. There were few statistically significant effects of BPA treatment,
11 in either the continuous- or stop-dose arms, on clinical chemistry endpoints or organ weights,
12 and these effects could not be clearly defined as treatment-related, but rather were attributed to
13 biological variability.

14 The approach used by the NTP to determine if neoplasms are likely related to treatment has
15 always focused on biological judgment, encompassing a range of factors, rather than on blind
16 application of statistical rules^{22; 28}. This approach to evaluate the histopathology data was
17 followed in the present study for the neoplastic and non-neoplastic lesions. There were relatively
18 few neoplastic lesions that showed potential treatment effects. There were many non-neoplastic
19 lesions in both males and females that were variable across control and BPA treatment levels. To
20 assess these lesions carefully for any potential treatment effects, the CAFE test was applied for
21 lesion incidence in the one-year study, and the survival-adjusted Poly-3 test was used for lesion
22 incidence in the two-year study. The pairwise comparisons conducted as part of these analyses
23 can detect non-monotonic effects, but do not incorporate the severity scores assigned to many of

1 the non-neoplastic lesions during the microscopic evaluation. The JT/SW test, which assumes a
2 monotonically increasing response with increasing dose and is blind to non-monotonic
3 responses, was applied to incorporate severity scores. Because non-monotonic dose responses
4 have been central to the discussion of the effects of BPA and other potential hormonally active
5 agents, another test was applied that incorporates both incidence and severity scores and does not
6 assume monotonicity⁷. This test (RTE) has not been widely used in toxicology studies, although
7 it was used in the previous BPA subchronic study conducted at NCTR¹⁴. Although the use of
8 multiple statistical tests coupled with the multitude of endpoints examined and lack of correction
9 for multiple comparisons can lead to erroneous inferences based on *p*-values alone, the results of
10 all statistical tests are presented in the Results section and Supplemental Appendices XXXIII and
11 XXXIV, primarily to guide the selection of lesions that might require additional evaluation.

12 At the terminal sacrifice of females in the stop-dose BPA study arm, there was a statistically
13 significant increase in the incidence of mammary gland adenocarcinoma (22% versus 6%,
14 $p = 0.016$) and the combination of adenoma/adenocarcinoma (24% versus 8%, $p = 0.018$) in the
15 2.5 µg BPA/kg bw/day dose group. This incidence is marginally higher than the limited data
16 available for historical controls of this rat strain at NCTR utilizing the same diet,^{34; 37} which
17 indicate a background rate of 11–16% for mammary gland adenocarcinoma in two-year-old
18 females. In the continuous-dose BPA study arm, the incidence of adenocarcinoma and the
19 combination of adenoma/adenocarcinoma was 8% and 12%, respectively, in the control group.
20 The incidence in each of the BPA continuous-dose groups varied between 6 and 18% for
21 adenocarcinoma and between 9 and 20% for combined adenoma/adenocarcinoma, none of which
22 was significant.

1 There were no treatment-related non-neoplastic changes in the mammary gland of interim or
2 terminal sacrifice female stop-dose animals. In the interim and terminal BPA continuous-dose
3 arm, there was an increase in atypical foci in the mammary gland at 2.5 µg BPA/kg bw/day (14%
4 versus 0% and 15% versus 4% for the interim and terminal dose group animals, respectively).
5 There was also an increase in ductal dilatation at the interim sacrifice in animals administered 25
6 µg BPA/kg bw/day (32% versus 9%).

7 In contrast to BPA treatments, the reference estrogen EE₂ had a clearly interpretable impact on
8 the females. The high dose (0.5 µg EE₂/kg bw/day) induced an increased incidence of
9 adenocarcinoma (38% versus 8% in controls) and dilatation of ducts and alveoli in the mammary
10 glands of terminal animals. In the mammary glands of interim females, the incidences of lobular
11 hyperplasia and dilatation of ducts were increased in the high EE₂ dose group.

12 The only other statistically significant neoplastic lesion in BPA-treated females was a significant
13 trend ($p = 0.037$) for uterine stromal polyps in the interim sacrifice continuous BPA dose arm
14 animals. There were no significant effects on stromal polyp incidence in the terminal sacrifice
15 continuous-dose animals. Likewise, stromal polyps were not induced in the stop-dose BPA or
16 EE₂ animals.

17 In stop-dose, interim sacrifice BPA females, there was an increase in cystic endometrial
18 hyperplasia and squamous metaplasia in the uterus at 25,000 µg BPA/kg bw/day. An increase in
19 cystic endometrial hyperplasia was also noted at 2,500 and 25,000 µg BPA/kg bw/day in the
20 terminal stop-dose animals. An increase in this lesion was not observed in the continuous-dose
21 BPA animals, but did occur at the interim sacrifice with the high dose EE₂ animals. An increase
22 in squamous metaplasia of the uterus also occurred at the interim sacrifice with the high dose

1 EE₂ animals. Apoptosis in the uterus was increased at 25,000 µg BPA/kg bw/day in the interim
2 continuous-dose animals and in the interim high dose EE₂ animals.

3 There was an increasing trend for vaginal epithelial hyperplasia in interim sacrifice continuous
4 BPA dose females and the incidence was increased at 25,000 µg BPA/kg bw/day, although not in
5 the primary CAFE test pairwise comparison. Vaginal epithelial hyperplasia was increased to
6 nearly the same magnitude at all doses from 25–25,000 µg BPA/kg bw/day, in terminal
7 continuous-dose BPA animals. An increased incidence of vaginal epithelial hyperplasia was also
8 observed with the interim sacrifice 0.5 µg EE₂/kg bw/day dose group, which was accompanied
9 by an increased incidence of epithelial mucification. There was also a significant increase in
10 follicular cysts in the ovary at the interim sacrifice in stop-dose animals administered 25,000 µg
11 BPA/kg bw/day and in animals administered 0.5 µg EE₂/kg bw/day. Likewise, ovarian interstitial
12 cell hypertrophy was increased at the interim sacrifice in continuous-dose animals administered
13 2,500 µg BPA/kg bw/day and in animals administered 0.5 µg EE₂/kg bw/day. Also in the high
14 dose EE₂ females, the estrous cycle was disrupted by the time of evaluation at approximately 16-
15 weeks of age and the one-year sacrifice animals showed multiple organ weight changes and
16 histological changes expected of estrogenic stimulation in the ovary, uterus, and vagina.

17 The incidence of cardiomyopathy was increased in the stop-dose BPA terminal sacrifice females
18 at 2.5, 250, 2,500, and 25,000 µg BPA/kg bw/day, although background incidence was high at
19 this age. Cardiomyopathy was also increased in the high dose EE₂ females, at both the interim
20 and terminal sacrifices.

21 For males, there were no BPA treatment-related neoplastic effects in any organ in stop-dose or
22 continuous-dose interim or terminal sacrifice males. There were also no treatment-related non-
23 neoplastic effects in stop-dose interim or terminal sacrifice males. In continuous-dose, interim

1 sacrifice males, there was an increase in exfoliated germ cells and an increase in lymphocyte
2 infiltration in the epididymis at 25,000 µg BPA/kg bw/day. There was also increased lymphocyte
3 infiltration in the epididymis in interim and terminal sacrifice 0.5 µg EE₂/kg bw/day males. In
4 the terminal sacrifice continuous-and stop-dose males, hyperplasia of the pars distalis of the
5 pituitary was increased at 25,000 µg BPA/kg bw/day; this lesion was also observed in 0.5 µg
6 EE₂/kg bw/day males. Other non-neoplastic lesions in males showed variable increases in some
7 dose groups without a pattern in dose response or across study arms. In the thyroid gland of
8 continuous-dose BPA males at terminal sacrifice, an increase in C-cell hyperplasia was noted at
9 2,500 µg BPA/kg bw/day, with high variability across dose groups and study arms for this
10 endpoint. In addition, TSH levels were not elevated in any BPA dose group. Multiple step
11 sections of the prostate lobes were examined in this study, since prostate has been a target organ
12 identified in the BPA literature. Increases in dorsal/lateral prostate inflammation were variable
13 across a high background in both interim and terminal sacrifice animals, with variable increases
14 in incidence across most BPA dose groups. Inflammation in the aging rat prostate is common
15 and has been associated with increasing prolactin levels¹¹ and there were no treatment-related
16 hyperplasia or other non-neoplastic lesions observed in the prostate lobes.

17 As expected from the previous NCTR BPA subchronic study conducted under identical
18 conditions to those reported here¹⁴, males were less responsive to EE₂ than the females. This is
19 consistent with other rat studies (*e.g.*, Howdeshell et al., 2008; Ryan et al., 2010, and references
20 therein)^{25;43}. The only significant effect observed^{25;43} in males in the NCTR BPA subchronic study at
21 0.5 µg EE₂/kg bw/day was an increase in mammary gland hyperplasia at 90 days of age¹⁴. Our
22 previous work with EE₂ administered in the diet indicated increased mammary gland hyperplasia
23 in young male animals (140 days of age) that ingested a dose approximating the low dose in this

1 study, with an attenuated response in two-year-old animals²⁹. In that study, a 5-fold lower dose
2 (approximately 0.1 µg EE₂/kg bw/day) had no effect on male mammary gland hyperplasia in
3 older animals. The lack of an increase of male mammary hyperplasia by EE₂ in the current study
4 is likely due to the age of animals at examination. In addition, measurements of serum EE₂ levels
5 at approximate maximum concentration (C_{max}) were made at various ages in animals from the
6 NCTR BPA subchronic study¹⁰. Like BPA, serum levels of EE₂ at a given dose level declined
7 with age; that is, peak serum levels after an oral dose of 0.5 µg EE₂/kg bw were ~500 pM, ~10
8 pM, and below the LOD of 5 pM on PND 4, 21, and 80, respectively¹⁰. Thus, in the present
9 study, although the EE₂ dosing was continuous throughout the study, the highest internal
10 exposures occurred in preweaning animals. In the case of the low dose, 0.05 µg EE₂/kg bw/day,
11 serum levels would be expected to be less than 1 pM by the time of weaning.

12 After the present study began, analysis of samples from a separate study conducted under
13 identical conditions (NCTR BPA subchronic study)¹⁴ indicated that vehicle controls housed in
14 the same room as animals dosed with ≥100,000 µg BPA/kg bw/day had blood levels of BPA-
15 glucuronide consistent with the lowest exposure dose in the study, which was 2.5 µg/kg
16 bw/day¹⁰. Thus, evaluation of treatment effects observed in the subchronic study needed to
17 consider the background exposure to BPA. Since clear adverse effects occurred only at doses ≥4
18 times the top dose used in the current study (100,000 µg versus 25,000 µg BPA/kg bw/day) and
19 there were robust effects of the reference estrogen EE₂ at doses of 0.5 and 5 µg/kg bw/day, the
20 background BPA exposure was considered to have no impact on the study^{14; 15}.

21 In the present study, a subset of the animals was housed for a short period early in the study in
22 the same room as animals dosed with 250,000 µg BPA/kg bw/day for a CLARITY-BPA
23 academic grantee study. As discussed in the Statistical Methods section, a conservative approach

1 was taken in this study that assumed all animals that were housed for any period of their lives in
2 the same rooms as the animals dosed with 250,000 µg BPA/kg bw/day were potentially exposed
3 to low levels of BPA. An additional statistical analysis excluding these animals, referred to
4 throughout the text as a sensitivity analysis, was conducted for each endpoint. It was reasoned
5 that if inadvertent exposure of vehicle controls to environmental BPA approximately 10-fold
6 higher (*i.e.*, 2.5 µg BPA/kg bw/day) than had been anticipated was masking robust effects of
7 BPA at the lower end of the dose range, this would be detected with the sensitivity analysis. The
8 results of the sensitivity analyses indicated that any inadvertent BPA exposure early in the study
9 had minimal impact on the conclusions derived from the statistical tests.

10 There were trends and effects of BPA treatment in several female organs, primarily at the two
11 highest doses. In the uterus, cystic endometrial hyperplasia was elevated in interim and terminal
12 sacrifice animals in the stop-dose study arm at 25,000 µg BPA/kg bw/day (interim) and at 2,500
13 and 25,000 µg BPA/kg bw/day (terminal). Uterine squamous metaplasia was also increased in
14 interim stop-dose sacrifice animals at 25,000 µg BPA/kg bw/day, although none of these uterine
15 effects were significant using the CAFE or Poly-3 tests that were considered the primary
16 statistical tests in the study. In continuous-dose interim sacrifice females, there were significant
17 trends for apoptosis in luminal epithelial cells of the endometrium and squamous metaplasia,
18 with a statistically significant elevation of the apoptosis at 25,000 µg BPA/kg bw/day. In the
19 ovary, there were trends in interim sacrifice animals for depletion of corpora lutea and interstitial
20 cell hypertrophy in the continuous-dose arm and a strong trend and increase in follicular cysts at
21 25,000 µg BPA/kg bw/day in stop-dose BPA groups. In continuous-dose BPA groups, there was
22 a trend for increased hyperplasia in vaginal epithelium in interim sacrifice animals with a
23 significant elevation at 25,000 µg BPA/kg bw/day, although not in the CAFE analysis. There

1 was also a trend for vaginal epithelial hyperplasia in continuous-dose BPA terminal sacrifice
2 animals, with significant pairwise comparisons at 25 µg BPA/kg bw/day and above, with the
3 incidences being similar across these dose groups. There were no significant BPA effects on
4 vaginal epithelial hyperplasia in stop-dose animals.

5 An increase in exfoliated germ cells and lymphocyte cellular infiltration in the epididymis at one
6 year in the continuous-dose study arm and hyperplasia in the pars distalis of the pituitary at two
7 years in both continuous- and stop-dose study arms at 25,000 µg BPA/kg bw/day were notable
8 effects in males.

9 In conclusion, in the CLARITY-BPA core study, BPA produced minimal effects that were
10 distinguishable from background in this study, particularly below 25,000 µg BPA/kg bw/day. In
11 contrast, the high EE₂ dose elicited several strong effects in females. Many of the statistically
12 significant BPA effects were not dose-responsive or occurred in only one dose group. There was
13 not a clear pattern of consistent responses in the stop-dose and continuous-dose study arms.

14 Although animals in the stop-dose and continuous-dose arms were handled differently and were
15 not statistically compared, in several cases statistically significant increases in lesion incidences
16 in BPA treatment groups relative to the vehicle control in one study arm were similar to the
17 vehicle control group in the other study arm (see, for example, atypical foci in female mammary
18 gland, the non-neoplastic effects in female and male kidney, female thyroid, and prostate lobes).

19 This suggests that these observed increases within a given study arm were within the range of
20 normal biological variation.

21

1 References

- 2 1. Acconcia F, Pallottini V, Marino M Molecular Mechanisms of Action of BPA. Dose
3 Response. 2015; 13(4). 10.1177/1559325815610582
- 4 2. ANSES. 2013. Opinion of the French Agency for Food, Environmental and Occupational
5 Health & Safety on the assessment of the risks associated with bisphenol A for human health,
6 and on toxicological data and data on the use of bisphenols S, F, M, B, AP, AF and BADGE.
7 <https://www.anses.fr/en/system/files/CHIM2009sa0331Ra-0EN.PDF>.
- 8 3. Bailer AJ, Portier CJ Effects of treatment-induced mortality and tumor-induced mortality on
9 tests for carcinogenicity in small samples. *Biometrics*. 1988; 44(2):417-431.
- 10 4. Bieler GS, Williams RL Ratio estimates, the delta method, and quantal response tests for
11 increased carcinogenicity. *Biometrics*. 1993; 49(3):793-801.
- 12 5. Braun JM Early-life exposure to EDCs: role in childhood obesity and neurodevelopment. *Nat*
13 *Rev Endocrinol*. 2017; 13(3):161-173. 10.1038/nrendo.2016.186
- 14 6. Brown NM, Setchell KDR Animal models impacted by phytoestrogens in commercial chow:
15 implications for pathways induced by hormones. *Laboratory Investigation*. 2001; 81:735-747.
- 16 7. Brunner E, Domhof S, Langer F. *Nonparametric Analysis of Longitudinal Data in Factorial*
17 *Experiments*. New York, New York: John Wiley and Sons; 2002.
- 18 8. Butchbach ME, Edwards JD, Schussler KR, Burghes AH A novel method for oral delivery of
19 drug compounds to the neonatal SMNDelta7 mouse model of spinal muscular atrophy. *J*
20 *Neurosci Methods*. 2007; 161(2):285-290. 10.1016/j.jneumeth.2006.11.002
- 21 9. Camacho L, Lewis SM, Vanlandingham MM, Juliar BE, Olson GR, Patton RE, Gamboa da
22 Costa G, Woodling K, Sepehr E, Bryant MS et al. Comparison of endpoints relevant to toxicity
23 assessments in 3 generations of CD-1 mice fed irradiated natural and purified ingredient diets
24 with varying soy protein and isoflavone contents. *Food Chem Toxicol*. 2016; 94:39-56.
25 10.1016/j.fct.2016.05.014
- 26 10. Churchwell MI, Camacho L, Vanlandingham MM, Twaddle NC, Sepehr E, Delclos KB,
27 Fisher JW, Doerge DR Comparison of life-stage-dependent internal dosimetry for bisphenol A,
28 ethinyl estradiol, a reference estrogen, and endogenous estradiol to test an estrogenic mode of
29 action in Sprague Dawley rats. *Toxicol Sci*. 2014; 139(1):4-20. 10.1093/toxsci/kfu021
- 30 11. Creasy D, Bube A, de Rijk E, Kandori H, Kuwahara M, Masson R, Nolte T, Reams R, Regan
31 K, Rehm S et al. Proliferative and nonproliferative lesions of the rat and mouse male
32 reproductive system. *Toxicol Pathol*. 2012; 40(6 Suppl):40S-121S. 10.1177/0192623312454337
- 33 12. Delclos KB, Bucci TJ, Lomax LG, Latendresse JR, Warbritton A, Weis CC, Newbold RR
34 Effects of dietary genistein exposure during development on male and female CD (Sprague-
35 Dawley) rats. *Reprod Toxicol*. 2001; 15(6):647-663.
- 36 13. Delclos KB, Weis CC, Bucci TJ, Olson G, Mellick P, Sadovova N, Latendresse JR, Thorn B,
37 Newbold RR Overlapping but distinct effects of genistein and ethinyl estradiol (EE(2)) in female

- 1 Sprague-Dawley rats in multigenerational reproductive and chronic toxicity studies. *Reprod*
2 *Toxicol.* 2009; 27(2):117-132. 10.1016/j.reprotox.2008.12.005
- 3 14. Delclos KB, Camacho L, Lewis SM, Vanlandingham MM, Latendresse JR, Olson GR, Davis
4 KJ, Patton RE, Gamboa da Costa G, Woodling KA et al. Toxicity evaluation of bisphenol A
5 administered by gavage to Sprague Dawley rats from gestation day 6 through postnatal day 90.
6 *Toxicol Sci.* 2014; 139(1):174-197. 10.1093/toxsci/kfu022
- 7 15. Delclos KB, Doerge DR Response to Hunt et al., Invalid controls undermine conclusions of
8 FDA studies. *Toxicol Sci.* 2014; 141(3).
- 9 16. Dixon D, Alison R, Bach U, Colman K, Foley GL, Harleman JH, Haworth R, Herbert R,
10 Heuser A, Long G et al. Nonproliferative and proliferative lesions of the rat and mouse female
11 reproductive system. *J Toxicol Pathol.* 2014; 27(3-4 Suppl):1S-107S. 10.1293/tox.27.1S
- 12 17. Doerge DR, Twaddle NC, Vanlandingham M, Fisher JW Pharmacokinetics of bisphenol A in
13 neonatal and adult Sprague-Dawley rats. *Toxicol Appl Pharmacol.* 2010; 247(2):158-165.
14 10.1016/j.taap.2010.06.008
- 15 18. Doerge DR, Vanlandingham M, Twaddle NC, Delclos KB Lactational transfer of bisphenol
16 A in Sprague-Dawley rats. *Toxicol Lett.* 2010; 199(3):372-376. 10.1016/j.toxlet.2010.09.022
- 17 19. Doerge DR, Twaddle NC, Vanlandingham M, Brown RP, Fisher JW Distribution of
18 bisphenol A into tissues of adult, neonatal, and fetal Sprague-Dawley rats. *Toxicol Appl*
19 *Pharmacol.* 2011; 255(3):261-270. 10.1016/j.taap.2011.07.009
- 20 20. European Food Safety Authority E Scientific Opinion on the risks to public health related to
21 the presence of bisphenol A (BPA) in foodstuffs: PART II - Toxicological assessment and risk
22 characterization. *EFSA Journal.* 2015; 13(1):3978. 10.2903/j.efsa.2015.3978
- 23 21. Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, Toppari J, Zoeller RT
24 EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting
25 Chemicals. *Endocr Rev.* 2015; 36(6):E1-E150. 10.1210/er.2015-1010
- 26 22. Haseman JK Use of statistical decision rules for evaluating laboratory animal carcinogenicity
27 studies. *Fund Appl Toxicol.* 1990; 14(637-648).
- 28 23. Health Canada Health Canada's Updated Assessment of Bisphenol A (BPA) Exposure from
29 Food Sources. 2012.
- 30 24. Heindel JJ, Newbold RR, Bucher JR, Camacho L, Delclos KB, Lewis SM, Vanlandingham
31 M, Churchwell MI, Twaddle NC, McLellen M et al. NIEHS/FDA CLARITY-BPA research
32 program update. *Reprod Toxicol.* 2015; 58:33-44. 10.1016/j.reprotox.2015.07.075
- 33 25. Howdeshell KL, Furr J, Lambright CR, Wilson VS, Ryan BC, Gray LE, Jr. Gestational and
34 lactational exposure to ethinyl estradiol, but not bisphenol A, decreases androgen-dependent
35 reproductive organ weights and epididymal sperm abundance in the male long evans hooded rat.
36 *Toxicol Sci.* 2008; 102(2):371-382. 10.1093/toxsci/kfm306
- 37 26. Jonckheere AR A distribution-free k-sample test against ordered alternatives. *Biometrika.*
38 1954; 41:133-145.


- 1 27. Kenward MG, Roger JH Small sample inference for fixed effects from restricted maximum
2 likelihood. *Biometrics*. 1997; 53(3):983-997. 10.2307/2533558
- 3 28. Kissling GE, Haseman JK, Zeiger E Proper interpretation of chronic toxicity studies and their
4 statistics: A critique of "Which level of evidence does the US National Toxicology Program
5 provide? Statistical considerations using the Technical Report 578 on Ginkgo biloba as an
6 example". *Toxicol Lett*. 2015; 237(2):161-164. 10.1016/j.toxlet.2014.09.016
- 7 29. Latendresse JR, Bucci TJ, Olson G, Mellick P, Weis CC, Thorn B, Newbold RR, Delclos KB
8 Genistein and ethinyl estradiol dietary exposure in multigenerational and chronic studies induce
9 similar proliferative lesions in mammary gland of male Sprague-Dawley rats. *Reprod Toxicol*.
10 2009; 28(3):342-353. 10.1016/j.reprotox.2009.04.006
- 11 30. Le Corre L, Besnard P, Chagnon MC BPA, an energy balance disruptor. *Crit Rev Food Sci
12 Nutr*. 2015; 55(6):769-777. 10.1080/10408398.2012.678421
- 13 31. Lewis SM, Lee FW, Ali AA, Allaben WT, Weis CC, Leakey JE Modifying a displacement
14 pump for oral gavage dosing of solution and suspension preparations to adult and neonatal mice.
15 *Lab Anim (NY)*. 2010; 39(5):149-154. 10.1038/labani0510-149
- 16 32. Nadal A, Fuentes E, Ripoll C, Villar-Pazos S, Castellano-Munoz M, Soriano S, Martinez-
17 Pinna J, Quesada I, Alonso-Magdalena P Extranuclear-initiated estrogenic actions of endocrine
18 disrupting chemicals: Is there toxicology beyond paracelsus? *J Steroid Biochem Mol Biol*. 2018;
19 176:16-22. 10.1016/j.jsbmb.2017.01.014
- 20 33. NTP (National Toxicology Program). Carcinogenesis Bioassay of Bisphenol A (CAS No. 80-
21 05-7) in F344 Rats and B6C3F1 Mice (Feed Study). *Natl Toxicol Program Tech Rep Ser*. 1982;
22 215:1-116.
- 23 34. NTP (National Toxicology Program). Toxicology and carcinogenesis studies of genistein
24 (Cas No. 446-72-0) in Sprague-Dawley rats (feed study). *Natl Toxicol Program Tech Rep Ser*.
25 2008; (545):1-240.
- 26 35. NTP (National Toxicology Program). Multigenerational reproductive study of genistein (Cas
27 No. 446-72-0) in Sprague-Dawley rats (feed study). *Natl Toxicol Program Tech Rep Ser*. 2008;
28 (539):1-266.
- 29 36. NTP (National Toxicology Program). Multigenerational reproductive toxicology study of
30 ethinyl estradiol (CAS No. 57-63-6) in Sprague-Dawley rats. *Natl Toxicol Program Tech Rep
31 Ser*. 2010; (547):1-312.
- 32 37. NTP (National Toxicology Program). Toxicology and carcinogenesis study of ethinyl
33 estradiol (CAS No. 57-63-6) in Sprague-Dawley rats (feed study). *Natl Toxicol Program Tech
34 Rep Ser*. 2010; (548):1-210.
- 35 38. OEHHA Proposition 65: Bisphenol A listed as Known to the State of California to Cause
36 Reproductive Toxicity. 2015.
- 37 39. Peddada SD, Kissling GE A survival-adjusted quantal-response test for analysis of tumor
38 incidence rates in animal carcinogenicity studies. *Environmental Health Perspectives*. 2005;
39 114(4):537-541. 10.1289/ehp.8590

- 1 40. Peretz J, Vrooman L, Ricke WA, Hunt PA, Ehrlich S, Hauser R, Padmanabhan V, Taylor
2 HS, Swan SH, VandeVoort CA et al. Bisphenol A and reproductive health: update of
3 experimental and human evidence, 2007-2013. *Environ Health Perspect.* 2014; 122(8):775-786.
4 10.1289/ehp.1307728
- 5 41. Rochester JR Bisphenol A and human health: a review of the literature. *Reprod Toxicol.*
6 2013; 42:132-155. 10.1016/j.reprotox.2013.08.008
- 7 42. Rudmann D, Cardiff R, Chouinard L, Goodman D, Kuttler K, Marxfeld H, Molinolo A,
8 Treumann S, Yoshizawa K, Inhand Mammary ZsP et al. Proliferative and nonproliferative
9 lesions of the rat and mouse mammary, Zymbal's, preputial, and clitoral glands. *Toxicol Pathol.*
10 2012; 40(6 Suppl):7S-39S. 10.1177/0192623312454242
- 11 43. Ryan BC, Hotchkiss AK, Crofton KM, Gray LE, Jr. In utero and lactational exposure to
12 bisphenol A, in contrast to ethinyl estradiol, does not alter sexually dimorphic behavior, puberty,
13 fertility, and anatomy of female LE rats. *Toxicol Sci.* 2010; 114(1):133-148.
14 10.1093/toxsci/kfp266
- 15 44. Schug TT, Heindel JJ, Camacho L, Delclos KB, Howard P, Johnson AF, Aungst J, Keefe D,
16 Newbold R, Walker NJ et al. A new approach to synergize academic and guideline-compliant
17 research: the CLARITY-BPA research program. *Reprod Toxicol.* 2013; 40:35-40.
18 10.1016/j.reprotox.2013.05.010
- 19 45. Seachrist DD, Bonk KW, Ho SM, Prins GS, Soto AM, Keri RA A review of the carcinogenic
20 potential of bisphenol A. *Reprod Toxicol.* 2016; 59:167-182. 10.1016/j.reprotox.2015.09.006
- 21 46. Shirley E A non-parametric equivalent of Williams' test for contrasting increasing dose levels
22 of a treatment. *Biometrics.* 1977; 33:386-389.
- 23 47. Terpstra TJ The asymptotic normality and consistency of Kendall's test against trend when
24 ties are present in one ranking. *Indagationes Mathematicae.* 1952; 14:327-333.
- 25 48. Thigpen JE, Setchell KDR, Saunders HE, Haseman JK, Grant MG, Forsythe DB Selecting
26 the appropriate rodent diet for endocrine disruptor research and testing studies. *ILAR Journal.*
27 2004; 45(4):401-416.
- 28 49. Thigpen JE, Setchell KD, Padilla-Banks E, Haseman JK, Saunders HE, Caviness GF,
29 Kissling GE, Grant MG, Forsythe DB Variations in phytoestrogen content between different mill
30 dates of the same diet produces significant differences in the time of vaginal opening in CD-1
31 mice and F344 rats but not in CD Sprague-Dawley rats. *Environ Health Perspect.* 2007;
32 115(12):1717-1726. *Environmental health perspectives.* 10.1289/ehp.10165
- 33 50. Thigpen JE, Setchell KDR, Kissling GE, Locklear J, Caviness GF, Whiteside T, Belcher SM,
34 Brown NM, Collins BJ, Lih FB et al. The estrogenic content of rodent diets, bedding, cages, and
35 water bottles and its effect on bisphenol A studies. *Journal of the American Association for*
36 *Laboratory Animal Science.* 2013; 52(2):130-141.
- 37 51. Twaddle NC, Churchwell MI, Newbold RR, Delclos KB, Doerge DR Determination using
38 liquid-chromatography-electrospray tandem mass spectroscopy of ethinylestradiol serum

- 1 pharmacokinetics in adult Sprague-Dawley rats. *J Chromatogr B Analyt Technol Biomed Life*
2 *Sci.* 2003; 793(2):309-315.
- 3 52. Twaddle NC, Churchwell MI, Vanlandingham M, Doerge DR Quantification of deuterated
4 bisphenol A in serum, tissues, and excreta from adult Sprague-Dawley rats using liquid
5 chromatography with tandem mass spectrometry. *Rapid Commun Mass Spectrom.* 2010;
6 24(20):3011-3020. 10.1002/rcm.4733
- 7 53. Tyl RW, Myers CB, Marr MC, Thomas BF, Keimowitz AR, Brine DR, Veselica MM, Fail
8 PA, Chang TY, Seely JC et al. Three-generation reproductive toxicity study of dietary bisphenol
9 A in CD Sprague-Dawley rats. *Toxicol Sci.* 2002; 68(1):121-146.
- 10 54. Tyl RW, Myers CB, Marr MC, Sloan CS, Castillo NP, Veselica MM, Seely JC, Dimond SS,
11 Van Miller JP, Shiotsuka RN et al. Two-generation reproductive toxicity study of dietary
12 bisphenol A in CD-1 (Swiss) mice. *Toxicol Sci.* 2008; 104(2):362-384.
- 13 55. U.S. FDA (U.S. Food and Drug Administration). 2014 Updated safety assessment of
14 bisphenol A (BPA) for use in food contact applications. 2014.
15 <https://www.fda.gov/downloads/NewsEvents/PublicHealthFocus/UCM424266.pdf>.
- 16 56. U.S. FDA (U.S. Food and Drug Administration). Final report for the review of literature and
17 data on BPA. 2014.
18 [https://www.fda.gov/downloads/Food/IngredientsPackagingLabeling/FoodAdditivesIngredients/
19 UCM424011.pdf](https://www.fda.gov/downloads/Food/IngredientsPackagingLabeling/FoodAdditivesIngredients/UCM424011.pdf).
- 20 57. Villar-Pazos S, Martinez-Pinna J, Castellano-Munoz M, Alonso-Magdalena P, Marroqui L,
21 Quesada I, Gustafsson JA, Nadal A Molecular mechanisms involved in the non-monotonic effect
22 of bisphenol-A on Ca²⁺ entry in mouse pancreatic beta-cells. *Sci Rep.* 2017; 7(1):11770.
23 10.1038/s41598-017-11995-3
- 24 58. Wetherill YB, Akingbemi BT, Kanno J, McLachlan JA, Nadal A, Sonnenschein C, Watson
25 CS, Zoeller RT, Belcher SM In vitro molecular mechanisms of bisphenol A action. *Reprod*
26 *Toxicol.* 2007; 24:183-186.
- 27 59. Williams DA A note on Shirley's nonparametric test for comparing several dose levels with a
28 zero-dose control. *Biometrics.* 1986; 42:183-186.
- 29 60. Yang X, Doerge DR, Teeguarden JG, Fisher JW Development of a physiologically based
30 pharmacokinetic model for assessment of human exposure to bisphenol A. *Toxicol Appl*
31 *Pharmacol.* 2015; 289(3):442-456. 10.1016/j.taap.2015.10.016
- 32 61. Zoeller RT, Brown TR, Doan LL, Gore AC, Skakkebaek NE, Soto AM, Woodruff TJ, Vom
33 Saal FS Endocrine-disrupting chemicals and public health protection: a statement of principles
34 from The Endocrine Society. *Endocrinology.* 2012; 153(9):4097-4110. 10.1210/en.2012-1422


1

2 Year BPA Toxicity Study




2

1 **Figure 1. Scheme for Chronic BPA Toxicity Study Design**




2
3 **Figure 2. Kaplan-Meier Survival Curve for Terminal Sacrifice Female BPA Continuous-Dose Arm (Weeks 4-104). See Table 18 for data**
4 **analysis results.**




1

2 **Figure 3. Kaplan-Meier Survival Curve for Terminal Sacrifice Female EE₂ Continuous-Dose Arm (Weeks 4-104).** See Table 18 for data
3 **analysis results.**




1

2 **Figure 4. Kaplan-Meier Survival Curve for Terminal Sacrifice Female BPA Stop-Dose Arm (Week 4-104).** See Table 19 for data analysis
3 **results.**




1

2 **Figure 5. Kaplan-Meier Survival Curve for Terminal Sacrifice Male BPA Continuous-Dose Arm (Weeks 4-104). See Table 20 for data**
3 **analysis results.**




1

2 **Figure 6. Kaplan-Meier Survival Curve for Terminal Sacrifice Male EE₂ Continuous-Dose Arm (Weeks 4-104). See Table 20 for data**
3 **analysis results.**




1


2 **Figure 7. Kaplan-Meier Survival Curve for Terminal Sacrifice Male BPA Stop-Dose Arm (Week 4-104).** See Table 21 for data analysis
3 **results.**




1
 2 **Figure 8. Body Weight for Interim Sacrifice Female BPA Continuous-Dose Arm. Data tabulated in Table 24.**




1
2 **Figure 9. Body Weight for Interim Sacrifice Female EE₂ Continuous-Dose Arm. Data tabulated in Table 24.**



1
2 **Figure 10. Body Weight for Terminal Sacrifice Female BPA Continuous-Dose Arm. Data tabulated in Table 25.**




1
 2 **Figure 11. Body Weight for Terminal Sacrifice Female EE₂ Continuous-Dose Arm. Data tabulated in Table 25.**




1


2 **Figure 12. Body Weight for Interim Sacrifice Female BPA Stop-Dose Arm. Data tabulated in Table 26.**




1
 2 **Figure 13. Body Weight for Terminal Sacrifice Female BPA Stop-Dose Arm. Data tabulated in Table 27.**




1
2 **Figure 14. Body Weight for Interim Sacrifice Male BPA Continuous-Dose Arm. Data tabulated in Table 28.**




1
2 **Figure 15. Body Weight for Interim Sacrifice Male EE₂ Continuous-Dose Arm. Data tabulated in Table 28.**




1
2 **Figure 16. Body Weight for Terminal Sacrifice Male BPA Continuous-Dose Arm. Data tabulated in Table 29.**




1
2 **Figure 17. Body Weight for Terminal Sacrifice Male EE₂ Continuous-Dose Arm. Data tabulated in Table 29.**




1
2 **Figure 18. Body Weight for Interim Sacrifice Male BPA Stop-Dose Arm. Data tabulated in Table 30.**




1
2 **Figure 19. Body Weight for Terminal Sacrifice Male BPA Stop-Dose Arm. Data tabulated in Table 31.**



1
2 **Figure 20. Kaplan-Meier Time to Aberrant Cycling Curve for BPA Continuous-Dose Arm. See Table 36 for data analysis results.**



1
2 **Figure 21. Kaplan-Meier Time to Aberrant Cycling Curve for EE₂ Continuous-Dose Arm. See Table 36 for data analysis results.**



1
2 **Figure 22. Kaplan-Meier Time to Aberrant Cycling Curve for BPA Stop-Dose Arm. See Table 37 for data analysis results.**

1 **Table 2. Experimental Design and Materials and Methods in the Two-Year Chronic Gavage**
 2 **Toxicology Study of Bisphenol A (NCTR E0219001), Including Interim (One-Year) Assessment**

Experimental Design and Materials and Methods	
Study Laboratory	National Center for Toxicological Research (NCTR); Jefferson, AR
Test Article	Bisphenol A (BPA), >99% (CAS #80-05-7), TCI America, Portland, OR [Catalogue #B0494, Lot #6052012, ground to a fine powder by Batelle, Inc., Columbus, OH]
Control Article, Reference Estrogen	Ethinyl estradiol (EE ₂), >98% (CAS #57-63-6), Sigma-Aldrich Corporation, St. Louis, MO [Catalogue #E4876, Lot #071M1492V]
Control Article, Vehicle	Carboxymethylcellulose, sodium salt, Sigma-Aldrich Corporation, St. Louis, MO, [Catalogue #C-5013, Lot #041M0105V] used as a 0.3% (w/w) aqueous solution
Strain and Species	Rats: Sprague-Dawley/CD23/Nctr BR
Animal Source	NCTR breeding colony (Jefferson, AR)
Time Held Before Study	Breeder animals for the study were obtained from the breeding colony at weaning (approximately PND 21) and placed under study conditions (TestDiet low phytoestrogen 5K96 diet, polysulfone rat cages, hardwood chip bedding, glass water bottles with silicone stoppers) until mated at PND 70 – 100 for females and PND 77– 105 for males.
Age When Exposure Began	Sperm- or in situ vaginal plug-positive females were dosed from GD 6 (sperm or plug detection = GD 0)
Date of First Exposure for F ₀ (GD 6)	Mating #1 09/08/2012 Mating #2 10/06/2012 Mating #3 11/03/2012 Mating #4 12/01/2012 Mating #5 12/29/2012
Route of Exposure	Oral gavage (for pups <PND 5, gavage needle did not enter esophagus)
Duration of Exposure	Dams were dosed daily until start of parturition. There was no dosing on the day of birth (PND 0), and pups were dosed directly from PND 1 until PND 21 for stop-dose group animals and from PND 1 until the day prior to termination for continuous-dose group animals
Date of Last Exposure	01/14/2015
Age at Necropsy	Scheduled interim necropsy at 1 year (365 ± 20 days of age) Scheduled terminal necropsy at 2 years (104 ± 3 weeks of age) Moribund and dead animals necropsied on removal
Size of Study Groups	For vehicle and BPA dose groups: 20-26 litters in the interim necropsy groups, and 46 – 50 litters in the terminal necropsy groups For EE ₂ dose groups: 26 litters (interim and terminal necropsy groups)
Method of Animal Allocation	F ₀ females from the NCTR breeding colony were randomly allocated to dose groups prior to mating to give approximately equal mean body weights per dose group. Sires were selected randomly with the specification that there would be no brother/sister or first cousin matings. After the first mating, the numbers of mating pairs assigned to dose groups were adjusted to meet any deficits in pups available in a particular dose group. Pups were randomly culled to a maximum of 5 males and 5 females on PND 1, no fostering was conducted. The minimum litter size for keeping a litter on study was 3 males and 3 females. Up to 3 pups per sex per litter were assigned to the study at weaning; additional pups were assigned to studies conducted by CLARITY-BPA academic investigators and reported elsewhere. The rotating order of assignment of pups of a given sex to the study was as follows: 1) continuous-dose, 2-year sacrifice; 2) stop-dose, 2-year sacrifice; 3) continuous-dose, 1-year sacrifice; 4) continuous-dose, 2-year sacrifice; 5) stop-dose, 2-year sacrifice; and 6) stop-dose, 1-year sacrifice.
Animals per Cage	Pregnant females were housed singly and litters were kept with their dams until weaning at PND 21. Animals were pair housed after weaning in same sex pairs within dose groups. If an animal died or was removed as moribund, the cage mate remained single housed.

CLARITY-BPA Core Study, NTP RR 9

Experimental Design and Materials and Methods	
Method of Animal Identification	Tail tattoo; newborns identified by paw tattoo until tail tattoo identification, which occurred within one week of weaning at PND 21
Microbiological Surveillance	Sentinel animals were maintained in each of the animal rooms and animals were removed for surveillance approximately every three months during room occupancy. Animal room supplies (food, water, and bedding) and swabs from the animal rooms were also evaluated.
Diet	Rodent chow, verified casein diet 10 IF, round pellets, irradiated, 5K96 (TestDiet, Purina Mills, Richmond, IN) [Catalogue #1810069] Fed <i>ad libitum</i>
Water	Millipore-filtered tap water (NCTR well water) via water bottle, available <i>ad libitum</i> . Water samples were screened by the Chemistry Support Group, Division of Biochemical Toxicology, NCTR, as part of the normal surveillance procedures of the NCTR.
Cages	Polysulfone (Ancare Corporation, Bellmore, NY) Changed twice weekly, rotated every two weeks.
Bedding	Hardwood chips (P.J. Murphy, Montville, NJ) Changed weekly Alpha-dri® (Shepherd Specialty Papers, Watertown, TN) was used for animals that developed lower body lesions as recommended by Veterinary Services
Cage Bonnets	Microisolator tops (Ancare Corporation, Bellmore, NY)
Racks	Metal animal cage racks (Allentown Caging Equipment Co., Allentown, NJ). Changed every two weeks and rotated every two weeks.
Animal Room Environment	Temperature: 23° ± 3 °C Relative humidity: 50% ± 20% Room fluorescent light: 12 hours/day (on 6 AM, off 6 PM) Room air changes: at least 10/hour
Exposure Concentrations	Vehicle control (0.3% CMC) BPA: 2.5, 25, 250, 2,500, and 25,000 µg/kg bw/day EE ₂ : 0.05 and 0.5 µg/kg bw/day
Dose administration volume	BPA, EE ₂ , and vehicle were administered at a rate of 5 mL/kg bw/day.
Type and Frequency of Observation	Twice daily morbidity/mortality checks, abnormal clinical observations recorded weekly or when a significant clinical observation was noted. Daily body weights for dams from GD 6 through parturition. Pups weighed daily from PND 1 to PND 21. Pups in continuous-dose arm were weighed daily until PND 90 ± 3 and weekly thereafter. Pups in the stop-dose arm were weighed weekly after weaning. Feed consumption was measured weekly for approximately the first 13 weeks and monthly afterwards. Litter parameters: number of pups alive and dead on day of birth (PND 0); number of pups alive and dead and live litter weight by sex on PND 1. Females (26 animals from 13 randomly selected cages per dose group) were monitored daily for vaginal opening from PND 22. Vaginal smears were collected for 14 consecutive days from these same animals beginning at 16 ± 2 weeks of age. One month after these vaginal smears were completed, the same animals had vaginal smears collected for 5 consecutive days monthly until the animal did not show evidence of cycling (three or more consecutive days of estrus (E, E/D or P/E) or five consecutive days that did not include an E) for two consecutive months.
Method of Sacrifice	Asphyxiation with carbon dioxide
Necropsy (F ₀ Dams)	F ₀ dams that were observed to be sperm-positive or had an <i>in situ</i> vaginal plug observed during mating were removed after litters were weaned, after litters that did not meet study criteria were euthanized, or after GD 26 if no litter was delivered. The uterus was removed and implantation sites were counted.

CLARITY-BPA Core Study, NTP RR 9

Experimental Design and Materials and Methods	
Necropsy (Dead or moribund F ₀ dams and all postweaning F ₁ animals)	Animals underwent a gross examination and complete necropsy as described for interim and terminal sacrifice animals (see below). In addition to tissues designated for processing and/or histopathology in the protocol, the following tissues were examined microscopically to assess possible cause of death in all dead or moribund animals: esophagus, colon, ileum, lung, nose, stomach, trachea, and any gross lesions.
Necropsy (Interim sacrifice, PND 365 ± 20)	Animals were fasted overnight. Animals were anesthetized with carbon dioxide and blood was collected from the retro-orbital sinus prior to euthanasia and complete necropsy. Weighed organs (males): adrenals, brain, epididymides, heart, kidneys, liver, pituitary (after 48-hour fixation), seminal vesicles with coagulating gland, spleen, testes, thymus, thyroid with parathyroid (after 48-hour fixation), epididymal, and retroperitoneal fat pads. Weighed organs (females): adrenals, brain, heart, kidneys, liver, ovaries (with oviducts), pituitary (after 48-hour fixation), spleen, thymus, thyroid with parathyroid (after 48-hour fixation), uterus (blotted), ovarian and parametrial (combined), and retroperitoneal fat pads.
Hematology (Interim sacrifice, PND 365 ± 20)	The following endpoints were evaluated in an aliquot of whole blood: hematocrit, hemoglobin concentration, erythrocyte, leukocyte, reticulocyte, and platelet counts, leukocyte differential count, mean corpuscular volume, and mean corpuscular hemoglobin.
Clinical Chemistry (Interim sacrifice, PND 365 ± 20)	The following endpoints were measured in serum: total protein, albumin, urea nitrogen, creatinine, alanine aminotransferase, gamma glutamyl transpeptidase, sorbitol dehydrogenase, aspartate aminotransferase, alkaline phosphatase, total bile acids, glucose, cholesterol, triglycerides, insulin, leptin, cardiac troponins T and I, T3, T4, and TSH.
Sperm analysis (Interim sacrifice, PND 365 ± 20)	Testicular spermatid head counts (left testis); epididymal sperm counts, morphology, and motility evaluations (left epididymis).
Necropsy and histopathology (Terminal sacrifice, 104 ± 3 weeks)	Procedures were similar to those used for the interim sacrifice, except that the animals were not fasted, blood was not collected, and there were no hematology, clinical chemistry, sperm, or organ weight data collected.
Histopathology (Interim sacrifice, PND 365 ± 20 and terminal sacrifice, 104 ± 3 weeks)	The following organs, as well as all gross lesions, were evaluated microscopically: <i>Males</i> - adrenals, aorta (thoracic), bone marrow (femur), brain, right epididymis, heart, kidneys, liver, 5 th left mammary gland (inguinal), pancreas, parathyroid, pituitary, prostate (dorsal/lateral and ventral), seminal vesicles with coagulating gland, spleen, right testis, thymus, and thyroid. For the dorsal/lateral prostate, 6 step sections cut at 100 µm intervals were evaluated. Subsets of intermediate sections were collected and stored unstained for potential additional evaluation. <i>Females</i> - adrenals, aorta (thoracic), bone marrow (femur), brain, heart, kidneys, liver, 5 th left mammary gland (inguinal), ovaries, oviduct, pancreas, parathyroid, pituitary, spleen, thymus, thyroid, uterus, and vagina. All tissues, except testes and eyes, were fixed in 10 % NBF and stained with H&E for microscopic evaluation. Testes and eyes were fixed in modified Davidson's fixative and testes were stained with periodic acid-Schiff (PAS) stain. Fixation times for the tissues listed for histopathology, except the brain, were limited to 96 – 120 hours. Brain remained in fixative until processing.
Tissues removed, fixed in 10% NBF, processed to block and stored (Interim sacrifice, PND 365 ± 20 and terminal sacrifice, 104 ± 3 weeks)	Clitoral gland, esophagus, epididymal fat pad, ovarian/parametrial fat pad, retroperitoneal fat pad, Harderian gland, cecum, colon, rectum, duodenum, ileum, jejunum, lung with bronchi, lymph nodes (mandibular and mesenteric), nose, penis, preputial gland, salivary glands, skin, forestomach, glandular stomach, trachea, and urinary bladder.

1 **Table 3. Numbers of F₀ Breeding Pairs Assigned to Study^a**

Matings	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	0.05 EE ₂	0.50 EE ₂	Total
Mating 1	16	16	16 ^b	16	16	16	10	14	120
Mating 2	17	17	17	17	17	17	9	9	120
Mating 3	17	17	17	17	17	17	9	9	120
Mating 4	15	15	17	16	14 ^c	14	13 ^c	14	118
Mating 5	15	16	20	18	15	11	10	15	120
Total, Matings 1-5	80	81	87	84	79	75	51	61	598

2 ^aDoses of BPA and EE₂ are µg/kg bw/day.3 ^bOnly 15 pairs were mated due to the death of a male prior to breeding.4 ^cDue to the deaths of male breeders, one female in each of these groups was mated with a male that had previously mated with a control female.5 **Table 4. Number of Litters Produced Per Mating^a**

Matings	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	0.05 EE ₂	0.50 EE ₂	Total
Mating 1	16	15	8	9	13	12	9	12	95
Mating 2	14	13	10	14	15	16	8	8	98
Mating 3	15	13	13	13	15	16	6	8	99
Mating 4	13	13	13	12	12	11	10	10	94
Mating 5	15	11	17	16	9	10	8	13	99
Total, Matings 1-5	73	65	61	64	64	65	41	51	485

6 ^aDoses of BPA and EE₂ are µg/kg bw/day.7 **Table 5. Number of Litters Contributing Pups to Interim and/or Terminal Assessments^a**

Matings	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	0.05 EE ₂	0.50 EE ₂	Total
Mating 1	16	14	9	7	13	12	6	10	88
Mating 2	13	13	10	14	15	14	7	8	94
Mating 3	15	12	12	11	14	14	4	6	88
Mating 4	12	12	13	11	11	11	8	4	84
Mating 5	15	11	16	16	8	9	2	3	84
Total, Matings 1-5	71	62	60	59	61	60	27	31	438

8 ^aDoses of BPA and EE₂ are µg/kg bw/day.

1 **Table 6. Number of Male and Female Pups Represented in Interim (1-Year) Sacrifice from Each Mating, Continuous-Dose^a**

Continuous-Dose	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	0.05 EE ₂	0.50 EE ₂	Total
Males, Mating 1	6	6	4	2	4	4	6	8	40
Males, Mating 2	4	4	4	6	6	6	6	8	44
Males, Mating 3	4	6	4	4	6	6	4	4	38
Males, Mating 4	6	4	4	4	2	4	8	4	36
Males, Mating 5	2	2	4	8	2	2	2	2	24
Total males, Matings 1-5	22	22	20	24	20	22	26	26	182
Females, Mating 1	8	6	4	4	6	4	6	8	46
Females, Mating 2	5	4	4	6	6	6	6	8	45
Females, Mating 3	6	4	4	4	4	6	4	6	38
Females, Mating 4	2	2	4	4	4	4	8	2	30
Females, Mating 5	2	6	6	6	0	4	2	2	28
Total females, Matings 1-5	23	22	22	24	20	24	26	26	187

2 ^aDoses of BPA and EE₂ are µg/kg bw/day.3 **Table 7. Number of Male and Female Pups Represented in Interim (1 Year) Sacrifice from Each Mating, Stop-Dose^a**

Stop-Dose	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	Total
Males, Mating 1	4	4	2	2	6	6	24
Males, Mating 2	6	4	2	6	6	4	28
Males, Mating 3	6	4	6	4	6	6	32
Males, Mating 4	2	4	6	4	2	4	24
Males, Mating 5	2	4	4	4	0	2	16
Total males, Matings 1-5	20	20	20	19	20	22	121
Females, Mating 1	4	6	2	2	4	6	24
Females, Mating 2	4	6	4	4	6	6	30
Females, Mating 3	6	6	2	4	6	6	30
Females, Mating 4	4	4	6	4	2	4	24
Females, Mating 5	2	0	6	8	2	0	18
Total females, Matings 1-5	20	22	20	22	20	22	126

4 ^aDoses of BPA are µg/kg bw/day.

1 **Table 8. Number of Male and Female Pups Represented in Terminal (2 Year) Sacrifice from Each Mating, Continuous-Dose^a**

Continuous-Dose	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	0.05 EE ₂	0.50 EE ₂	Total
Males, Mating 1	13	12	6	6	10	10	6	10	73
Males, Mating 2	11	10	8	12	12	12	6	8	79
Males, Mating 3	12	10	10	8	12	12	4	4	72
Males, Mating 4	12	8	12	10	8	8	8	2	68
Males, Mating 5	2	8	12	14	8	4	2	2	52
Total males, Matings 1-5	50	48	48	50	50	46	26	26	344
Females, Mating 1	14	12	6	6	10	10	6	10	74
Females, Mating 2	10	10	8	12	12	10	6	8	76
Females, Mating 3	12	10	10	8	12	10	4	4	70
Females, Mating 4	10	8	10	10	8	8	8	2	64
Females, Mating 5	4	8	12	14	8	8	2	2	58
Total females, Matings 1-5	50	48	46	49	50	46	26	26	341

2 ^aDoses of BPA and EE₂ are µg/kg bw/day.3 **Table 9. Number of Male and Female Pups Represented in Terminal (2 Year) Sacrifice from Each Mating, Stop-Dose^a**

Stop-Dose	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	Total
Males, Mating 1	14	12	6	6	10	10	58
Males, Mating 2	10	10	8	12	12	12	64
Males, Mating 3	12	10	10	8	12	12	64
Males, Mating 4	12	8	12	10	10	8	60
Males, Mating 5	2	8	12	14	6	4	46
Total males, Matings 1-5	50	48	48	50	50	46	292
Females, Mating 1	14	12	6	6	10	10	58
Females, Mating 2	10	10	8	12	12	12	64
Females, Mating 3	12	10	10	8	12	12	64
Females, Mating 4	10	10	12	10	10	8	60
Females, Mating 5	4	8	12	14	6	4	48
Total females, Matings 1-5	50	50	48	50	50	46	294

4 ^aDoses of BPA are µg/kg bw/day.

1 **Table 10. Dam Body Weights from Time of Mating to Parturition in Vehicle, BPA, and EE₂ Dose Groups (Mean ± S.E.M.)^a**

Body Weight	Vehicle n = 72	2.5 BPA n = 65	25 BPA n = 61	250 BPA n = 63	2500 BPA n = 63	25000 BPA n = 64	0.05 EE ₂ n = 41	0.5 EE ₂ n = 51
Baseline (GD 0/ GD 1), g	244 ± 3	248 ± 3	248 ± 4	244 ± 3	246 ± 3	252 ± 4	247 ± 4	253 ± 4
GD 6, g	275 ± 3	281 ± 4	278 ± 4	274 ± 4	278 ± 3	283 ± 4	278 ± 5	284 ± 4
Parturition, g	393 ± 4	406 ± 5	397 ± 6	394 ± 5	402 ± 5	396 ± 5	398 ± 6	402 ± 6

2 ^aNumber of dams producing litters given under dose group column headings. Doses of BPA and EE₂ are µg/kg bw/day.

3 Gestational weight at parturition was analyzed separately for the BPA and EE₂ dose groups using ANOCOVA, with terms for treatment group, dam weight at baseline as a
4 covariate, litter size as a covariate, and the interaction between treatment and litter size. Data were collected at baseline on GD 0 or GD 1 and daily from GD 6 to parturition.

5 Gestational weight at parturition was defined as the last dam body weight prior to delivery. Pairwise comparisons of treatment means to the control group were performed using
6 contrasts with Dunnett's adjustment for multiple comparisons. Tests of trend, increasing treatment effect with increasing dose, were performed for the BPA and vehicle control
7 groups only. All tests were performed as two-sided tests at the 0.05 significance level. There were no statistically significant results. There were also no significant treatment
8 effects in the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Materials and Methods, Statistical Methods).

9 Full results of the statistical analyses are found in Supplemental Appendix XVII.

1 **Table 11. Implantation Sites And Litter Parameters For Vehicle, BPA, And EE₂ Dose Groups (Mean ± S.E.M)^a**

Endpoint	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	0.05 EE ₂	0.5 EE ₂
Implantation sites	12.8 ± 0.5 (78)	12.4 ± 0.6 (74)	11.2 ± 0.7 (74)	11.2 ± 0.6 (78)	11.6 ± 0.6 (74)	12.2 ± 0.6 (70)	11.7 ± 0.8 (49)	12.1 ± 0.7 (59)
Litter size ^b	11.8 ± 0.4 (73)	12.6 ± 0.3 (65)	11.9 ± 0.5 (61)	11.6 ± 0.5 (64)	12.3 ± 0.4 (64)	11.5 ± 0.4 (64)	11.8 ± 0.6 (41)	12.2 ± 0.4 (51)
Males ^b	5.8 ± 0.2 (73)	6.4 ± 0.3 (65)	6.2 ± 0.3 (61)	5.7 ± 0.2 (64)	6.2 ± 0.3 (64)	5.5 ± 0.3 (64)	6.1 ± 0.4 (41)	5.8 ± 0.3 (51)
Females ^b	5.8 ± 0.2 (73)	6.0 ± 0.3 (65)	5.6 ± 0.3 (61)	5.7 ± 0.4 (64)	5.8 ± 0.3 (64)	5.8 ± 0.3 (64)	5.4 ± 0.4 (41)	6.1 ± 0.3 (51)
Unsexed ^c	0.2 ± 0.1 (73)	0.2 ± 0.1 (65)	0.1 ± 0 (61)	0.2 ± 0.1 (64)	0.3 ± 0.1 (64)	0.2 ± 0.1 (64)	0.3 ± 0.2 (41)	0.3 ± 0.1 (51)
Born dead	0 ± 0 (73)	0.08 ± 0.05 (65)	0.02 ± 0.02 (61)	0 ± 0 (64)	0.02 ± 0.02 (64)	0.02 ± 0.02 (64)	0 ± 0 (41)	0.04 ± 0.04 (51)
% Males ^d	49.4 ± 1.5 (73)	51.5 ± 2.3 (65)	52.2 ± 2.2 (61)	50.6 ± 2.0 (64)	50.9 ± 1.8 (64)	47.3 ± 2.3 (64)	53.2 ± 2.4 (41)	48.0 ± 2.1 (51)
% Females ^d	49.5 ± 1.5 (73)	47.0 ± 2.3 (65)	47.0 ± 2.2 (61)	47.9 ± 2.1 (64)	46.7 ± 1.7 (64)	51.5 ± 2.3 (64)	44.8 ± 2.2 (41)	49.6 ± 2.1 (51)
% Unsexed	1.1 ± 0.4 (73)	1.6 ± 0.6 (65)	0.8 ± 0.3 (61)	1.5 ± 0.7 (64)	2.3 ± 0.9 (64)	1.1 ± 0.6 (64)	1.9 ± 1.1 (41)	2.4 ± 1.0 (51)
Litter weight, total ^e	78.6 ± 2.3 (73)	80.7 ± 2.6 (62)	80.2 ± 2.8 (61)	75.6 ± 2.9 (64)	78.7 ± 2.4 (63)	75.3 ± 2.6 (64)	76.7 ± 3.9 (39)	76.6 ± 3.3 (50)
Litter weight, males ^e	40.1 ± 1.7 (73)	43.6 ± 2.3 (62)	43.5 ± 2.2 (61)	39.1 ± 1.6 (64)	41.6 ± 1.8 (63)	38.1 ± 2.0 (64)	41.8 ± 2.9 (39)	37.8 ± 2.1 (50)
Litter weight, females ^e	38.5 ± 1.6 (73)	37.2 ± 2.3 (62)	36.7 ± 2.0 (61)	36.4 ± 2.2 (64)	37.0 ± 1.7 (63)	37.2 ± 1.7 (64)	34.9 ± 2.4 (39)	38.9 ± 2.4 (50)
Mean pup weight ^f	7.0 ± 0.1 (73)	6.8 ± 0.1 (62)	7.0 ± 0.1 (61)	6.9 ± 0.1 (64)	6.9 ± 0.1 (63)	7.0 ± 0.1 (64)	6.8 ± 0.1 (39)	6.9 ± 0.2 (50)
Mean male pup weight ^f	7.1 ± 0.1 (73)	7.0 ± 0.1 (62)	7.2 ± 0.1 (61)	7.1 ± 0.1 (64)	7.0 ± 0.1 (63)	7.2 ± 0.1 (64)	7.1 ± 0.1 (39)	7.0 ± 0.2 (50)
Mean female pup weight ^f	6.8 ± 0.1 (73)	6.6 ± 0.1 (62)	6.8 ± 0.1 (61)	6.8 ± 0.1 (64)	6.7 ± 0.1 (63)	6.9 ± 0.1 (64)	6.6 ± 0.1 (39)	6.7 ± 0.2 (50)

2 ^aBPA and EE₂ doses are µg/kg bw/day. Numbers in parentheses are numbers of dams (for implantation sites) or litters from which data were collected. All analyses and
3 adjustments for multiple comparisons were performed separately for the BPA and EE₂ treatments. Dunnett's method was used to adjust for multiple comparisons. Tests of trend,
4 for increasing treatment effect with increasing dose, were performed for the vehicle and BPA groups. All tests were performed as two-sided tests at the 0.05 significance level.
5 There were no statistically significant treatment effects for any endpoint. There were also no significant treatment effects in the sensitivity analysis that excluded all animals that
6 overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Materials and Methods, Statistical Methods). Full results of the analyses are found in Supplemental
7 Appendices XVIII (implantation sites) and XIX (all other endpoints).

8 ^bLitter size (number alive) and numbers of males and females were analyzed using Poisson regression.

9 ^cUnsexed pups (*i.e.*, pups that could not be definitively assigned as male or female) were assigned as males for analysis of sex proportions and of female and male counts.

10 ^dSex proportions were analyzed using logistic regression.

CLARITY-BPA Core Study, NTP RR 9

- 1 Litter weight data (g), across and by sex, were analyzed using contrasts within a one-way ANOVA to test for treatment effects.
- 2 Litter mean pup weights (g) were analyzed using ANOCOVA, with litter size as a covariate, to test for treatment effects.

1 **Table 12. Survival of Female Pups from PND 1 to Weaning in the Vehicle, BPA, and EE₂ Dose**
 2 **Groups^a**

Preweaning Females	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	0.05 EE₂	0.5 EE₂
Number of female pups after PND 1 culling	311	266	259	250	260	244	153	180
Dead	5	11	7	6	2	3	8	5
Missing	3	5	2	5	13	6	5	3
Moribund	1	1	5	4	1	2	2	0
Reallocated ^b	8	8	8	8	8	8	8	8
Pups surviving to weaning	294	241	237	227	236	225	130	164
Percent survival at weaning	95	91	92	91	91	92	85	91
Survival analysis, <i>p</i> -value	0.361 ^c	0.245	0.280	0.245	0.245	0.313	0.005**	0.369

3 ^aBPA and EE₂ doses are µg/kg bw/day. Cox proportional hazard analyses were performed separately for the BPA and EE₂ dose
 4 groups. Female pups removed as dead or moribund were considered uncensored, while pups surviving to weaning were
 5 considered censored. Multiple comparisons of treatments to the vehicle control were adjusted using Holm's method. All tests
 6 were performed as two-sided tests at the 0.05 significance level. Statistically significant effects are indicated by asterisks (**,
 7 *p* < 0.01). There were no additional significant treatment effects in the sensitivity analysis that excluded all animals that
 8 overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Materials and Methods, Statistical Methods). The full
 9 statistical report for this endpoint is found in Supplemental Appendix XX.

10 ^bThe reallocated pups were removed by design on PND 15 for the associated CLARITY-BPA study that will be reported
 11 separately.

12 ^cA test of dose trend, increasing treatment effect with increasing dose, was performed for vehicle and BPA groups only. The *p*-
 13 value for the trend analysis is given in the vehicle column; *p*-values in BPA and EE₂ columns are for pairwise comparisons to the
 14 vehicle control.

1 **Table 13. Survival of Male Pups from PND 1 to Weaning in the Vehicle, BPA, and EE₂ Dose**
 2 **Groups^a**

Preweaning Males	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	0.05 EE₂	0.5 EE₂
Number of male pups after PND 1 culling	338	300	281	292	292	275	156	208
Dead	5	1	4	8	4	2	8	5
Missing	9	14	5	9	6	1	5	6
Moribund	1	3	1	0	1	4	2	0
Reallocated ^b	8	8	8	8	8	8	8	8
Pups surviving to weaning	315	274	263	267	273	260	141	197
Percent survival at weaning	93	91	94	91	93	95	90	95
Survival analysis, <i>p</i> -value	0.143 ^c	1.000	1.000	1.000	1.000	1.000	0.062	0.656

3 ^aBPA and EE₂ doses are µg/kg bw/day. Cox proportional hazard analyses were performed separately for the BPA and EE₂ dose
 4 groups. Male pups removed as dead or moribund were considered uncensored, while pups surviving to weaning were considered
 5 censored. Multiple comparisons of treatments to the vehicle control were adjusted using Holm's method. All tests were
 6 performed as two-sided tests at the 0.05 significance level. There were no statistically significant treatment effects. There were
 7 also no significant treatment effects in the sensitivity analysis that excluded all animals that overlapped with animals treated with
 8 250,000 µg BPA/kg bw/day (see Materials and Methods, Statistical Methods). The full statistical report for this endpoint is found
 9 in Supplemental Appendix XX.

10 ^bThe reallocated pups were removed by design on PND 15 for the associated CLARITY-BPA study that will be reported
 11 separately.

12 ^cA test of dose trend, increasing treatment effect with increasing dose, was performed for vehicle and BPA groups only. The *p*-
 13 value for the trend analysis is given in the vehicle column; *p*-values in BPA and EE₂ columns are for pairwise comparisons to the
 14 vehicle control.

1 **Table 14. Survival of Female Pups from Weaning to Interim (1 Year) Sacrifice in the Continuous**
 2 **Vehicle, BPA, and EE₂ Dose Groups^a**

Interim Sacrifice Females	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	0.05 EE₂	0.50 EE₂
Females initially allocated for interim evaluation	23	22	22	24	20	24	26	26
Moribund	1 ^b	0	0	2 ^d	0	0	1 ^e	0
Natural deaths	1 ^b	0	1 ^c	0	0	0	1 ^e	0
Animals surviving to scheduled termination	21	22	21	22	20	24	24	26
Percent survival at end of study	91	100	95	92	100	100	92	100
Survival analysis, <i>p</i> -value	0.470 ^f	1.000	1.000	1.000	1.000	1.000	0.921	0.605

3 ^aBPA and EE₂ doses are µg/kg bw/day. Cox proportional hazard analyses were performed separately for the BPA and EE₂ dose
 4 groups for all female pups assigned to the continuously dosed interim sacrifice group at weaning. Female pups removed as dead
 5 or moribund were considered uncensored, while animals surviving to scheduled removal were considered censored. Since there
 6 was 100% survival in both BPA and EE₂ dose groups, a modified analysis in which one was added to the number of all
 7 uncensored observations was conducted to allow estimability. Multiple comparisons of treatments to the vehicle control were
 8 adjusted using Holm's method. All tests were performed as two-sided tests at the 0.05 significance level. There were no
 9 statistically significant treatment effects. There were also no significant treatment effects in the sensitivity analysis that excluded
 10 all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Materials and Methods, Statistical
 11 Methods). The full statistical report for this endpoint is found in Supplemental Appendix XXI.

12 ^bOne animal had nephropathy, while the cause of death/morbidity of the second animal was uncertain (Subappendix VI in
 13 Supplemental Appendix XXXII).

14 ^cNephropathy was the cause of death (Subappendix VI in Supplemental Appendix XXXII).

15 ^dNephropathy was the cause of death/morbidity in one animal and a mammary fibroadenoma in the second animal (Subappendix
 16 VI in Supplemental Appendix XXXII).

17 ^eOne animal had a mammary adenocarcinoma, while the cause of death/morbidity in the second animal was uncertain
 18 (Subappendix VI in Supplemental Appendix XXXII).

19 ^fA test of dose trend, increasing treatment effect with increasing dose, was performed for vehicle and BPA groups only. The *p*-
 20 value for the trend analysis is given in the vehicle column; *p*-values in BPA and EE₂ columns are for pairwise comparisons to the
 21 vehicle control.

1 **Table 15. Survival of Female Pups from Weaning to Interim (1 Year) Sacrifice in the Stop-Dose**
 2 **Vehicle and BPA Groups^a**

Interim Sacrifice Females	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Females initially allocated for interim evaluation	20	22	20	22	20	22
Moribund	0	0	0	0	0	2 ^b
Natural deaths	0	0	0	0	0	0
Animals surviving to scheduled termination	20	22	20	22	20	20
Percent survival at end of study	100	100	100	100	100	91
Survival analysis, <i>p</i> -value	0.455 ^c	1.000	1.000	1.000	1.000	1.000

3 ^aBPA doses are µg/kg bw/day. Cox proportional hazard analyses were performed for the BPA dose groups for all female pups
 4 assigned to the stop-dose interim sacrifice group at weaning. Female pups removed as dead or moribund were considered
 5 uncensored, while animals surviving to scheduled removal were considered censored. Since there was 100% survival in most
 6 dose groups, a modified analysis in which one was added to the number of all uncensored observations was conducted to allow
 7 estimability. Multiple comparisons of treatments to the vehicle control were adjusted using Holm's method. All tests were
 8 performed as two-sided tests at the 0.05 significance level. There were no statistically significant treatment effects. There were
 9 also no significant treatment effects in the sensitivity analysis that excluded all animals that overlapped with animals treated with
 10 250,000 µg BPA/kg bw/day (see Materials and Methods, Statistical Methods). The full statistical report for this endpoint is found
 11 in Supplemental Appendix XXI.

12 ^bOne animal had nephropathy and the second animal had a malignant meningioma of the cerebellum as the primary cause of
 13 morbidity/death (Subappendix VI in Supplemental Appendix XXXII).

14 ^cA test of dose trend, increasing treatment effect with increasing dose, was performed and the *p*-value for the trend analysis is
 15 given in the vehicle column; *p*-values in BPA columns are for pairwise comparisons to the vehicle control.

1 **Table 16. Survival of Male Pups from Weaning to Interim (1 Year) Sacrifice in the Continuous**
 2 **Vehicle, BPA, and EE₂ Dose Groups^a**

Interim Sacrifice Males	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	0.05 EE₂	0.5 EE₂
Males initially allocated for interim evaluation	22	22	20	24	20	22	26	26
Moribund	4 ^b	0	1 ^c	0	0	0	2 ^e	0
Natural deaths	0	0	1 ^c	0	2 ^d	1 ^d	2 ^e	3 ^d
Animals surviving to scheduled termination	18	22	18	24	18	21	22	23
Percent survival at end of study	82	100	90	100	90	95	85	88
Survival analysis, <i>p</i> -value	0.666 ^f	0.597	1.000	0.597	1.000	0.789	1.000	1.000

3 ^aBPA and EE₂ doses are µg/kg bw/day. Cox proportional hazard analyses were performed separately for the BPA and EE₂ dose
 4 groups for all male pups assigned to the continuously dosed interim sacrifice group at weaning. Animals removed as dead or
 5 moribund were considered uncensored, while animals surviving to scheduled removal were considered censored. Since there was
 6 100% survival in some of the BPA dose groups, a modified analysis in which one was added to the number of all uncensored
 7 observations was conducted to allow estimability. Multiple comparisons of treatments to the vehicle control were adjusted using
 8 Holm's method. All tests were performed as two-sided tests at the 0.05 significance level. There were no statistically significant
 9 treatment effects. There were also no significant treatment effects in the sensitivity analysis that excluded all animals that
 10 overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Materials and Methods, Statistical Methods). The full
 11 statistical report for this endpoint is found in Supplemental Appendix XXI.

12 ^bTwo animals had malignant lymphomas in their spleens, while the cause of death could not be determined for 2 animals
 13 (Subappendix VI in Supplemental Appendix XXXII).

14 ^cOne animal had a perforated esophagus and another had a hemorrhaged lung (Subappendix VI in Supplemental Appendix
 15 XXXII).

16 ^dCause of death/morbidity was uncertain (Subappendix VI in Supplemental Appendix XXXII).

17 ^eOne animal had nephropathy, one animal was removed due to an abscessed skin wound, and the cause of death/morbidity for
 18 two animals was uncertain (Subappendix VI in Supplemental Appendix XXXII).

19 ^fA test of dose trend, increasing treatment effect with increasing dose, was performed for vehicle and BPA groups only. The *p*-
 20 value for the trend analysis is given in the vehicle column; *p*-values in BPA and EE₂ columns are for pairwise comparisons to the
 21 vehicle control.

1 **Table 17. Survival of Male Pups from Weaning to Interim (1 Year) Sacrifice in the Stop-Dose**
 2 **Vehicle and BPA Groups^a**

Interim Sacrifice Males	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Males initially allocated for interim evaluation	20	20	20	19	20	22
Moribund	0	0	0	0	0	0
Natural deaths	0	0	1 ^b	0	0	0
Animals surviving to scheduled termination	20	20	19	19	20	22
Percent survival at end of study	100	100	95	100	100	100
Survival analysis, <i>p</i> -value	0.927 ^c	1.000	1.000	1.000	1.000	1.000

3 ^aBPA doses are µg/kg bw/day. Cox proportional hazard analyses were performed for the BPA dose groups for all male pups
 4 assigned to the stop-dose interim sacrifice group at weaning. Animals removed as dead or moribund were considered uncensored,
 5 while animals surviving to scheduled removal were considered censored. Since there was 100% survival in some dose groups, a
 6 modified analysis in which one was added to the number of all uncensored observations was conducted to allow estimability.
 7 Multiple comparisons of treatments to the vehicle control were adjusted using Holm's method. All tests were performed as two-
 8 sided tests at the 0.05 significance level. There were no statistically significant treatment effects. There were also no significant
 9 treatment effects in the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg
 10 BPA/kg bw/day (see Materials and Methods, Statistical Methods). The full statistical report for this endpoint is found in
 11 Supplemental Appendix XXI.

12 ^bCause of death/morbidity was uncertain (Subappendix VI in Supplemental Appendix XXXII).

13 ^cA test of dose trend, increasing treatment effect with increasing dose, was performed and the *p*-value for the trend analysis is
 14 given in the vehicle column; *p*-values in BPA columns are for pairwise comparisons to the vehicle control.

1 **Table 18. Survival of Female Pups from Weaning to Terminal (2 Year) Sacrifice in the Continuous**
 2 **Vehicle, BPA, and EE₂ Dose Groups^a**

Terminal Sacrifice Females	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	0.05 EE₂	0.50 EE₂
Females initially allocated for terminal evaluation	50	48	46	49	50	46	26	26
Moribund	28	28	31	31	33	35	18	18
Natural deaths	6	1	1	5	7	3	1	4
Animals surviving to scheduled termination	16	19	14	13	10	8	7	4
Percent survival at end of study	32	40	30	27	20	17	27	15
Survival analysis, <i>p</i> -value	0.071 ^b	1.000	1.000	1.000	0.502	1.000	0.396	0.188

3 ^aBPA and EE₂ doses are µg/kg bw/day. Cox proportional hazard analyses were performed separately for the BPA and EE₂ dose
 4 groups for all female pups assigned to the continuously dosed terminal sacrifice group at weaning. Animals removed as dead or
 5 moribund were considered uncensored, while animals surviving to scheduled removal were considered censored. Multiple
 6 comparisons of treatments to the vehicle control were adjusted using Holm's method. All tests were performed as two-sided tests
 7 at the 0.05 significance level. There were no statistically significant treatment effects. There were also no significant treatment
 8 effects in the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day
 9 (see Materials and Methods, Statistical Methods). The full statistical report for this endpoint is found in Supplemental Appendix
 10 XXII.

11 ^bA test of dose trend, increasing treatment effect with increasing dose, was performed for vehicle and BPA groups only. The *p*-
 12 value for the trend analysis is given in the vehicle column; *p*-values in BPA and EE₂ columns are for pairwise comparisons to the
 13 vehicle control.

1 **Table 19. Survival of Female Pups from Weaning to Terminal (2 Year) Sacrifice in the Stop-Dose**
 2 **Vehicle and BPA Groups^a**

Terminal Sacrifice Females	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Females initially allocated for terminal evaluation	50	50	48	50	50	46
Moribund	36	32	32	35	30	31
Natural deaths	3	6	3	2	3	2
Animals surviving to scheduled termination	11	12	13	13	17	13
Percent survival at end of study	22	24	27	26	34	28
Survival analysis, <i>p</i> -value	0.203 ^b	1.000	1.000	1.000	1.000	1.000

3 ^aBPA doses are µg/kg bw/day. Cox proportional hazard analyses were performed for the BPA dose groups for all female pups
 4 assigned to the stop-dose interim sacrifice group at weaning. Animals removed as dead or moribund were considered uncensored,
 5 while animals surviving to scheduled removal were considered censored. Multiple comparisons of treatments to the vehicle
 6 control were adjusted using Holm's method. All tests were performed as two-sided tests at the 0.05 significance level. There were
 7 no statistically significant treatment effects. There were also no significant treatment effects in the sensitivity analysis that
 8 excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Materials and Methods,
 9 Statistical Methods). The full statistical report for this endpoint is found in Supplemental Appendix XXII.

10 ^bA test of dose trend, increasing treatment effect with increasing dose, was performed and the *p*-value for the trend analysis is
 11 given in the vehicle column; *p*-values in BPA columns are for pairwise comparisons to the vehicle control.

1 **Table 20. Survival of Male Pups from Weaning to Terminal (2 Year) Sacrifice in the Continuous**
 2 **Vehicle, BPA, and EE₂ Dose Groups^a**

Terminal Sacrifice Males	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	0.05 EE₂	0.50 EE₂
Males initially allocated for terminal evaluation	50	48	48	50	50	46	26	26
Moribund	24	16	27	21	24	27	14	10
Natural deaths	11	16	4	15	10	8	3	4
Animals surviving to scheduled termination	15	16	17	14	16	11	9	12
Percent survival at end of study	30	33	35	28	32	24	35	46
Survival analysis, <i>p</i> -value	0.327 ^b	1.000	1.000	1.000	1.000	1.000	0.879	0.419

3 ^aBPA and EE₂ doses are µg/kg bw/day. Cox proportional hazard analyses were performed separately for the BPA and EE₂ dose
 4 groups for all male pups assigned to the continuously dosed terminal sacrifice group at weaning. Animals removed as dead or
 5 moribund were considered uncensored, while animals surviving to scheduled removal were considered censored. Multiple
 6 comparisons of treatments to the vehicle control were adjusted using Holm's method. All tests were performed as two-sided tests
 7 at the 0.05 significance level. There were no statistically significant treatment effects. There were also no significant treatment
 8 effects in the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day
 9 (see Materials and Methods, Statistical Methods). The full statistical report for this endpoint, including is found in Supplemental
 10 Appendix XXII.

11 ^bA test of dose trend, increasing treatment effect with increasing dose, was performed for vehicle and BPA groups only. The *p*-
 12 value for the trend analysis is given in the vehicle column; *p*-values in BPA and EE₂ columns are for pairwise comparisons to the
 13 vehicle control.

1 **Table 21. Survival of Male Pups from Weaning to Terminal (2 Year) Sacrifice in the Stop-Dose**
 2 **Vehicle and BPA Groups^a**

Terminal Sacrifice Males	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Males initially allocated for terminal evaluation	50	48	48	50	50	46
Moribund	20	20	24	29	27	29
Natural deaths	13	12	8	8	8	8
Animals surviving to scheduled termination	17	16	16	13	15	9
Percent survival at end of study	34	33	33	26	30	20
Survival analysis, <i>p</i> -value	0.053 ^b	1.000	1.000	0.424	1.000	0.209

3 ^aBPA doses are µg/kg bw/day. Cox proportional hazard analyses were performed for the BPA dose groups for all male pups
 4 assigned to the stop-dose interim sacrifice group at weaning. Animals removed as dead or moribund were considered uncensored,
 5 while animals surviving to scheduled removal were considered censored. Multiple comparisons of treatments to the vehicle
 6 control were adjusted using Holm's method. All tests were performed as two-sided tests at the 0.05 significance level. There were
 7 no statistically significant treatment effects. There were also no significant treatment effects in the sensitivity analysis that
 8 excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Materials and Methods,
 9 Statistical Methods). The full statistical report for this endpoint is found in Supplemental Appendix XXII.

10 ^bA test of dose trend, increasing treatment effect with increasing dose, was performed and the *p*-value for the trend analysis is
 11 given in the vehicle column; *p*-values in BPA columns are for pairwise comparisons to the vehicle control.

1 **Table 22. Prewean Body Weights (g) of Female Pups in the Vehicle, BPA, and EE₂ Dose Groups**
 2 **(Mean ± S.E.M.)^a**

Postnatal Day	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	0.05 EE ₂	0.5 EE ₂
1	6.8 ± 0.1 (71)	6.7 ± 0.1 (60)	6.8 ± 0.1 (57)	6.8 ± 0.1 (58)	6.7 ± 0.1 (59)	6.8 ± 0.1 (59)	6.6 ± 0.1 (34)	6.9 ± 0.1 (47)
4	10.6 ± 0.1 (71)	10.1 ± 0.2 (59)	10.5 ± 0.2 (57)	10.4 ± 0.1 (58)	10.3 ± 0.2 (58)	10.4 ± 0.2 (59)	10.1 ± 0.2* (34)	10.9 ± 0.2 (47)
7	15.8 ± 0.2 (71)	15.2 ± 0.2 (59)	15.6 ± 0.2 (57)	15.3 ± 0.2 (58)	15.1 ± 0.3 (58)	15.4 ± 0.2 (59)	15.0 ± 0.3* (34)	16.0 ± 0.3 (47)
14	30.6 ± 0.4 (71)	30.1 ± 0.4 (59)	30.9 ± 0.4 (57)	30.0 ± 0.4 (58)	29.6 ± 0.4 (58)	29.9 ± 0.4 (59)	29.9 ± 0.6 (34)	31.4 ± 0.4 (47)
21	50.1 ± 0.6 (70)	49.5 ± 0.7 (56)	50.6 ± 0.6 (55)	49.2 ± 0.7 (56)	48.6 ± 0.7 (56)	49.1 ± 0.6 (57)	50.2 ± 0.9 (33)	51.9 ± 0.7 (47)

3 ^aBPA and EE₂ doses are µg/kg bw/day. Numbers of litters are shown in parentheses. Analysis was performed using contrasts
 4 within sex- and PND-stratified one-way repeated measures, mixed model ANOVA to test for treatment effects accounting for
 5 litter correlation assuming a compound symmetric correlation structure. Pairwise comparisons of treatment group means to the
 6 vehicle control group mean were performed using contrasts with Dunnett's method of adjustment for multiple comparisons
 7 separately for BPA and EE₂ groups. Tests of trends, increasing treatment effect with increasing dose, were performed for the
 8 BPA and control groups. All tests were performed as two-sided tests at the 0.05 significance level. Full results of the analyses are
 9 presented in Supplemental Appendix XXIII. Values that are significantly different from the vehicle control are indicated with an
 10 asterisk (*, *p* < 0.05). There were no additional significant treatment effects in the sensitivity analysis that excluded all animals
 11 that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Materials and Methods, Statistical Methods).

1 **Table 23. Prewean Body Weights (g) of Male Pups in the Vehicle, BPA, and EE₂ Dose Groups**
 2 **(Mean ± S.E.M.)^a**

Postnatal Day	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	0.05 EE ₂	0.5 EE ₂
1	7.2 ± 0.1 (71)	7.1 ± 0.1 (60)	7.3 ± 0.1 (57)	7.2 ± 0.1 (58)	7.1 ± 0.1 (59)	7.3 ± 0.1 (59)	7.0 ± 0.1 (32)	7.2 ± 0.1 (49)
4	11.4 ± 0.2 (71)	11 ± 0.1 (59)	11.4 ± 0.2 (57)	11.2 ± 0.2 (58)	10.9 ± 0.2 (58)	11.4 ± 0.2 (59)	10.8 ± 0.2 (32)	11.3 ± 0.2 (48)
7	16.9 ± 0.2 (71)	16.4 ± 0.2 (59)	16.8 ± 0.3 (57)	16.4 ± 0.2 (58)	16.2 ± 0.3 (58)	16.7 ± 0.2 (59)	16.1 ± 0.4 (32)	16.6 ± 0.3 (48)
14	32.3 ± 0.4 (71)	31.7 ± 0.4 (59)	32.4 ± 0.4 (57)	31.5 ± 0.4 (58)	31.3 ± 0.4 (58)	31.7 ± 0.4 (59)	31.8 ± 0.6 (32)	32.5 ± 0.5 (48)
21	53.0 ± 0.6 (70)	52.2 ± 0.6 (56)	53.6 ± 0.6 (55)	51.8 ± 0.7 (56)	51.5 ± 0.7 (56)	52.4 ± 0.7 (57)	53.0 ± 1.0 (32)	54.0 ± 0.8 (47)

3 ^aBPA and EE₂ doses are µg/kg bw/day. Numbers of litters are shown in parentheses. Analysis was performed using contrasts
 4 within sex- and PND-stratified one-way repeated measures, mixed model ANOVA to test for treatment effects accounting for
 5 litter correlation assuming a compound symmetric correlation structure. Pairwise comparisons of treatment group means to the
 6 vehicle control group mean were performed using contrasts with Dunnett's method of adjustment for multiple comparisons
 7 separately for BPA and EE₂ groups. Tests of trends, increasing treatment effect with increasing dose, were performed for the
 8 BPA and control groups. All tests were performed as two-sided tests at the 0.05 significance level. Full results of the analyses are
 9 presented in Supplemental Appendix XXIII. There were no statistically significant trends or pairwise comparisons to controls.
 10 There were also no significant treatment effects in the sensitivity analysis that excluded all animals that overlapped with animals
 11 treated with 250,000 µg BPA/kg bw/day (see Materials and Methods, Statistical Methods).

1 **Table 24. Female Postwean Body Weights (g), Vehicle, BPA, and EE₂ Continuous-Dose, Interim**
 2 **(1 Year) Sacrifice (Mean ± S.E.M.)^a**

Week	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	0.05 EE ₂	0.5 EE ₂
4	76 ± 1 (23)	77 ± 2 (22)	76 ± 2 (22)	74 ± 2 (24)	73 ± 1 (20)	75 ± 2 (24)	75 ± 2 (26)	81 ± 2 (26)
8	196 ± 5 (23)	203 ± 4 (22)	205 ± 4 (22)	196 ± 4 (24)	196 ± 4 (20)	197 ± 4 (24)	201 ± 4 (26)	209 ± 4 (26)
12	268 ± 6 (22)	277 ± 6 (22)	278 ± 6 (22)	266 ± 6 (24)	262 ± 5 (20)	262 ± 6 (24)	273 ± 7 (26)	262 ± 5 (26)
16	302 ± 8 (22)	314 ± 7 (22)	317 ± 7 (22)	299 ± 7 (24)	293 ± 5 (20)	293 ± 7 (24)	308 ± 7 (26)	291 ± 5 (26)
20	322 ± 8 (22)	342 ± 9 (22)	345 ± 8 (22)	316 ± 8 (24)	311 ± 6 (20)	316 ± 10 (24)	332 ± 8 (26)	312 ± 6 (26)
24	340 ± 10 (22)	363 ± 12 (22)	362 ± 9 (22)	331 ± 9 (24)	331 ± 6 (20)	332 ± 11 (24)	352 ± 9 (26)	330 ± 8 (26)
28	354 ± 10 (22)	382 ± 13 (22)	380 ± 11 (22)	344 ± 10 (24)	346 ± 7 (20)	351 ± 12 (24)	365 ± 9 (26)	348 ± 8 (26)
32	370 ± 13 (22)	403 ± 14 (22)	395 ± 11 (22)	360 ± 11 (24)	362 ± 8 (20)	366 ± 13 (24)	384 ± 10 (26)	367 ± 10 (26)
36	384 ± 14 (22)	422 ± 16b (22)	410 ± 12 (22)	374 ± 12 (24)	376 ± 9 (20)	378 ± 14 (24)	398 ± 10 (26)	384 ± 10 (26)
40	396 ± 15 (22)	439 ± 18 ^b (22)	422 ± 12 (22)	377 ± 10 (23)	394 ± 10 (20)	396 ± 14 (24)	417 ± 11 (25)	397 ± 10 (26)
44	410 ± 16 (22)	455 ± 19 ^b (22)	434 ± 13 (22)	389 ± 11 (23)	409 ± 12 (20)	409 ± 16 (24)	434 ± 11 (25)	412 ± 11 (26)
48	421 ± 18 (21)	476 ± 20 ^b (22)	447 ± 14 (21)	408 ± 13 (22)	424 ± 12 (20)	428 ± 17 (24)	449 ± 13 (24)	427 ± 12 (26)
52	436 ± 19 (21)	494 ± 22 ^b (22)	460 ± 15 (21)	427 ± 14 (22)	436 ± 13 (20)	441 ± 18 (24)	468 ± 14 (24)	440 ± 12 (26)

3 ^aBPA and EE₂ doses are µg/kg bw/day. Numbers of litters are shown in parentheses. Outlier identification and exclusion are
 4 described in Materials and Methods and Supplemental Appendix XXIV. Analyses were conducted separately for BPA and EE₂
 5 dose groups. Pairwise comparisons of means were performed using contrasts within a two-way repeated measures, mixed model
 6 ANOVA. Model terms were treatment group, weeks, and the interaction. Within-group correlations were modeled using a
 7 heterogeneous first-order autoregressive (ARH(1)) correlation structure, which allows for correlated differences in variability
 8 across time points. Tests of trends, increasing treatment effect with increasing dose, were performed for the BPA and vehicle
 9 control groups. Pairwise comparisons of treatment groups to the vehicle control group were conducted with Dunnett's method to
 10 adjust for multiple comparisons. All tests were performed as two-sided tests at the 0.05 significance level. Full results of the
 11 analyses are presented in Supplemental Appendix XXIV. There were no statistically significant trends or pairwise comparisons to
 12 controls. There were also no significant treatment effects in the sensitivity analysis that excluded all animals that overlapped with
 13 animals treated with 250,000 µg BPA/kg bw/day (see Materials and Methods, Statistical Methods).

14 ^bMean body weights at the later time points, weeks 36 to 52, were 10 – 13% higher than control means in the 2.5 µg BPA/kg
 15 bw/day. The Dunnett-corrected *p*-values were 0.080, 0.058, 0.071, 0.065, and 0.062, for weeks 36, 40, 44, 48, and 52,
 16 respectively.

1 **Table 25. Female Postwean Body Weights (g), Vehicle, BPA, and EE₂ Continuous-Dose, Terminal**
 2 **(2 Year) Sacrifice (Mean ± S.E.M.)^a**

Week	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	0.05 EE ₂	0.5 EE ₂
4	75 ± 1 (50)	76 ± 1 (48)	78 ± 1 (46)	76 ± 1 (49)	74 ± 1 (50)	76 ± 1 (46)	76 ± 1 (26)	80 ± 2* (26)
8	196 ± 3 (50)	201 ± 3 (48)	202 ± 2 (46)	199 ± 2 (49)	198 ± 3 (50)	204 ± 3 ^b (45)	200 ± 4 (26)	212 ± 4* (26)
12	266 ± 4 (50)	269 ± 4 (48)	270 ± 4 (46)	267 ± 3 (49)	266 ± 4 (50)	269 ± 3 (45)	269 ± 6 (26)	268 ± 6 (26)
16	302 ± 5 (50)	305 ± 5 (47)	303 ± 5 (46)	299 ± 3 (49)	300 ± 4 (50)	302 ± 4 (45)	299 ± 6 (26)	299 ± 7 (26)
20	324 ± 6 (50)	327 ± 6 (47)	325 ± 6 (46)	319 ± 4 (49)	319 ± 5 (50)	321 ± 4 (45)	320 ± 7 (26)	320 ± 9 (26)
24	342 ± 6 (50)	345 ± 7 (46)	346 ± 6 (45)	336 ± 5 (49)	336 ± 5.3 (50)	338 ± 5 (45)	339 ± 8 (26)	338 ± 10 (26)
28	359 ± 7 (50)	360 ± 7 (46)	362 ± 7 (45)	354 ± 5 (49)	352 ± 6 (50)	356 ± 5 (45)	351 ± 8 (26)	354 ± 11 (26)
32	372 ± 8 (50)	376 ± 8 (46)	376 ± 8 (45)	366 ± 6 (49)	366 ± 6 (50)	369 ± 6 (45)	366 ± 9 (26)	373 ± 12 (26)
36	387 ± 8 (50)	392 ± 9 (46)	393 ± 8 (45)	384 ± 6 (49)	375 ± 7 (50)	379 ± 6 (45)	375 ± 9 (26)	390 ± 13 (26)
40	402 ± 9 (50)	407 ± 10 (46)	407 ± 10 (45)	396 ± 7 (48)	388 ± 8 (49)	394 ± 7 (45)	392 ± 10 (26)	406 ± 13 (26)
44	417 ± 10 (50)	421 ± 11 (45)	419 ± 10 (45)	410 ± 8 (47)	403 ± 8 (48)	410 ± 8 (45)	403 ± 11 (26)	421 ± 14 (26)
48	431 ± 10 (50)	438 ± 12 (44)	437 ± 12 (44)	426 ± 8 (48)	419 ± 8 (48)	424 ± 8 (45)	418 ± 11 (26)	439 ± 15 (26)
52	447 ± 10 (50)	456 ± 13 (44)	451 ± 12 (44)	448 ± 8 (48)	434 ± 9 (48)	442 ± 9 (45)	433 ± 12 (26)	450 ± 15 (26)
56	463 ± 11 (50)	474 ± 14 (44)	463 ± 13 (44)	466 ± 9 (47)	449 ± 10 (48)	457 ± 9 (45)	450 ± 13 (26)	459 ± 16 (25)
60	478 ± 12 (50)	492 ± 15 (44)	484 ± 14 (43)	487 ± 10 (47)	468 ± 11 (48)	474 ± 10 (45)	462 ± 13 (26)	475 ± 18 (25)
64	495 ± 12 (49)	510 ± 16 (44)	502 ± 15 (42)	504 ± 10 (47)	477 ± 11 (44)	491 ± 10 (45)	477 ± 14 (26)	485 ± 20 (25)
68	506 ± 12 (47)	532 ± 17 (44)	519 ± 16 (41)	528 ± 11 (46)	489 ± 13 (39)	506 ± 11 (44)	497 ± 15 (24)	492 ± 23 (24)
72	520 ± 14 (44)	544 ± 18 (43)	544 ± 18 (38)	547 ± 11 (44)	497 ± 12 (36)	520 ± 12 (42)	521 ± 16 (21)	506 ± 24 (22)
76	531 ± 16 (40)	549 ± 19 (39)	564 ± 21 (34)	564 ± 13 (41)	500 ± 12 (33)	522 ± 12 (38)	530 ± 19 (17)	521 ± 26 (21)
80	542 ± 16 (39)	562 ± 22 (34)	560 ± 19 (26)	571 ± 13 (40)	514 ± 13 (31)	537 ± 12 (33)	544 ± 18 (15)	531 ± 34 (17)
84	533 ± 15 (35)	577 ± 24 (33)	574 ± 20 (26)	579 ± 15 (38)	521 ± 14 (27)	542 ± 14 (29)	552 ± 20 (14)	551 ± 40 (15)
88	534 ± 18 (32)	584 ± 26 (31)	585 ± 22 (24)	588 ± 20 (27)	527 ± 17 (24)	556 ± 15 (28)	539 ± 23 (13)	564 ± 51 (11)
92	530 ± 15 (26)	584 ± 22 (26)	565 ± 21 (18)	608 ± 23 (22)	526 ± 19 (21)	564 ± 16 (27)	561 ± 22 (12)	512 ± 27 (8)
96	531 ± 17 (23)	604 ± 23 (22)	594 ± 20 (16)	616 ± 25* (19)	540 ± 23 (18)	569 ± 19 (21)	563 ± 26 (10)	525 ± 34 (7)
100	537 ± 21 (17)	621 ± 26 (21)	594 ± 16 (14)	634 ± 32* (16)	528 ± 17 (13)	584 ± 18 (17)	597 ± 34 (7)	542 ± 36 (6)
104	534 ± 22 (17)	619 ± 28 (18)	607 ± 18 (13)	622 ± 36* (12)	524.2 ± 22 (11)	597 ± 34 (9)	602 ± 35 (7)	562 ± 50 (4)

3 ^aBPA and EE₂ doses are µg/kg bw/day. Numbers of litters are shown in parentheses. Outlier identification and exclusion are
 4 described in Materials and Methods and Supplemental Appendix XXV. Pairwise comparisons of means were performed using
 5 contrasts within a two-way repeated measures, mixed model ANOVA. Model terms were treatment group, weeks, and the
 6 interaction. Within-group correlations were modeled using a heterogeneous first-order autoregressive (ARH(1)) correlation
 7 structure, which allows for correlated differences in variability across time points. Tests of trends, increasing treatment effect
 8 with increasing dose, were performed for the BPA and vehicle control groups. Pairwise comparisons of treatment groups to the

CLARITY-BPA Core Study, NTP RR 9

1 vehicle control group were conducted with Dunnett's method to adjust for multiple comparisons. All tests were performed as
2 two-sided tests at the 0.05 significance level. Full results of the analyses are presented in Supplemental Appendix XXV.
3 Significant effects are indicated with asterisks (*, $p < 0.05$).
4 ^bIn the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see
5 Materials and Methods, Statistical Methods), the mean for week 8, 25,000 µg BPA/kg bw/day was significantly different
6 ($p = 0.031$) from the vehicle control mean.

1 **Table 26. Female Postwean Body Weights (g), Vehicle and BPA Stop-Dose, Interim (1 Year)**
 2 **Sacrifice (Mean ± S.E.M.)^a**

Week	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
4	58 ± 3 (20)	54 ± 3 (22)	55 ± 3 (20)	54 ± 2 (22)	55 ± 3 (20)	51 ± 2 (22)
8	192 ± 5 (20)	184 ± 3 (22)	190 ± 4 (20)	190 ± 5 (22)	188 ± 5 (20)	184 ± 4 (21)
12	270 ± 7 (20)	263 ± 5 (20)	270 ± 7 (20)	266 ± 6 (22)	272 ± 8 (20)	262 ± 6 (21)
16	304 ± 11 (18)	302 ± 5 (22)	305 ± 9 (20)	305 ± 7 (22)	310 ± 8 (20)	303 ± 8 (21)
20	331 ± 11 (20)	329 ± 7 (22)	328 ± 10 (20)	330 ± 8 (22)	338 ± 10 (20)	326 ± 8 (21)
24	351 ± 12 (20)	350 ± 8 (22)	344 ± 11 (20)	348 ± 8 (22)	358 ± 12 (20)	344 ± 9 (21)
28	369 ± 12 (20)	366 ± 9 (22)	360 ± 12 (20)	368 ± 10 (22)	373 ± 14 (20)	361 ± 9 (21)
32	386 ± 14 (20)	391 ± 10 (20)	374 ± 13 (20)	381 ± 11 (22)	392 ± 15 (20)	374 ± 10 (21)
36	400 ± 14 (20)	399 ± 10 (22)	389 ± 15 (20)	399 ± 13 (22)	404 ± 15 (20)	386 ± 10 (21)
40	410 ± 16 (18)	419 ± 12 (22)	404 ± 16 (20)	418 ± 15 (20)	421 ± 17 (20)	407 ± 12 (20)
44	439 ± 17 (20)	433 ± 12 (22)	419 ± 16 (20)	431 ± 16 (22)	438 ± 18 (20)	420 ± 12 (20)
48	459 ± 18 (20)	453 ± 14 (22)	436 ± 17 (20)	449 ± 18 (22)	452 ± 18 (20)	440 ± 13 (20)
52	477 ± 19 (20)	468 ± 14 (22)	450 ± 19 (20)	468 ± 20 (22)	466 ± 19 (20)	455 ± 14 (20)

3 ^aBPA doses are µg/kg bw/day. Numbers of litters are shown in parentheses. Outlier identification and exclusion are described in
 4 Materials and Methods and Supplemental Appendix XXIV. Pairwise comparisons of means were performed using contrasts
 5 within a two-way repeated measures, mixed model ANOVA. Model terms were treatment group, weeks, and the interaction.
 6 Within-group correlations were modeled using a heterogeneous first-order autoregressive (ARH(1)) correlation structure, which
 7 allows for correlated differences in variability across time points. Tests of trends, increasing treatment effect with increasing
 8 dose, were performed for the BPA and vehicle control groups. Pairwise comparisons of treatment groups to the vehicle control
 9 group were conducted with Dunnett's method to adjust for multiple comparisons. All tests were performed as two-sided tests at
 10 the 0.05 significance level. Full results of the analyses are presented in Supplemental Appendix XXIV. There were no
 11 statistically significant trends or pairwise comparisons to controls. There were also no significant treatment effects in the
 12 sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see
 13 Materials and Methods, Statistical Methods).

1 **Table 27. Female Postwean Body Weights (g), Vehicle and BPA Stop-Dose, Terminal (2 Year)**
 2 **Sacrifice (Mean ± S.E.M.)^a**

Week	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
4	57 ± 2* (50)	56 ± 2 (50)	54 ± 2 (48)	53 ± 1 (50)	52 ± 2 ^b (50)	54 ± 1 (46)
8	190 ± 4 (50)	190 ± 2 (50)	189 ± 2 (48)	193 ± 2 (50)	187 ± 4 (50)	190 ± 2 (46)
12	270 ± 5 (50)	270 ± 3 (50)	268 ± 3 (48)	271 ± 4 (50)	267 ± 5 (50)	270 ± 4 (46)
16	312 ± 7 (50)	312 ± 4 (50)	307 ± 5 (48)	310 ± 5 (50)	305 ± 6 (50)	311 ± 5 (46)
20	338 ± 8 (50)	339 ± 5 (50)	330 ± 5 (46)	334 ± 5 (50)	330 ± 7 (50)	338 ± 5 (46)
24	359 ± 8 (50)	361 ± 5 (50)	349 ± 6 (48)	353 ± 6 (50)	350 ± 7 (49)	358 ± 6 (46)
28	379 ± 10 (50)	375 ± 6 (50)	365 ± 7 (48)	370 ± 7 (50)	366 ± 8 (49)	376 ± 6 (46)
32	393 ± 10 (50)	393 ± 6 (48)	380 ± 7 (48)	384 ± 8 (50)	381 ± 8 (49)	392 ± 7 (46)
36	409 ± 10 (50)	409 ± 7 (50)	397 ± 8 (48)	403 ± 9 (50)	394 ± 9 (49)	409 ± 8 (46)
40	420 ± 11 (43)	428 ± 8 (47)	414 ± 9 (44)	418 ± 10 (44)	411 ± 10 (47)	427 ± 9 (44)
44	436 ± 11 (47)	446 ± 9 (50)	426 ± 9 (48)	435 ± 10 (50)	426 ± 10 (48)	445 ± 9 (46)
48	457 ± 12 (49)	466 ± 10 (50)	446 ± 10 (48)	451 ± 10 (50)	444 ± 11 (49)	463 ± 10 (46)
52	479 ± 12 (49)	489 ± 10 (49)	462 ± 10 (47)	474 ± 11 (50)	459 ± 11 (49)	477 ± 11 (46)
56	497 ± 13 (49)	506 ± 10 (49)	482 ± 11 (47)	496 ± 12 (50)	480 ± 12 (49)	495 ± 12 (45)
60	516 ± 14 (48)	524 ± 11 (46)	502 ± 11 (47)	515 ± 12 (50)	496 ± 12 (48)	513 ± 14 (44)
64	536 ± 15 (48)	549 ± 13 (45)	520 ± 12 (47)	537 ± 12 (50)	517 ± 13 (48)	533 ± 15 (43)
68	558 ± 16 (47)	573 ± 13 (44)	540 ± 13 (43)	546 ± 13 (46)	537 ± 14 (47)	550 ± 15 (39)
72	571 ± 18 (44)	580 ± 13 (39)	552 ± 14 (41)	561 ± 14 (44)	556 ± 16 (45)	552 ± 14 (35)
76	570 ± 19 (36)	598 ± 14 (40)	568 ± 15 (39)	574 ± 15 (41)	568 ± 16 (41)	575 ± 16 (35)
80	576 ± 18 (34)	619 ± 15 (39)	575 ± 15 (35)	586 ± 18 (36)	580 ± 17 (38)	589 ± 16 (35)
84	588 ± 21 (31)	633 ± 18 (32)	601 ± 18 (30)	605 ± 19 (34)	591 ± 19 (36)	604 ± 19 (31)
88	595 ± 22 (28)	624 ± 20 (26)	599 ± 18 (26)	614 ± 22 (31)	606 ± 21 (33)	613 ± 20 (29)
92	591 ± 28 (23)	626 ± 23 (20)	590 ± 21 (20)	626 ± 24 (28)	609 ± 24 (31)	625 ± 22 (26)
96	600 ± 33 (20)	608 ± 20 (16)	595 ± 25 (16)	651 ± 29 (23)	633 ± 28 (24)	616 ± 24 (22)
100	600 ± 30 (17)	625 ± 21 (16)	614 ± 28 (15)	650 ± 37 (18)	614 ± 34 (19)	610 ± 29 (17)
104	608 ± 45 (11)	631 ± 23 (13)	595 ± 25 (13)	630 ± 39 (13)	641 ± 35 (17)	623 ± 35 (13)

3 ^aBPA doses are µg/kg bw/day. Numbers of litters are shown in parentheses. Outlier identification and exclusion are described in
 4 Materials and Methods and Supplemental Appendix XXV. Pairwise comparisons of means were performed using contrasts
 5 within a two-way repeated measures, mixed model ANOVA. Model terms were treatment group, weeks, and the interaction.
 6 Within-group correlations were modeled using a heterogeneous first-order autoregressive (ARH(1)) correlation structure, which
 7 allows for correlated differences in variability across time points. Tests of trends, increasing treatment effect with increasing
 8 dose, were performed for the BPA and vehicle control groups. Pairwise comparisons of treatment groups to the vehicle control

CLARITY-BPA Core Study, NTP RR 9

1 group were conducted with Dunnett's method to adjust for multiple comparisons. All tests were performed as two-sided tests at
2 the 0.05 significance level. Full results of the analyses are presented in Supplemental Appendix XXV. The only significant effect
3 is indicated with an asterisk (dose trend, week 4, $p = 0.037$).
4 ^bIn the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 μg BPA/kg bw/day (see
5 Materials and Methods, Statistical Methods), the mean for week 4, 2,500 μg BPA/kg bw/day was significantly different
6 (approximately 12% lower, $p = 0.016$) from the vehicle control mean.

1 **Table 28. Male Postwean Body Weights (g), Vehicle, BPA, and EE₂ Continuous-Dose, Interim (1**
 2 **Year) Sacrifice (Mean ± S.E.M.)^a**

Week	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	0.05 EE ₂	0.5 EE ₂
4	84 ± 2 (22)	83 ± 2 (22)	85 ± 2 (20)	81 ± 2 (24)	83 ± 2 (20)	80 ± 1 (22)	84 ± 2 (26)	88 ± 2 (26)
8	298 ± 7 (22)	299 ± 7 (22)	296 ± 7 (20)	288 ± 7 (24)	296 ± 8 (20)	290 ± 5 (21)	298 ± 7 (26)	304 ± 5 (26)
12	424 ± 9 (22)	429 ± 8 (22)	429 ± 10 (20)	416 ± 8 (24)	426 ± 11 (20)	417 ± 8 (21)	431 ± 9 (26)	437 ± 6 (26)
16	494 ± 10 (22)	505 ± 9 (22)	500 ± 11 (20)	490 ± 8 (24)	496 ± 12 (20)	484 ± 9 (21)	504 ± 10 (26)	505 ± 8 (26)
20	540 ± 10 (22)	554 ± 11 (22)	553 ± 13 (19)	541 ± 10 (24)	542 ± 13 (20)	532 ± 10 (21)	551 ± 12 (25)	550 ± 10 (24)
24	578 ± 12 (22)	590 ± 12 (22)	586 ± 14 (19)	576 ± 12 (24)	579 ± 14 (20)	568 ± 12 (21)	588 ± 13 (25)	584 ± 9 (26)
28	604 ± 13 (21)	621 ± 12 (22)	612 ± 15 (19)	607 ± 12 (24)	610 ± 16 (20)	596 ± 13 (21)	613 ± 14 (25)	611 ± 10 (26)
32	627 ± 14 (21)	643 ± 13 (22)	636 ± 16 (19)	633 ± 12 (24)	635 ± 18 (20)	620 ± 14 (21)	636 ± 14 (25)	634 ± 10 (26)
36	645 ± 15 (21)	667 ± 14 (22)	653 ± 17 (19)	653 ± 13 (24)	656 ± 19 (20)	639 ± 14 (21)	660 ± 15 (25)	652 ± 12 (25)
40	664 ± 17 (20)	690 ± 16 (22)	673 ± 18 (19)	674 ± 14 (24)	675 ± 21 (19)	659 ± 15 (21)	681 ± 16 (24)	673 ± 13 (25)
44	688 ± 16 (19)	707 ± 17 (22)	689 ± 19 (19)	691 ± 14 (24)	693 ± 21 (19)	676 ± 17 (21)	697 ± 17 (25)	687 ± 13 (25)
48	702 ± 18 (19)	724 ± 20 (22)	715 ± 20 (18)	712 ± 15 (24)	706 ± 24 (18)	693 ± 17 (21)	712 ± 19 (24)	715 ± 14 (23)
52	720 ± 20 (18)	742 ± 21 (22)	729 ± 22 (18)	732 ± 16 (24)	724 ± 26 (18)	714 ± 19 (21)	730 ± 21 (22)	724 ± 16 (23)

3 ^aBPA and EE₂ doses are µg/kg bw/day. Numbers of litters are shown in parentheses. Outlier identification and exclusion are
 4 described in Materials and Methods and Supplemental Appendix XXIV. Analyses were conducted separately for BPA and EE₂
 5 dose groups. Pairwise comparisons of means were performed using contrasts within a two-way repeated measures, mixed model
 6 ANOVA. Model terms were treatment group, weeks, and the interaction. Within-group correlations were modeled using a
 7 heterogeneous first-order autoregressive (ARH(1)) correlation structure, which allows for correlated differences in variability
 8 across time points. Tests of trends, increasing treatment effect with increasing dose, were performed for the BPA and vehicle
 9 control groups. Pairwise comparisons of treatment groups to the vehicle control group were conducted with Dunnett's method to
 10 adjust for multiple comparisons. All tests were performed as two-sided tests at the 0.05 significance level. Full results of the
 11 analyses are presented in Supplemental Appendix XXIV. There were no statistically significant trends or pairwise comparisons to
 12 controls. There were also no significant treatment effects in the sensitivity analysis that excluded all animals that overlapped with
 13 animals treated with 250,000 µg BPA/kg bw/day (see Materials and Methods, Statistical Methods).

1 **Table 29. Male Postwean Body Weights (g), Vehicle, BPA, And EE₂ Continuous-Dose, Terminal (2**
 2 **Year) Sacrifice (Mean ± S.E.M.)^a**

Week	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	0.05 EE ₂	0.5 EE ₂
4	84 ± 1 (50)	84 ± 1 (48)	86 ± 1 (48)	84 ± 1 (50)	82 ± 1 (50)	85 ± 1 (46)	82 ± 2 (26)	88 ± 2 (26)
8	295 ± 4 (50)	302 ± 4 (48)	297 ± 4 (48)	290 ± 4 (50)	292 ± 4 (50)	305 ± 4 (46)	297 ± 5 (26)	306 ± 5 (26)
12	429 ± 7 (49)	434 ± 5 (47)	425 ± 5 (48)	419 ± 5 (50)	420 ± 5 (50)	435 ± 5 (46)	428 ± 8 (26)	431 ± 8 (26)
16	503 ± 10 (49)	506 ± 6 (47)	496 ± 6 (48)	492 ± 6 (50)	496 ± 6 (50)	505 ± 6 (46)	504 ± 10 (26)	502 ± 10 (26)
20	550 ± 11 (49)	554 ± 7 (45)	546 ± 8 (48)	543 ± 6 (50)	543 ± 7 (50)	552 ± 6 (46)	553 ± 11 (26)	549 ± 12 (26)
24	586 ± 12 (49)	591 ± 7 (47)	583 ± 8 (48)	581 ± 7 (50)	577 ± 8 (50)	586 ± 7 (46)	586 ± 13 (26)	581 ± 11 (26)
28	614 ± 14 (49)	620 ± 8 (46)	609 ± 9 (48)	612 ± 7 (50)	603 ± 9 (50)	614 ± 8 (46)	614 ± 13 (26)	608 ± 13 (24)
32	639 ± 16 (49)	643 ± 9 (46)	631 ± 10 (48)	641 ± 8 (50)	625 ± 9 (50)	637 ± 8 (46)	637 ± 14 (26)	632 ± 13 (26)
36	647 ± 10 (48)	663 ± 10 (46)	654 ± 10 (47)	661 ± 9 (50)	643 ± 9 (50)	656 ± 9 (46)	658 ± 16 (26)	655 ± 14 (26)
40	667 ± 10 (48)	685 ± 10 (46)	672 ± 11 (48)	682 ± 10 (49)	660 ± 9 (50)	674 ± 9 (46)	678 ± 16 (26)	673 ± 15 (26)
44	684 ± 11 (47)	700 ± 10 (45)	691 ± 12 (47)	703 ± 11 (49)	678 ± 10 (49)	687 ± 10 (46)	696 ± 17 (26)	692 ± 16 (26)
48	700 ± 12 (47)	717 ± 11 (45)	707 ± 13 (47)	729 ± 11 (48)	696 ± 10 (49)	707 ± 10 (44)	712 ± 18 (26)	710 ± 17 (26)
52	719 ± 13 (47)	732 ± 12 (45)	719 ± 12 (44)	746 ± 10 (47)	712 ± 11 (48)	727 ± 11 (43)	726 ± 20 (26)	726 ± 18 (26)
56	736 ± 13 (47)	750 ± 13 (45)	745 ± 14 (46)	765 ± 11 (46)	726 ± 12 (47)	750 ± 12 (41)	754 ± 20 (24)	742 ± 18 (26)
60	748 ± 13 (47)	768 ± 13 (45)	756 ± 16 (45)	784 ± 12 (45)	743 ± 12 (46)	770 ± 13 (40)	783 ± 19 (23)	760 ± 18 (26)
64	765 ± 14 (46)	791 ± 14 (44)	779 ± 17 (44)	803 ± 13 (45)	755 ± 14 (46)	791 ± 14 (40)	803 ± 21 (23)	771 ± 20 (25)
68	783 ± 15 (45)	805 ± 14 (42)	800 ± 19 (44)	818 ± 14 (43)	784 ± 15 (43)	815 ± 16 (37)	828 ± 22 (22)	788 ± 26 (24)
72	792 ± 17 (42)	821 ± 15 (41)	822 ± 20 (40)	838 ± 15 (40)	799 ± 16 (42)	832 ± 17 (37)	848 ± 24 (22)	806 ± 24 (22)
76	801 ± 19 (41)	840 ± 16 (40)	842 ± 20 (39)	858 ± 15 (39)	817 ± 17 (40)	848 ± 19 (34)	864 ± 24 (22)	832 ± 24 (21)
80	819 ± 19 (38)	858 ± 18 (38)	846 ± 22 (36)	868 ± 17 (39)	828 ± 17 (37)	862 ± 20 (31)	873 ± 27 (20)	855 ± 25 (20)
84	827 ± 21 (34)	867 ± 19 (37)	858 ± 25 (29)	890 ± 19 (36)	833 ± 16 (33)	875 ± 21 (29)	889 ± 29 (18)	854 ± 25 (19)
88	826 ± 23 (30)	865 ± 19 (35)	867 ± 25 (27)	894 ± 20 (31)	829 ± 18 (30)	871 ± 21 (25)	917 ± 28 (15)	870 ± 27 (16)
92	823 ± 27 (26)	858 ± 22 (31)	873 ± 26 (25)	905 ± 24 (24)	819 ± 17 (27)	868 ± 22 (24)	925 ± 31 (14)	872 ± 27 (17)
96	831 ± 30 (23)	864 ± 24 (25)	883 ± 23 (22)	914 ± 24 (24)	834 ± 19 (24)	860 ± 27 (16)	925 ± 34 (13)	873 ± 28 (16)
100	823 ± 36 (20)	854 ± 26 (21)	856 ± 25 (19)	904 ± 29 (22)	846 ± 22 (20)	894 ± 23 (14)	926 ± 42 (10)	888 ± 30 (15)
104	818 ± 40 (18)	877 ± 25 (16)	847 ± 30 (17)	946 ± 36 (14)	842 ± 22 (16)	864 ± 12 (12)	901 ± 53 (9)	853 ± 23 (13)

3 ^aBPA and EE₂ doses are µg/kg bw/day. Numbers of litters are shown in parentheses. Outlier identification and exclusion are
 4 described in Materials and Methods and Supplemental Appendix XXV. Pairwise comparisons of means were performed using
 5 contrasts within a two-way repeated measures, mixed model ANOVA. Model terms were treatment group, weeks, and the
 6 interaction. Within-group correlations were modeled using a heterogeneous first-order autoregressive (ARH(1)) correlation
 7 structure, which allows for correlated differences in variability across time points. Tests of trends, increasing treatment effect
 8 with increasing dose, were performed for the BPA and vehicle control groups. Pairwise comparisons of treatment groups to the

CLARITY-BPA Core Study, NTP RR 9

1 vehicle control group were conducted with Dunnett's method to adjust for multiple comparisons. All tests were performed as
2 two-sided tests at the 0.05 significance level. Full results of the analyses are presented in Supplemental Appendix XXV. There
3 were no statistically significant trends or pairwise comparisons to controls. There were also no significant treatment effects in the
4 sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see
5 Materials and Methods, Statistical Methods).

1 **Table 30. Male Postwean Body Weights (g), Vehicle and BPA Stop-Dose, Interim (1 Year) Sacrifice**
 2 **(Mean ± S.E.M.)^a**

Week	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
4	61 ± 2 (20)	58 ± 3 (20)	59 ± 3 (20)	60 ± 3 (19)	57 ± 3 (20)	61 ± 2 (22)
8	274 ± 7 (20)	269 ± 8 (20)	271 ± 6 (20)	270 ± 9 (19)	261 ± 6 (20)	277 ± 4 (22)
12	424 ± 11 (20)	432 ± 9 (20)	426 ± 7 (20)	430 ± 12 (19)	413 ± 8 (20)	436 ± 8 (22)
16	505 ± 14 (20)	529 ± 12 (20)	512 ± 9 (20)	515 ± 14 (19)	503 ± 11 (20)	522 ± 9 (22)
20	561 ± 15 (20)	587 ± 14 (20)	572 ± 11 (19)	566 ± 15 (19)	560 ± 12 (20)	581 ± 10 (22)
24	597 ± 16 (20)	628 ± 16 (20)	610 ± 12 (19)	603 ± 16 (19)	593 ± 11 (20)	618 ± 11 (22)
28	627 ± 18 (20)	658 ± 17 (20)	642 ± 14 (18)	630 ± 17 (19)	623 ± 14 (20)	645 ± 12 (22)
32	652 ± 19 (20)	685 ± 18 (20)	671 ± 15 (19)	655 ± 18 (19)	651 ± 15 (20)	667 ± 12 (22)
36	675 ± 21 (20)	710 ± 19 (20)	701 ± 18 (17)	677 ± 19 (19)	674 ± 17 (20)	685 ± 13 (22)
40	684 ± 22 (18)	737 ± 21 (19)	717 ± 18 (19)	687 ± 18 (18)	692 ± 18 (20)	709 ± 14 (22)
44	717 ± 23 (20)	761 ± 21 (20)	738 ± 19 (19)	716 ± 20 (19)	712 ± 19 (20)	726 ± 15 (22)
48	731 ± 25 (20)	783 ± 23 (19)	758 ± 22 (19)	735 ± 22 (19)	735 ± 20 (20)	743 ± 16 (22)
52	753 ± 26 (20)	803 ± 23 (20)	775 ± 23 (19)	743 ± 23 (18)	751 ± 22 (20)	759 ± 17 (22)

3 ^aBPA doses are µg/kg bw/day. Numbers of litters are shown in parentheses. Outlier identification and exclusion are described in
 4 Materials and Methods and Supplemental Appendix XXIV. Pairwise comparisons of means were performed using contrasts
 5 within a two-way repeated measures, mixed model ANOVA. Model terms were treatment group, weeks, and the interaction.
 6 Within-group correlations were modeled using a heterogeneous first-order autoregressive (ARH(1)) correlation structure, which
 7 allows for correlated differences in variability across time points. Tests of trends, increasing treatment effect with increasing
 8 dose, were performed for the BPA and vehicle control groups. Pairwise comparisons of treatment groups to the vehicle control
 9 group were conducted with Dunnett's method to adjust for multiple comparisons. All tests were performed as two-sided tests at
 10 the 0.05 significance level. Full results of the analyses are presented in Supplemental Appendix XXIV. There were no
 11 statistically significant trends or pairwise comparisons to controls. There were also no significant treatment effects in the
 12 sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see
 13 Materials and Methods, Statistical Methods).

1 **Table 31. Male Postwean Body Weights (g), Vehicle and BPA Stop-Dose, Terminal (2 Years)**
 2 **Sacrifice (Mean ± S.E.M.)^a**

Week	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
4	61 ± 2* (50)	60 ± 2 (48)	59 ± 2 (48)	56 ± 2 (50)	58 ± 2 (50)	57 ± 2 (46)
8	270 ± 4 (49)	273 ± 5 (48)	281 ± 4 (48)	279 ± 4 (50)	271 ± 4 (50)	268 ± 5 (46)
12	428 ± 5 (49)	425 ± 6 (48)	437 ± 6 (48)	433 ± 5 (50)	426 ± 6 (50)	428 ± 7 (46)
16	509 ± 6 (49)	508 ± 7 (48)	522 ± 8 (48)	515 ± 7 (50)	511 ± 6 (50)	515 ± 8 (46)
20	567 ± 6 (49)	564 ± 8 (48)	582 ± 10 (48)	572 ± 8 (50)	569 ± 7 (50)	574 ± 9 (43)
24	606 ± 7 (49)	602 ± 9 (48)	619 ± 10 (48)	613 ± 9 (50)	608 ± 8 (49)	612 ± 10 (45)
28	637 ± 8 (48)	630 ± 10 (48)	648 ± 11 (45)	642 ± 10 (50)	635 ± 8 (49)	639 ± 10 (45)
32	664 ± 9 (47)	655 ± 10 (48)	673 ± 12 (48)	665 ± 10 (50)	661 ± 9 (49)	664 ± 11 (45)
36	688 ± 10 (49)	681 ± 11 (48)	698 ± 12 (48)	687 ± 11 (50)	683 ± 9 (49)	688 ± 12 (45)
40	704 ± 10 (47)	695 ± 11 (44)	724 ± 14 (44)	705 ± 14 (44)	700 ± 10 (46)	710 ± 14 (42)
44	732 ± 12 (46)	724 ± 12 (48)	746 ± 14 (47)	731 ± 14 (50)	723 ± 10 (48)	732 ± 15 (43)
48	752 ± 12 (49)	745 ± 13 (48)	763 ± 15 (48)	749 ± 15 (50)	744 ± 11 (49)	755 ± 16 (43)
52	772 ± 13 (49)	763 ± 14 (47)	781 ± 15 (48)	757 ± 14 (49)	756 ± 12 (49)	770 ± 17 (43)
56	789 ± 14 (49)	778 ± 15 (47)	800 ± 16 (48)	773 ± 15 (49)	778 ± 13 (49)	792 ± 18 (42)
60	811 ± 15 (48)	799 ± 17 (46)	813 ± 17 (46)	798 ± 16 (46)	793 ± 14 (49)	810 ± 19 (42)
64	831 ± 16 (48)	815 ± 16 (44)	832 ± 18 (46)	816 ± 17 (45)	815 ± 15 (47)	826 ± 20 (42)
68	855 ± 16 (46)	834 ± 18 (43)	846 ± 19 (46)	837 ± 17 (45)	836 ± 16 (45)	848 ± 22 (39)
72	874 ± 17 (46)	851 ± 19 (42)	861 ± 22 (43)	837 ± 19 (42)	858 ± 18 (44)	866 ± 22 (35)
76	884 ± 17 (44)	870 ± 21 (39)	896 ± 22 (40)	874 ± 19 (37)	869 ± 18 (41)	878 ± 24 (34)
80	888 ± 18 (43)	883 ± 23 (39)	913 ± 25 (38)	892 ± 22 (33)	875 ± 20 (40)	893 ± 30 (29)
84	896 ± 17 (39)	873 ± 22 (35)	920 ± 25 (36)	895 ± 24 (30)	879 ± 18 (37)	915 ± 32 (26)
88	906 ± 18 (37)	885 ± 26 (31)	932 ± 23 (33)	908 ± 30 (26)	874 ± 21 (34)	918 ± 34 (23)
92	903 ± 16 (32)	879 ± 25 (27)	911 ± 22 (31)	935 ± 35 (21)	887 ± 23 (30)	955 ± 28 (20)
96	903 ± 19 (29)	874 ± 28 (25)	901 ± 26 (27)	941 ± 44 (17)	884 ± 27 (27)	925 ± 30 (16)
100	928 ± 20 (21)	876 ± 29 (18)	893 ± 30 (21)	953 ± 49 (13)	878 ± 26 (25)	932 ± 31 (14)
104	908 ± 23 (16)	845 ± 30 (16)	908 ± 33 (16)	941 ± 45 (13)	863 ± 33 (16)	894 ± 37 (10)

3 ^aBPA doses are µg/kg bw/day. Numbers of litters are shown in parentheses. Outlier identification and exclusion are described in
 4 Materials and Methods and Supplemental Appendix XXV. Pairwise comparisons of means were performed using contrasts
 5 within a two-way repeated measures, mixed model ANOVA. Model terms were treatment group, weeks, and the interaction.
 6 Within-group correlations were modeled using a heterogeneous first-order autoregressive (ARH(1)) correlation structure, which
 7 allows for correlated differences in variability across time points. Tests of trends, increasing treatment effect with increasing
 8 dose, were performed for the BPA and vehicle control groups. Pairwise comparisons of treatment groups to the vehicle control

CLARITY-BPA Core Study, NTP RR 9

1 group were conducted with Dunnett's method to adjust for multiple comparisons. All tests were performed as two-sided tests at
2 the 0.05 significance level. Full results of the analyses are presented in Supplemental Appendix XXV. The only significant effect
3 is indicated with an asterisk (dose trend, week 4, $p = 0.043$). There were no additional significant treatment effects in the
4 sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 μg BPA/kg bw/day (see
5 Materials and Methods, Statistical Methods).

1 **Table 32. Vaginal Opening, Age and Body Weight (Means \pm S.E.M.) at Occurrence, Vehicle, BPA, and EE₂ Continuous-Dose^a**

Endpoint	Vehicle (26) ^b	2.5 BPA (25)	25 BPA (24)	250 BPA (25)	2500 BPA (25)	25000 BPA (24)	0.05 EE ₂ (25)	0.5 EE ₂ (21)
Age, days	35.9 \pm 1.1	35.2 \pm 0.7	36.5 \pm 0.8	37.8 \pm 1.4	34.1 \pm 0.5	35.4 \pm 0.6	35.5 \pm 0.7	34.8 \pm 2.8
Body weight, g	120.5 \pm 4.6	117.1 \pm 5.0	128.6 \pm 4.6	131.1 \pm 5.8	109.6 \pm 2.6	121.0 \pm 4.3	123.0 \pm 4.8	117.1 \pm 11.8

2 ^aBPA and EE₂ doses are μ g/kg bw/day. Twenty-six females (13 cages) from the 2-year continuous-dose groups were scheduled to be assessed for age and weight at vaginal
3 opening and undergo vaginal cytology later in the study to evaluate estrous cyclicity. There were no litter mates among these animals. Several dose groups have less than 26
4 animals due to either failure to record the information or delayed start of monitoring for vaginal opening. These incidents were documented in protocol deviations. BPA and EE₂
5 dose groups were analyzed separately. Analyses were performed using contrasts within a one-way ANOVA to test for treatment effect. Tests of trends, increasing treatment effect
6 with increasing dose, were performed for the BPA and vehicle control groups. Comparisons of dosed groups to vehicle control for age and body weight were performed with
7 Dunnett's method for adjusted contrasts. All tests were performed as two-sided tests at the 0.05 significance level. The full statistical report is found in Supplemental Appendix
8 XXVI. There were no statistically significant treatment effects. There were no additional significant treatment effects in the sensitivity analysis that excluded all animals that
9 overlapped with animals treated with 250,000 μ g BPA/kg bw/day (see Materials and Methods, Statistical Methods).

10 ^bNumbers in parentheses are the number of animals examined.

11 **Table 33. Vaginal Opening, Age and Body Weight (Means \pm S.E.M.) at Occurrence, Vehicle and BPA Stop-Dose^a**

Endpoint	Vehicle (26) ^b	2.5 BPA (26)	25 BPA (25)	250 BPA (26)	2500 BPA (26)	25000 BPA (26)
Age, days	41.1 \pm 1.8	42.1 \pm 2.5	40.0 \pm 1.5	39.6 \pm 1.2	42.4 \pm 1.2	38.0 \pm 1.3
Body weight, g	-	-	-	-	-	-

12 ^aBPA doses are μ g/kg bw/day. Twenty-six females (13 cages) from the 2-year stop-dose groups were scheduled to be assessed for age and weight at vaginal opening and undergo
13 vaginal cytology later in the study to evaluate estrous cyclicity. There were no litter mates among these animals. The 25 μ g BPA/kg bw/day dose group had one animal for which
14 the date of vaginal opening was not recorded. Due to a technical error, 31 animals in the stop-dose arm did not have body weights recorded on the day of vaginal opening and thus
15 this endpoint was not analyzed (Supplemental Appendix II, protocol deviations #72 - 74). Analysis was performed using contrasts within a one-way ANOVA to test for treatment
16 effect. Tests of trends, increasing treatment effect with increasing dose, were performed for the BPA and vehicle control groups. Comparisons of dosed groups to vehicle control
17 for age and body weight were performed with Dunnett's method for adjusted contrasts. All tests were performed as two-sided tests at the 0.05 significance level. The full statistical
18 report is found in Supplemental Appendix XXVI. There were no statistically significant treatment effects. There were no additional significant treatment effects in the sensitivity
19 analysis that excluded all animals that overlapped with animals treated with 250,000 μ g BPA/kg bw/day (see Materials and Methods, Statistical Methods).

20 ^bNumbers in parentheses are the number of animals examined.

1 **Table 34. Estrous Cycle Analysis, Vehicle, BPA, and EE₂ Continuous-Dose^a**

Endpoint	Vehicle (26) ^b	2.5 BPA (25)	25 BPA (26)	250 BPA (25)	2500 BPA (26)	25000 BPA (25)	0.05 EE ₂ (26)	0.5 EE ₂ (26)
# readable smears	362	348	359	348	362	348	363	361
% Diestrus	57.7	54.0	55.2	49.4	59.9	55.7	54.3	15.5
% Proestrus	13.8	14.9	11.1	17.2	13.8	12.6	11.0	0.8
% Estrus	28.5	31.0	33.7	33.3	26.2	31.6	34.7	83.7
Cycle length, days ^c	4.37 ± 0.18 ^d	4.56 ± 0.29 ^d	4.47 ± 0.21 ^e	5.20 ± 0.51 ^e	4.33 ± 0.15 ^e	4.84 ± 0.31 ^f	4.72 ± 0.33 ^d	5.58 ± 0.64 ^g
Abnormal Diestrus^h								
Abnormal	4	2	4	1	4	5	6	2
Normal	22	23	22	24	22	20	20	24
% Abnormal	15.4	8.0	15.4	4.0	15.4	20.0	23.1	7.7
Abnormal Estrus^h								
Abnormal	3	3	4	4	2	4	4	25
Normal	23	22	22	21	24	21	22	1
% Abnormal	11.5	12.0	15.4	16.0	7.7	16.0	15.4	96.2 ^{***}
Abnormal Proestrus^h								
Abnormal	0	0	0	1	1	1	0	0
Normal	26	25	26	24	25	24	26	26
% Abnormal	0	0	0	4.0	3.8	4.0	0	0
Combined Abnormal								
Abnormal	7	5	8	5	7	9	10	26
Normal	19	20	18	20	19	16	16	0
% Abnormal	26.9	20.0	30.8	20.0	26.9	36.0	38.5	100 ^{***}

2 ^aBPA and EE₂ doses are µg/kg bw/day. At 16 ± 2 weeks, daily vaginal smears were collected for 14 consecutive days from 26 animals (13 cages) assigned to the continuous-dose
3 study arm, two-year sacrifice. There were no litter mates among the animals.

4 ^bNumbers in parentheses are the number of animals examined. Any deviations from this number due to exclusions are indicated by footnotes.

5 ^cCycle length: first day of estrus in one sequence of contiguous days to the first day of estrus in the following sequence of stages. For cycle length, cycle days were defined from
6 the first day of estrus in one sequence of contiguous days to the first day of estrus in the following sequence of stages. Cycles were considered censored if the last stage of data
7 collection was either diestrus or proestrus. The number of animals, n, for this endpoint includes all animals with at least one uncensored cycle.

8 ^dn = 23.

9 ^en = 24.

10 ^fn = 22.

11 ^gn = 12.

12 ^hAbnormal (extended) diestrus was defined as four or more consecutive days of diestrus; abnormal estrus was defined as three or more consecutive days of estrus; and extended
13 proestrus was defined as two or more consecutive days of proestrus. The Cochran-Armitage trend test (one-sided) was performed, and Fisher's exact test (two-sided) was
14 conducted for comparisons of dosed groups to control. *P*-values for pairwise comparisons were corrected using Holm's method, and unadjusted *p*-values are also presented in the
15 full statistical report (Supplemental Appendix XXVII). BPA and EE₂ dose groups were analyzed separately. Statistically significant treatment effects are shown with asterisks and
16 were confined to the high EE₂ dose group; ***, *p* < 0.001. There were no additional significant effects in the sensitivity analysis that excluded all animals that overlapped with
17 animals treated with 250,000 µg BPA/kg bw/day (see Materials and Methods, Statistical Methods).

1 **Table 35. Estrous Cycle Analysis, Vehicle and BPA Stop-Dose^a**

Endpoint	Vehicle (26) ^b	2.5 BPA (26)	25 BPA (26)	250 BPA (26)	2500 BPA (26)	25000 BPA (26)
# readable smears	360	360	361	363	362	359
% Diestrus	56.4	60.3	52.4	51.2	58.3	58.8
% Proestrus	13.1	9.2	14.4	15.2	13.8	10.3
% Estrus	30.6	30.6	33.2	33.6	27.9	30.9
Cycle length, days ^c	4.08 ± 0.12 ^d	4.23 ± 0.13 ^e	4.17 ± 0.12 ^f	4.47 ± 0.23 ^g	4.42 ± 0.15	4.38 ± 0.17 ^h
Abnormal Diestrusⁱ						
Abnormal	5	5	2	1	4	5
Normal	21	21	24	25	22	21
% Abnormal	19.2	19.2	7.7	3.8	15.4	19.2
Abnormal Estrusⁱ						
Abnormal	5	2	3	5	2	3
Normal	21	24	23	21	24	23
% Abnormal	19.2	7.7	11.5	19.2	7.7	11.5
Abnormal Proestrusⁱ						
Abnormal	2	1	1	0	0	0
Normal	24	25	25	26	26	26
% Abnormal	7.7	3.8	3.8	0	0	0
Combined Abnormal						
Abnormal	10	7	5	6	6	8
Normal	16	19	21	20	20	18
% Abnormal	38.5	26.9	19.2 ^j	23.1	23.1	30.8

2 ^aBPA doses are µg/kg bw/day. At 16 ± 2 weeks, daily vaginal smears were collected for 14 consecutive days from 26 animals (13 cages) assigned to the stop-dose study arm, two-
3 year sacrifice. There were no litter mates among the animals.

4 ^bNumbers in parentheses are the number of animals examined. Any deviations from this number due to exclusions are indicated by footnotes.

5 ^cCycle length: first day of estrus in one sequence of contiguous days to the first day of estrus in the following sequence of stages. For cycle length, cycle days were defined from
6 the first day of estrus in one sequence of contiguous days to the first day of estrus in the following sequence of stages. Cycles were considered censored if the last stage of data
7 collection was either diestrus or proestrus. The number of animals, n, for this endpoint includes all animals with at least one uncensored cycle.

8 ^dn = 20.

9 ^en = 22.

10 ^fn = 23.

11 ^gn = 25.

12 ^hn = 24.

13 ⁱAbnormal (extended) diestrus was defined as four or more consecutive days of diestrus; abnormal estrus was defined as three or more consecutive days of estrus; and extended
14 proestrus was defined as two or more consecutive days of proestrus. The Cochran-Armitage trend test (one-sided) was performed, and Fisher's exact test (two-sided) was
15 conducted for comparisons of dosed groups to control. *P*-values for pairwise comparisons were corrected using Holm's method, and unadjusted *p*-values are also presented in the
16 full statistical report (Supplemental Appendix XXVII). There were no statistically significant treatment effects.

17 ^jIn the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Materials and Methods, Statistical Methods), there
18 was a significant difference for combined abnormal for BPA stop-dose 25 µg/kg bw/day compared to the vehicle control group (*p* = 0.038). The proportion of total % abnormal in
19 the 25 µg BPA/kg bw/day stop-dose group was lower than in the vehicle control (5.0% abnormal in the dosed group compared to 33.3% abnormal in the control).

1 **Table 36. Time to Onset of Aberrant Estrous Cycles in Vehicle, BPA, and EE₂ Continuous-Dose Groups^a**

Statistic	Vehicle (26) ^b	2.5 BPA (25)	25 BPA (25)	250 BPA (25)	2500 BPA (26)	25000 BPA (25)	0.05 EE ₂ (26)	0.5 EE ₂ (26)
% uncensored	88	96	100	84	81	96	88	23
% aberrant at start (left censored)	4	0	0	8	4	4	4	77
% with normal cycles at removal (right censored)	8	4	0	8	15	0	8	0
Median onset of aberrant cycles, weeks (lower and upper 95% confidence intervals)	56.8 (42.0, 66.9)	47.0 (36.9, 52.0)	51.9 (42.1, 56.9)	56.9 (46.9, 61.9)	52.0 (46.9, 56.7)	46.9 (41.7, 56.9)	51.8 (37, 62.1)	21.9*** (21.7, 22)
<i>p</i> -value	-	0.74	0.80	0.79	0.80	0.79	0.36	<0.001***

2 ^aBPA and EE₂ doses are µg/kg bw/day. One month after the collection of the 14 consecutive vaginal smears to evaluate the estrous cycle (Table 34), the same animals from the
3 continuous-dose, two-year study arm were monitored monthly for cycling status with five consecutive daily vaginal smears. The criteria for declaring an animal as having an
4 aberrant estrous cycle were 3 or more consecutive days of estrus (E, E/D, or P/E) or five consecutive days that did not include an estrus. The animal was no longer monitored after
5 two consecutive months with an aberrant cycle, and the time of onset of aberrant cycling was defined as having occurred at the first swab date of two consecutive months of
6 aberrant estrous cycle data. Separate analyses were conducted for the BPA and EE₂ dose groups. An accelerated failure time model assuming a lognormal distribution was used for
7 analysis, and multiple comparisons were adjusted using Holm's method for treatment comparisons to the control. All tests were performed as two-sided tests at the 0.05
8 significance level. The full statistical report is found in Supplemental Appendix XXVIII. Statistically significant results are marked with asterisks (***, *p* < 0.001). There were no
9 additional significant effects in the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Materials and Methods,
10 Statistical Methods).

11 ^bNumbers in parentheses are the number of animals examined.

1 **Table 37. Time to Onset of Aberrant Estrous Cycles in Vehicle and BPA Stop-Dose Groups^a**

Statistic	Vehicle (26) ^b	2.5 BPA (26)	25 BPA (26)	250 BPA (26)	2500 BPA (25)	25000 BPA (26)
% uncensored	88	77	96	88	80	92
% aberrant at start (left censored)	0	8	0	8	4	0
% with normal cycles at removal (right censored)	12	15	4	4	16	8
Median onset of aberrant cycles, weeks (lower and upper 95% confidence intervals)	41.9 (41.3, 51.7)	51.7 (36.9, 57.0)	46.8 (41.9, 56.9)	51.9 (41.9, 56.9)	56.9* (51.7, 66.6)	52.1 (41.9, 61.9)
<i>p</i> -value	-	1.00	0.83	1.00	0.03*	0.52

2 ^aBPA doses are µg/kg bw/day. One month after the collection of the 14 consecutive vaginal smears to evaluate the estrous cycle (Table 35), the same animals from the stop-dose
3 two-year study arm were monitored monthly for cycling status with five consecutive daily vaginal smears. The criteria for declaring an animal as having an aberrant estrous cycle
4 were 3 or more consecutive days of estrus (E, E/D, or P/E) or five consecutive days that did not include an estrus. The animal was no longer monitored after two consecutive
5 months with an aberrant cycle, and the time of onset of aberrant cycling was defined as having occurred at the first swab date of two consecutive months of aberrant estrous cycle
6 data. An accelerated failure time model assuming a lognormal distribution was used for analysis, and multiple comparisons were adjusted using Holm's method for treatment
7 comparisons to the control. All tests were performed as two-sided tests at the 0.05 significance level. The full statistical report is found in Supplemental Appendix XXVIII.
8 Statistically significant results are marked with an asterisk (*, *p* < 0.05). There were no additional significant effects in the sensitivity analysis that excluded all animals that
9 overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Materials and Methods, Statistical Methods).

10 ^bNumber in parentheses are the number of animals examined.

1 **Table 38. Female Hematology, Vehicle, BPA, and EE₂ Continuous-Dose, Interim Sacrifice (Mean ± S.E.M.)^a**

Endpoint, units	Vehicle (21) ^b	2.5 BPA (22)	25 BPA (21)	250 BPA (22)	2500 BPA (20)	25000 BPA (24)	0.05 EE ₂ (24)	0.5 EE ₂ (26)
Hematocrit, %	47.3 ± 0.4	46.0 ± 0.4	45.7 ± 0.5	47.4 ± 0.5	46.8 ± 0.5	47.5 ± 0.3	47.1 ± 0.5	46.7 ± 0.8
Hemoglobin, g/dL	16.4 ± 0.1*	16.0 ± 0.1	16.0 ± 0.2	16.5 ± 0.2	16.3 ± 0.2	16.5 ± 0.1	16.4 ± 0.2	16.3 ± 0.2
Red Blood Cells, 10 ⁶ /mm ³	8.3 ± 0.1	8.2 ± 0.1	8.1 ± 0.1	8.5 ± 0.1	8.3 ± 0.1	8.4 ± 0.1	8.3 ± 0.1	8.2 ± 0.1
% Reticulocytes	1.3 ± 0.1	1.3 ± 0	1.2 ± 0	1.4 ± 0.1	1.3 ± 0.1	1.2 ± 0.0	1.2 ± 0.0	1.2 ± 0.1
Packed Cell Volume, %	47.3 ± 0.4	46.0 ± 0.4	45.9 ± 0.5	47.4 ± 0.5	46.9 ± 0.5	47.5 ± 0.3	47.2 ± 0.5	46.9 ± 0.7
Mean Corpuscular Volume, μm ³	57.0 ± 0.4	56.5 ± 0.3	56.9 ± 0.4	56.0 ± 0.5	56.4 ± 0.4	56.6 ± 0.3	56.5 ± 0.3	56.8 ± 0.3
Mean Corpuscular Hemoglobin, pg	19.7 ± 0.2	19.6 ± 0.1	19.9 ± 0.2	19.4 ± 0.2	19.6 ± 0.1	19.7 ± 0.1	19.7 ± 0.1	19.8 ± 0.1
Mean Corpuscular Hemoglobin Concentration, g/dL	34.6 ± 0.1	34.8 ± 0.1	35.1 ± 0.2**	34.8 ± 0.1	34.7 ± 0.1	34.9 ± 0.1	34.8 ± 0.1	34.9 ± 0.1
Platelets, 10 ³ /mm ³	650.4 ± 21.3**	651.5 ± 28.5	651.0 ± 22.8	635.1 ± 21.5	633.1 ± 16.2	585.9 ± 20.5*	598.1 ± 17.4 ^c	597.7 ± 18.9*
White Blood Cells, 10 ³ /mm ³	8.4 ± 0.3	7.5 ± 0.3	7.9 ± 0.4	7.8 ± 0.4	8.1 ± 0.4	7.6 ± 0.3	8.0 ± 0.4	7.8 ± 0.4
Neutrophils, 10 ³ /mm ³	2.1 ± 0.2	2.1 ± 0.1	2.1 ± 0.2	2.0 ± 0.2	2.1 ± 0.2	1.8 ± 0.2	2.1 ± 0.2	2.0 ± 0.1
% Neutrophils	24.9 ± 2.3	29.6 ± 2.6	26.0 ± 1.4	25.6 ± 1.7	26.1 ± 1.6	23.8 ± 1.2	25.7 ± 1.5	25.6 ± 1.0
Lymphocytes, 10 ³ /mm ³	5.5 ± 0.3	4.6 ± 0.3	4.9 ± 0.3	5.0 ± 0.3	5.2 ± 0.3	5.1 ± 0.2	5.2 ± 0.3	5.1 ± 0.2
% Lymphocytes	66.1 ± 2.2	61.0 ± 2.5	62.9 ± 1.8	64.7 ± 1.8	64.6 ± 1.5	67.6 ± 1.5	65.4 ± 1.6	66.5 ± 1.0
Monocytes, 10 ³ /mm ³	0.6 ± 0.1*	0.6 ± 0.1	0.8 ± 0.1	0.7 ± 0.1	0.7 ± 0.1	0.6 ± 0.1	0.6 ± 0	0.5 ± 0
% Monocytes	7.4 ± 0.4	7.9 ± 0.6	9.5 ± 0.9 ^d	8.4 ± 0.8	8.0 ± 0.6	7.1 ± 0.5	7.2 ± 0.4	6.6 ± 0.4
Basophils, 10 ³ /mm ³	0.01 ± 0	0.01 ± 0	0.02 ± 0	0.01 ± 0	0.01 ± 0	0.01 ± 0	0.01 ± 0	0.01 ± 0
% Basophils	0.2 ± 0	0.2 ± 0	0.3 ± 0.1	0.2 ± 0	0.1 ± 0	0.2 ± 0	0.2 ± 0	0.2 ± 0
Eosinophils, 10 ³ /mm ³	0.12 ± 0.1	0.09 ± 0.01	0.11 ± 0.01	0.09 ± 0.01*	0.10 ± 0.01	0.10 ± 0.01	0.12 ± 0.01	0.09 ± 0.01*
% Eosinophils	1.4 ± 0.1	1.3 ± 0.1	1.4 ± 0.1	1.1 ± 0.1	1.2 ± 0.1	1.3 ± 0.1	1.5 ± 0.2	1.1 ± 0.1*

2 ^aBPA and EE₂ doses are μg/kg bw/day. A non-parametric ANOVA based on mid-ranks was used to evaluate the effect of treatment. The average of the left and right ranks was
3 used for ties. The five BPA treatments were compared to the vehicle control within each sex and dosing regimen. Similarly, the EE₂ reference estrogen control treatments were
4 compared to the vehicle control. Dunnett's adjustment was used for pairwise multiple comparisons relative to the control. Orthogonal contrasts were used to test for trend over
5 increasing BPA dose concentrations. All statistical tests are two-sided. Statistical significance was assessed at the 0.05 level. Statistically significant effects are indicated by
6 asterisks (*, $p < 0.05$; **, $p < 0.01$). Asterisks in the vehicle column indicate a significant trend in the BPA dose groups versus the vehicle control group. Full results of the
7 analyses are presented in Supplemental Appendix XXIX.

8 ^bNumbers in parentheses are the number of animals examined.

9 ^cPlatelet numbers in 0.05 EE₂ dose group significantly different from vehicle control ($p = 0.002$) in the sensitivity analysis that excluded all animals that overlapped with animals
10 treated with 250,000 μg BPA/kg bw/day.

11 ^d% monocytes in 25 BPA dose group significantly different from vehicle control ($p = 0.033$) in the sensitivity analysis that excluded all animals that overlapped with animals
12 treated with 250,000 μg BPA/kg bw/day.

1 **Table 39. Female Hematology, Vehicle and BPA Stop-Dose, Interim Sacrifice (Mean ± S.E.M.)^a**

Endpoint, units	Vehicle (20) ^b	2.5 BPA (22)	25 BPA (20)	250 BPA (22)	2500 BPA (20)	25000 BPA (19)
Hematocrit, %	46.9 ± 0.4	47.1 ± 0.4	47.3 ± 0.6	46.9 ± 0.5	46.6 ± 0.7	47.4 ± 0.4
Hemoglobin, g/dL	16.2 ± 0.1	16.4 ± 0.1	16.4 ± 0.2	16.2 ± 0.2	16.1 ± 0.2	16.3 ± 0.2
Red Blood Cells, 10 ⁶ /mm ³	8.3 ± 0.1*	8.3 ± 0.1	8.4 ± 0.1	8.4 ± 0.1	8.4 ± 0.1	8.5 ± 0.1
% Reticulocytes	1.3 ± 0.1	1.3 ± 0.1	1.2 ± 0.1	1.3 ± 0.1	1.3 ± 0.1	1.4 ± 0.1
Packed Cell Volume, %	47.0 ± 0.4	47.2 ± 0.4	47.3 ± 0.6	47.0 ± 0.5	46.6 ± 0.7	47.4 ± 0.4
Mean Corpuscular Volume, μm ³	56.2 ± 0.3	57.0 ± 0.4	56.3 ± 0.4	55.7 ± 0.5	55.7 ± 0.4	55.6 ± 0.3
Mean Corpuscular Hemoglobin, pg	19.5 ± 0.1*	19.9 ± 0.1	19.5 ± 0.2	19.3 ± 0.2	19.2 ± 0.2	19.1 ± 0.1
Mean Corpuscular Hemoglobin Concentration, g/dL	34.6 ± 0.1	34.8 ± 0.1	34.6 ± 0.1	34.6 ± 0.1	34.5 ± 0.1	34.4 ± 0.1
Platelets, 10 ³ /mm ³	645.1 ± 32.6	586.7 ± 21.6	592.6 ± 29.1	594.0 ± 26.2	646.1 ± 36.2	621.1 ± 19.5
White Blood Cells, 10 ³ /mm ³	8.0 ± 0.4	7.3 ± 0.4	8.2 ± 0.5	8.3 ± 0.4	8.7 ± 1.2	7.1 ± 0.4
Neutrophils, 10 ³ /mm ³	2.0 ± 0.1	1.7 ± 0.2	1.9 ± 0.2	2.1 ± 0.2	2.5 ± 0.7	1.7 ± 0.1
% Neutrophils	24.8 ± 1.1	23.5 ± 1.3	23.4 ± 1.2	25.1 ± 1.8	25.5 ± 1.7	24.1 ± 1.3
Lymphocytes, 10 ³ /mm ³	5.3 ± 0.3	4.9 ± 0.3	5.4 ± 0.3	5.3 ± 0.3	5.4 ± 0.4	4.6 ± 0.3
% Lymphocytes	66.3 ± 1.3	67.0 ± 1.6	66.3 ± 1.3	64.9 ± 1.8	65.6 ± 2.1	66.1 ± 1.7
Monocytes, 10 ³ /mm ³	0.6 ± 0	0.6 ± 0	0.7 ± 0.1	0.7 ± 0.1	0.8 ± 0.2	0.6 ± 0.1
% Monocytes	7.4 ± 0.5	8.0 ± 0.6	8.8 ± 0.8	8.4 ± 0.8	7.6 ± 0.8	8.5 ± 0.7
Basophils, 10 ³ /mm ³	0.01 ± 0	0.01 ± 0	0.02 ± 0	0.02 ± 0.01	0.01 ± 0	0.01 ± 0
% Basophils	0.1 ± 0*	0.2 ± 0	0.2 ± 0	0.3 ± 0.1	0.1 ± 0	0.1 ± 0
Eosinophils, 10 ³ /mm ³	0.11 ± 0.01	0.1 ± 0.01	0.1 ± 0.01	0.12 ± 0.01	0.09 ± 0.01	0.09 ± 0.01
% Eosinophils	1.35 ± 0.11	1.34 ± 0.13	1.28 ± 0.08	1.37 ± 0.09	1.17 ± 0.12	1.27 ± 0.1

2 ^aBPA doses are μg/kg bw/day. A non-parametric ANOVA based on mid-ranks was used to evaluate the effect of treatment. The five BPA treatments were compared to the vehicle
3 control, and Dunnett's adjustment was used for pairwise multiple comparisons relative to the control. Orthogonal contrasts were used to test for trend over increasing BPA dose
4 concentrations. All statistical tests are two-sided. Asterisks in the vehicle column indicate a significant trend (*, *p* < 0.05). Statistical significance was assessed at the 0.05 level.

5 Full results of the analyses are presented in Supplemental Appendix XXIX.

6 ^bNumbers in parentheses are the number of animals examined.

1 **Table 40. Male Hematology, Vehicle, BPA, and EE₂ Continuous-Dose, Interim Sacrifice (Mean ± S.E.M.)^a**

Endpoint, units	Vehicle (18) ^b	2.5 BPA (22)	25 BPA (18)	250 BPA (24)	2500 BPA (18)	25000 BPA (21)	0.05 EE ₂ (22)	0.5 EE ₂ (23)
Hematocrit, %	47.7 ± 0.4**	47.7 ± 0.5	46.9 ± 0.6	47.9 ± 0.4	47.8 ± 0.5	49.0 ± 0.5	48.8 ± 0.4	48.6 ± 0.3
Hemoglobin, g/dL	16.1 ± 0.1*	16.3 ± 0.2	16.0 ± 0.2	16.3 ± 0.1	16.3 ± 0.2	16.7 ± 0.2*	16.6 ± 0.1*	16.5 ± 0.1
Red Blood Cells, 10 ⁶ /mm ³	9.3 ± 0.1	9.3 ± 0.1	9.3 ± 0.1	9.4 ± 0.1	9.4 ± 0.1	9.4 ± 0.1	9.4 ± 0.1	9.5 ± 0.1
% Reticulocytes	1.3 ± 0.1	1.3 ± 0.1	1.3 ± 0.1	1.3 ± 0	1.3 ± 0.1	1.3 ± 0.1	1.2 ± 0.1	1.2 ± 0.1
Packed Cell Volume, %	47.7 ± 0.4**	47.7 ± 0.5	47.1 ± 0.6	47.9 ± 0.4	47.8 ± 0.5	49.0 ± 0.5	48.7 ± 0.4	48.6 ± 0.3
Mean Corpuscular Volume, μm ³	51.2 ± 0.2*	51.5 ± 0.3	50.5 ± 0.3	51.1 ± 0.3	51.0 ± 0.4	52.3 ± 0.5	51.7 ± 0.3	51.4 ± 0.3
Mean Corpuscular Hemoglobin, pg	17.3 ± 0.1*	17.6 ± 0.1	17.2 ± 0.1	17.4 ± 0.1	17.5 ± 0.2	17.8 ± 0.2	17.6 ± 0.1	17.4 ± 0.1
Mean Corpuscular Hemoglobin Concentration, g/dL	33.9 ± 0.1	34.1 ± 0.1	34.1 ± 0.1	34.1 ± 0.1	34.2 ± 0.1	34.0 ± 0.1	34.0 ± 0.1	34.0 ± 0.1
Platelets, 10 ³ /mm ³	751.3 ± 32.6*	716.2 ± 25.1 ^c	749.1 ± 45.3 ^d	702.3 ± 37.3	754.3 ± 18.1	671 ± 28.4	709.7 ± 26.7	740.6 ± 22.3
White Blood Cells, 10 ³ /mm ³	9.8 ± 0.5	10.3 ± 0.3	9.8 ± 0.4	10.5 ± 0.3	9.9 ± 0.6	9.4 ± 0.5	10.5 ± 0.5	11.1 ± 0.5
Neutrophils, 10 ³ /mm ³	2.3 ± 0.2	2.4 ± 0.2	2.2 ± 0.2	2.5 ± 0.2	2.1 ± 0.2	2.2 ± 0.2	2.2 ± 0.2	2.5 ± 0.1
% Neutrophils	22.9 ± 0.8	23.4 ± 1.4	22.5 ± 1.2	23.5 ± 1.0	22.1 ± 1.8	23.3 ± 1.2	21.4 ± 1.2	22.4 ± 0.9
Lymphocytes, 10 ³ /mm ³	6.6 ± 0.4	6.8 ± 0.3	6.5 ± 0.3	6.9 ± 0.2	6.9 ± 0.5	6.2 ± 0.4	7.1 ± 0.4	7.5 ± 0.4
% Lymphocytes	67.0 ± 1.1	66.0 ± 1.5	66.4 ± 1.8	66.0 ± 1.5	69.0 ± 1.8	65.9 ± 1.3	67.8 ± 1.4	67.5 ± 1.3
Monocytes, 10 ³ /mm ³	0.8 ± 0.1	0.9 ± 0.1	0.9 ± 0.1	1.0 ± 0.1	0.7 ± 0.1	0.9 ± 0.1	1.0 ± 0.1	1.0 ± 0.1
% Monocytes	8.2 ± 0.9	8.6 ± 0.7	9.5 ± 0.9	9.0 ± 0.8	7.5 ± 0.7	9.1 ± 0.6	9.3 ± 0.7	8.6 ± 0.6
Basophils, 10 ³ /mm ³	0.02 ± 0	0.02 ± 0	0.02 ± 0	0.02 ± 0	0.01 ± 0	0.02 ± 0	0.02 ± 0	0.03 ± 0.01
% Basophils	0.2 ± 0	0.2 ± 0	0.2 ± 0	0.2 ± 0	0.1 ± 0	0.2 ± 0	0.2 ± 0	0.2 ± 0.1
Eosinophils, 10 ³ /mm ³	0.17 ± 0.02	0.18 ± 0.02	0.15 ± 0.01	0.13 ± 0.01	0.13 ± 0.01	0.14 ± 0.02	0.14 ± 0.01	0.15 ± 0.01
% Eosinophils	1.71 ± 0.14	1.74 ± 0.23	1.53 ± 0.13	1.23 ± 0.1*	1.29 ± 0.09	1.44 ± 0.16	1.37 ± 0.11	1.33 ± 0.1

2 ^aBPA and EE₂ doses are μg/kg bw/day. A non-parametric ANOVA based on mid-ranks was used to evaluate the effect of treatment. The average of the left and right ranks was
3 used for ties. The five BPA treatments were compared to the vehicle control within each sex and dosing regimen. Similarly, the EE₂ reference estrogen control treatments were
4 compared to the vehicle control. Dunnett's adjustment was used for pairwise multiple comparisons relative to the control. Orthogonal contrasts were used to test for trend over
5 increasing BPA dose concentrations. All statistical tests are two-sided. Statistical significance was assessed at the 0.05 level. Statistically significant effects are indicated by
6 asterisks (*, *p* < 0.05; **, *p* < 0.01). Asterisks in the vehicle column indicate a significant trend. Asterisks in the BPA or EE₂ dose group columns indicate significant differences in
7 pairwise comparisons to the vehicle group. Full results of the analyses are presented in Supplemental Appendix XXIX.

8 ^bNumbers in parentheses are the number of animals examined. Any deviations from this number due to exclusions or missing data are indicated by footnotes.

9 ^cn = 21 in 2.5 μg BPA/kg bw/day platelet count due to missing data (no result reported) for one animal.

10 ^dn = 17 in 25 μg BPA/kg bw/day platelet count due to missing data (no result reported) for one animal.

1 **Table 41. Male Hematology, Vehicle and BPA Stop-Dose, Interim Sacrifice (Mean ± S.E.M.)^a**

Endpoint, units	Vehicle (19) ^b	2.5 BPA (20)	25 BPA (19)	250 BPA (19)	2500 BPA (20)	25000 BPA (22)
Hematocrit, %	48.5 ± 0.5	48.2 ± 0.4	47.5 ± 0.6	48.0 ± 0.6	47.0 ± 0.8	46.8 ± 1.0
Hemoglobin, g/dL	16.4 ± 0.2	16.3 ± 0.1	16.1 ± 0.2	16.2 ± 0.2	15.8 ± 0.3	15.9 ± 0.3
Red Blood Cells, 10 ⁶ /mm ³	9.5 ± 0.1	9.4 ± 0.1	9.3 ± 0.13	9.5 ± 0.1	9.2 ± 0.2	9.1 ± 0.2
% Reticulocytes	1.3 ± 0.1	1.2 ± 0.1	1.3 ± 0.1	1.2 ± 0.1	1.2 ± 0.1	1.2 ± 0.1
Packed Cell Volume, %	48.5 ± 0.5	48.2 ± 0.4	47.6 ± 0.6	48.0 ± 0.6	46.9 ± 0.8	46.8 ± 1.0
Mean Corpuscular Volume, μm ³	51.3 ± 0.3	51.2 ± 0.4	51.2 ± 0.3	50.7 ± 0.4	51.7 ± 1.0	51.4 ± 0.5
Mean Corpuscular Hemoglobin, pg	17.3 ± 0.1	17.3 ± 0.1	17.4 ± 0.1	17.1 ± 0.2	17.4 ± 0.3	17.5 ± 0.2
Mean Corpuscular Hemoglobin Concentration, g/dL	33.7 ± 0.1 ^c	33.8 ± 0.1	33.9 ± 0.1	33.6 ± 0.1	33.7 ± 0.1	33.9 ± 0.1
Platelets, 10 ³ /mm ³	753.5 ± 24.6	785.7 ± 24.1	769.0 ± 37.7	712.8 ± 35.2	742.3 ± 12.2	764.3 ± 30.3
White Blood Cells, 10 ³ /mm ³	10.5 ± 0.4	11.7 ± 1.0	10.3 ± 0.4	10.9 ± 0.6	10.8 ± 0.5	11.4 ± 0.8
Neutrophils, 10 ³ /mm ³	2.4 ± 0.2	3.5 ± 0.6	2.7 ± 0.3	2.8 ± 0.3	2.3 ± 0.1	2.4 ± 0.2
% Neutrophils	23.9 ± 2.0*	28.4 ± 2.3	25.9 ± 2.2	25.2 ± 2.1	21.0 ± 0.8	21.8 ± 1.6
Lymphocytes, 10 ³ /mm ³	7.1 ± 0.45	6.9 ± 0.4	6.4 ± 0.3	7.0 ± 0.5	7.5 ± 0.35	7.7 ± 0.6
% Lymphocytes	66.2 ± 2.2	60.9 ± 2.3	62.7 ± 2.2	63.5 ± 2.1	69.5 ± 0.9	67.5 ± 1.7
Monocytes, 10 ³ /mm ³	0.9 ± 0.1	1.1 ± 0.1	1.0 ± 0.1	1.0 ± 0.1	0.9 ± 0.1	1.1 ± 0.2
% Monocytes	8.3 ± 1.0	9.1 ± 0.8	9.6 ± 0.7	9.8 ± 1.0	8.1 ± 0.6	8.9 ± 0.9
Basophils, 10 ³ /mm ³	0.02 ± 0	0.02 ± 0	0.02 ± 0	0.02 ± 0	0.02 ± 0	0.02 ± 0
% Basophils	0.2 ± 0	0.2 ± 0	0.2 ± 0	0.2 ± 0	0.2 ± 0	0.2 ± 0
Eosinophils, 10 ³ /mm ³	0.15 ± 0.01	0.16 ± 0.01	0.16 ± 0.02	0.15 ± 0.02	0.13 ± 0.01	0.17 ± 0.01
% Eosinophils	1.46 ± 0.12	1.42 ± 0.09	1.58 ± 0.13	1.39 ± 0.13	1.23 ± 0.12	1.54 ± 0.11

2 ^aBPA doses are μg/kg bw/day. A non-parametric ANOVA based on mid-ranks was used to evaluate the effect of treatment. The five BPA treatments were compared to the vehicle
3 control, and Dunnett's adjustment was used for pairwise multiple comparisons relative to the control. Orthogonal contrasts were used to test for trend over increasing BPA dose
4 concentrations. All statistical tests are two-sided. Statistical significance was assessed at the 0.05 level. An asterisk in the vehicle column indicates a significant trend (*, *p* < 0.05)
5 versus the vehicle control. Full results of the analyses are presented in Supplemental Appendix XXIX.

6 ^bNumbers in parentheses are the number of animals examined.

7 ^cSignificant trend (*p* = 0.04) for mean corpuscular hemoglobin concentration in sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 μg
8 BPA/kg bw/day.

1 **Table 42. Female Clinical Chemistry, Vehicle, BPA, and EE₂ Continuous-Dose, Interim Sacrifice (Mean ± S.E.M.)^a**

Endpoint, units	Vehicle (21) ^b	2.5 BPA (22)	25 BPA (21)	250 BPA (22)	2500 BPA (20)	25000 BPA (24)	0.05 EE ₂ (24)	0.5 EE ₂ (26)
Urea nitrogen, mg/dL	14.4 ± 0.6	13.5 ± 0.3	14.0 ± 0.4	15.5 ± 0.6	14.5 ± 0.7	14.4 ± 0.4	14.5 ± 0.5	15.6 ± 0.6
Creatinine, mg/dL	0.5 ± 0	0.5 ± 0	0.5 ± 0	0.5 ± 0	0.5 ± 0	0.5 ± 0	0.5 ± 0	0.5 ± 0
Total protein, mg/dL	7.5 ± 0.1	7.6 ± 0.1	7.8 ± 0.1	7.4 ± 0.1	7.7 ± 0.1	7.6 ± 0.1	7.6 ± 0.1	7.7 ± 0.1
Albumin, g/dL	4.1 ± 0.1	4.0 ± 0.1	4.1 ± 0.1	4.0 ± 0.1	4.2 ± 0.1	4.2 ± 0.1	4.2 ± 0.1	4.2 ± 0.0
Alkaline phosphatase, U/L	54.3 ± 2.8	62.9 ± 3.6	72.1 ± 7.3	71.0 ± 5.5*	63.9 ± 3.6	58.1 ± 3.6	67.6 ± 3.8*	68.1 ± 5.5
Alanine aminotransferase, U/L	31.0 ± 3.0	37.5 ± 6.8	37.6 ± 4.8	34.2 ± 2.5	32.0 ± 2.3	29.0 ± 1.8	30.5 ± 1.6	37.0 ± 2.6
Aspartate aminotransferase, U/L	90.8 ± 8.0	82.5 ± 4.7	86.7 ± 10.6	76.2 ± 3.7	79.2 ± 4.5	78.9 ± 6.0	78.5 ± 3.7	80.3 ± 3.6
Sorbitol dehydrogenase, U/L	27.4 ± 4.2	30.5 ± 5.7	33.2 ± 5.5	24.1 ± 2.1	22.3 ± 2.1	24.2 ± 3.1	26.8 ± 2.0	19.4 ± 2.0
Gamma-glutamyl transferase, U/L	4.4 ± 0.3	4.1 ± 0.3	4.6 ± 0.3	4.0 ± 0.3	4.2 ± 0.3	4.2 ± 0.3	3.8 ± 0.2 ^c	3.9 ± 0.3
Total bile acids, μmol/L	47.0 ± 5.8	53.5 ± 9.9	49.7 ± 5.3	53.0 ± 5.3	51.4 ± 5.7	42.3 ± 5.6	50.6 ± 7.1	72.0 ± 9.1
Cholesterol, mg/dL	109.5 ± 4.4	111.7 ± 7.2	128.9 ± 11.1	107.6 ± 4.6	111.3 ± 7.6	107.7 ± 8.4	127.5 ± 6.6	121.5 ± 4.9
Glucose, mg/dL	130.0 ± 6.0	126.0 ± 4.8	130.2 ± 5	124.8 ± 4.8	122.1 ± 4.3	136.1 ± 6.6	128.8 ± 4.5	120.6 ± 3.3
Triglycerides, ng/mL	266 ± 24.3	258.6 ± 24.3	299.6 ± 41.5	237.5 ± 30.3	330.7 ± 40.3	331.6 ± 67.7	282.9 ± 34.5	369.4 ± 39.2
Insulin, mg/mL	1.5 ± 0.2	2.2 ± 0.4	2.0 ± 0.3	1.6 ± 0.2	1.6 ± 0.2	2.1 ± 0.5	2.0 ± 0.3	1.3 ± 0.1
Leptin, ng/mL	19.3 ± 2.4	27.8 ± 3.5	24.5 ± 3.1	18.5 ± 2.5	19.8 ± 2.1	20.7 ± 2.7	23.7 ± 2.9	17.9 ± 1.8
Troponin T, pg/mL ^d	10.3 ± 1.6	8.0 ± 1.7	10.2 ± 2.2	6.6 ± 1.9	5.9 ± 1.5	6.5 ± 1.9	6.3 ± 1.4	6.9 ± 1.9
T3, ng/dL	71.6 ± 3.5	72.1 ± 4.1	79.2 ± 4.3	70.8 ± 3	78.2 ± 3.5	73.3 ± 2.5	79.3 ± 2.6	78.0 ± 3.5
T4, μg/dL	3.8 ± 0.2 ^e	3.9 ± 0.2	3.8 ± 0.2	3.8 ± 0.2	3.9 ± 0.2	4.1 ± 0.2	4.2 ± 0.2	3.8 ± 0.2
TSH, ng/mL	3.7 ± 0.7	4.4 ± 0.9	3.6 ± 0.4	4.2 ± 0.4	4.9 ± 0.7	4.5 ± 0.4	3.4 ± 0.3	5.1 ± 0.5*

2 ^aBPA and EE₂ doses are μg/kg bw/day. A non-parametric ANOVA based on mid-ranks was used to evaluate the effect of treatment. The average of the left and right ranks was
3 used for ties. The five BPA treatments were compared to the vehicle control within each sex and dosing regimen. Similarly, the EE₂ reference estrogen control treatments were
4 compared to the vehicle control. Dunnett's adjustment was used for pairwise multiple comparisons relative to the control. Orthogonal contrasts were used to test for trend over
5 increasing BPA dose concentrations. All statistical tests are two-sided. Statistical significance was assessed at the 0.05 level. Statistically significant effects are indicated by
6 asterisks. Asterisks in the BPA or EE₂ dose group columns indicate significant differences in pairwise comparisons to the vehicle group (*, *p* < 0.05). Full results of the analyses
7 are presented in Supplemental Appendix XXIX.

8 ^bNumbers in parentheses are the number of animals examined. Any deviations from this number due to exclusions or missing data are indicated by footnotes.

9 ^cGamma-glutamyl transferase in 0.05 μg EE₂ /kg bw/day group significantly different from vehicle control (*p* = 0.018) in the sensitivity analysis that excluded all animals that
10 overlapped with animals treated with 250,000 μg BPA/kg bw/day.

11 ^dTroponin I was also measured, but the overall percentage of samples above the limit of detection was less than 5%, so no statistical analysis was conducted.

12 ^en = 20 in vehicle T4 assay due to insufficient quantity of serum for assay for one animal.

1 **Table 43. Female Clinical Chemistry, Vehicle and BPA Stop-Dose, Interim Sacrifice (Mean ± S.E.M.)^a**

Endpoint, units	Vehicle (20) ^b	2.5 BPA (22)	25 BPA (20)	250 BPA (22)	2500 BPA (20)	25000 BPA (19)
Urea nitrogen, mg/dL	13.9 ± 0.5	14.0 ± 0.5	14.5 ± 0.5	14.1 ± 0.5	14.3 ± 0.5	14.3 ± 0.5
Creatinine, mg/dL	0.5 ± 0.0	0.5 ± 0.0	0.5 ± 0.0	0.4 ± 0.0	0.5 ± 0.0	0.5 ± 0.0
Total protein, mg/dL	7.4 ± 0.1	7.7 ± 0.1	7.6 ± 0.1	7.6 ± 0.1	7.5 ± 0.1	7.7 ± 0.1
Albumin, g/dL	4.1 ± 0.1**	4.2 ± 0.1	4.0 ± 0.0	4.0 ± 0.1	4.0 ± 0.1	4.2 ± 0.0
Alkaline phosphatase, U/L	67.2 ± 3.8	75.4 ± 5.3	72.9 ± 3.8	62.5 ± 3.0	69.0 ± 6.0	83.1 ± 7.2
Alanine aminotransferase, U/L	29.2 ± 2.0	33.3 ± 2.9	35.2 ± 3.8	29.5 ± 2.0	29.7 ± 2.8	35.4 ± 3.6
Aspartate aminotransferase, U/L	77.5 ± 3.1	81.5 ± 5.7	82.8 ± 6.5	72.4 ± 3.3	76.5 ± 4.0	86.5 ± 7.9
Sorbitol dehydrogenase, U/L	24.5 ± 3.0 ^c	29.1 ± 3.5	31.8 ± 4.6	28.0 ± 1.9	22.3 ± 2.4	31.2 ± 2.7
Gamma-glutamyl transferase, U/L	4.4 ± 0.3	4.3 ± 0.3	3.6 ± 0.4	3.8 ± 0.3	3.8 ± 0.3	3.9 ± 0.3
Total bile acids, µmol/L	43.3 ± 4.1	48.9 ± 5.8	56.5 ± 6.1	44.8 ± 4.2	46.0 ± 4.7	59.2 ± 7.5
Cholesterol, mg/dL	116.9 ± 6.7	116.0 ± 7.4	108.6 ± 6.7	111.9 ± 5.1	113.4 ± 4.4	125.8 ± 12.5
Glucose, mg/dL	129.8 ± 3.8	137.2 ± 5.9	128.2 ± 4.5	128.4 ± 4.2	125.6 ± 5.4	125.4 ± 5.5
Triglycerides, ng/mL	261.2 ± 21.4	373.7 ± 68.4	253.2 ± 38.4	274.6 ± 55.8	342.2 ± 49.8	315.2 ± 27.7
Insulin, mg/mL	2.0 ± 0.3	2.6 ± 0.4	1.5 ± 0.2	2.3 ± 0.5	2.0 ± 0.3	2.1 ± 0.3
Leptin, ng/mL	24.2 ± 3.1	28.1 ± 3.4	22.2 ± 2.9	22.4 ± 2.5	22.2 ± 2.7	24.2 ± 2.8
T3, ng/dL	68.1 ± 3.3	72.1 ± 3.6	75.8 ± 3.2	71.0 ± 2.8	71.4 ± 4.1	78.7 ± 4.7
Troponin T, pg/mL ^d	7.0 ± 1.8	6.3 ± 1.5	3.6 ± 1.0	5.3 ± 1.0	6.5 ± 2.2	8.7 ± 2.9
T4, µg/dL	3.7 ± 0.2	3.6 ± 0.2	4.1 ± 0.2	3.7 ± 0.1	3.7 ± 0.2	3.7 ± 0.2
TSH, ng/mL	4.6 ± 0.8	3.5 ± 0.4	3.8 ± 0.5	4.8 ± 0.7	4.3 ± 0.5	4.7 ± 0.5

2 ^aBPA doses are µg/kg bw/day. A non-parametric ANOVA based on mid-ranks was used to evaluate the effect of treatment. The five BPA treatments were compared to the vehicle
3 control, and Dunnett's adjustment was used for pairwise multiple comparisons relative to the control. Orthogonal contrasts were used to test for trend over increasing BPA dose
4 concentrations. All statistical tests are two-sided. Statistical significance was assessed at the 0.05 level. Asterisks in the vehicle column indicates a significant trend (**, *p* < 0.01)
5 versus the vehicle control. Full results of the analyses are presented in Supplemental Appendix XXIX.

6 ^bNumbers in parentheses are the number of animals examined.

7 ^cSignificant trend (*p* = 0.002) for sorbitol dehydrogenase in the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day.

8 ^dTroponin I was also measured, but the overall percentage of samples above the limit of detection was less than 5%, so no statistical analysis was conducted.

1 **Table 44. Male Clinical Chemistry, Vehicle, BPA, and EE2 Continuous-Dose, Interim Sacrifice (Mean ± S.E.M.)^a**

Endpoint, units	Vehicle (18) ^b	2.5 BPA (22)	25 BPA (18)	250 BPA (24)	2500 BPA (18)	25000 BPA (21)	0.05 EE ₂ (22)	0.5 EE ₂ (23)
Urea nitrogen, mg/dL	14.2 ± 0.4	14.0 ± 0.3	14.3 ± 0.5	14.5 ± 0.4	14.3 ± 0.6	14.1 ± 0.3	14.4 ± 0.3	14.6 ± 0.4
Creatinine, mg/dL	0.4 ± 0	0.4 ± 0	0.4 ± 0	0.4 ± 0	0.4 ± 0	0.4 ± 0	0.4 ± 0	0.4 ± 0
Total protein, mg/dL	7.4 ± 0.1	7.3 ± 0.1	7.3 ± 0.1	7.2 ± 0.1	7.3 ± 0.1	7.3 ± 0.1	7.3 ± 0.1	7.2 ± 0.1
Albumin, g/dL	3.7 ± 0**	3.7 ± 0	3.6 ± 0	3.6 ± 0 ^c	3.7 ± 0.1	3.7 ± 0	3.7 ± 0	3.7 ± 0
Alkaline phosphatase, U/L	130.6 ± 24.1	107.2 ± 5.5	99.9 ± 5.4	98.7 ± 3.9	107.6 ± 7.7	99.7 ± 4.9	107.3 ± 4.5	104.2 ± 5.9
Alanine aminotransferase, U/L	30.1 ± 1.6	33.8 ± 2.4	27.3 ± 2.0	29.6 ± 1.3	32.0 ± 2.3	31.0 ± 1.9	30.6 ± 2.7	33.7 ± 2.0
Aspartate aminotransferase, U/L	69.7 ± 3.2	73.4 ± 4.8	73.5 ± 6.7	68.7 ± 2.4	76.7 ± 5.7	76.3 ± 6.4	79.9 ± 8.5	71.2 ± 3.0
Sorbitol dehydrogenase, U/L	24.5 ± 2.4	26.8 ± 2.7	26.6 ± 2.7	27.4 ± 3.0	24.4 ± 2.7	25.9 ± 2.8	31.5 ± 4.8	22.8 ± 2.0
Gamma-glutamyl transferase, U/L	4.1 ± 0.3	4.6 ± 0.3	4.2 ± 0.3	4.4 ± 0.3	4.8 ± 0.4	4.4 ± 0.3	4.2 ± 0.2	3.9 ± 0.2
Total bile acids, μmol/L	32.8 ± 2.7*	33.3 ± 4.1	32.5 ± 2.4	35.8 ± 3.4	42.0 ± 4.7	28.1 ± 2.7	38.6 ± 4.3	35.6 ± 3.2
Cholesterol, mg/dL	118.0 ± 6.4	116.9 ± 4.8	118.3 ± 6.7	107.4 ± 4.4	127.3 ± 6.7	107.2 ± 5.2	120.4 ± 6.4	117.5 ± 7.1
Glucose, mg/dL	126.1 ± 4.8	125.9 ± 3.9	127.1 ± 4.4	127.3 ± 6.1	136.3 ± 5.8	119.0 ± 3.4	125.4 ± 3.8	123.7 ± 4.1
Triglycerides, ng/mL	267.9 ± 23.4	278.2 ± 19.5	276.1 ± 20.6	252.9 ± 18.7	304.6 ± 24.3	283.0 ± 13.5	266.8 ± 19.1	338.4 ± 21.8*
Insulin, mg/mL	2.0 ± 0.2	1.6 ± 0.1	1.5 ± 0.1	1.4 ± 0.1	1.7 ± 0.3	1.8 ± 0.1	1.3 ± 0.1*	1.6 ± 0.1
Leptin, ng/mL	26 ± 2.5	29.2 ± 3.0	23.8 ± 2.3	26.3 ± 2.6	26.7 ± 3.0	29.4 ± 2.8	25.4 ± 2.6	27.2 ± 1.9
Troponin T, pg/mL ^d	7.4 ± 2.5**	5.9 ± 1.4	9.8 ± 2.4	8.5 ± 2.2	6.4 ± 1.5	11.8 ± 2.2	5.1 ± 1.3	7.2 ± 1.6
T3, ng/dL	62.8 ± 2.7	57.8 ± 3.4	63.3 ± 2.3	60.5 ± 3.0	67.3 ± 4.1	67.0 ± 4.0 ^e	70.5 ± 4.1	66.4 ± 3.5
T4, μg/dL	5.0 ± 0.3*	4.3 ± 0.3	5.0 ± 0.2	4.9 ± 0.2	4.7 ± 0.2	5.5 ± 0.2	5.1 ± 0.2	4.7 ± 0.2
TSH, ng/mL	3.6 ± 0.3	3.4 ± 0.3	3.4 ± 0.3	3.5 ± 0.4	3.5 ± 0.4	3.5 ± 0.4	4.1 ± 0.3	3.2 ± 0.4

2 ^aBPA and EE₂ doses are μg/kg bw/day. A non-parametric ANOVA based on mid-ranks was used to evaluate the effect of treatment. The average of the left and right ranks was
3 used for ties. The five BPA treatments were compared to the vehicle control within each sex and dosing regimen. Similarly, the EE₂ reference estrogen control treatments were
4 compared to the vehicle control. Dunnett's adjustment was used for pairwise multiple comparisons relative to the control. Orthogonal contrasts were used to test for trend over
5 increasing BPA dose concentrations. All statistical tests are two-sided. Statistical significance was assessed at the 0.05 level. Statistically significant effects are indicated by
6 asterisks (*, *p* < 0.05; **, *p* < 0.01). Asterisks in the vehicle column indicate a significant trend in the BPA dose groups versus the vehicle control. Asterisks in the BPA or EE₂
7 dose group columns indicate significant differences in pairwise comparisons to the vehicle group. Full results of the analyses are presented in Supplemental Appendix XXIX.

8 ^bNumbers in parentheses are the number of animals examined.

9 ^cAlbumin in 250 μg BPA/kg bw/day group significantly different from vehicle control (*p* = 0.012) in the sensitivity analysis that excluded all animals that overlapped with animals
10 treated with 250,000 μg BPA/kg bw/day.

11 ^dTroponin I was also measured, but the overall percentage of samples above the limit of detection was less than 5%, so no statistical analysis was conducted.

12 ^en = 20 in 2,500 BPA T3 assay due to insufficient quantity of serum for assay for one animal.

1 **Table 45. Male Clinical Chemistry, Vehicle and BPA Stop-Dose, Interim Sacrifice (Mean ± S.E.M.)^a**

Endpoint, units	Vehicle (20) ^b	2.5 BPA (20)	25 BPA (19)	250 BPA (19)	2500 BPA (20)	25000 BPA (22)
Urea nitrogen, mg/dL	14.1 ± 0.4	13.7 ± 0.3	15.0 ± 1.0	13.8 ± 0.6	14.4 ± 0.4	19.6 ± 3.7
Creatinine, mg/dL	0.4 ± 0	0.4 ± 0	0.5 ± 0	0.5 ± 0	0.4 ± 0	0.6 ± 0.1
Total protein, mg/dL	7.3 ± 0.1	7.1 ± 0.1	7.0 ± 0.1*	7.2 ± 0.1	7.2 ± 0.1	7.2 ± 0.1
Albumin, g/dL	3.6 ± 0	3.6 ± 0	3.5 ± 0.1	3.6 ± 0.1	3.6 ± 0.1	3.6 ± 0.1
Alkaline phosphatase, U/L	108.8 ± 7.9	100.4 ± 4.2	104.5 ± 5.7	103.5 ± 11.3	100.5 ± 5.3	102.9 ± 6.0
Alanine aminotransferase, U/L	32.4 ± 3.1	32.3 ± 2.0	28.5 ± 1.5	32.6 ± 5.5	26.7 ± 1.2	29.0 ± 2.6
Aspartate aminotransferase, U/L	84.6 ± 8.8	85.3 ± 4.5	82.7 ± 7.4	77.2 ± 7.1	68.8 ± 3.1	69.9 ± 3.6
Sorbitol dehydrogenase, U/L	25.0 ± 2.8	27.4 ± 2.8	32.0 ± 3.2	28.9 ± 2.8	26.7 ± 2.3	28.6 ± 2.9
Gamma-glutamyl transferase, U/L	4.3 ± 0.4	4.1 ± 0.3	4.2 ± 0.4	3.7 ± 0.3	4.8 ± 0.2	4.3 ± 0.3
Total bile acids, μmol/L	36.4 ± 3.1*	34.6 ± 3.2	25.0 ± 2.7*	32.6 ± 6.5	33.7 ± 4.3	35.0 ± 2.5
Cholesterol, mg/dL	123.5 ± 5.6	115.5 ± 5.9	115.3 ± 6.7	117.8 ± 8.9	132.7 ± 4.7	147.7 ± 14.2
Glucose, mg/dL	128.7 ± 5.3	121.9 ± 3.2	130.8 ± 5.9	120.1 ± 4.1	131.3 ± 4.7	125.2 ± 3.4
Triglycerides, ng/mL	285.2 ± 20.0	252.3 ± 15.4	282.3 ± 26.1	279.9 ± 16.5	355.2 ± 22	329.8 ± 24.2
Insulin, mg/mL	1.5 ± 0.2	1.5 ± 0.2	1.9 ± 0.2	1.5 ± 0.1	1.7 ± 0.2	1.6 ± 0.2
Leptin, ng/mL	26.8 ± 3.5	26.8 ± 1.7	32.9 ± 3.7	25.5 ± 3.4	28.0 ± 3.0	28.1 ± 2.8
Troponin T, pg/mL ^d	8.0 ± 1.9	5.9 ± 1.7	4.2 ± 1.3	7.7 ± 2.3	4.8 ± 1.6	5.1 ± 1.8
T3, ng/dL	65.8 ± 3.1	63.3 ± 3.3	56.7 ± 3.0	60.6 ± 4.5	69.4 ± 2.9	66.6 ± 2.8
T4, μg/dL	4.9 ± 0.2*	4.8 ± 0.2	4.7 ± 0.2	4.7 ± 0.2	4.7 ± 0.3	4.2 ± 0.2 ^c
TSH, ng/mL	4.0 ± 0.4	4.2 ± 0.4	3.8 ± 0.5	4.5 ± 0.5	5.0 ± 0.6	3.9 ± 0.4

2 ^aBPA doses are μg/kg bw/day. A non-parametric ANOVA based on mid-ranks was used to evaluate the effect of treatment. The five BPA treatments were compared to the vehicle
3 control, and Dunnett's adjustment was used for pairwise multiple comparisons relative to the control. Orthogonal contrasts were used to test for trend over increasing BPA dose
4 concentrations. All statistical tests are two-sided. Statistical significance was assessed at the 0.05 level. Statistically significant effects are indicated by asterisks (*, $p < 0.05$).
5 Asterisks in the vehicle column indicate a significant trend, while asterisks in BPA dose group columns indicate significant differences in pairwise comparisons to the vehicle
6 group. Full results of the analyses are presented in Supplemental Appendix XXIX.

7 ^bNumbers in parentheses are the number of animals examined.

8 ^c25,000 μg BPA/kg bw/day T4 significantly different from vehicle control ($p = 0.015$) in the sensitivity analysis that excluded all animals that overlapped with animals treated with
9 250,000 μg BPA/kg bw/day.

10 ^dTroponin I was also measured, but the overall percentage of samples above the limit of detection was less than 5%, so no statistical analysis was conducted.

CLARITY-BPA Core Study, NTP RR 9

1 **Table 46. Female Organ Weights, Vehicle, BPA, and EE₂ Continuous-Dose, Interim Sacrifice (Mean ± S.E.M.)^a**

Endpoint, units	Vehicle (21) ^b	2.5 BPA (22)	25 BPA (21)	250 BPA (22)	2500 BPA (20)	25000 BPA (24)	0.05 EE ₂ (24)	0.5 EE ₂ (26)
Body Weight at Necropsy								
g	420 ± 19	477 ± 22	445 ± 15	411 ± 14	422 ± 13	425 ± 17	453 ± 13	423 ± 12
Adrenal								
Absolute, mg	72.4 ± 2.0	76.4 ± 2.8	74.9 ± 3.8	75.4 ± 4.7	76.5 ± 3.8	73.3 ± 3.1	75.3 ± 4.2	92.2 ± 3.8***
Ratio to Brain, mg/g	34.8 ± 1.0	36.2 ± 1.4	35.6 ± 1.7	36.2 ± 2.2	37.4 ± 1.9	35.4 ± 1.5	36.0 ± 1.9	44.7 ± 1.9***
Ratio to bw, mg/g	0.18 ± 0.01	0.16 ± 0.01	0.17 ± 0.01	0.19 ± 0.01	0.18 ± 0.01	0.18 ± 0.01	0.17 ± 0.01	0.22 ± 0.01***
Brain								
Absolute, g	2.09 ± 0.02	2.11 ± 0.03	2.10 ± 0.02	2.08 ± 0.02	2.05 ± 0.03	2.08 ± 0.03	2.09 ± 0.02	2.07 ± 0.02
Ratio to bw, mg/g	5.16 ± 0.23	4.60 ± 0.19	4.82 ± 0.16	5.18 ± 0.17	4.93 ± 0.13	5.04 ± 0.18	4.71 ± 0.14	4.98 ± 0.13
Ovarian/Parametrial Fat Pad								
Absolute, g	14.1 ± 1.2	17.1 ± 1.0	14.4 ± 0.8	14.4 ± 0.8	14.8 ± 1.0	14.2 ± 0.9	15.5 ± 0.8	11.4 ± 0.6
Ratio to Brain, g/g	6.72 ± 0.54	8.13 ± 0.47	6.83 ± 0.35	6.93 ± 0.40	7.21 ± 0.44	6.83 ± 0.40	7.42 ± 0.35	5.50 ± 0.30
Ratio to bw, mg/g	32.3 ± 1.8	36.3 ± 1.7	32.2 ± 1.2	34.8 ± 1.2	34.7 ± 1.6	33.2 ± 1.3	34.1 ± 1.0	26.7 ± 1.0***
Retroperitoneal Fat Pad								
Absolute, g	14.1 ± 1.5	19.8 ± 2.0*	16.1 ± 1.4	14.1 ± 1.1	14.1 ± 1.2	14.7 ± 1.2	15.6 ± 1.2	13.0 ± 0.9
Ratio to Brain, g/g	6.72 ± 0.70	9.41 ± 0.97*	7.64 ± 0.67	6.76 ± 0.52	6.84 ± 0.55	7.09 ± 0.56	7.41 ± 0.58	6.26 ± 0.44
Ratio to bw, mg/g	32.4 ± 2.7	40.0 ± 2.8	35.0 ± 2.1	33.5 ± 1.7	32.9 ± 2.5	33.7 ± 1.6	33.7 ± 2.0	30.0 ± 1.5
Heart								
Absolute, g	1.31 ± 0.05	1.44 ± 0.04	1.42 ± 0.04	1.29 ± 0.03	1.31 ± 0.04	1.38 ± 0.04	1.40 ± 0.04	1.42 ± 0.04
Ratio to Brain, g/g	0.63 ± 0.02	0.68 ± 0.02	0.67 ± 0.02	0.62 ± 0.01	0.64 ± 0.02	0.66 ± 0.02	0.67 ± 0.02	0.68 ± 0.02
Ratio to bw, mg/g	3.16 ± 0.08	3.06 ± 0.08	3.21 ± 0.10	3.18 ± 0.09	3.13 ± 0.08	3.30 ± 0.08	3.13 ± 0.09	3.36 ± 0.04*
Kidney								
Absolute, g	2.27 ± 0.07	2.54 ± 0.08	2.51 ± 0.10	2.23 ± 0.06	2.31 ± 0.08	2.30 ± 0.07 ^c	2.42 ± 0.08 ^c	2.61 ± 0.08**
Ratio to Brain, g/g	1.09 ± 0.03	1.21 ± 0.04	1.20 ± 0.05	1.07 ± 0.03	1.12 ± 0.03	1.11 ± 0.03	1.15 ± 0.04	1.26 ± 0.04**
Ratio to bw, mg/g	5.50 ± 0.17	5.43 ± 0.17	5.69 ± 0.22	5.47 ± 0.12	5.51 ± 0.17	5.59 ± 0.13	5.34 ± 0.10	6.19 ± 0.10***
Liver								
Absolute, g	10.7 ± 0.5	12.4 ± 0.7	12.2 ± 0.5	10.8 ± 0.3	11.3 ± 0.5	11.6 ± 0.7	12.1 ± 0.4	12.8 ± 0.5**
Ratio to Brain, g/g	5.12 ± 0.24	5.90 ± 0.36	5.81 ± 0.25	5.18 ± 0.16	5.49 ± 0.21	5.60 ± 0.30	5.77 ± 0.20	6.17 ± 0.21**
Ratio to bw, mg/g	25.5 ± 0.6*	25.9 ± 0.8	27.3 ± 0.6	26.4 ± 0.6	26.7 ± 0.7	27.2 ± 0.7	26.7 ± 0.7	30.1 ± 0.5***
Ovary								
Absolute, mg	140 ± 8 ^d	147 ± 7	142 ± 6 ^d	138 ± 5 ^d	140 ± 7 ^d	140 ± 5 ^d	143 ± 4 ^d	115 ± 8 ^{*,d}
Ratio to Brain, mg/g	67 ± 3	70 ± 4	68 ± 3	66 ± 2	68 ± 3	68 ± 3	68 ± 2	56 ± 4*
Ratio to bw, mg/g	0.33 ± 0.02	0.32 ± 0.02	0.33 ± 0.01	0.34 ± 0.01	0.33 ± 0.01	0.34 ± 0.02	0.32 ± 0.01	0.28 ± 0.02*
Pituitary								
Absolute, mg	20.6 ± 1.1	21.2 ± 1.3	23.5 ± 1.8	20.4 ± 1.5	20.2 ± 1.4	21.6 ± 1.1	22.7 ± 1.7	26.9 ± 1.2**
Ratio to Brain, mg/g	9.9 ± 0.5	10.0 ± 0.6	11.2 ± 0.9	9.8 ± 0.7	9.9 ± 0.7	10.4 ± 0.5	10.8 ± 0.8	13.1 ± 0.6**
Ratio to bw, mg/g	0.05 ± 0	0.05 ± 0	0.05 ± 0	0.05 ± 0	0.05 ± 0	0.05 ± 0	0.05 ± 0	0.06 ± 0**

CLARITY-BPA Core Study, NTP RR 9

Endpoint, units	Vehicle (21) ^b	2.5 BPA (22)	25 BPA (21)	250 BPA (22)	2500 BPA (20)	25000 BPA (24)	0.05 EE ₂ (24)	0.5 EE ₂ (26)
Spleen								
Absolute, mg	598 ± 25	648 ± 27	638 ± 17	600 ± 20	642 ± 23	638 ± 26	645 ± 21	646 ± 25
Ratio to Brain, mg/g	286 ± 11	307 ± 13	304 ± 8	288 ± 9	314 ± 10	307 ± 11	308 ± 10	311 ± 11
Ratio to bw, mg/g	1.44 ± 0.05	1.37 ± 0.04	1.45 ± 0.05	1.48 ± 0.05	1.54 ± 0.05	1.52 ± 0.05	1.43 ± 0.04	1.52 ± 0.04
Thymus								
Absolute, mg	150 ± 11	185 ± 16	155 ± 12	135 ± 12	142 ± 9	151 ± 10	137 ± 10	137 ± 9
Ratio to Brain, mg/g	72 ± 5	88 ± 8	74 ± 6	65 ± 6	70 ± 5	73 ± 5	65 ± 5	66 ± 4
Ratio to bw, mg/g	0.37 ± 0.01	0.39 ± 0.03	0.35 ± 0.02	0.33 ± 0.03	0.34 ± 0.02	0.36 ± 0.02	0.30 ± 0.02	0.32 ± 0.02
Thyroid								
Absolute, mg	38.2 ± 1.7	37.4 ± 1.6	37.2 ± 1.5	35.8 ± 1.2	37.8 ± 2.0	38.5 ± 1.5	39.0 ± 1.8	36.5 ± 1.2
Ratio to Brain, mg/g	18.3 ± 0.8	17.8 ± 0.8	17.8 ± 0.7	17.2 ± 0.6	18.5 ± 1.0	18.6 ± 0.7	18.6 ± 0.8	17.7 ± 0.6
Ratio to bw, mg/g	0.09 ± 0	0.08 ± 0	0.08 ± 0	0.09 ± 0	0.09 ± 0	0.09 ± 0	0.09 ± 0	0.09 ± 0
Uterus								
Absolute, mg	773 ± 45	742 ± 52	872 ± 60 ^e	757 ± 58	831 ± 51	832 ± 61	777 ± 38	827 ± 37
Ratio to Brain, mg/g	371 ± 22	354 ± 26	414 ± 26	364 ± 28	411 ± 29	403 ± 30	372 ± 19	399 ± 16
Ratio to bw, mg/g	1.92 ± 0.15	1.64 ± 0.14	1.98 ± 0.15	1.89 ± 0.16	2.05 ± 0.17	2.07 ± 0.21	1.76 ± 0.11	1.97 ± 0.09

^aBPA and EE₂ doses are µg/kg bw/day. The indicated organs were collected from animals at the interim (one-year) necropsy and weights recorded. BPA and EE₂ groups were analyzed separately. Paired organs are presented and were analyzed as combined weights. ANOVA was performed for absolute organ weights to determine the effect of treatment on organ weight. Separate ANOCOVA were performed to determine the effect of treatment on organ weight adjusted for brain weight or receiving weight. Comparisons of dosed groups versus vehicle control were performed using Dunnett's method to adjust for multiple comparisons. Tests of trends, increasing treatment effect with increasing dose, were also performed for vehicle and BPA groups. Tests were conducted as two-sided at the 0.05 significance level. Statistically significant effects are indicated by asterisks (*, *p* < 0.05; **, *p* < 0.01; ***, *p* < 0.001); asterisks in the vehicle column indicate a significant trend, while asterisks in BPA or EE₂ dose group columns indicate significant differences in pairwise comparisons to the vehicle group. There were no additional statistically significant effects in the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Statistical Methods). The complete statistical report is found in Supplemental Appendix XXX.

^bNumbers in parentheses are the number of animals examined. Any deviations from this number due to exclusions are indicated by footnotes.

^cFor kidneys, n = 23 for both the 25,000 BPA and 0.05 EE₂ dose groups.

^dFor ovaries, n = 20 for vehicle group, 17 for 25 BPA, 21 for 250 BPA, 18 for 2,500 BPA, 21 for 25,000 BPA, and 23 for both 0.05 and 0.5 EE₂ dose groups.

^eFor uterus, n = 20 for 25 BPA dose group.

1 **Table 47. Female Organ Weights, Vehicle and BPA Stop-Dose, Interim Sacrifice (Mean ± S.E.M.)^a**

Endpoint, units	Vehicle (20) ^b	2.5 BPA (22)	25 BPA (20)	250 BPA (22)	2500 BPA (20)	25000 BPA (20)
Body weight						
g	465 ± 19	455 ± 14	437 ± 19	453 ± 19	454 ± 19	444 ± 14
Adrenal						
Absolute, mg	73.1 ± 2.9	70.0 ± 1.6	71.6 ± 2.7	71.2 ± 2.4	68.5 ± 2.9	75.6 ± 3.1
Ratio to Brain, mg/g	34.9 ± 1.3	33.4 ± 0.7	34.3 ± 1.3	34.8 ± 1.2	32.8 ± 1.3	36.5 ± 1.4
Ratio to bw, mg/g	0.16 ± 0.01	0.16 ± 0.01	0.17 ± 0	0.16 ± 0.01	0.16 ± 0.01	0.17 ± 0.01
Brain						
Absolute, g	2.09 ± 0.02	2.10 ± 0.02	2.09 ± 0.03	2.05 ± 0.02	2.09 ± 0.02	2.07 ± 0.02
Ratio to bw, mg/g	4.60 ± 0.14	4.68 ± 0.13	4.93 ± 0.20	4.68 ± 0.18	4.75 ± 0.20	4.75 ± 0.14
Ovarian/Parametrial Fat Pad						
Absolute, g	17.2 ± 1.2	16.2 ± 0.7	14.3 ± 1.0 ^c	15.3 ± 1.1	16.3 ± 1.1	15.0 ± 0.9
Ratio to Brain, g/g	8.17 ± 0.53	7.72 ± 0.33	6.84 ± 0.45 ^c	7.47 ± 0.51	7.79 ± 0.53	7.22 ± 0.41
Ratio to bw, mg/g	36.3 ± 1.3	35.4 ± 1.0	32.4 ± 1.1 ^c	33.3 ± 1.6	35.6 ± 1.7	33.3 ± 1.1
Retroperitoneal Fat Pad						
Absolute, g	18.2 ± 1.6	15.4 ± 1.5	17.0 ± 1.8	17.1 ± 1.5	16.2 ± 1.3	16.4 ± 1.4
Ratio to Brain, g/g	8.66 ± 0.67	7.36 ± 0.73	8.10 ± 0.87	8.28 ± 0.69	7.71 ± 0.61	7.93 ± 0.68
Ratio to bw, mg/g	38.1 ± 1.8	33.3 ± 2.6	37.0 ± 2.7	36.3 ± 2.1	34.8 ± 2.0	36.0 ± 2.3
Heart						
Absolute, g	1.43 ± 0.05	1.36 ± 0.02	1.35 ± 0.04	1.37 ± 0.04	1.38 ± 0.04	1.35 ± 0.04
Ratio to Brain, g/g	0.68 ± 0.02	0.65 ± 0.01	0.65 ± 0.02	0.67 ± 0.02	0.66 ± 0.02	0.65 ± 0.02
Ratio to bw, mg/g	3.11 ± 0.08	3.02 ± 0.07	3.13 ± 0.09	3.07 ± 0.10	3.06 ± 0.07	3.06 ± 0.08
Kidney						
Absolute, g	2.47 ± 0.11	2.30 ± 0.09 ^d	2.28 ± 0.09	2.41 ± 0.1 ^d	2.35 ± 0.09	2.38 ± 0.08
Ratio to Brain, g/g	1.18 ± 0.04	1.10 ± 0.04	1.09 ± 0.04	1.17 ± 0.04	1.12 ± 0.04	1.15 ± 0.04
Ratio to bw, mg/g	5.34 ± 0.12	5.17 ± 0.23	5.24 ± 0.12	5.38 ± 0.15	5.22 ± 0.14	5.39 ± 0.15
Liver						
Absolute, g	12.3 ± 0.7	11.5 ± 0.4	11.2 ± 0.6	12.1 ± 0.6	12.0 ± 0.6	11.6 ± 0.4
Ratio to Brain, g/g	5.86 ± 0.28	5.52 ± 0.19	5.38 ± 0.27	5.89 ± 0.26	5.70 ± 0.25	5.63 ± 0.20
Ratio to bw, mg/g	26.4 ± 0.8	25.4 ± 0.6	25.7 ± 0.6	26.8 ± 0.8	26.4 ± 0.9	26.3 ± 0.6
Ovary						
Absolute, mg	157 ± 6 [*]	149 ± 4	148 ± 6	147 ± 4	147 ± 6	136 ± 5 [*]
Ratio to Brain, mg/g	75 ± 3 [*]	71 ± 2	71 ± 3	72 ± 2	70 ± 3	66 ± 3 [*]
Ratio to bw, mg/g	0.34 ± 0.02 [*]	0.33 ± 0.01	0.35 ± 0.02	0.33 ± 0.02	0.33 ± 0.01	0.31 ± 0.01
Pituitary						
Absolute, mg	21.1 ± 1	20.3 ± 0.8	19.9 ± 1.3	20.1 ± 0.7	19 ± 0.9	20.3 ± 1.1
Ratio to Brain, mg/g	10.0 ± 0.4	9.7 ± 0.4	9.6 ± 0.7	9.8 ± 0.3	9.1 ± 0.4	9.8 ± 0.5
Ratio to bw, mg/g	0.05 ± 0	0.04 ± 0	0.05 ± 0	0.05 ± 0	0.04 ± 0	0.05 ± 0

CLARITY-BPA Core Study, NTP RR 9

Endpoint, units	Vehicle (20) ^b	2.5 BPA (22)	25 BPA (20)	250 BPA (22)	2500 BPA (20)	25000 BPA (20)
Spleen						
Absolute, mg	678 ± 30	618 ± 16	612 ± 24 ^e	693 ± 24	659 ± 30	611 ± 17
Ratio to Brain, mg/g	323 ± 11	295 ± 7 ^e	293 ± 11 ^e	339 ± 12	315 ± 14	295 ± 8
Ratio to bw, mg/g	1.47 ± 0.05	1.37 ± 0.04	1.41 ± 0.04	1.56 ± 0.06	1.48 ± 0.07	1.40 ± 0.05
Thymus						
Absolute, mg	154 ± 7	139 ± 6 ^f	142 ± 10	164 ± 14	150 ± 11	167 ± 12
Ratio to Brain, mg/g	74 ± 3	67 ± 3	68 ± 5	80 ± 7	72 ± 5	80 ± 6
Ratio to bw, mg/g	0.34 ± 0.02	0.31 ± 0.02	0.32 ± 0.02	0.37 ± 0.03	0.34 ± 0.03	0.38 ± 0.02
Thyroid						
Absolute, mg	37.8 ± 2.2	36.0 ± 1.6	36.3 ± 1.7	36.3 ± 1.3	38.2 ± 2.3	36.9 ± 1.7
Ratio to Brain, mg/g	18.0 ± 1	17.2 ± 0.8	17.4 ± 0.8	17.7 ± 0.6	18.3 ± 1.1	17.8 ± 0.8
Ratio to bw, mg/g	0.08 ± 0	0.08 ± 0	0.08 ± 0	0.08 ± 0	0.08 ± 0	0.08 ± 0
Uterus						
Absolute, mg	744 ± 46	699 ± 45	795 ± 80	843 ± 76 ^g	747 ± 54	789 ± 51
Ratio to Brain, mg/g	356 ± 22	334 ± 22	382 ± 40	410 ± 35	360 ± 28	381 ± 24
Ratio to bw, mg/g	1.67 ± 0.14	1.58 ± 0.12	1.87 ± 0.19	1.93 ± 0.20	1.74 ± 0.16	1.83 ± 0.14

^aBPA doses are µg/kg bw/day. The indicated organs were collected from animals at the interim (one-year) necropsy and weights recorded. Paired organs are presented and were analyzed as combined weights. ANOVA was performed for absolute organ weights to determine the effect of treatment on organ weight. Separate ANOCOVA were performed to determine the effect of treatment on organ weight adjusted for brain weight or receiving body weight. Comparisons of dosed groups versus vehicle control were performed using Dunnett's method to adjust for multiple comparisons. Tests of trends, increasing treatment effect with increasing dose, were also performed. Tests were conducted as two-sided at the 0.05 significance level. Statistically significant effects are indicated by asterisks (*, $p < 0.05$); asterisks in the vehicle column indicate a significant trend, while asterisks in BPA dose group columns indicate significant differences in pairwise comparisons to the vehicle group. The complete statistical report is found in Supplemental Appendix XXX.

^bNumbers in parentheses are the number of animals examined. Any deviations from this number due to exclusions are indicated by footnotes.

^c25 BPA ovarian/parametrial fat pad weight significantly different from vehicle control in sensitivity analysis (see Statistical Methods) that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day: absolute weight, 25.7% lower than control ($p = 0.010$); brain as covariate, 25% lower than control ($p = 0.010$); body weight as covariate, 13.7% lower than control ($p = 0.035$).

^dn = 21 for kidneys in the 2.5 and 250 BPA dose groups. One kidney weight in each indicated dose group was excluded because kidneys had grossly observable cysts.

^eSpleen weight statistically different from vehicle control in sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Statistical Methods): 2.5 BPA, brain covariate, 13.1% lower than control ($p = 0.039$); 25 BPA absolute and brain covariate, 14.2% and 13.7% lower than control, respectively ($p = 0.023$ for both).

^fn = 21 for thymus in the 2.5 BPA dose group, one (627 mg) excluded as a statistical outlier.

^gn = 21 for uterus in the 250 BPA dose group, one (4,680 mg) excluded as it was the only uterus noted to be fluid filled.

1 Table 48. Male Organ Weights, Vehicle, BPA, and EE₂ Continuous-Dose, Interim Sacrifice (Mean ± S.E.M.)^a

Endpoint, units	Vehicle (18) ^b	2.5 BPA (22)	25 BPA (18)	250 BPA (24)	2500 BPA (18)	25000 BPA (21)	0.05 EE ₂ (22)	0.5 EE ₂ (23)
Body Weight at Necropsy								
g	701 ± 19	722 ± 20	709 ± 21	713 ± 15	704 ± 26	695 ± 18	712 ± 21	704 ± 16
Adrenal								
Absolute, mg	60.1 ± 2.8	64.2 ± 2.8	68.0 ± 2.4	62.5 ± 2.1	61.7 ± 2.6	57.4 ± 1.7	62.6 ± 2.2 ^c	62.9 ± 1.8
Ratio to Brain, mg/g	26.1 ± 1.2	27.8 ± 1.1	29.7 ± 1.1	27.8 ± 0.8	27.0 ± 1.0	25.7 ± 0.8	27.4 ± 0.9	27.1 ± 0.7
Ratio to bw, mg/g	0.09 ± 0	0.09 ± 0	0.10 ± 0	0.09 ± 0	0.09 ± 0	0.08 ± 0	0.09 ± 0	0.09 ± 0
Brain								
Absolute, g	2.30 ± 0.02	2.31 ± 0.03	2.30 ± 0.04	2.24 ± 0.03	2.28 ± 0.03	2.24 ± 0.02	2.29 ± 0.02	2.32 ± 0.02
Ratio to bw, mg/g	3.32 ± 0.07	3.25 ± 0.10	3.27 ± 0.08	3.18 ± 0.08	3.30 ± 0.10	3.26 ± 0.08	3.27 ± 0.09	3.32 ± 0.07
Epididymides								
Absolute, g	1.28 ± 0.04	1.21 ± 0.04	1.32 ± 0.02	1.27 ± 0.04	1.27 ± 0.04	1.25 ± 0.02	1.24 ± 0.03	1.34 ± 0.03
Ratio to Brain, g/g	0.56 ± 0.02	0.53 ± 0.02	0.58 ± 0.01	0.56 ± 0.02	0.56 ± 0.01	0.56 ± 0.01	0.54 ± 0.01	0.58 ± 0.01
Ratio to bw, mg/g	1.85 ± 0.06	1.70 ± 0.07	1.89 ± 0.06	1.79 ± 0.06	1.83 ± 0.06	1.82 ± 0.06	1.76 ± 0.06	1.90 ± 0.04
Epididymal Fat Pad								
Absolute, g	13.0 ± 0.7	14.5 ± 0.8	13.6 ± 0.6	14.1 ± 0.8	14.3 ± 1.2	14.2 ± 1.0	14.2 ± 0.8	12.8 ± 0.8
Ratio to Brain, g/g	5.62 ± 0.26	6.28 ± 0.37	5.91 ± 0.23	6.29 ± 0.39	6.24 ± 0.50	6.35 ± 0.45	6.18 ± 0.32	5.54 ± 0.33
Ratio to bw, mg/g	18.5 ± 0.8	19.8 ± 0.7	19.2 ± 0.7	19.5 ± 1.0	20.0 ± 1.1	20.2 ± 1.2	19.8 ± 0.7	18.0 ± 0.8
Retroperitoneal Fat Pad								
Absolute, g	22.2 ± 1.8	22.8 ± 1.6	24.5 ± 2.5	22.9 ± 1.9	21.8 ± 2.7	23.6 ± 2.4	22.6 ± 2.3	21.0 ± 2.3
Ratio to Brain, g/g	9.59 ± 0.74	9.88 ± 0.69	10.57 ± 1.02	10.19 ± 0.81	9.56 ± 1.21	10.59 ± 1.09	9.79 ± 0.97	9.04 ± 1.01
Ratio to bw, mg/g	31.3 ± 2.0	30.9 ± 1.5	33.7 ± 2.6	31.5 ± 2.3	29.7 ± 2.7	33.2 ± 2.9	30.9 ± 2.5	29.0 ± 2.7
Heart								
Absolute, g	2.04 ± 0.06	2.14 ± 0.05	2.26 ± 0.08	2.21 ± 0.07	2.19 ± 0.07	1.99 ± 0.04	2.11 ± 0.06	2.12 ± 0.05
Ratio to Brain, g/g	0.89 ± 0.02	0.93 ± 0.02	0.99 ± 0.04	0.98 ± 0.03	0.96 ± 0.03	0.89 ± 0.02	0.92 ± 0.02	0.91 ± 0.02
Ratio to bw, mg/g	2.92 ± 0.07	3.00 ± 0.09	3.20 ± 0.10	3.11 ± 0.10	3.14 ± 0.09	2.88 ± 0.05	2.99 ± 0.08	3.02 ± 0.08
Kidney								
Absolute, g	4.08 ± 0.15 ^d	4.20 ± 0.12	4.15 ± 0.17 ^d	4.05 ± 0.11	4.00 ± 0.17 ^d	3.88 ± 0.08	4.01 ± 0.13 ^d	4.17 ± 0.12
Ratio to Brain, g/g	1.77 ± 0.05	1.82 ± 0.05	1.80 ± 0.06	1.80 ± 0.04	1.75 ± 0.07	1.73 ± 0.04	1.75 ± 0.05	1.80 ± 0.05
Ratio to bw, mg/g	5.83 ± 0.14	5.85 ± 0.14	5.87 ± 0.15	5.70 ± 0.12	5.67 ± 0.16	5.62 ± 0.11	5.63 ± 0.10	5.91 ± 0.09
Liver								
Absolute, mg	22.1 ± 0.9	21.1 ± 0.7	22.6 ± 1.0	22.4 ± 0.6	22.1 ± 1.0	20.6 ± 0.6	22.2 ± 0.7	23.1 ± 0.6
Ratio to Brain, g/g	9.58 ± 0.34	9.15 ± 0.29	9.84 ± 0.34	9.97 ± 0.26	9.71 ± 0.43	9.21 ± 0.26	9.66 ± 0.29	9.96 ± 0.29
Ratio to bw, mg/g	31.4 ± 0.6	29.3 ± 0.6*	31.9 ± 0.8	31.4 ± 0.5	31.4 ± 0.6	29.7 ± 0.5	31.1 ± 0.5	32.7 ± 0.4
Pituitary								
Absolute, mg	14.6 ± 0.7	14.6 ± 0.6	15.2 ± 0.6	16.1 ± 1.2	15.4 ± 0.8	15.1 ± 0.6	15.6 ± 0.6	16.0 ± 0.5
Ratio to Brain, mg/g	6.3 ± 0.2	6.3 ± 0.3	6.7 ± 0.3	7.1 ± 0.5	6.7 ± 0.4	6.7 ± 0.3	6.8 ± 0.3	6.9 ± 0.2
Ratio to bw, mg/g	0.02 ± 0	0.02 ± 0	0.02 ± 0	0.02 ± 0	0.02 ± 0	0.02 ± 0	0.02 ± 0	0.02 ± 0

CLARITY-BPA Core Study, NTP RR 9

Endpoint, units	Vehicle (18) ^b	2.5 BPA (22)	25 BPA (18)	250 BPA (24)	2500 BPA (18)	25000 BPA (21)	0.05 EE ₂ (22)	0.5 EE ₂ (23)
Seminal Vesicles								
Absolute, g	1.18 ± 0.04	1.11 ± 0.05	1.14 ± 0.05	1.17 ± 0.05	1.10 ± 0.06	1.19 ± 0.04	1.27 ± 0.06	1.12 ± 0.04
Ratio to Brain, g/g	0.51 ± 0.02	0.48 ± 0.02	0.50 ± 0.02	0.52 ± 0.02	0.48 ± 0.02	0.53 ± 0.02	0.56 ± 0.03	0.49 ± 0.02
Ratio to bw, mg/g	1.70 ± 0.06	1.56 ± 0.07	1.64 ± 0.09	1.66 ± 0.08	1.58 ± 0.10	1.73 ± 0.08	1.82 ± 0.10	1.60 ± 0.05
Spleen								
Absolute, g	0.92 ± 0.03	0.96 ± 0.03	0.97 ± 0.04	0.96 ± 0.03	0.96 ± 0.04	0.87 ± 0.03	0.94 ± 0.04	1.01 ± 0.05
Ratio to Brain, g/g	0.40 ± 0.01	0.42 ± 0.01	0.42 ± 0.02	0.43 ± 0.01	0.42 ± 0.02	0.39 ± 0.01	0.41 ± 0.02	0.44 ± 0.02
Ratio to bw, mg/g	1.33 ± 0.05	1.33 ± 0.04	1.39 ± 0.06	1.36 ± 0.04	1.36 ± 0.05	1.26 ± 0.04	1.32 ± 0.04	1.44 ± 0.07
Testes								
Absolute, mg	3.59 ± 0.12	3.44 ± 0.13	3.62 ± 0.08	3.38 ± 0.14	3.56 ± 0.08	3.51 ± 0.12	3.48 ± 0.09	3.56 ± 0.09
Ratio to Brain, g/g	1.56 ± 0.05	1.50 ± 0.06	1.58 ± 0.04	1.50 ± 0.06	1.56 ± 0.03	1.57 ± 0.05	1.52 ± 0.04	1.54 ± 0.04
Ratio to bw, mg/g	5.16 ± 0.18	4.82 ± 0.21	5.18 ± 0.19	4.77 ± 0.21	5.12 ± 0.13	5.14 ± 0.22	4.96 ± 0.18	5.09 ± 0.13
Thymus								
Absolute, mg	150 ± 11	138 ± 9	125 ± 12	158 ± 10	140 ± 10	150 ± 11	124 ± 11	154 ± 10
Ratio to Brain, g/g	65 ± 5	60 ± 4	54 ± 5	71 ± 4	62 ± 5	67 ± 5	54 ± 5	67 ± 4
Ratio to bw, mg/g	0.22 ± 0.02	0.20 ± 0.02	0.18 ± 0.02	0.22 ± 0.01	0.20 ± 0.02	0.22 ± 0.02	0.17 ± 0.01	0.22 ± 0.01
Thyroid								
Absolute, mg	43.5 ± 2.0	42.7 ± 2.4	44.0 ± 2.5	42.2 ± 1.6	40.9 ± 1.9	44.5 ± 1.8	43.6 ± 2.0	43.7 ± 1.5
Ratio to Brain, mg/g	18.8 ± 0.8	18.5 ± 1.0	19.1 ± 1.0	18.8 ± 0.7	17.8 ± 0.7	19.9 ± 0.8	19.0 ± 0.9	18.9 ± 0.6
Ratio to bw, mg/g	0.06 ± 0	0.06 ± 0	0.06 ± 0	0.06 ± 0	0.06 ± 0	0.06 ± 0	0.06 ± 0	0.06 ± 0

^aBPA and EE₂ doses are µg/kg bw/day. The indicated organs were collected from animals at the interim (one-year) necropsy and weights recorded. BPA and EE₂ groups were analyzed separately. Paired organs are presented and were analyzed as combined weights. ANOVA was performed for absolute organ weights to determine the effect of treatment on organ weight. Separate ANOCOVA were performed to determine the effect of treatment on organ weight adjusted for brain weight or receiving weight. Comparisons of dosed groups versus vehicle control were performed using Dunnett's method to adjust for multiple comparisons. Tests of trends, increasing treatment effect with increasing dose, were also performed for vehicle and BPA groups. Tests were conducted as two-sided at the 0.05 significance level. Statistically significant effects are indicated by asterisks (*, *p* < 0.05). There were no additional statistically significant effects in the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Statistical Methods). The complete statistical report is found in Supplemental Appendix XXX.

^bNumbers in parentheses are the number of animals examined. Any deviations from this number due to exclusions are indicated by footnotes.

^cFor adrenal, n = 21 for the 0.05 EE₂ dose group.

^dFor kidneys, n = 17 for vehicle, 25 BPA, and 2,500 BPA dose groups; n = 21 for 0.05 EE₂ dose group.

1 **Table 49. Male Organ Weights, Vehicle and BPA Stop-Dose, Interim Sacrifice (Mean ± S.E.M.)^a**

Endpoint, units	Vehicle (20) ^b	2.5 BPA (20)	25 BPA (19)	250 BPA (19)	2500 BPA (20)	25000 BPA (22)
Body Weight at Necropsy						
g	735 ± 26	787 ± 23	760 ± 22	733 ± 21	738 ± 21	743 ± 17
Adrenal						
Absolute, mg	63.4 ± 2.0	65.7 ± 2.1	67.9 ± 3.3	68.9 ± 2.7	65.4 ± 3.5	68.3 ± 3.3
Ratio to Brain, mg/g	27.3 ± 0.8	28.2 ± 0.9	29.3 ± 1.5	30.0 ± 1.3	28.7 ± 1.4	29.6 ± 1.3
Ratio to bw, mg/g	0.09 ± 0	0.08 ± 0	0.09 ± 0	0.10 ± 0	0.09 ± 0	0.09 ± 0
Brain						
Absolute, g	2.32 ± 0.02	2.33 ± 0.02	2.32 ± 0.03	2.30 ± 0.03	2.28 ± 0.02	2.30 ± 0.03
Ratio to bw, mg/g	3.24 ± 0.12	3.00 ± 0.08	3.10 ± 0.09	3.17 ± 0.07	3.13 ± 0.09	3.13 ± 0.08
Epididymides						
Absolute, g	1.31 ± 0.03	1.28 ± 0.03	1.30 ± 0.03	1.32 ± 0.03	1.26 ± 0.04	1.37 ± 0.02
Ratio to Brain, g/g	0.56 ± 0.01	0.55 ± 0.02	0.56 ± 0.01	0.57 ± 0.02	0.56 ± 0.02	0.60 ± 0.01
Ratio to bw, mg/g	1.83 ± 0.08	1.65 ± 0.06	1.73 ± 0.05	1.83 ± 0.07	1.73 ± 0.07	1.87 ± 0.05
Epididymal Fat Pad						
Absolute, g	13.9 ± 0.7	16.0 ± 0.9	14.9 ± 1.0	13.5 ± 0.6	14.8 ± 1.0 ^c	14.6 ± 0.7
Ratio to Brain, g/g	5.99 ± 0.31	6.85 ± 0.38	6.38 ± 0.44	5.82 ± 0.26	6.52 ± 0.41	6.38 ± 0.33
Ratio to bw, mg/g	18.8 ± 0.5	20.3 ± 0.9	19.2 ± 0.9	18.3 ± 0.7	19.8 ± 0.9	19.6 ± 0.7
Retroperitoneal Fat Pad						
Absolute, g	25.0 ± 2.3	27.8 ± 2.0	25.6 ± 2.3	23.0 ± 1.7	23.4 ± 2.7	25.0 ± 2.1
Ratio to Brain, g/g	10.8 ± 1.0	11.9 ± 0.8	11.0 ± 1.0	10.0 ± 0.7	10.3 ± 1.2	10.9 ± 0.9
Ratio to bw, mg/g	33.1 ± 2.1	34.7 ± 1.6	33.0 ± 2.3	31.3 ± 2.0	31.0 ± 2.9	33.0 ± 2.2
Heart						
Absolute, g	2.27 ± 0.07	2.45 ± 0.09	2.40 ± 0.08	2.25 ± 0.08	2.22 ± 0.07	2.35 ± 0.10
Ratio to Brain, g/g	0.98 ± 0.03	1.05 ± 0.04	1.03 ± 0.04	0.97 ± 0.03	0.98 ± 0.03	1.02 ± 0.05
Ratio to bw, mg/g	3.12 ± 0.08	3.13 ± 0.09	3.18 ± 0.11	3.09 ± 0.10	3.04 ± 0.10	3.20 ± 0.16
Kidney						
Absolute, g	4.38 ± 0.15	4.43 ± 0.15	4.54 ± 0.11	4.32 ± 0.11	4.17 ± 0.15	4.33 ± 0.10 ^d
Ratio to Brain, g/g	1.89 ± 0.07	1.90 ± 0.06	1.95 ± 0.05	1.88 ± 0.05	1.83 ± 0.06	1.89 ± 0.04
Ratio to bw, mg/g	5.98 ± 0.09	5.62 ± 0.09	6.01 ± 0.13	5.94 ± 0.15	5.64 ± 0.08	5.78 ± 0.09
Liver						
Absolute, mg	23.6 ± 0.9	24.4 ± 0.7	25.1 ± 1.0	23.2 ± 0.8	24.8 ± 1.0	25.1 ± 0.9
Ratio to Brain, g/g	10.2 ± 0.4	10.5 ± 0.3	10.8 ± 0.4	10.1 ± 0.3	10.9 ± 0.4	10.9 ± 0.4
Ratio to bw, mg/g	32.1 ± 0.4*	31.1 ± 0.5	33.1 ± 1.0	31.8 ± 0.8	33.6 ± 0.7	33.9 ± 1.2
Pituitary						
Absolute, mg	15.1 ± 0.6	16.5 ± 0.9	15.3 ± 0.3	15.6 ± 0.6	14.5 ± 0.4	15.1 ± 0.5
Ratio to Brain, mg/g	6.5 ± 0.2	7.1 ± 0.4	6.6 ± 0.1	6.8 ± 0.2	6.4 ± 0.2	6.6 ± 0.2
Ratio to bw, mg/g	0.02 ± 0	0.02 ± 0	0.02 ± 0	0.02 ± 0	0.02 ± 0	0.02 ± 0

CLARITY-BPA Core Study, NTP RR 9

Endpoint, units	Vehicle (20) ^b	2.5 BPA (20)	25 BPA (19)	250 BPA (19)	2500 BPA (20)	25000 BPA (22)
Seminal Vesicles						
Absolute, g	1.22 ± 0.05	1.23 ± 0.06	1.27 ± 0.09	1.12 ± 0.05	1.12 ± 0.07	1.17 ± 0.04
Ratio to Brain, g/g	0.53 ± 0.02	0.53 ± 0.02	0.54 ± 0.04	0.48 ± 0.02	0.49 ± 0.03	0.51 ± 0.02
Ratio to bw, mg/g	1.69 ± 0.08	1.58 ± 0.07	1.70 ± 0.13	1.54 ± 0.07	1.52 ± 0.09	1.59 ± 0.07
Spleen						
Absolute, g	1.00 ± 0.03	1.04 ± 0.04	1.02 ± 0.03	1.03 ± 0.05	1.07 ± 0.06	1.06 ± 0.06
Ratio to Brain, g/g	0.43 ± 0.01	0.45 ± 0.02	0.44 ± 0.01	0.45 ± 0.02	0.47 ± 0.03	0.46 ± 0.02
Ratio to bw, mg/g	1.38 ± 0.05	1.33 ± 0.06	1.34 ± 0.04	1.42 ± 0.07	1.46 ± 0.08	1.44 ± 0.10
Testes						
Absolute, g	3.64 ± 0.07	3.59 ± 0.08	3.63 ± 0.09	3.49 ± 0.09	3.55 ± 0.15	3.71 ± 0.06
Ratio to Brain, g/g	1.57 ± 0.03	1.54 ± 0.04	1.57 ± 0.05	1.52 ± 0.04	1.56 ± 0.07	1.62 ± 0.03
Ratio to bw, mg/g	5.05 ± 0.17	4.62 ± 0.13	4.82 ± 0.13	4.82 ± 0.18	4.84 ± 0.18	5.04 ± 0.14
Thymus						
Absolute, mg	137 ± 9	123 ± 5	154 ± 10	130 ± 8	134 ± 9	145 ± 8
Ratio to Brain, mg/g	59 ± 4	53 ± 2	66 ± 4	57 ± 3	59 ± 4	63 ± 40
Ratio to bw, mg/g	0.19 ± 0.01	0.16 ± 0.01	0.20 ± 0.01	0.18 ± 0.01	0.18 ± 0.01	0.20 ± 0.1
Thyroid						
Absolute, mg	43.1 ± 1.9	43.4 ± 2.5	44.9 ± 1.8	41.2 ± 1.9	42.2 ± 2.4	45.4 ± 2.7
Ratio to Brain, mg/g	18.6 ± 0.8	18.6 ± 1.1	19.4 ± 0.8	18.0 ± 0.9	18.6 ± 1.0	19.7 ± 1.1
Ratio to bw, mg/g	0.06 ± 0	0.06 ± 0	0.06 ± 0	0.06 ± 0	0.06 ± 0	0.06 ± 0

^aBPA doses are µg/kg bw/day. The indicated organs were collected from animals at the interim (one-year) necropsy and weights recorded. Paired organs are presented and were analyzed as combined weights. ANOVA was performed for absolute organ weights to determine the effect of treatment on organ weight. Separate ANOCOVA were performed to determine the effect of treatment on organ weight adjusted for brain weight or receiving weight. Comparisons of dosed groups versus vehicle control were performed using Dunnett's method to adjust for multiple comparisons. Tests of trends, increasing treatment effect with increasing dose, were also performed for vehicle and BPA groups. Tests were conducted as two-sided at the 0.05 significance level. Statistically significant effects are indicated by asterisks (*, *p* < 0.05); asterisks in the vehicle column indicate a significant trend. There were no additional statistically significant effects in the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Statistical Methods). The complete statistical report is found in Supplemental Appendix XXX.

^bNumbers in parentheses are the number of animals examined. Any deviations from this number due to exclusions are indicated by footnotes.

^cFor epididymal fat pad, n = 19 for 2,500 BPA dose group.

^dFor kidney, n = 20 for 25,000 BPA dose group.

1 **Table 50. Sperm Analysis, Vehicle, BPA, and EE₂ Continuous-Dose, Interim Sacrifice (Mean ± S.E.M.)^a**

Endpoint, units	Vehicle (18) ^b	2.5 BPA (22)	25 BPA (18)	250 BPA (24)	2500 BPA (18)	25000 BPA (21)	0.05 EE ₂ (22)	0.5 EE ₂ (23)
Testicular spermatid heads, 10 ⁶ /g	83.4 ± 9.5	76.8 ± 7.7	88.5 ± 6.1	81.5 ± 6.8	85.1 ± 7.1	76.6 ± 6.0	70.0 ± 4.7	73.7 ± 4.5
Cauda sperm counts, 10 ⁶ /g	991 ± 78	999 ± 88	1076 ± 68	998 ± 69	1062 ± 51	1027 ± 81	892 ± 72	857 ± 53
Cauda sperm, % Motility	65.9 ± 4.6	64.0 ± 5.1	72.4 ± 3.1	66.7 ± 4.5	69.9 ± 3.4	69.4 ± 4.2	67.2 ± 4.8	70.8 ± 2.7
Cauda sperm, head, abnormal counts per animal	0.00 ± 0	0.05 ± 0.05	0.06 ± 0.06	0.08 ± 0.06	0.11 ± 0.08	0.00 ± 0	0.23 ± 0.10	0.04 ± 0.04
Cauda sperm, tail, abnormal counts per animal	0.17 ± 0.10	0.36 ± 0.13	0.17 ± 0.10	0.08 ± 0.06	0.11 ± 0.08	0.14 ± 0.08	0.23 ± 0.10	0.13 ± 0.08
Cauda sperm, head and tail combined, abnormal counts per animal	0.17 ± 0.10	0.41 ± 0.14	0.22 ± 0.11	0.17 ± 0.08	0.22 ± 0.11	0.14 ± 0.08	0.45 ± 0.14	0.17 ± 0.09

2 ^aBPA and EE₂ doses are µg/kg bw/day. Values presented are means ± S.E.M. BPA and EE₂ groups were analyzed separately. Testicular spermatid head counts, cauda sperm
3 counts, and percent sperm motility were analyzed using an ANOVA model. Analysis of sperm morphology data was performed using a generalized linear model with a Poisson
4 distribution and a log link function. Pairwise comparisons to the vehicle control group were adjusted for multiple comparisons using Dunnett's method. Tests of trends, increasing
5 treatment effect with increasing dose, were also performed for vehicle and BPA groups only. All tests were conducted as two-sided at the 0.05 significance level. There were no
6 significant treatment effects. There were also no significant treatment effects in the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000
7 µg BPA/kg bw/day (see Statistical Methods). The full statistical report is found in Supplemental Appendix XXXI.

8 ^bNumbers in parentheses are numbers of animals examined.

1 **Table 51. Sperm Analysis, Vehicle and BPA Stop-Dose, Interim Sacrifice (Mean ± S.E.M.)^a**

Endpoint, units	Vehicle (20) ^b	2.5 BPA (20)	25 BPA (19)	250 BPA (19)	2500 BPA (20)	25000 BPA (22)
Testicular spermatid heads, 10 ⁶ /g	76.5 ± 9.4	77.7 ± 4.8	72.2 ± 5.3	72.5 ± 6.3	73.6 ± 9.0	75.8 ± 4.7
Cauda sperm counts, 10 ⁶ /g	1,059 ± 87	1,186 ± 83	1,017 ± 66	1,111 ± 66	1,020 ± 89	1,016 ± 81
Cauda sperm % Motility	74.8 ± 4.3	75.8 ± 2.3	72.4 ± 3.4	70.2 ± 4.2	67.9 ± 5.6	77.7 ± 2.2
Cauda sperm, head, abnormal counts per animal	0.00 ± 0	0.00 ± 0	0.11 ± 0.07	0.05 ± 0.05	0.10 ± 0.07	0.00 ± 0
Cauda sperm, tail, abnormal counts per animal	0.15 ± 0.09	0.15 ± 0.09	0.21 ± 0.11	0.11 ± 0.07	0.20 ± 0.10	0.00 ± 0
Cauda sperm, head and tail combined, abnormal counts per animal	0.15 ± 0.09	0.015 ± 0.09	0.32 ± 0.13	0.16 ± 0.09	0.30 ± 0.12	0.00 ± 0

2 ^aBPA doses are µg/kg bw/day. Values presented are means ± S.E.M. Testicular spermatid head counts, cauda sperm counts, and percent sperm motility were analyzed using an
3 ANOVA model. Analysis of sperm morphology data was performed using a generalized linear model with a Poisson distribution and a log link function. Pairwise comparisons to
4 the vehicle control group were adjusted for multiple comparisons using Dunnett's method. Tests of trends, increasing treatment effect with increasing dose, were also performed.
5 All tests were conducted as two-sided at the 0.05 significance level. There were no significant treatment effects. Also, there were no additional statistically significant effects in the
6 sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Statistical Methods). The full statistical report is found in
7 Supplemental Appendix XXXI.

8 ^bNumbers in parentheses are numbers of animals examined.

1 **Table 52. Neoplastic Lesions in the Mammary Gland of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA^{a, b}**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Adenocarcinoma	Interim ^c	Incidence	0/23	1/22 (4%)	1/22 (4%)	0/24	0/20	0/24
	Terminal	Incidence	4/50 (8%)	6/48 (12%)	6/46 (13%)	5/49 (10%)	9/50 (18%)	3/46 (6%)
		Poly-3 Incidence	4/34.4 (12%)	6/32.9 (18%)	6/30.4 (20%)	5/34.6 (14%)	9/31.3 (29%)	3/31.2 (10%)
		Terminal Incidence	3/16 (19%)	6/19 (32%)	1/14 (7%)	0/13 (0%)	3/10 (30%)	0/8 (0%)
		Time-to-First	673	719 (T)	434	377	561	685
		Poly-3 <i>p</i> -value	0.412	0.336	0.286	0.504	0.071	0.555N
		Multiple Incidence ^d	2/50 (4%)	3/48 (6%)	3/46 (7%)	2/49 (4%)	3/50 (6%)	1/46 (2%)
Adenoma or Adenocarcinoma	Interim ^c	Incidence	0/23	1/22 (4%)	1/22 (4%)	0/24	0/20	0/24
	Terminal	Incidence	6/50 (12%)	7/48 (15%)	8/46 (17%)	6/49 (12%)	10/50 (20%)	4/46 (9%)
		Poly-3 Incidence	6/34.9 (17%)	7/32.9 (21%)	8/30.4 (26%)	6/34.8 (17%)	10/31.3 (32%)	4/31.8 (13%)
		Terminal Incidence	4/16 (25%)	7/19 (37%)	3/14 (21%)	0/13 (0%)	4/10 (40%)	0/8 (0%)
		Time-to-First	564	719 (T)	434	377	561	542
		Poly-3 <i>p</i> -value	0.513N	0.452	0.271	0.624	0.126	0.428N
		Multiple incidence ^d	2/50 (4%)	3/48 (6%)	3/46 (7%)	3/49 (6%)	3/50 (6%)	1/46 (2%)
Fibroadenoma	Interim	Incidence	2/23 (9%)	3/22 (13%)	3/22 (13%)	1/24 (4%)	2/20 (10%)	6/24 (25%)
		Terminal Incidence	2/21 (10%)	3/22 (14%)	2/21 (10%)	0/22 (0%)	2/20 (10%)	6/24 (25%)
		Time-to-First	361 (T)	356 (T)	311	256	362 (T)	362 (T)
		CAFE <i>p</i> -value	0.150	0.478	0.478	0.484N	0.641	0.136
		Multiple Incidence ^d	0/23 (0%)	0/22 (0%)	1/22 (5%)	0/24 (0%)	0/20 (0%)	1/24 (4%)
	Terminal	Incidence	41/50 (82%)	40/48 (83%)	33/46 (72%)	39/49 (80%)	35/50 (70%)	38/46 (83%)
		Poly-3 Incidence	41/47.0 (87%)	40/43.7 (92%)	33/38.4 (86%)	39/45.3 (86%)	35/42.3 (83%)	38/42.2 (90%)
		Terminal Incidence	13/16 (81%)	17/19 (90%)	12/14 (86%)	10/13 (77%)	7/10 (70%)	7/8 (88%)
		Time-to-First	431	321	434	261	419	467
		Poly-3 <i>p</i> -value	0.410N	0.366	0.567N	0.565N	0.366N	0.457
Multiple Incidence ^d	21/50 (42%)	32/48 (67%)	20/46 (43%)	32/49 (65%)	21/50 (42%)	31/46 (67%)		

2 ^aBPA doses are µg/kg bw/day. Statistical analyses were conducted for any lesion that was diagnosed in two animals in any dose group in the interim sacrifice groups or in the EE₂
3 terminal sacrifice groups or four animals in the control and BPA groups in the terminal sacrifice. A complete tabulation of all neoplastic lesions is found in Supplemental Appendix
4 XXXII and complete results of the statistical analyses are found in Supplemental Appendices XXXIII (interim sacrifice) and XXXIV (terminal sacrifice). Details of the statistical
5 methods are found in Materials and Methods and in Supplemental Appendices XXXIII (interim sacrifice) and XXXIV (terminal sacrifice). Data are presented as follows:
6 Incidence, lesions observed/number of animals examined microscopically with percent animals affected in parentheses; Poly-3 Incidence, Poly-3 adjusted neoplasm incidence after
7 adjustment for intercurrent mortality in terminal sacrifice animals; Terminal Incidence, lesions observed/number of animals reaching terminal sacrifice that were microscopically
8 examined. Time-to-First, age of animal in which lesion was first observed, T in parentheses indicates that the first observation occurred at terminal sacrifice. For interim sacrifice
9 data: CAFE *p*-value, *p*-value for Cochran-Armitage trend test in vehicle column, Fisher's exact test versus vehicle control in dose columns. For terminal sacrifice data, the Poly-3
10 *p*-value for the trend test is given in the vehicle column and values for pairwise comparisons to vehicle control are shown in dose columns. Significant trends are shown in the

CLARITY-BPA Core Study, NTP RR 9

1 vehicle column, while significant pairwise comparisons to the vehicle control are shown in BPA and EE₂ dose group columns. All *p*-values are one-sided and not corrected for
2 multiple comparisons. “N” next to a *p*-value indicates a result that is a negative trend or negative relative to control. Significant effects are indicated with asterisks. *, *p* < 0.05; **,
3 *p* < 0.01; ***, *p* < 0.001.
4 ^bThere were no statistically significant effects in the female mammary gland in the continuous BPA dose groups in the interim or terminal sacrifice animals.
5 ^cStatistical analysis was not conducted since no group had 2 or more lesions diagnosed. There were no multiple adenocarcinomas in interim sacrifice animals.
6 ^dProportion of animals examined that had multiple neoplasms. These animals with multiple neoplasms are included in the incidence with multiple neoplasms row and were not analyzed separately. The
7 numbers of mammary neoplasms found in each female are tabulated in Supplemental Appendix XXXII, Subappendix VII.

1 **Table 53. Neoplastic Lesions in the Mammary Gland of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE₂^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle ^b	0.05 EE ₂	0.5 EE ₂
Adenocarcinoma ^c	Interim	Incidence ^d	0/23 (0%)	2/26 (8%)	0/26 (0%)
		Terminal Incidence	0/21 (0%)	1/24 (4%)	0/26 (0%)
		Time-to-First	-	257	-
		CAFE <i>p</i> -value	0.639N	0.276	-
	Terminal	Incidence	4/50 (8%)	2/26 (8%)	10/26 (38%)
		Poly-3 Incidence	4/34.4 (12%)	2/16.8 (12%)	10/17.6 (57%)
		Terminal Incidence	3/16 (19%)	0/7 (0%)	3/4 (75%)
		Time-to-First	673	490	488
		Poly-3 <i>p</i> -value	<0.001***	0.667	<0.001***
		Multiple Incidence ^e	2/50 (4%)	0/26	4/26 (15%)
Fibroadenoma	Interim	Incidence ^d	2/23 (9%)	2/26 (8%)	4/26 (15%)
		Terminal Incidence	2/21 (10%)	2/24 (8%)	4/26 (15%)
		Time-to-First	361 (T)	361 (T)	360 (T)
		CAFE <i>p</i> -value	0.297	0.647N	0.395
	Terminal	Incidence	41/50 (82%)	18/26 (69%)	14/26 (54%)
		Poly-3 Incidence	41/47.0 (87%)	18/22.3 (81%)	14/20.2 (69%)
		Terminal Incidence	13/16 (81%)	5/7 (71%)	2/4 (50%)
		Time-to-First	431	460	360
		Poly-3 <i>p</i> -value	0.041N*	0.354N	0.056N
		Multiple Incidence ^e	21/50 (42%)	11/26 (42%)	4/26 (15%)

2 ^aEE₂ doses are µg/kg bw/day. See legend to Table 52 for description of data presentation. Adenocarcinoma incidence was significantly increased in the 0.5 µg EE₂/kg bw/day dose
3 group relative to vehicle control and there was a significant dose trend.

4 ^bThe continuous vehicle control group data are the same as those shown for the continuous-dose BPA data in Table 52.

5 ^cNo mammary gland adenomas were diagnosed in interim or terminal sacrifice EE₂ females, so no tabulation of adenoma or adenocarcinoma is included.

6 ^dThere were no animals with multiple mammary gland neoplasms in the interim sacrifice females.

7 ^eProportion of animals examined that had multiple neoplasms. These animals with multiple neoplasms are included in the incidence row and were not analyzed separately. The
8 numbers of mammary neoplasms found in each female are tabulated in Supplemental Appendix XXXII, Subappendix VII.

1 **Table 54. Neoplastic Lesions in the Mammary Gland of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA	
Adenocarcinoma ^b	Terminal	Incidence	3/50 (6%)	11/50 (22%)	5/48 (10%)	7/49 (14%)	9/50 (18%)	5/46 (11%)	
		Poly-3 Incidence	3/32.3 (9%)	11/33.3 (33%)	5/32.1 (16%)	7/35.4 (20%)	9/36.6 (25%)	5/32.0 (16%)	
		Terminal Incidence	1/11 (9%)	2/12 (17%)	2/13 (15%)	0/13 (0%)	5/17 (29%)	0/13 (0%)	
		Time-to-First	681	573	458	450	488	615	
		Poly-3 <i>p</i> -value	0.453	0.016*	0.348	0.189	0.083	0.346	
		Multiple Incidence ^d	1/50 (2%)	1/50 (2%)	1/48 (2%)	2/49 (4%)	1/50 (2%)	2/46 (4%)	
Adenoma or Adenocarcinoma ^b	Terminal	Incidence	4/50 (8%)	12/50 (24%)	5/48 (10%)	9/49 (18%)	9/50 (18%)	6/46 (13%)	
		Poly-3 Incidence	4/33.0 (12%)	12/33.3 (36%)	5/32.1 (16%)	9/35.9 (25%)	9/36.6 (25%)	6/32.8 (18%)	
		Terminal Incidence	1/11 (9%)	3/12 (25%)	2/13 (15%)	1/13 (8%)	5/17 (29%)	0/13 (0%)	
		Time-to-First	514	573	458	450	488	463	
		Poly-3 <i>p</i> -value	0.483	0.018*	0.482	0.140	0.149	0.360	
		Multiple Incidence ^d	1/50 (2%)	1/50 (2%)	1/48 (2%)	2/49 (4%)	1/50 (2%)	2/46 (4%)	
Fibroadenoma	Interim	Incidence ^c	4/20 (20%)	1/22 (4%)	1/20 (5%)	1/22 (4%)	1/20 (5%)	2/22 (9%)	
		Terminal Incidence	4/20 (20%)	1/22 (4%)	1/20 (5%)	1/22 (4%)	1/20 (5%)	2/20 (10%)	
		Time-to-First	363 (T)	365 (T)	365 (T)	363 (T)	364 (T)	363 (T)	
		CAFE <i>p</i> -value	0.191N	0.144N	0.171N	0.144N	0.171N	0.286N	
		Terminal	Incidence	43/50 (86%)	45/50 (90%)	37/48 (77%)	42/49 (86%)	36/50 (72%)	34/46 (74%)
			Poly-3 Incidence	43/47.7 (90%)	45/47.5 (95%)	37/42.2 (88%)	42/46.2 (91%)	36/45.5 (79%)	34/40.6 (84%)
	Terminal Incidence		8/11(73%)	11/12 (92%)	11/13 (85%)	11/13 (85%)	12/17 (71%)	12/13 (92%)	
	Time-to-First		385	400	339	448	390	383	
	Poly-3 <i>p</i> -value		0.021N*	0.319	0.489N	0.600	0.099N	0.257N	
	Multiple Incidence ^d		29/50 (58%)	32/50 (64%)	28/48 (58%)	31/49 (63%)	29/50 (58%)	28/46 (61%)	

2 ^aBPA doses are µg/kg bw/day. See legend to Table 52 for description of data presentation. There was a significant increase in adenocarcinoma, and combined adenoma or
3 adenocarcinoma, in the 2.5 BPA µg/kg bw/day dose group relative to vehicle controls.

4 ^bNo adenomas or adenocarcinomas were diagnosed in the mammary glands of interim sacrifice stop-dose females.

5 ^cThere were no interim sacrifice females with multiple fibroadenomas.

6 ^dProportion of animals examined that had multiple neoplasms. These animals with multiple neoplasms are included in the incidence row and were not analyzed separately. The
7 numbers of mammary neoplasms found in each female are tabulated in Supplemental Appendix XXXII, Subappendix VII.

1 **Table 55. Non-Neoplastic Lesions in the Mammary Gland of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Atypical focus	Interim	Incidence	0/23 (0%)	3/22 [^] (14%)	2/22 (9%)	2/24 (8%)	0/20 (0%)	0/24 (0%)
		Severity Profile	-	1 2 0 0	0 2 0 0	2 0 0 0	-	-
	Terminal	Incidence	2/50 (4%)	7/48 [^] (15%)	1/46 (2%)	5/49 (10%)	3/50 (6%)	3/46 (6%)
		Severity Profile	0 2 0 0 (2.0)	3 2 2 0 (1.9)	0 1 0 0 (2.0)	0 5 0 0 (2.0)	1 2 0 0 (1.7)	1 2 0 0 (1.7)
		Poly-3 Incidence	2/34.4 (6%)	7/33.6 (21%)	1/28.2 (4%)	5/33.3 (15%)	3/29.7 (10%)	3/31.7 (10%)
Dilatation, duct	Interim	Incidence	2/23 (9%)	2/22 (9%)	7/22 ^{^^} (32%)	1/24 (4%)	2/20 (10%)	2/24 (8%)
		Severity Profile	1 1 0 0 (1.5)	0 0 0 2 (4.0)	2 4 1 0 (1.9)	0 0 1 0 (3.0)	1 0 1 0 (2.0)	1 0 1 0 (2.0)
	Terminal	Incidence	15/50 (30%)	16/48 (33%)	7/46 ^{^N} (15%)	9/49 (18%)	9/50 (18%)	14/46 (30%)
		Severity Profile	0 10 5 0 (2.3)	0 12 2 2 (2.4)	0 6 1 0 (2.1)	0 6 3 0 (1.7)	0 4 5 0 (2.6)	2 9 3 0 (2.1)
		Poly-3 Incidence	15/38.1 (39%)	16/39.4 (41%)	7/31.9 (22%)	9/35.7 (25%)	9/33.1 (27%)	14/36.4 (38%)
Hyperplasia, lobular	Interim	Incidence	10/23 (44%)	14/22 (64%)	13/22 (59%)	15/24 (62%)	13/20 (65%)	12/24 (50%)
		Severity Profile	5 5 0 0 (1.5)	7 7 0 0 (1.5)	7 6 0 0 (1.5)	11 3 1 0 (1.3)	10 2 0 1 (2.2)	9 1 1 1 (1.5)
	Terminal	Incidence	43/50 (86%)	41/48 (85%)	30/46 ^{^^N} (65%)	38/49 (78%)	40/50 ^{^N} (80%)	37/46 (80%)
		Severity Profile	1 8 13 21 (3.3)	1 7 11 22 (3.3)	1 7 10 12 (3.1)	0 7 17 14 (3.2)	1 14 11 14 (3.0)	4 9 5 19 (3.1)
		Poly-3 Incidence	43/45.4 ^{*N} (95%)	41/42.5 (96%)	30/36.7 ^{*N} (82%)	38/43.7 (87%)	40/43.2 (93%)	37/43.4 (85%)
Dilatation, alveolus ^b	Terminal	Incidence	9/50 (18%)	14/48 (29%)	5/46 (11%)	7/49 (14%)	7/50 (14%)	11/46 (24%)
		Severity Profile	1 7 1 0 (2.2)	1 11 2 0 (2.1)	0 5 0 0 (2.0)	0 7 0 0 (2.0)	0 6 1 0 (2.1)	0 9 2 0 (2.2)
		Poly-3 Incidence	9/36.0 (25%)	14/38.0 (37%)	5/30.9 (16%)	7/35.2 (20%)	7/32.3 (22%)	11/34.6 (32%)

2 ^aBPA doses are µg/kg bw/day. Statistical analyses were conducted for any lesion that was diagnosed in two animals in any dose group in the interim sacrifice groups or in the EE₂
3 terminal sacrifice groups or four animals in the control and BPA groups in the terminal sacrifice. A complete tabulation of all non-neoplastic lesions is found in Supplemental
4 Appendix XXXII and complete results of the statistical analyses are found in Supplemental Appendices XXXIII (interim sacrifice) and XXXIV (terminal sacrifice). Details of the
5 statistical methods are found in Materials and Methods and in Supplemental Appendices XXXIII and XXXIV. Selected non-neoplastic lesions are tabulated in this report. Data are
6 presented as follows: Incidence, lesions observed/number of animals examined microscopically, with percent animals affected in parentheses; Severity Profile, number of animals
7 diagnosed with minimal/ mild/ moderate/ marked lesions, with the average severity in affected animals given in parentheses, based upon severity scores of 1, minimal; 2, mild; 3,
8 moderate; and 4, marked.; Poly-3 Incidence, Poly-3 adjusted lesion incidence after adjustment for intercurrent mortality in the terminal sacrifice animals. Lesions in interim
9 sacrifice animals were analyzed by the CAFE test (Cochran-Armitage trend test and Fisher's exact test to compare the incidence in each dose group to the vehicle control) and by

CLARITY-BPA Core Study, NTP RR 9

1 the Jonckheere-Terpstra (JT) trend test/Shirley-Williams (SW) pairwise comparison test to incorporate severity scores. Because the JT/SW test enforces an assumption of a
2 monotonic response, a relative treatment effect (RTE) analysis that also incorporates severity scores, but does not enforce monotonicity, was also conducted. Significant JT/SW
3 results that violated the monotonicity requirement are not shown in the tables, but are reported in Supplemental Appendices XXXIII and XXXIV. Lesions in terminal sacrifice
4 animals were analyzed by the Poly-3 test to adjust for intercurrent mortality, as well as by the JT/SW and RTE tests. All pairwise tests were one-sided and not corrected for
5 multiple comparisons. Significant trends are shown in the vehicle column, while significant pairwise comparisons to the vehicle control are shown in BPA or EE₂ dose group
6 columns. The CAFE or Poly-3 tests for interim and terminal sacrifice animals, respectively, were considered as the primary statistical tests and positive significant results for those
7 tests are shown with asterisks. Pound and caret signs indicate results from the JT/SW and RTE tests, respectively. *, #, ^, $p < 0.05$; **, ##, ^^, $p < 0.01$; ***, ###, ^^, $p < 0.001$.
8 “N” superscript next to significance markers indicates a result that is a negative trend or negative relative to control.
9 ^bNo alveolar dilatation was diagnosed in interim sacrifice females.

1 **Table 56. Non-Neoplastic Lesions in the Mammary Gland of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE₂^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle ^b	0.05 EE ₂	0.5 EE ₂
Atypical focus ^c	Terminal	Incidence	2/50 (4%)	2/26 (8%)	3/26 (12%)
		Severity Profile	0 2 0 0 (2.0)	1 1 0 0 (1.5)	2 1 0 0 (1.3)
		Poly-3 Incidence	2/34.4 (6%)	2/16.1 (12%)	3/16.2 (19%)
Dilatation, duct	Interim	Simple Incidence	2/23 ^{***, ###, ^^} (9%)	3/26 (12%)	22/26 ^{***, ###, ^^} (85%)
		Severity Profile	1 1 0 0 (1.5)	1 2 0 0 (1.7)	6 12 2 2 (2.0)
	Terminal	Incidence	15/50 ^{###, ^^} (30%)	6/26 (23%)	21/26 ^{###, ^^} (81%)
		Severity Profile	0 10 5 0 (2.3)	0 3 3 0 (2.5)	0 10 7 4 (2.7)
		Poly-3 Incidence	15/38.1 ^{***} (39%)	6/19.0 (32%)	21/24.2 ^{***} (87%)
Hyperplasia, lobular	Interim	Incidence	10/23 ^{***, ###, ^^} (44%)	13/26 (50%)	23/26 ^{***, ###, ^^} (88%)
		Severity Profile	5 5 0 0 (1.5)	6 6 1 0 (1.6)	11 11 1 0 (1.6)
	Terminal	Incidence	43/50 (86%)	24/26 (92%)	23/26 (88%)
		Severity Profile	1 8 13 21 (3.3)	1 8 4 11 (3.0)	1 10 4 8 (2.8)
		Poly-3 Incidence	43/45.4 (95%)	24/24.5 (98%)	23/25.1 (92%)
Dilatation, alveolus ^d	Terminal	Incidence	9/50 ^{###, ^^} (18%)	5/26 (19%)	22/26 ^{###, ^^} (85%)
		Severity Profile	1 7 1 0 (2.0)	0 5 0 0 (2.0)	0 18 4 0 (2.2)
		Poly-3 Incidence	9/36.0 ^{***} (25%)	5/18.8 (27%)	22/24.1 ^{***} (91%)

2 ^aEE₂ doses are µg/kg bw/day. See legend to Table 55 or description of data presentation.3 ^bThe continuous vehicle control group data are the same as those shown for the continuous-dose BPA data in Table 55.4 ^cThere were no atypical foci diagnosed in the interim vehicle, 0.05, or 0.5 µg EE₂/kg bw/day groups (0/23, 0/26, and 0/26, respectively), so there is no tabulation of data for the
5 interim sacrifice animals for this lesion.6 ^dNo alveolar dilatation was diagnosed in interim sacrifice females.

7

1 **Table 57. Non-Neoplastic Lesions in the Mammary Gland of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Atypical focus ^b	Terminal	Incidence	6/50 (12%)	2/50 (4%)	6/48 (12%)	8/49 (16%)	7/50 (14%)	5/46 (11%)
		Severity Profile	1 4 1 0 (2.0)	0 1 1 0 (2.5)	1 5 0 0 (1.8)	3 4 1 0 (1.8)	0 5 0 2 (2.6)	2 3 0 0 (1.6)
		Poly-3 Incidence	6/33.0 (18%)	2/32.0 (6%)	6/32.4 (18%)	8/36.2 (22%)	7/35.8 (20%)	5/32.6 (15%)
Dilatation, duct	Interim	Incidence	4/20 ^{*, #, ^N} (20%)	2/22 (9%)	1/20 (5%)	1/22 ^{^N} (4%)	1/20 (5%)	1/22 ^{#, ^N} (4%)
		Severity Profile	2 1 1 0 (1.8)	1 1 0 0 (1.5)	0 1 0 0 (2.0)	1 0 0 0 (1.0)	0 1 0 0 (2.0)	1 0 0 0 (1.0)
	Terminal	Incidence	16/50 (32%)	5/50 ^{#, ^^N} (10%)	9/48 ^{#, ^N} (19%)	9/49 ^{#, ^N} (18%)	7/50 ^{#, ^^N} (14%)	11/46 ^{#N} (24%)
		Severity Profile	0 9 4 3 (2.6)	0 5 0 0 (2.0)	2 4 2 1 (2.2)	0 6 3 0 (2.3)	0 6 1 0 (2.1)	0 7 4 0 (2.4)
		Poly-3 Incidence	16/37.0 (43%)	5/34.5 ^{**N} (14%)	9/33.7 (27%)	9/35.3 (26%)	7/36.4 ^{*N} (19%)	11/36.2 (30%)
		Severity Profile	10 4 1 0 (1.4)	8 3 1 0 (1.4)	5 1 2 0 (1.6)	8 3 1 0 (1.4)	4 3 0 0 (1.4)	6 4 2 0 (1.7)
Hyperplasia, lobular	Interim	Incidence	15/20 (75%)	12/22 (54%)	8/20 ^{*, ^N} (40%)	12/22 (54%)	7/20 ^{*, ^N} (35%)	12/22 (54%)
		Severity Profile	10 4 1 0 (1.4)	8 3 1 0 (1.4)	5 1 2 0 (1.6)	8 3 1 0 (1.4)	4 3 0 0 (1.4)	6 4 2 0 (1.7)
	Terminal	Incidence	41/50 (82%)	40/50 (80%)	39/48 (81%)	39/49 (80%)	36/50 (72%)	38/46 (83%)
		Severity Profile	1 8 15 17 (3.2)	0 8 12 20 (3.3)	3 14 11 11 (2.8)	2 9 13 15 (3.1)	3 5 7 21 (3.3)	2 10 9 17 (3.1)
Dilatation, alveolus ^c	Terminal	Incidence	8/50 (16%)	4/50 (8%)	4/48 (8%)	8/49 (16%)	3/50 ^{^N} (6%)	7/46 (15%)
		Severity Profile	0 4 4 0 (2.5)	0 4 0 0 (2.0)	0 2 2 0 (2.5)	0 6 2 0 (2.2)	1 2 0 0 (1.7)	1 6 0 0 (1.9)
		Poly-3 Incidence	8/34.8 (23%)	4/33.7 (12%)	4/30.5 (13%)	8/34.9 (23%)	3/35.7 (8%)	7/34.9 (20%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bThere was a 5% incidence (1/20) of atypical hyperplasia in the mammary gland of female stop-dose vehicle control interim sacrifice animals and all BPA dose interim sacrifice
4 dose groups had a 0% incidence (0/22, 0/20, 0/22, 2/20, 0/22 for 2.5, 25, 250, 2,500, and 25,000 µg BPA/kg bw/day, respectively).5 ^cNo alveolar dilatation was diagnosed in interim sacrifice females.

6

Table 58. Neoplastic Lesions in the Uterus of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA^a

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Stromal polyps	Interim	Incidence	1/23 (4%)	0/22 (0%)	1/21 (5%)	0/24 (0%)	3/20 (15%)	3/24 (12%)
		Terminal Incidence	1/21 (5%)	0/22 (0%)	1/21 (5%)	0/22 (0%)	3/20 (15%)	3/24 (12%)
		Time-to-First	362 (T)	-	360 (T)	-	362 (T)	362 (T)
		CAFE <i>p</i> -value	0.037*	0.511 ^N	0.733	0.489 ^N	0.252	0.321
	Terminal	Incidence	5/50 (10%)	3/48 (6%)	7/45 (16%)	2/49 (4%)	4/48 (8%)	3/46 (6%)
		Poly-3 Incidence	5/36.4 (14%)	3/34.6 (9%)	7/29.5 (24%)	2/33.5 (6%)	4/29.2 (14%)	3/32.2 (9%)
		Terminal Incidence	1/16 (6%)	0/19 (0%)	4/14 (29%)	0/13 (0%)	0/10 (0%)	0/8 (0%)
		Time-to-First	506	321	441	542	673	569
		Poly-3 <i>p</i> -value	0.333 ^N	0.383 ^N	0.231	0.247 ^N	0.638 ^N	0.424 ^N

^aBPA doses are µg/kg bw/day. See legend to Table 52 for description of data presentation. There were no statistically significant effects in the terminal sacrifice animals. There was a significant trend across BPA dose levels in the interim sacrifice animals.

Table 59. Neoplastic Lesions in the Uterus of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE₂^a

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle ^b	0.05 EE ₂	0.5 EE ₂
Stromal polyps	Terminal	Incidence	5/50 (10%)	3/26 (12%)	1/26 (4%)
		Poly-3 Incidence	5/36.4 (14%)	3/17.4 (17%)	1/15.7 (6%)
		Terminal Incidence	1/16 (6%)	0/7 (0%)	0/4 (0%)
		Time-to-First	506	485	527
		Poly-3 <i>p</i> -value	0.383 ^N	0.529	0.389 ^N

^aEE₂ doses are µg/kg bw/day. See legend to Table 52 for description of data presentation. There were no statistically significant effects in the terminal sacrifice animals. Interim sacrifice animals are not tabulated as no group had two or more lesions.

^bThe continuous vehicle control group data are the same as those shown for the continuous-dose BPA data in Table 58.

1 **Table 60. Neoplastic Lesions in the Uterus of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Stromal polyps	Terminal	Incidence	7/49 (14%)	4/49 (8%)	5/48 (10%)	6/49 (12%)	4/49 (8%)	1/46 (2%)
		Poly-3 Incidence	7/33.0 (21%)	4/32.3 (12%)	5/32.5 (15%)	6/35.9 (17%)	4/35.8 (11%)	1/31.0 (3%)
		Terminal Incidence	2/11 (18.2%)	1/12 (8%)	1/13 (8%)	1/13 (8%)	1/17 (6%)	0/13 (0%)
		Time-to-First	467	446	461	497	539	706
		Poly-3 <i>p</i> -value	0.041 ^{*N}	0.263 ^N	0.384 ^N	0.433 ^N	0.207 ^N	0.032 ^{*N}

2 ^aBPA doses are µg/kg bw/day. See legend to Table 52 for description of data presentation. Interim sacrifice animals are not tabulated as no group had two or more lesions.

CLARITY-BPA Core Study, NTP RR 9

1 **Table 61. Non-Neoplastic Lesions in the Uterus of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Apoptosis	Interim	Incidence	2/23 ^{*, #, ^^} (9%)	1/22 (4%)	4/21 (19%)	5/24 (21%)	5/20 (25%)	9/24 ^{*, #, ^^} (38%)
		Severity Profile	0/0/0/2 (4.0)	0/0/0/1 (4.0)	0/1/1/2 (3.2)	0/1/0/4 (3.6)	0/0/3/2 (3.4)	0/1/5/3 (3.2)
Hyperplasia, cystic, endometrium	Interim	Incidence	5/23 (22%)	1/22 (4%)	4/21 (19%)	3/24 (12%)	7/20 (35%)	4/24 (17%)
		Severity Profile	1 2 1 1 (2.4)	1 0 0 0 (1.0)	1 2 1 0 (2.0)	1 1 1 0 (2.0)	0 6 1 0 (2.1)	0 3 0 1 (2.5)
	Terminal	Incidence	30/50 (60%)	20/48 ^{^N} (42%)	26/45 (58%)	23/49 (47%)	22/48 (46%)	26/46 (56%)
		Severity Profile Poly-3 incidence	4 18 5 3 (2.2) 30/41.9 (72%)	2 13 5 0 (2.2) 20/40.1 ^{*N} (50%)	0 16 7 3 (2.5) 26/36.9 (70%)	4 12 6 1 (2.2) 23/40.6 (57%)	4 8 8 2 (2.4) 22/35.8 (61%)	1 14 10 1 (2.4) 26/39.2 (66%)
Hyperplasia, endometrium	Interim	Incidence	2/23 (9%)	7/22 [^] (32%)	5/21 (24%)	7/24 [^] (29%)	5/20 (25%)	2/24 (8%)
		Severity Profile	0 2 0 0 (2.0)	3 3 1 0 (1.7)	0 4 1 0 (2.2)	2 4 1 0 (1.9)	1 2 2 0 (2.2)	0 2 0 0 (2.0)
	Terminal	Incidence	10/50 (20%)	15/48 (31%)	12/45 (27%)	15/49 (31%)	15/48 (31%)	12/46 (26%)
		Severity Profile Poly-3 incidence	2 8 0 0 (1.8) 10/39.1 (26%)	5 8 2 0 (1.6) 15/36.4 (41%)	2 8 2 0 (2.0) 12/31.9 (38%)	6 7 0 2 (1.9) 15/37.1 (40%)	10 5 0 0 (1.3) 15/35.9 (42%)	2 7 1 2 (2.2) 12/36.2 (33%)
Metaplasia, squamous	Interim	Incidence	1/23 ^{*, #, ^} (4%)	1/22 (4%)	4/21 (19%)	3/24 (12%)	3/20 (15%)	5/24 ^b (21%)
		Severity Profile	0 1 0 0 (2.0)	0 1 0 0 (2.0)	3 1 0 0 (1.2)	3 0 0 0 (1.0)	2 0 1 0 (1.7)	5 0 0 0 (1.0)
	Terminal	Incidence	2/50 (4%)	4/48 (8%)	4/45 (9%)	1/49 (2%)	4/48 (8%)	6/46 (13%)
		Severity Profile Poly-3 incidence	1 1 0 0 (1.5) 2/35.7 (6%)	2 2 0 0 (1.5) 4/35 (11%)	1 2 0 1 (2.2) 4/29.5 (14%)	1 0 0 0 (1.0) 1/32.8 (3%)	1 3 0 0 (1.8) 4/31.1 (13%)	4 1 1 0 (1.5) 6/33.9 (18%)
Dilatation, lumen	Interim	Incidence	0/23 (0%)	1/22 (4%)	2/21 (10%)	2/24 (8%)	1/20 (5%)	2/24 (8%)
		Severity Profile	-	0 0 1 0 (3.0)	0 0 0 2 (4.0)	0 0 0 2 (4.0)	0 0 0 1 (4.0)	0 0 0 2 (4.0)
	Terminal	Incidence	2/50 ^{#, ^} (4%)	2/48 (4%)	3/45 (7%)	4/49 (8%)	5/48 (10%)	6/46 (13%)
		Severity Profile Poly-3 incidence	0 0 0 2 (4.0) 2/35.6 [*] (6%)	0 0 0 2 (4.0) 2/33.5 (6%)	0 0 0 3 (4.0) 3/28.5 (10%)	0 0 1 3 (3.8) 4/34.5 (12%)	0 0 0 5 4.0 5/30.1 (17%)	0 0 1 5 (3.8) 6/33.0 ^c (18%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.

3 ^bIn the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Statistical Methods), there was a significant
4 ($p = 0.048$) difference for the CAFE test for the pairwise comparison of the 25,000 µg BPA/kg bw/day group to the vehicle control (squamous metaplasia, 5/20 (25%) versus 0/15
5 (0%).

CLARITY-BPA Core Study, NTP RR 9

1
2
3 In the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Statistical Methods), there was a significant Poly-3 test ($p = 0.035$) for the pairwise comparison of the 25,000 µg BPA/kg bw/day group to the vehicle control group (lumen dilatation, Poly-3 incidences, 5/26.8 (19%) versus 0/24 (0%).

1 **Table 62. Non-Neoplastic Lesions in the Uterus of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE₂^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	0.05 EE ₂	0.5 EE ₂
Apoptosis	Interim	Incidence	2/23 ^{***, ###, ^^} (9%)	6/25 (24%)	18/26 ^{***, ###, ^^} (69%)
		Severity Profile	0 0 0 2 (4.0)	0 1 2 3 (3.3)	0 2 6 10 (3.4)
Hyperplasia, cystic, endometrium	Interim	Incidence	5/23 ^{*, ##, ^} (22%)	6/25 (24%)	14/26 ^{*, #, ^} (54%)
		Severity Profile	1 2 1 1 (2.4)	3 3 0 0 (1.5)	4 6 2 2 (2.1)
	Terminal	Incidence	30/50 (60%)	14/26 (54%)	14/26 (54%)
		Severity Profile Poly-3 Incidence	4 18 5 3 (2.2) 30/41.9 (72%)	1 7 4 2 (2.5) 14/21.8 (64%)	1 8 2 3 (2.5) 14/20.2 (69%)
Hyperplasia, endometrium	Interim	Incidence	2/23 (9%)	4/25 (16%)	0/26 (0%)
		Severity Profile	0 2 0 0 (2.0)	0 4 0 0 (2.0)	-
	Terminal	Incidence	10/50 (20%)	10/26 [^] (38%)	2/26 (8%)
		Severity Profile Poly-3 Incidence	2 8 0 0 (1.8) 10/39.1 (26%)	3 6 0 1 (1.9) 10/19.4 [*] (52%)	1 1 0 0 (1.5) 2/16.2 (12%)
Metaplasia, squamous	Interim	Incidence	1/23 ^{***, ###, ^^} (4%)	2/25 (8%)	14/26 ^{***, ###, ^^} (54%)
		Severity Profile	0 1 0 0 (2.0)	1 0 1 0 (2.0)	8 4 2 0 (1.4)
	Terminal	Incidence	2/50 [#] (4%)	2/26 (8%)	4/26 (15%)
		Severity Profile Poly-3 Incidence	1 1 0 0 (1.5) 2/35.7 [*] (6%)	0 2 0 0 (2.0) 2/16.1 (12%)	3 0 1 0 (1.5) 4/16.9 (24%)
Dilatation, lumen	Interim	Incidence	0/23 (0%)	1/25 (4%)	0/26 (0%)
		Severity Profile	-	0/0/0/1 (4.0)	-
	Terminal	Incidence	2/50 (4%)	2/26 (8%)	3/26 (12%)
		Severity Profile Poly-3 Incidence ^b	0 0 0 2 (4.0) 2/35.6 (6%)	0 0 0 2 (4.0) 2/16.9 (12%)	0 0 0 3 (4.0) 3/16.0 ^c (19%)

2 ^aEE₂ doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bThe continuous vehicle control group data are the same as those shown for the continuous-dose BPA data in Table 61.4 ^cIn the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Statistical Methods), there was a significant EE₂
5 dose trend ($p = 0.008$) and a significant pairwise comparison ($p = 0.013$) for the 0.5 µg EE₂/kg bw/day dose group versus the vehicle control group (lumen dilatation, Poly-3
6 incidences 3/10.5 (29%) versus 0/24 (0%)).

1 **Table 63. Non-Neoplastic Lesions in the Uterus of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Apoptosis	Interim	Incidence	2/20 (10%)	3/22 (14%)	2/20 (10%)	2/22 (9%)	1/20 (5%)	6/22 (27%)
		Severity Profile	0 0 0 2 (4.0)	0 1 0 2 (3.3)	0 0 1 1 (3.5)	0 0 2 0 (3.0)	0 0 0 1 (4.0)	0 1 0 5 (3.7)
Hyperplasia, cystic, endometrium	Interim	Incidence	2/20 (10%)	4/22 (18%)	2/20 (10%)	2/22 (9%)	1/20 (5%)	7/22 ^{#,^} (32%)
		Severity Profile	0 1 0 1 (3.0)	0 2 2 0 (2.5)	0 2 0 0 (2.0)	0 2 0 0 (2.0)	0 0 0 1 (4.0)	2 4 0 1 (2.0)
	Terminal	Incidence	18/49 ^{#,^} (37%)	23/49 (47%)	22/48 (46%)	25/49 (51%)	28/49 ^{#,^} (57%)	24/46 [#] (52%)
		Severity Profile	3 8 5 2 (2.3)	1 18 4 0 (2.1)	1 15 5 1 (2.3)	3 15 6 1 (2.2)	0 18 6 4 (2.5)	4 11 6 3 (2.3)
Hyperplasia, endometrium	Interim	Incidence	6/20 (30%)	9/22 (41%)	5/20 (25%)	7/22 (32%)	6/20 (30%)	9/22 (41%)
		Severity Profile	1 4 1 0 (2.0)	1 6 2 0 (2.1)	2 2 1 0 (1.8)	2 4 1 0 (1.9)	0 6 0 0 (2.0)	0 7 2 0 (2.2)
	Terminal	Simple Incidence	18/49 (37%)	14/49 (29%)	17/48 (35%)	14/49 (29%)	12/49 (24%)	10/46 (22%)
		Severity Profile	6 12 0 0 (1.7)	8 6 0 0 (1.4)	7 9 0 1 (1.7)	6 7 1 0 (1.6)	2 10 0 0 (1.8)	1 8 1 0 (2.0)
Metaplasia, squamous	Interim	Incidence	0/20 (0%)	2/22 (9%)	1/20 (5%)	1/22 (4%)	0/20 (0%)	4/22 ^{##,^^} (18%)
		Severity Profile	-	2 0 0 0 (1.0)	0 1 0 0 (2.0)	1 0 0 0 (1.0)	-	1 3 0 0 (1.8)
	Terminal	Incidence	5/49 (10%)	1/49 ^{^N} (2%)	2/48 (4%)	2/49 (4%)	4/49 (8%)	3/46 (6%)
		Severity Profile	3 2 0 0 (1.4)	1 0 0 0 (1.0)	1 1 0 0 (1.5)	0 2 0 0 (2.0)	3 1 0 0 (1.2)	3 0 0 0 (1.0)
Dilatation, lumen	Interim	Incidence	1/20 (5%)	0/22 (0%)	1/20 (5%)	4/22 [^] (18%)	1/20 (5%)	0/22 (0%)
		Severity Profile	0 0 0 1 (4.0)	-	0 0 0 1 (4.0)	0 0 1 3 (3.8)	0 0 1 0 (3.0)	-
	Terminal	Incidence	3/49 ^{#,^,^N} (6%)	6/49 (12%)	2/48 (4%)	4/49 (8%)	2/49 (4%)	0/46 (0%)
		Severity Profile	0 0 1 2 (3.7)	0 0 0 6 (4.0)	0 0 0 2 (4.0)	0 0 0 4 (4.0)	0 0 1 1 (3.5)	-
		Poly-3 Incidence	3/32.5 ^{*N} (9%)	6/33.0 (18%)	2/31.3 (6%)	4/33.8 (12%)	2/35.2 (6%)	0/30.9 (0%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bIn the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Statistical Methods), there was a significant Poly-3
4 test ($p = 0.038$) for the comparison of 2,500 µg BPA/kg bw/day group to vehicle control (endometrial cystic hyperplasia, Poly-3 incidences, 23/43.3 (53%) versus 12/28.2 (43%)).

1 **Table 64. Non-Neoplastic Lesions in the Ovary of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Atrophy	Interim	Incidence	10/23 (44%)	7/22 (32%)	9/22 (41%)	14/24 (58%)	11/20 (55%)	11/24 (46%)
		Severity Profile	1 4 0 5 (2.9)	0 3 0 4 (3.1)	0 2 0 7 (3.6)	6 4 0 4 (2.1)	2 1 0 8 (3.3)	0 2 0 9 (3.6)
	Terminal	Incidence	47/50 (94%)	45/48 (94%)	44/46 (96%)	46/49 (94%)	45/50 (90.0%)	46/46 (100%)
		Severity Profile	0 24 15 8 (2.7)	1 27 9 8 (2.5)	1 25 8 10 (2.6)	0 27 11 8 (2.6)	0 26 7 12 (2.7)	0 23 12 11 (2.7)
		Poly-3 Incidence	47/48.7 (96%)	45/45.1 (100%)	44/44.2 (100%)	46/47.0 (98%)	45/45.8 (98%)	46/46.0 (100%)
Cyst, follicle	Interim	Incidence	8/23 (35%)	4/22 (18%)	10/22 (46%)	5/24 (21%)	10/20 (50%)	11/24 (46%)
		Severity Profile	- _b	-	-	-	-	-
	Terminal	Incidence	3/50 (6%)	3/48 (6%)	2/46 (4%)	7/49 (14%)	6/50 (12%)	4/46 (9%)
		Severity Profile	- _b	-	-	-	-	-
		Poly-3 Incidence	3/35.7 (8%)	3/33.4 (9%)	2/28.9 (7%)	7/34.5 (20%)	6/30.8 (20%)	4/32.3 (12%)
Depletion, Corpus luteum	Interim	Incidence	4/23* (17%)	4/22 (18%)	7/22 (32%)	4/24 (17%)	8/20 (40%)	9/24 (38%)
		Severity Profile	- _b	-	-	-	-	-
Hypertrophy, Interstitial cell	Interim	Incidence	4/23*, #, ^ (17%)	4/22 (18%)	6/22 (27%)	3/24 (12%)	8/20^ (40%)	9/24 (38%)
		Severity Profile	0 4 0 0 (2.0)	0 3 1 0 (2.2)	0 2 4 0 (2.7)	0 0 2 1 (3.3)	0 6 2 0 (2.2)	1 7 1 0 (2.0)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bSeverity scores were not assigned for this lesion.

1 **Table 65. Non-Neoplastic Lesions in the Ovary of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE₂^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle ^b	0.05 EE ₂	0.5 EE ₂
Atrophy	Interim	Incidence	10/23 ^{***, ###, ^^} (44%)	9/25 (36%)	26/26 ^{***, ###, ^^} (100%)
		Severity Profile	1 4 0 5 (2.9)	0 3 0 6 (3.3)	0 0 0 26 (4.0)
	Terminal	Incidence	47/50 ^{###, ^^} (94%)	25/26 (96%)	26/26 ^{###, ^^} (100%)
		Severity Profile	0 24 15 8 (2.7)	0 12 7 6 (2.8)	0 1 1 24 (3.9)
		Poly-3 Incidence	47/48.7 (96%)	25/26.0 (96%)	26/26.0 (100%)
Cyst, follicle	Interim	Incidence	8/23 ^{***} (35%)	9/25 (36%)	26/26 ^{***} (100%)
		Severity Profile	- ^c	-	-
	Terminal	Incidence	3/50 (6%)	0/26 (0%)	3/26 (12%)
		Severity Profile	- ^c	-	-
		Poly-3 Incidence	3/35.7 (8%)	0/15.9 (0%)	3/16.1 (19%)
Depletion, Corpus luteum	Interim	Incidence	4/23 ^{***} (17%)	6/25 (24%)	26/26 ^{***} (100%)
		Severity Profile	- ^c	-	-
Hypertrophy, Interstitial cell	Interim	Incidence	4/23 ^{***, ###, ^^} (17%)	5/25 (20.0%)	26/26 ^{***, ###, ^^} (100%)
		Severity Profile	0 4 0 0 (2.0)	0 4 1 0 (2.2)	1 13 10 2 (2.5)

2 ^aEE₂ doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bThe continuous vehicle control group data are the same as those shown for the continuous-dose BPA data in Table 64.4 ^cSeverity scores were not assigned for this lesion.

1 **Table 66. Non-Neoplastic Lesions in the Ovary of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Atrophy	Interim	Incidence	10/20 (50%)	9/22 (41%)	11/20 (55%)	6/22 (27%)	12/20 (60%)	15/22 (68%)
		Severity Profile	2 6 0 2 (2.2)	1 4 0 4 (2.8)	8 1 0 2 (1.6)	1 3 0 2 (2.5)	5 4 0 3 (2.1)	4 5 0 6 (2.5)
	Terminal	Incidence	47/49 (96%)	48/49 (98%)	46/47 (98%)	50/50 (100%)	49/50 (98%)	44/46 (96%)
		Severity Profile	1 23 16 7 (2.6)	0 34 11 3 (2.4)	1 28 11 6 (2.5)	1 33 7 9 (2.5)	0 25 16 8 (2.7)	0 23 12 9 (2.7)
		Poly-3 Incidence	47/47.5 (99%)	48/48.1 (100%)	46/46.1 (100%)	50/50.0 (100%)	49/49.0 (100%)	44/44.8 (98%)
Cyst, follicle	Interim	Incidence	5/20 ^{***} (25%)	6/22 (27%)	4/20 (20%)	7/22 (32%)	11/20 (55%)	18/22 ^{***} (82%)
		Severity Profile	- _b	-	-	-	-	-
	Terminal	Incidence	4/49 (8%)	4/49 (8%)	2/47 (4%)	1/50 (2%)	2/50 (4%)	4/46 (9%)
		Severity Profile	- _b	-	-	-	-	-
		Poly-3 Incidence	4/32.0 (12%)	4/33.5 (12%)	2/30.2 (7%)	1/34.6 (3%)	2/35.7 (6%)	4/32.4 (12%)
Depletion, Corpus luteum	Interim	Incidence	2/20 (10%)	4/22 (18%)	2/20 (10%)	2/22 (9%)	3/20 (15%)	6/22 (27%)
		Severity Profile	- _b	-	-	-	-	-
Hypertrophy, Interstitial cell	Interim	Incidence	4/20 (20%)	3/22 (14%)	1/20 (5%)	2/22 (9%)	3/20 (15%)	5/22 (23%)
		Severity Profile	0 1 3 0 (2.8)	0 2 1 0 (2.3)	0 1 0 0 (2.0)	0 2 0 0 (2.0)	0 3 0 0 (2.0)	0 4 1 0 (2.2)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bSeverity scores were not assigned for this lesion.

1 **Table 67. Non-Neoplastic Lesions in the Vagina of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Hyperplasia, epithelium	Interim	Incidence	3/23 ^{**} , ^{##} , ^{^^} (13%)	2/22 (9%)	2/21 (10%)	4/24 (17%)	6/20 (30%)	8/24 [#] , [^] (33%)
		Severity Profile	0 1 2 0 (2.7)	0 1 1 0 (2.5)	0 1 1 0 (2.5)	0 0 4 0 (3.0)	0 1 5 0 (2.8)	0 1 7 0 (2.9)
	Terminal	Incidence	4/49 ^{##} , ^{^^} (8%)	5/48 (10%)	12/45 ^{##} , [^] (27%)	10/49 [#] (20%)	11/50 [#] , [^] (22%)	12/46 [#] , [^] (26%)
		Severity Profile	0 1 2 1 ((3.0)	0 1 4 0 (2.8)	1 3 6 2 (2.8)	0 7 3 0 (2.3)	0 3 5 3 (3.0)	0 6 4 2 (2.7)
		Poly-3 Incidence	4/35.2 ^{**} (11%)	5/35.3 (14%)	12/33.7 [*] (36%)	10/36.5 (27%)	11/33.4 [*] (33%)	12/36.8 [*] (33%)
Mucification, epithelium	Interim	Incidence	10/23 (44%)	12/22 (54%)	7/21 (33%)	9/24 (38%)	7/20 (35%)	8/24 (33%)
		Severity Profile	0 6 1 3 (2.7)	0 7 4 1 (2.5)	0 0 3 4 (3.6)	0 1 5 3 (3.2)	0 0 2 5 (3.7)	1 3 1 3 (2.8)
	Terminal	Incidence	46/49 (94%)	37/48 (77%)	34/45 (76%)	39/49 (80%)	34/50 ^{^N} (68%)	40/46 (87%)
		Severity Profile	0 13 12 21 (3.2)	0 7 8 22 (3.4)	0 7 11 16 (3.3)	0 4 14 21 (3.4)	0 8 9 17 (3.3)	1 10 8 21 (3.2)
		Poly-3 Incidence	46/47.2 (97%)	37/42.0 (88%)	34/39.3 ^{*N} (87%)	39/45.2 ^{*N} (86%)	34/42.8 ^{**N} (79%)	40/43.6 (92%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.

1 **Table 68. Non-Neoplastic Lesions in the Vagina of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE₂^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle ^b	0.05 EE ₂	0.5 EE ₂
Hyperplasia, epithelium	Interim	Incidence	3/23 ^{***, ###, ^^} (13%)	7/25 (28%)	20/26 ^{***, ###, ^^} (77%)
		Severity Profile	0 1 2 0 (2.7)	0 4 3 0 (2.4)	0 9 11 0 (2.6)
	Terminal	Incidence	4/49 (8%)	5/26 (19%)	2/26 (8%)
		Severity Profile	0 1 2 1 (3.0)	0 1 2 2 (3.2)	0 1 1 0 (2.5)
		Poly-3 Incidence	4/35.2 (11%)	5/18.6 (27%)	2/15.8 (13%)
Mucification, epithelium	Interim	Incidence	10/23 ^{*, #, ^} (44%)	15/25 (60%)	18/26 ^{#, ^} (69%)
		Severity Profile	0 6 1 3 (2.7)	0 5 1 9 (3.3)	1 4 6 7 (3.1)
	Terminal	Incidence	46/49 (94%)	21/26 (81%)	23/26 (88%)
		Severity Profile	0 13 12 21 (3.2)	0 4 5 12 (3.4)	0 6 8 9 (3.1)
		Poly-3 Incidence	46/47.2 (97%)	21/24.0 (87%)	23/24.8 (93%)

2 ^aEE₂ doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bThe continuous vehicle control group data are the same as those shown for the continuous-dose BPA data in Table 67.

1 **Table 69. Non-Neoplastic Lesions in the Vagina of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA^{a, b}**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Hyperplasia, epithelium	Interim	Incidence	2/20 (10%)	4/22 (18%)	2/20 (10%)	1/22 (4%)	2/20 (10%)	6/22 (27%)
		Severity Profile	0 0 2 0 (3.0)	0 0 4 0 (3.0)	0 0 2 0 (3.0)	0 0 0 1 (4.0)	0 1 1 0 (2.5)	0 1 5 0 (2.8)
	Terminal	Incidence	6/49 (12%)	10/50 (20%)	3/47 (6%)	7/49 (14%)	7/49 (14%)	7/46 (15%)
		Severity Profile	0 3 2 1 (2.7)	0 5 4 1 (2.6)	0 1 1 1 (3.0)	0 2 4 1 (2.9)	0 1 5 1 (3.0)	0 0 5 2 (3.3)
		Poly-3 Incidence	6/33.7 (18%)	10/35.4 (28%)	3/31.8 (9%)	7/35.9 (20%)	7/37.6 (19%)	7/34.6 (20%)
Mucification, epithelium	Interim	Incidence	8/20 (40%)	11/22 (50%)	9/20 (45%)	11/22 (50%)	8/20 (40%)	10/22 (46%)
		Severity Profile	1 2 1 4 (3.0)	0 3 4 4 (3.1)	0 3 4 2 (2.9)	0 6 2 3 (2.7)	0 1 3 4 (3.4)	0 2 3 5 (3.3)
	Terminal	Incidence	40/49 (82%)	46/50 (92%)	37/47 (79%)	44/49 (90%)	39/49 (80%)	34/46 (74%)
		Severity Profile	0 7 12 21 (3.4)	1 7 15 23 (3.3)	0 9 9 19 (3.3)	2 12 12 18 (3.0)	0 8 9 22 (3.4)	1 5 11 17 (3.3)
		Poly-3 Incidence	40/45.8 (87%)	46/48.1 (96%)	37/42.4 (87%)	44/47.9 (92%)	39/44.6 (88%)	34/39.7 (86%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bIn the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Statistical Methods), there was also a significant
4 Poly-3 dose trend ($p = 0.029$) for polymorphonuclear cellular infiltration (not shown in Table). The p -value for trend with all animals included was 0.136.

1 **Table 70. Non-Neoplastic Lesions in the Pituitary of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Hyperplasia, pars distalis	Interim	Incidence	18/23 (78%)	17/22 (77%)	18/22 (82%)	15/24 (62%)	16/20 (80%)	20/24 (83%)
		Severity Profile	8 6 3 1 (1.8)	7 6 3 1 (1.9)	7 4 5 2 (2.1)	8 4 2 1 (1.7)	8 6 1 1 (1.7)	7 8 4 1 (2.0)
	Terminal	Incidence	27/50 (54%)	22/48 (46%)	32/46 (70%)	26/49 (53%)	29/49 (59%)	23/46 (50%)
		Severity Profile	0 3 12 12 (3.3)	1 2 5 14 (3.5)	0 4 12 16 (3.4)	1 5 7 13 (3.2)	3 10 4 12 (2.9)	1 6 6 10 (3.1)
		Poly-3 Incidence	27/43.6 (62%)	22/40.2 (55%)	32/40.6 ^b (79%)	26/44.2 (59%)	29/42.7 (68%)	23/39.7 (58%)
Angiectasis	Interim ^c	Incidence	1/23 (4%)	0/22 (0%)	1/22 (5%)	0/24 (0%)	0/20 (0%)	0/24 (0%)
		Severity Profile	0 1 0 0 (2.0)	-	0 1 0 0 (2.0)	-	-	-
	Terminal	Incidence	10/50 (20%)	8/48 (17%)	4/46 (9%)	9/49 (18%)	9/49 (18%)	9/46 (20%)
		Severity Profile	0 1 1 8 (3.7)	0 0 0 8 (4.0)	0 0 0 4 (4.0)	0 0 2 7 (3.8)	0 2 2 5 (3.3)	0 1 1 7 (3.7)
		Poly-3 Incidence	10/37.5 (27%)	8/35.4 (23%)	4/29.1 (14%)	9/34.8 (26%)	9/31.3 (29%)	9/32.2 (28%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.

3 ^bIn the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Statistical Methods), there was a significant Poly-3
4 test ($p = 0.026$) for the pairwise comparison of the 25 µg BPA/kg bw/day group to the vehicle control (hyperplasia of the pars distalis, Poly-3 incidences 30/37.0 (81%) versus
5 18/30.8 (58%)).

6 ^cThis lesion was not statistically analyzed and is not included in Supplemental Appendix XXXIII since no dose group had two or more lesions. The data are found in Supplemental
7 Appendix XXXII.

1 **Table 71. Non-Neoplastic Lesions in the Pituitary of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE₂^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle ^b	0.05 EE ₂	0.5 EE ₂
Hyperplasia, pars distalis	Interim	Incidence	18/23 ^{##, ^^} (78%)	20/25 (80%)	25/26 ^{##, ^^} (96%)
		Severity Profile	8 6 3 1 (1.8)	10 7 3 0 (1.6)	4 11 6 4 (2.4)
	Terminal	Incidence	27/50 ^{#, ^^N} (54%)	16/26 (62%)	6/26 ^{##, ^^N} (23%)
		Severity Profile Poly-3 Incidence	0 3 12 12 (3.3) 27/43.6 (62%)	0 3 5 8 (3.3) 16/23.6 (68%)	0 1 2 3 (3.3) 6/16.9 (36%)
Angiectasis	Interim	Incidence	1/23 ^{*, #, ^} (4%)	2/25 (8%)	6/26 ^{#, ^} (23%)
		Severity Profile	0 1 0 0 (2.0)	0 1 0 1 (3.0)	0 4 1 1 (2.5)
	Terminal	Incidence	10/50 ^{###, ^^} (20%)	5/26 (19%)	17/26 ^{###, ^^} (65%)
		Severity Profile Poly-3 Incidence	0 1 1 8 (3.7) 10/37.5 ^{***} (27%)	0 0 0 5 (4.0) 5/17.1 (29%)	0 0 0 17 (4.0) 17/22.0 ^{***} (77%)

2 ^aEE₂ doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bThe continuous vehicle control group data are the same as those shown for the continuous-dose BPA data in Table 70.

CLARITY-BPA Core Study, NTP RR 9

1 **Table 72. Non-Neoplastic Lesions in the Pituitary of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Hyperplasia, pars distalis	Interim	Incidence	18/20 (90%)	16/22 (73%)	14/20 (70%)	20/22 (91%)	16/20 (80%)	18/22 (82%)
		Severity Profile	10 8 0 0 (1.4)	10 4 2 0 (1.5)	5 5 4 0 (1.9)	10 9 1 0 (1.6)	6 7 3 0 (1.8)	9 8 1 0 (1.6)
	Terminal	Incidence	25/49 (51%)	32/50 [^] (64%)	34/48 [^] (71%)	26/50 (52%)	28/50 (56%)	21/46 (46%)
		Severity Profile Poly-3 Incidence	3 7 7 8 (2.8) 25/42.2 (59%)	0 5 11 16 (3.3) 32/43.5 (74%)	2 6 14 12 (3.1) 34/45.0 (76%)	0 6 9 11 (3.2) 26/43.3 (60%)	3 7 5 13 (3.0) 28/45.3 (62%)	1 3 7 10 (3.2) 21/39.1 (54%)
Angiectasis	Interim	Incidence	0/20 (0%)	2/22 [^] (9%)	1/20 (5%)	0/22 (0%)	0/20 (0%)	0/22 (0%)
		Severity Profile	-	0 1 1 0 (2.5)	0 1 0 0 (2.0)	-	-	-
	Terminal	Incidence	12/49 (24%)	11/50 (22%)	8/48 (17%)	12/50 (24%)	14/50 (28%)	11/46 (24%)
		Severity Profile Poly-3 Incidence	0 0 0 12 (4.0) 12/35.3 (34%)	0 0 1 10 (3.9) 11/34.5 (32%)	0 1 2 5 (3.5) 8/32.7 (24%)	0 3 1 8 (3.4) 12/38.4 (31%)	0 1 2 11 (3.7) 14/37.6 (37%)	0 2 5 4 (3.2) 11/33.9 (32%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.

1 **Table 73. Non-Neoplastic Lesions in the Heart of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Cardiomyopathy	Interim	Incidence	7/23 (30%)	10/22 (46%)	9/22 (41%)	8/24 (33%)	9/20 (45%)	7/24 (29%)
		Severity Profile	6 1 0 0 (1.1)	8 2 0 0 (1.2)	7 2 0 0 (1.2)	8 0 0 0 (1.0)	8 1 0 0 (1.1)	6 1 0 0 (1.1)
	Terminal	Incidence	35/50 (70%)	30/48 (62%)	24/46 ^N (52%)	35/49 (71%)	33/50 (66%)	33/46 (72%)
		Severity Profile	24 10 1 0 (1.3)	18 7 4 1 (1.6)	18 5 1 0 (1.3)	25 9 1 0 (1.3)	24 7 1 1 (1.4)	23 9 0 1 (1.4)
		Poly-3 Incidence	35/43.5 (81%)	30/39.0 (77%)	24/34.6 (69%)	35/42.3 (83%)	33/38.4 (86%)	33/39.4 (84%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.

1 **Table 74. Non-Neoplastic Lesions in the Heart of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE₂^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle ^b	0.05 EE ₂	0.5 EE ₂
Cardiomyopathy	Interim	Incidence	7/23 ^{**} , ##, ^^ (30%)	8/26 (30.8%)	17/26 [*] , ##, ^^ (65%)
		Severity Profile	6 1 0 0 (1.1)	8 0 0 0 (1.0)	13 4 0 0 (1.2)
	Terminal	Incidence	35/50 [^] (70%)	19/26 (73%)	22/26 [#] , ^ (85%)
		Severity Profile	24 10 1 0 (1.3)	14 5 0 0 (1.3)	12 9 1 0 (1.5)
		Poly-3 Incidence	35/43.5 (81%)	19/22.6 (84%)	22/24.0 (92%)

2 ^aEE₂ doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bThe continuous vehicle control group data are the same as those shown for the continuous-dose BPA data in Table 73.

1 **Table 75. Non-Neoplastic Lesions in the Heart of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Cardiomyopathy	Interim	Incidence	6/20 (30%)	8/22 (36%)	7/20 (35%)	7/22 (32%)	6/20 (30%)	7/22 (32%)
		Severity Profile	6 0 0 0 (1.0)	8 0 0 0 (1.0)	6 1 0 0 (1.1)	5 2 0 0 (1.3)	6 0 0 0 (1.0)	5 2 0 0 (1.3)
	Terminal	Incidence	32/50 ^{##, ^^} (64%)	37/50 [^] (74%)	38/48 (79%)	37/50 ^{#, ^} (74%)	35/50 ^{#, ^} (70%)	35/46 ^{##, ^^} (76%)
		Severity Profile	26 3 3 0 (1.3)	22 13 2 0 (1.5)	29 7 2 0 (1.3)	21 14 2 0 (1.5)	17 13 5 0 (1.7)	16 14 5 0 (1.7)
		Poly-3 Incidence	32/42.9 (74%)	37/42.9 (86%)	38/43.1 (88%)	37/44.0 (84%)	35/44.0 (80%)	35/39.7 ^b (88%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bIn the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Statistical Methods), there was a significant Poly-3
4 test ($p = 0.049$) for the comparison of the 25,000 µg BPA/kg bw/day dose group to the vehicle controls (Poly-3 incidences 27/30.8 (88%) versus 22/31.6 (70%)).

1 **Table 76. Non-Neoplastic Lesions in the Kidney of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Nephropathy	Interim	Incidence	6/23 (26%)	7/22 (32%)	11/22 [^] (50%)	8/24 (33%)	11/20 [^] (55%)	7/24 (29%)
		Severity Profile	4 1 0 1 (1.7)	5 1 1 0 (1.4)	6 2 0 3 (2.0)	6 1 0 1 (1.5)	9 0 2 0 (1.4)	3 2 1 1 (2.0)
	Terminal	Incidence	19/50 (38%)	28/48 ^{^^} (58%)	21/46 (46%)	21/49 (43%)	21/50 (42%)	25/46 ^{#, ^} (54%)
		Severity Profile	18 0 1 0 (1.1)	16 9 0 3 (1.6)	17 2 1 1 (1.3)	12 5 2 2 (1.7)	12 4 3 2 (1.8)	18 3 1 3 (1.6)
		Poly-3 Incidence	19/39.9 (48%)	28/40.6 [*] (69%)	21/34.4 (61%)	21/38.5 (54%)	21/35.5 (59%)	25/38.2 (65%)
Cyst, renal tubule	Interim	Incidence	0/23 (0%)	7/22 ^{**} (32%)	3/22 (14%)	3/24 (12%)	3/20 (15%)	1/24 (4%)
		Severity Profile	- ^b	-	-	-	-	-
	Terminal	Incidence	9/50 (18%)	8/48 (17%)	12/46 (26%)	15/49 (31%)	12/50 (24%)	6/46 (13%)
		Severity Profile	- ^b	-	-	-	-	-
		Poly-3 Incidence	9/36.2 (25%)	8/34.3 (23%)	12/32.1 (37%)	15/36.1 ^c (42%)	12/33.9 (35%)	6/33.4 (18%)
Mineralization	Interim	Incidence	11/23 ^{*, #, ^^} (48%)	5/22 (23%)	11/22 (50%)	12/24 (50%)	11/20 (55%)	16/24 ^{#, ^} (67%)
		Severity Profile	11 0 0 0 (1.0)	3 1 1 0 (1.6)	7 2 1 1 (1.6)	11 1 0 0 (1.1)	8 3 0 0 (1.3)	10 3 3 0 (1.6)
	Terminal	Incidence	30/50 (60%)	23/48 (48%)	25/46 (54%)	25/49 (51%)	24/50 (48%)	26/46 (56%)
		Severity Profile	21 8 1 0 (1.3)	20 3 0 0 (1.1)	18 7 0 0 (1.3)	18 7 0 0 (1.3)	17 5 2 0 (1.4)	16 7 2 1 (1.5)
		Poly-3 Incidence	30/42.9 (70%)	23/37.8 (61%)	25/40.3 (62%)	25/40.6 (62%)	24/39.3 (61%)	26/38.6 (67%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bSeverity scores were not assigned for this lesion.4 ^cIn the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Statistical Methods), there was a significant Poly-3
5 test ($p = 0.033$) for the pairwise comparison of the 250 µg BPA/kg bw/day dose group to the vehicle control group (renal tubule cyst, Poly-3 incidences 15/32.9 (46%) versus
6 5/24.8 (20%)).

1 **Table 77. Non-Neoplastic Lesions in the Kidney of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE₂^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle ^b	0.05 EE ₂	0.5 EE ₂
Nephropathy	Interim	Incidence	6/23 ^{*, #, ^} (26%)	13/26 (50%)	15/26 ^{*, #, ^} (58%)
		Severity Profile	4 1 0 1 (1.7)	8 5 0 0 (1.4)	10 4 1 0 (1.4)
	Terminal	Incidence	19/50 ^{#, ^^} (38%)	14/26 [#] (54%)	15/26 ^{#, ^^} (58%)
		Severity Profile	18 0 1 0 (1.1)	10 3 1 0 (1.4)	6 5 3 1 (1.9)
		Poly-3 Incidence	19/39.9 [*] (48%)	14/21.0 (67%)	15/21.6 (70%)
Cyst, renal tubule	Interim	Incidence	0/23 (0%)	5/26 [*] (19%)	4/26 (15%)
		Severity Profile	- ^c	-	-
	Terminal	Incidence	9/50 (18%)	5/26 (19%)	6/26 (23%)
		Severity Profile	- ^c	-	-
		Poly-3 Incidence	9/36.2 (25%)	5/18.3 (27%)	6/17.6 (34%)
Mineralization	Interim	Incidence	11/23 (48%)	17/26 [^] (65%)	14/26 (54%)
		Severity Profile	11 0 0 0 (1.0)	10 6 1 0 (1.5)	7 5 1 1 (1.7)
	Terminal	Incidence	30/50 (60%)	10/26 (38%)	17/26 (65%)
		Severity Profile	21 8 1 0 (1.3)	4 5 1 0 (1.7)	10 7 0 0 (1.4)
		Poly-3 Incidence	30/42.9 (70%)	10/20.7 (48%)	17/22.0 (77%)

2 ^aEE₂ doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bThe continuous vehicle control group data are the same as those shown for the continuous-dose BPA data in Table 76.4 ^cSeverity scores were not assigned for this lesion.

1 **Table 78. Non-Neoplastic Lesions in the Kidney of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Nephropathy	Interim	Incidence	10/20 (50%)	10/22 (46%)	10/20 (50%)	11/22 (50%)	12/20 (60%)	13/22 (59%)
		Severity Profile	7 2 1 0 (1.4)	7 2 1 0 (1.4)	9 1 0 0 (1.1)	7 3 1 0 (1.5)	7 5 0 0 (1.4)	10 1 1 1 (1.5)
	Terminal	Incidence	28/49 ^{#, ^^} (57%)	25/50 (50%)	25/47 (53%)	29/49 (59%)	33/50 (66%)	30/46 [^] (65%)
		Severity Profile	17 8 1 2 (1.6)	16 4 2 3 (1.7)	17 3 5 0 (1.5)	22 5 1 1 (1.3)	15 11 3 4 (1.9)	10 11 6 3 (2.1)
		Poly-3 Incidence	28/39.2 (71.4%)	25/41.3 (60.5%)	25/38.4 (65.1%)	29/40.9 (71.0%)	33/43.3 (76.3%)	30/39.9 (75.1%)
Cyst, renal tubule	Interim	Incidence	4/20 (20%)	3/22 (14%)	4/20 (20%)	4/22 (18%)	6/20 (30%)	5/22 (23%)
		Severity Profile	- _b	-	-	-	-	-
	Terminal	Incidence	7/49 (14%)	15/50 (30%)	11/47 (23%)	8/49 (16%)	16/50 (32%)	11/46 (24%)
		Severity Profile	- _b	-	-	-	-	-
		Poly-3 Incidence	7/33.6 (21%)	15/34.9* (43%)	11/34.3 (32%)	8/36.1 (22%)	16/39.6 (40%)	11/34.4 (32%)
Mineralization	Interim	Incidence	13/20 (65%)	11/22 (50%)	11/20 (55%)	14/22 (64%)	13/20 (65%)	11/22 (50%)
		Severity Profile	8 4 0 1 (1.5)	9 2 0 0 (1.2)	6 4 0 1 (1.6)	8 6 0 0 (1.4)	6 6 1 0 (1.6)	8 3 0 0 (1.3)
	Terminal	Incidence	28/49 (57%)	22/50 (44%)	28/47 (60%)	26/49 (53%)	23/50 (46%)	23/46 (50%)
		Severity Profile	20 7 0 1 (1.4)	14 7 1 0 (1.4)	18 9 0 1 (1.4)	17 8 1 0 (1.4)	11 9 3 0 (1.7)	13 9 1 0 (1.5)
		Poly-3 Incidence	28/40.7 (69%)	22/39.1 (56%)	28/38.9 (72%)	26/42.4 (61%)	23/42.4 (54%)	23/39.1 (59%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bSeverity scores were not assigned for this lesion.

1 **Table 79. Non-Neoplastic Lesions in the Liver of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Infiltration, Mononuclear cells	Interim	Incidence	4/23 (17%)	6/22 (27%)	4/22 (18%)	5/24 (21%)	5/20 (25%)	4/24 (17%)
		Severity Profile	4 0 0 0 (1.0)	5 1 0 0 (1.2)	4 0 0 0 (1.0)	5 0 0 0 (1.0)	5 0 0 0 (1.0)	4 0 0 0 (1.0)
	Terminal	Incidence	37/50 ^{##, ^^N} (74%)	28/48 (58%)	35/46 (76%)	29/49 ^{#, ^N} (59%)	26/50 ^{##, ^^N} (52%)	24/46 ^{#, ^N} (52%)
		Severity Profile Poly-3 Incidence	27 9 1 0 (1.3) 37/44.3 ^{**N} (83%)	20 8 0 0 (1.3) 28/38.1 (74%)	29 6 0 0 (1.2) 35/38.7 (90%)	24 5 0 0 (1.2) 29/41.9 (69%)	21 5 0 0 (1.2) 26/38.7 ^{*N} (67%)	19 4 1 0 (1.2) 24/37.9 ^{*N} (63%)
Cystic degeneration	Terminal	Incidence	4/50 (8%)	3/48 (6%)	6/46 (13%)	3/49 (6%)	5/50 (10%)	1/46 (2%)
		Severity Profile	4 0 0 0 (1.0)	3 0 0 0 (1.0)	6 0 0 0 (1.0)	3 0 0 0 (1.0)	4 1 0 0 (1.2)	1 0 0 0 (1.0)
		Poly-3 Incidence	4/34.9 (12%)	3/33.3 (9%)	6/29.8 (20%)	3/33.2 (9%)	5/29.6 (17%)	1/31.2 (3%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.

1 **Table 80. Non-Neoplastic Lesions in the Liver of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE₂^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle ^b	0.05 EE ₂	0.5 EE ₂
Infiltration, Mononuclear cells	Interim	Incidence	4/23 (17%)	7/26 (27%)	2/26 (8%)
		Severity Profile	4 0 0 0 (1.0)	7 0 0 0 (1.0)	2 0 0 0 (1.0)
	Terminal	Incidence	37/50 ^{##, ^^^} N (74%)	17/26 (65%)	10/26 ^{##, ^^^} N (38%)
		Severity Profile	27 9 1 0 (1.3)	15 2 0 0 (1.1)	8 2 0 0 (1.2)
		Poly-3 Incidence	37/44.3 ^{**} N (83%)	17/21.6 (79%)	10/18.7 ^{**} N (54%)
Cystic degeneration	Terminal	Incidence	4/50 (8%)	4/26 (15%)	2/26 (8%)
		Severity Profile	4 0 0 0 (1.0)	4 0 0 0 (1.0)	1 1 0 0 (1.5)
		Poly-3 Incidence	4/34.9 (12%)	4/17.3 (23%)	2/15.2 (13%)

2 ^aEE₂ doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bThe continuous vehicle control group data are the same as those shown for the continuous-dose BPA data in Table 79.

1 **Table 81. Non-Neoplastic Lesions in the Liver of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA^{a, b}**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Infiltration, Mononuclear cells	Interim	Incidence	2/20 (10%)	10/22 ^{*, ^^} (46%)	7/20 (35%)	7/22 (32%)	2/20 (10%)	8/22 ^{*, #, ^} (36%)
		Severity Profile	1 1 0 0 (1.5)	10 0 0 0 (1.0)	7 0 0 0 (1.0)	7 0 0 0 (1.0)	2 0 0 0 (1.0)	8 0 0 0 (1.0)
	Terminal	Incidence	29/49 (59%)	28/50 (56%)	33/48 (69%)	25/50 (50%)	31/50 (62%)	31/46 (67%)
		Severity Profile	22 6 1 0 (1.3)	18 10 0 0 (1.4)	26 7 0 0 (1.2)	16 9 0 0 (1.4)	25 5 1 0 (1.2)	23 8 0 0 (1.3)
		Poly-3 Incidence	29/39.7 (73%)	28/38.9 (72%)	33/41.5 (80%)	25/39.8 (63%)	31/41.0 (76%)	31/37.2 (83%)
Cystic degeneration	Terminal	Incidence	2/49 ^{#, ^^} (4%)	1/50 (2%)	6/48 (12%)	5/50 (10%)	8/50 ^{#, ^} (16%)	7/46 ^{#, ^} (15%)
		Severity Profile	2 0 0 0 (1.0)	1 0 0 0 (1.0)	6 0 0 0 (1.0)	5 0 0 0 (1.0)	6 2 0 0 (1.2)	7 0 0 0 (1.0)
		Poly-3 Incidence	2/32.0 ^{**} (6%)	1/31.7 (3%)	6/32.0 (19%)	5/35.3 (14%)	8/37.5 (21%)	7/32.3 (22%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bIn the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Statistical Methods), there was a statistically
4 significant Poly-3 dose trend ($p = 0.036$; in the analysis that included all animals, $p = 0.222$) for mixed cell foci in terminal sacrifice animals (not shown in Table).

1 **Table 82. Non-Neoplastic Lesions in the Thyroid of Interim and Terminal Sacrifice Female Rats: Continuous-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Hyperplasia, C-cell	Interim	Incidence	14/23 (61%)	11/22 (50%)	15/21 (71%)	12/24 (50%)	8/20 (40%)	16/24 (67%)
		Severity Profile	8 6 0 0 (1.4)	9 2 0 0 (1.2)	12 3 0 0 (1.2)	9 3 0 0 (1.2)	4 3 1 0 (1.6)	12 3 1 0 (1.3)
	Terminal	Incidence	22/50 (44%)	17/48 (35%)	22/46 (48%)	18/49 (37%)	20/50 (40%)	17/46 (37%)
		Severity Profile Poly-3 Incidence	11 9 2 0 (1.6) 22/40.7 (54%)	12 3 2 0 (1.4) 17/37.3 (46%)	13 7 2 0 (1.5) 22/36.0 (61%)	11 7 0 0 (1.4) 18/38.4 (47%)	8 10 2 0 (1.7) 20/35.9 (56%)	7 8 2 0 (1.7) 17/36.6 (46%)
Hyperplasia, Follicular cell ^b	Terminal	Incidence	1/50 (2%)	6/48 ^a (12%)	4/46 (9%)	3/49 (6%)	1/50 (2%)	4/46 (9%)
		Severity Profile	0 1 0 0 (2.0)	0 2 4 0 (2.7)	0 2 1 1 (2.8)	0 2 1 0 (2.3)	0 0 0 1 (4.0)	0 2 2 0 (2.5)
		Poly-3 Incidence	1/34.2 (3%)	6/34.1 (18%)	4/30.1 (13%)	3/33.3 (9%)	1/29.1 (3%)	4/32.9 (12%)
Ultimobranchial cyst	Interim	Incidence	7/23 (30%)	7/22 (32%)	5/21 (24%)	8/24 (33%)	6/20 (30%)	11/24 (46%)
		Severity Profile	- ^c	-	-	-	-	-
	Terminal	Incidence	8/50 (16%)	2/48 (4%)	6/46 (13%)	3/49 (6%)	4/50 (8%)	7/46 (15%)
		Severity Profile Poly-3 Incidence	- ^c 8/36.4 (22%)	- 2/33.5 (6%)	- 6/30.2 (20%)	- 3/33.3 (9%)	- 4/30.2 (13%)	- 7/32.8 (21%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bData for follicular cell hyperplasia are not tabulated for interim sacrifice animals since no dose groups had two or more diagnoses of this lesion.4 ^cNo severity scores were assigned for ultimobranchial cysts.

1 **Table 83. Non-Neoplastic Lesions in the Thyroid of Interim and Terminal Sacrifice Female Rats: Continuous-Dose EE₂^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle ^b	0.05 EE ₂	0.5 EE ₂
Hyperplasia, C-cell	Interim	Incidence	14/23 (61%)	11/26 (42%)	13/26 (50%)
		Severity Profile	8 6 0 0 (1.4)	7 4 0 0 (1.4)	11 1 1 0 (1.2)
	Terminal	Incidence	22/50 (44%)	7/26 (27%)	9/25 (36%)
		Severity Profile	11 9 2 0 (1.6)	2 5 0 0 (1.7)	6 2 0 1 (1.6)
		Poly-3 Incidence	22/40.7 (54%)	7/18.7 (37%)	9/18.1 (50%)
Hyperplasia, Follicular cell ^c	Terminal	Incidence	1/50 (2%)	4/26 ^^ (15%)	0/25 (0%)
		Severity Profile	0 1 0 0 (2.0)	0 1 3 0 (2.8)	-
		Poly-3 Incidence	1/34.2 (3%)	4/17.9* (22%)	0/14.7 (0%)
Ultimobranchial cyst	Interim	Incidence	7/23 (30%)	7/26 (27%)	11/26 (42%)
		Severity Profile	- ^d	-	-
	Terminal	Incidence	8/50 (16%)	5/26 (19%)	8/25 (32%)
		Severity Profile	- ^d	-	-
		Poly-3 Incidence	8/36.4* (22%)	5/17.5 (29%)	8/17.4 (46%)

2 ^aEE₂ doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bThe continuous vehicle control group data are the same as those shown for the continuous-dose BPA data in Table 82.4 ^cData for follicular cell hyperplasia are not tabulated for interim sacrifice animals since no dose groups had two or more diagnoses of this lesion.5 ^dNo severity scores were assigned for ultimobranchial cysts.

1 **Table 84. Non-Neoplastic Lesions in the Thyroid of Interim and Terminal Sacrifice Female Rats: Stop-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Hyperplasia, C-cell	Interim	Incidence	10/20 (50%)	16/22 [^] (73%)	11/20 (55%)	12/22 (54%)	13/20 (65%)	9/22 (41%)
		Severity Profile	10 0 0 0 (1.0)	11 4 1 0 (1.4)	8 3 0 0 (1.3)	8 4 0 0 (1.3)	11 2 0 0 (1.2)	8 1 0 0 (1.1)
	Terminal	Incidence	26/48 (54%)	29/49 (59%)	17/45 (38%)	23/48 (48%)	28/50 (56%)	24/46 (52%)
		Severity Profile Poly-3 Incidence	8 15 2 1 (1.8) 26/40.5 (64%)	15 11 1 2 (1.7) 29/42.0 (69%)	11 5 0 1 (1.5) 17/34.9 (49%)	15 7 1 0 (1.4) 23/39.8 (58%)	10 12 4 2 (1.9) 28/42.6 (66%)	11 11 2 0 (1.6) 24/38.9 (62%)
Hyperplasia, Follicular cell ^b	Terminal	Incidence	4/48 (8%)	4/49 (8%)	7/45 (16%)	6/48 (12%)	5/50 (10%)	4/46 (9%)
		Severity Profile	0 2 2 0 (2.5)	1 3 0 0 (1.8)	0 5 2 0 (2.3)	0 4 2 0 (2.3)	0 3 2 0 (2.4)	0 3 1 0 (2.2)
		Poly-3 Incidence	4/32.8 (12%)	4/32.0 (12%)	7/31.6 (22%)	6/35.4 (17%)	5/35.9 (14%)	4/33.2 (12%)
Ultimobranchial cyst	Interim	Incidence	4/20 (20%)	6/22 (27%)	7/20 (35%)	4/22 (18%)	6/20 (30%)	6/22 (27%)
		Severity Profile	- ^c	-	-	-	-	-
	Terminal	Incidence	2/48 (4%)	7/49 (14%)	2/45 (4%)	9/48 (19%)	11/50 (22%)	3/46 (6%)
		Severity Profile Poly-3 Incidence	- ^c 2/31.4 (6%)	- 7/33.4 (21%)	- 2/29.5 (7%)	- 9/36.1* (25%)	- 11/38.6* (28%)	- 3/32.1 (9%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bData for follicular cell hyperplasia are not tabulated for interim sacrifice animals since no dose groups had two or more diagnoses of this lesion.4 ^cNo severity scores were assigned for ultimobranchial cysts.

1 **Table 85. Non-Neoplastic Lesions in the Epididymis of Interim and Terminal Sacrifice Male Rats: Continuous-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Exfoliated germ cells	Interim	Incidence	1/22 ^{*,#} , [^] (4%)	1/22 (4%)	1/20 (5%)	1/24 (4%)	0/20 (0%)	6/22 ^{*,##} , ^{^^} (27%)
		Severity Profile	1 0 0 0 (1.0)	1 0 0 0 (1.0)	0 1 0 0 (2.0)	1 0 0 0 (1.0)	-	6 0 0 0 (1.0)
	Terminal	Incidence	10/49 (20%)	8/48 (17%)	10/48 (21%)	12/50 (24%)	13/50 (26%)	6/46 (13%)
		Severity Profile	5 3 1 1 (1.8)	5 1 2 0 (1.6)	1 9 0 0 (1.9)	4 5 2 1 (2.0)	4 7 2 0 (1.8)	4 0 2 0 (1.7)
		Poly-3	10/36.5	8/35.5	10/35.4	12/37.4	13/38.0	6/30.1
		Incidence	(27%)	(23%)	(28%)	(32%)	(34%)	(20%)
Infiltration, cellular, lymphocyte	Interim	Incidence	0/22 ^{*,#} , [^] (0%)	1/22 (4%)	3/20 (15%)	2/24 (8%)	0/20 (0%)	5/22 ^{*,##} , ^{^^} (23%)
		Severity Profile	-	0 1 0 0 (2.0)	3 0 0 0 (1.0)	2 0 0 0 (1.0)	-	5 0 0 0 (1.0)
	Terminal	Incidence	10/49 (20%)	12/48 (25%)	13/48 (27%)	15/50 (30%)	14/50 (28%)	15/46 (33%)
		Severity Profile	8 2 0 0 (1.2)	12 0 0 0 (1.0)	11 2 0 0 (1.2)	13 2 0 0 (1.1)	12 2 0 0 (1.1)	13 2 0 0 (1.1)
		Poly-3	10/35.5	12/36.5	13/34.4	15/36.2	14/36.0	15/34.1
		Incidence	(28%)	(33%)	(38%)	(41%)	(39%)	(44%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.

1 **Table 86. Non-Neoplastic Lesions in the Epididymis of Interim and Terminal Sacrifice Male Rats: Continuous-Dose EE₂^a**

Lesion	Study Phase (Interim/Terminal)	Statistic ^b	Vehicle	0.05 EE ₂	0.5 EE ₂
Exfoliated germ cells	Interim	Incidence	1/22 (4%)	4/26 (15%)	2/26 (8%)
		Severity Profile	1 0 0 0 (1.0)	3 1 0 0 (1.2)	2 0 0 0 (1.0)
	Terminal	Incidence	10/49 (20%)	6/26 (23%)	4/26 (15%)
		Severity Profile	5 3 1 1 (1.8)	4 1 1 0 (1.5)	3 1 0 0 (1.2)
		Poly-3 Incidence	10/36.5 (27%)	6/18.3 (33%)	4/20.4 (20%)
Infiltration, cellular, lymphocyte	Interim	Incidence	0/22 ^{#, ^} (0%)	1/26 (4%)	3/26 ^{#, ^} (12%)
		Severity Profile	-	1 0 0 0 (1.0)	3 0 0 0 (1.0)
	Terminal	Incidence	10/49 [^] (20%)	5/26 (19%)	10/26 [^] (38%)
		Severity Profile	8 2 0 0 (1.2)	4 1 0 0 (1.2)	8 2 0 0 (1.2)
		Poly-3 Incidence	10/35.5 (28%)	5/18.3 (27%)	10/20.4 (49%)

2 ^aEE₂ doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bThe continuous vehicle control group data are the same as those shown for the continuous-dose BPA data in Table 85.

1 **Table 87. Non-Neoplastic Lesions in the Epididymis of Interim and Terminal Sacrifice Male Rats: Stop-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Exfoliated germ cells	Interim	Incidence	0/20 (0%)	3/20 ^a (15%)	1/20 (5%)	2/19 (10%)	1/20 (5%)	1/22 (4%)
		Severity Profile	-	1 2 0 0 (1.7)	0 1 0 0 (2.0)	2 0 0 0 (1.0)	0 1 0 0 (2.0)	1 0 0 0 (1.0)
	Terminal	Incidence	12/49 (24%)	15/48 (31%)	11/48 (23%)	13/50 (26%)	17/50 (34%)	9/46 (20%)
		Severity Profile Poly-3 Incidence	3 6 3 0 (2.0) 12/39.0 (31%)	5 7 3 0 (1.9) 15/38.3 (39%)	3 7 1 0 (1.8) 11/37.9 (29%)	3 9 1 0 (1.8) 13/36.1 (36%)	5 5 6 1 (2.2) 17/39.8 ^b (43%)	4 4 1 0 (1.7) 9/29.5 (30%)
Infiltration, cellular, lymphocyte	Interim	Incidence	1/20 (5%)	1/20 (5%)	4/20 (20%)	1/19 (5%)	2/20 (10%)	2/22 (9%)
		Severity Profile	1 0 0 0 (1.0)	1 0 0 0 (1.0)	4 0 0 0 (1.0)	1 0 0 0 (1.0)	2 0 0 0 (1.0)	2 0 0 0 (1.0)
	Terminal	Incidence	14/49 (29%)	16/48 (33%)	16/48 (33%)	14/50 (28%)	12/50 (24%)	13/46 (28%)
		Severity Profile Poly-3 Incidence	9 5 0 0 (1.4) 14/40.2 (35%)	13 3 0 0 (1.2) 16/36.8 (44%)	14 2 0 0 (1.1) 16/38.3 (42%)	11 3 0 0 (1.2) 14/35.3 (40%)	10 2 0 0 (1.2) 12/39.9 (30%)	12 1 0 0 (1.1) 13/29.6 (44%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bIn the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Statistical Methods), there was a statistically
4 significant ($p = 0.046$) difference in the pairwise comparison between the 2,500 µg BPA/kg bw/day dose group and the vehicle control (exfoliated germ cells, Poly-3 incidences
5 16/32.4 (49%) versus 7/27.3 (26%)).

1 **Table 88. Non-Neoplastic Lesions in the Dorsal/Lateral Prostate of Interim and Terminal Sacrifice Male Rats: Continuous-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Infiltration, cellular, lymphocyte	Interim	Incidence	4/22 (18%)	10/22 ^{^b} (46%)	5/20 (25%)	6/24 (25%)	5/20 (25%)	7/22 (32%)
		Severity Profile	4 0 0 0 (1.0)	9 1 0 0 (1.1)	5 0 0 0 (1.0)	5 1 0 0 (1.2)	5 0 0 0 (1.0)	5 2 0 0 (1.3)
	Terminal	Incidence	33/50 (66%)	26/48 (54%)	27/48 (56%)	27/50 (54%)	27/50 (54%)	20/46 (44%)
		Severity Profile	19 11 2 1 (1.5)	18 7 1 0 (1.3)	21 5 1 0 (1.3)	16 6 3 2 (1.5)	18 8 0 1 (1.4)	10 7 1 2 (1.8)
		Poly-3 Incidence	33/40.4 ^{*N} (82%)	26/38.2 (68%)	27/38.7 (70%)	27/39.6 (68%)	27/38.7 (70%)	20/33.0 (61%)
Suppurative inflammation	Interim	Incidence	18/22 (82%)	20/22 [^] (91%)	18/20 (90%)	22/24 [^] (92%)	18/20 ^{#, ^} (90%)	19/22 [#] (86%)
		Severity Profile	11 7 0 0 (1.4)	6 14 0 0 (1.7)	9 9 0 0 (1.5)	9 12 1 0 (1.6)	6 10 2 0 (1.8)	7 11 1 0 (1.7)
	Terminal	Incidence	41/50 (82%)	46/48 (96%)	47/48 (98%)	45/50 (90%)	43/50 (86%)	41/46 (89%)
		Severity Profile	8 26 4 3 (2.0)	10 26 9 1 (2.0)	9 30 8 0 (2.0)	17 24 2 2 (1.8)	8 28 6 1 (2.0)	12 20 6 3 (1.8)
		Poly-3 Incidence	41/45.6 (90%)	46/46.2 [*] (100%)	47/48.0 (98%)	45/47.7 (94%)	43/46.5 (92%)	41/43.3 (95%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bIn the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Statistical Methods), the lymphocyte cellular
4 infiltration in the 2.5 BPA dose group was also significant in the CAFE analysis (lymphocyte cellular infiltration, 9/16 (56%), in treated group versus 3/17 (18%), in controls,
5 $p = 0.025$).

1 **Table 89. Non-Neoplastic Lesions in the Dorsal/Lateral Prostate of Interim and Terminal Sacrifice Male Rats: Continuous-Dose EE₂^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle ^b	0.05 EE ₂	0.5 EE ₂
Infiltration, cellular, lymphocyte	Interim	Incidence	4/22 (18%)	9/26 (35%)	4/26 (15%)
		Severity Profile	4 0 0 0 (1.0)	9 0 0 0 (1.0)	4 0 0 0 (1.0)
	Terminal	Incidence	33/50 (66%)	17/26 (65%)	13/25 (52%)
		Severity Profile	19 11 2 1 (1.5)	10 6 1 0 (1.5)	6 6 0 1 (1.7)
		Poly-3 Incidence	33/40.4 (82%)	17/21.3 (80%)	13/20.1 (65%)
Suppurative inflammation	Interim	Incidence	18/22 (82%)	25/26 (96%)	25/26 (96%)
		Severity Profile	11 7 0 0 (1.4)	13 11 0 1 (1.6)	12 13 0 0 (1.5)
	Terminal	Incidence	41/50 (82%)	26/26 (100%)	22/25 (88%)
		Severity Profile	8 26 4 3 (2.0)	8 16 1 1 (1.8)	6 12 3 1 (2.0)
		Poly-3 Incidence	41/45.6 (90%)	26/26.0 (100%)	22/23.1 (95%)

2 ^aEE₂ doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bThe continuous vehicle control group data are the same as those shown for the continuous-dose BPA data in Table 88.

CLARITY-BPA Core Study, NTP RR 9

1 **Table 90. Non-Neoplastic Lesions in the Dorsal/Lateral Prostate of Interim and Terminal Sacrifice Male Rats: Stop-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Infiltration, cellular, lymphocyte	Interim	Incidence	9/20 (45%)	5/20 (25%)	4/20 (20%)	8/18 (44%)	8/20 (40%)	6/22 (27%)
		Severity Profile	9 0 0 0 (1.0)	4 1 0 0 (1.2)	3 1 0 0 (1.2)	8 0 0 0 (1.0)	5 3 0 0 (1.4)	6 0 0 0 (1.0)
	Terminal	Incidence	31/46 (67%)	30/48 (62%)	28/48 (58%)	27/50 (54%)	35/49 (71%)	22/45 ^{#, ^ N} (49%)
		Severity Profile	17 11 1 2 (1.6)	20 6 1 3 (1.6)	15 9 2 2 (1.7)	16 8 1 2 (1.6)	20 14 1 0 (1.5)	14 7 0 1 (1.5)
		Poly-3 Incidence	31/41.6 (74.6%)	30/41.1 (72.9%)	28/40.0 (70.0%)	27/38.9 (69.3%)	35/42.4 (82.6%)	22/33.2 (66.3%)
Suppurative inflammation	Interim	Incidence	18/20 (90%)	19/20 (95%)	16/20 (80%)	16/18 (89%)	19/20 (95%)	18/22 (82%)
		Severity Profile	5 13 0 0 (1.7)	12 7 0 0 (1.4)	6 10 0 0 (1.6)	7 9 0 0 (1.6)	9 10 0 0 (1.5)	5 12 1 0 (1.8)
	Terminal	Incidence	39/46 (85%)	46/48 (96%)	41/48 (85%)	42/50 (84%)	44/49 (90%)	38/45 (84%)
		Severity Profile	7 22 7 3 (2.2)	14 21 8 3 (2.0)	14 20 5 2 (1.9)	10 20 9 3 (2.1)	12 21 11 0 (2.0)	6 25 6 1 (2.1)
		Poly-3 Incidence	39/43.3 (90%)	46/46.7 (98%)	41/45.4 (90%)	42/45.2 (93%)	44/46.3 (95%)	38/41.2 (92%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.

1 **Table 91. Neoplastic Lesions in the Ventral Prostate of Interim and Terminal Sacrifice Male Rats: Continuous-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Adenoma	Terminal	Incidence	6/50 (12%)	7/48 (15%)	2/48 (4%)	4/49 (8%)	2/49 (4%)	6/46 (13%)
		Poly-3 Incidence	6/34.4 (17%)	7/34.4 (20%)	2/32.3 (6%)	4/32.9 (12%)	2/33.1 (6%)	6/29.4 (20%)
		Terminal Incidence	3/15 (20%)	4/16 (25%)	2/17 (12%)	2/14 (14%)	2/16 (12%)	3/11 (27%)
		Time-to-First	603	683	726 (T)	713	726 (T)	613
		Poly-3 <i>p</i> -value	0.287N	0.499	0.148N	0.394N	0.139N	0.506
		Multiple Incidence ^d	0/50 (0%)	2/48 (4%)	0/48 (0%)	0/49 (0%)	0/49 (0%)	3/46 (7%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 52 for description of data presentation.3 **Table 92. Neoplastic Lesions in the Ventral Prostate of Interim and Terminal Sacrifice Male Rats: Continuous-Dose EE₂^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle ^b	0.05 EE ₂	0.50 EE ₂
Adenoma	Terminal	Incidence	6/50 (12%)	2/26 (8%)	2/26 (8%)
		Poly-3 Incidence	6/34.4 (17%)	2/17.6 (11%)	2/20.7 (10%)
		Terminal Incidence	3/15 (20%)	2/9 (22%)	0/12 (0%)
		Time-to-First	603	725 (T)	462
		Poly-3 <i>p</i> -value	0.287N	0.433N	0.344N
		Multiple Incidence ^d	0/50 (0%)	1/26 (4%)	0/26 (0%)

4 ^aEE₂ doses are µg/kg bw/day. See legend to Table 52 for description of data presentation.5 ^bThe continuous vehicle control group data are the same as those shown for the continuous-dose BPA data in Table 91.

1 **Table 93. Neoplastic Lesions in the Ventral Prostate of Interim and Terminal Sacrifice Male Rats: Stop-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Adenoma	Terminal	Incidence	4/48 (8%)	4/47 (8%)	4/47 (8%)	2/50 (4%)	4/49 (8%)	6/45 (13%)
		Poly-3 Incidence	4/35.7 (11%)	4/33.0 (12%)	4/34.1 (12%)	2/30.8 (6%)	4/36.5 (11%)	6/28.7 (21%)
		Terminal Incidence	2/17 (12%)	2/16 (12%)	4/16 (25%)	2/13 (15%)	1/15 (7%)	1/9 (11%)
		Time-to-First	675	679	724 (T)	724 (T)	593	530
		Poly-3 <i>p</i> -value	0.273	0.601	0.619	0.407N	0.635N	0.233
		Multiple Incidence ^d	1/48 (2%)	2/47 (4%)	1/47 (2%)	1/50 (2%)	2/49 (4%)	2/45 (4%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 52 for description of data presentation.

CLARITY-BPA Core Study, NTP RR 9

1 **Table 94. Non-Neoplastic Lesions in the Ventral Prostate of Interim and Terminal Sacrifice Male Rats: Continuous-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Infiltration, cellular, lymphocyte	Interim	Incidence	8/22 (36%)	10/22 (45%)	10/20 (50%)	8/24 (33%)	9/20 (45%)	8/22 (36%)
		Severity Profile	8 0 0 0	8 2 0 0	9 1 0 0	7 1 0 0	8 1 0 0	7 1 0 0
	Terminal	Incidence	25/50 (50%)	14/48 ^{##, ^^ N} (29%)	15/48 ^{##, ^^ N} (31%)	15/49 ^{##, ^ N} (31%)	20/49 ^{# N} (41%)	15/46 ^{#, ^ N} (33%)
		Severity Profile	12 5 5 3	9 4 1 0	14 1 0 0	9 4 0 2	15 3 1 1	9 3 1 2
		Poly-3	25/40.8	14/38.2 ^{* N}	15/39.1 ^{* N}	15/39.4 ^{* N}	20/39.0	15/33.3
		Incidence	(61%)	(37%)	(38%)	(38%)	(51%)	(45%)
Suppurative inflammation	Interim	Incidence	10/22 ^{** , ##, ^^ N} (45%)	3/22 ^{*, #, ^^ N} (14%)	4/20 ^{#, ^ N} (20%)	5/24 ^{#, ^ N} (21%)	3/20 ^{*, #, ^^ N} (15%)	1/22 ^{** , ##, ^^ N} (5%)
		Severity Profile	9 1 0 0	3 0 0 0	2 2 0 0	4 1 0 0	3 0 0 0	1 0 0 0
	Terminal	Incidence	16/50 (32%)	5/48 ^{##, ^^ N} (10%)	5/48 ^{##, ^^ N} (10%)	6/49 ^{##, ^^ N} (12%)	5/49 ^{##, ^^ N} (10%)	11/46 ^{## N} (24%)
		Severity Profile	7 2 2 5	3 2 0 0	3 2 0 0	3 1 0 2	1 2 1 1	5 2 1 3
		Poly-3	16/38.1	5/34.6 ^{** N}	5/34.6 ^{** N}	6/35.3 ^{* N}	5/34.9 ^{** N}	11/31.9
		Incidence	(42%)	(14%)	(14%)	(17%)	(14%)	(34%)
Hyperplasia, epithelium	Interim	Incidence	0/22	0/22	0/20	1/24	0/20	0/22
		Severity Profile	-	-	-	0 1 0 0	-	-
	Terminal	Incidence	10/50 (20%)	12/48 (25%)	10/48 (21%)	18/49 [^] (37%)	12/49 (24%)	8/46 (17%)
		Severity Profile	1 6 3 0	2 6 3 1	2 4 4 0	1 13 3 1	3 6 3 0	2 2 2 2
		Poly-3	10/34.0	12/36.4	10/35.0	18/36.3	12/34.7	8/30.5
		Incidence	(29%)	(33%)	(28%)	(50%)	(35%)	(26%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.

1 **Table 95. Non-Neoplastic Lesions in the Ventral Prostate of Interim and Terminal Sacrifice Male Rats: Continuous-Dose EE₂^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle ^b	0.05 EE ₂	0.5 EE ₂
Infiltration, cellular, lymphocyte	Interim	Incidence	8/22 (36%)	13/26 (50%)	13/26 (50%)
		Severity Profile	8 0 0 0	11 2 0 0	12 1 0 0
	Terminal	Incidence	25/50 (50%)	6/26 ^{^^N} (23%)	14/26 (54%)
		Severity Profile	12 5 5 3	5 0 1 0	6 7 0 1
		Poly-3 Incidence	25/40.8 (61%)	6/19.2 ^{*N} (31%)	14/22.3 (63%)
Suppurative inflammation	Interim	Incidence	10/22 ^{*, #, ^N} (45%)	4/26 ^{*, #, ^N} (15%)	5/26 ^{*, #, ^N} (19%)
		Severity Profile	9 1 0 0	3 1 0 0	5 0 0 0
	Terminal	Incidence	16/50 (32%)	4/26 ^{^N} (15%)	8/26 (31%)
		Severity Profile	7 2 2 5	3 0 0 1	5 2 0 1
		Poly-3 Incidence	16/38.1 (42%)	4/18.7 (21%)	8/22.2 (36%)
Hyperplasia, epithelium	Interim	Incidence	0/22 (0%)	0/26 (0%)	0/26 (0%)
		Severity Profile	-	-	-
	Terminal	Incidence	10/50 (20%)	4/26 (15%)	7/26 (27%)
		Severity Profile	1 6 3 0	0 1 2 1	1 4 2 0
		Poly-3 Incidence	10/34.0 (29%)	4/17.6 (23%)	7/19.9 (35%)

2 ^aEE₂ doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bThe continuous vehicle control group data are the same as those shown for the continuous-dose BPA data in Table 94.

1 **Table 96. Non-Neoplastic Lesions in the Ventral Prostate of Interim and Terminal Sacrifice Male Rats: Stop-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Infiltration, cellular, lymphocyte	Interim	Incidence	9/20 (45%)	8/20 (40%)	9/20 (45%)	9/18 (50%)	8/20 (40%)	9/22 (41%)
		Severity Profile	8 1 0 0	7 1 0 0	8 1 0 0	8 1 0 0	7 1 0 0	9 0 0 0
	Terminal	Incidence	19/48 (40%)	17/47 (36%)	15/47 (32%)	16/50 (32%)	20/49 (41%)	18/45 (40%)
		Severity Profile	9 7 2 1	11 3 0 3	10 1 0 4	8 5 2 1	14 5 1 0	11 3 2 2
		Poly-3 Incidence	19/39.2 (48%)	17/37.7 (45%)	15/38.4 (39%)	16/34.5 (46%)	20/40.9 (49%)	18/33.2 (54%)
Suppurative inflammation	Interim	Incidence	3/20 (15%)	2/20 (10%)	2/20 (10%)	6/18 (33%)	4/20 (20%)	2/22 (9%)
		Severity Profile	2 1 0 0	2 0 0 0	2 0 0 0	6 0 0 0	4 0 0 0	2 0 0 0
	Terminal	Incidence	10/48 (21%)	9/47 (19%)	9/47 (19%)	8/50 (16%)	10/49 (20%)	9/45 (20%)
		Severity Profile	5 2 1 2	5 1 1 2	3 2 0 4	4 1 1 2	5 4 0 1	4 2 2 1
		Poly-3 Incidence	10/36.8 (27%)	9/35.2 (26%)	9/37.3 (24%)	8/33.7 (24%)	10/38.0 (26%)	9/30.1 (30%)
Hyperplasia, epithelium	Interim	Incidence	1/20 (5%)	1/20 (5%)	0/20 (0%)	2/18 (11%)	0/20 (0%)	0/22 (0%)
		Severity Profile	0 1 0 0	0 1 0 0	-	2 0 0 0	-	-
	Terminal	Incidence	17/48 (35%)	7/47 ^{##N} (15%)	17/47 (36%)	16/50 (32%)	14/49 (29%)	13/45 (29%)
		Severity Profile	0 12 3 2	2 3 1 1	4 8 3 2	4 9 1 2	1 13 0 0	1 10 0 2
		Poly-3 Incidence	17/38.9 (44%)	7/32.9 ^{*N} (21%)	17/36.0 (47%)	16/35.7 (45%)	14/37.4 (37%)	13/30.2 (43%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.

1 **Table 97. Non-Neoplastic Lesions in the Pituitary of Interim and Terminal Sacrifice Male Rats: Continuous-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Hyperplasia, pars distalis	Interim	Incidence	4/22 (18%)	6/22 (27%)	2/20 (10%)	4/24 (17%)	2/20 (10%)	4/22 (18%)
		Severity Profile	3 1 0 0 (1.2)	6 0 0 0 (1.0)	1 1 0 0 (1.5)	2 2 0 0 (1.5)	2 0 0 0 (1.0)	2 2 0 0 (1.5)
	Terminal	Incidence	11/48 ^{#, ^} (23%)	9/48 (19%)	19/48 [^] (40%)	15/50 (30%)	17/50 (34%)	19/45 ^{#, ^} (42%)
		Severity Profile	3 4 4 0 (2.1)	0 4 4 1 (2.7)	5 8 2 4 (1.7)	4 6 3 2 (2.2)	4 7 5 1 (2.2)	3 9 3 4 (2.4)
		Poly-3	11/36.2 ^{**}	9/36.3	19/37.8	15/37.8	17/38.5	19/34.2 [*]
		Incidence	(30%)	(25%)	(50%)	(40%)	(44%)	(56%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 **Table 98. Non-Neoplastic Lesions in the Pituitary of Interim and Terminal Sacrifice Male Rats: Continuous-Dose EE₂^{a, b}**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle ^c	0.05 EE ₂	0.5 EE ₂
Hyperplasia, pars distalis	Interim	Incidence	4/22 (18%)	7/26 (27%)	2/26 (8%)
		Severity Profile	3 1 0 0 (1.2)	4 2 1 0 (1.6)	1 1 0 0 (1.5)
	Terminal	Incidence	11/48 ^{#, ^} (23%)	10/26 (38%)	13/26 ^{#, ^} (50%)
		Severity Profile	3 4 4 0 (2.1)	2 4 4 0 (2.2)	3 7 3 0 (2.0)
		Poly-3	11/36.2 [*]	10/21.2	13/22.6 [*]
		Incidence	(30%)	(47%)	(58%)

4 ^aEE₂ doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.5 ^bIn the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Statistical Methods), there was a significant Poly-3
6 test ($p = 0.042$) for the pairwise comparison between the 0.05 µg EE₂/kg bw/day dose group and the vehicle control group for angiectasis in the pituitary gland (Poly-3 incidences
7 5/14.2 (35%) versus 2/24.2 (8%); data not shown in Table). In the analysis that included all animals, the Poly-3 incidences were 7/19.1 (37%) in the EE₂ group versus 6/33.5 (18%)
8 in the vehicle control group.9 ^cThe continuous vehicle control group data are the same as those shown for the continuous-dose BPA data in Table 97

CLARITY-BPA Core Study, NTP RR 9

1 **Table 99. Non-Neoplastic Lesions in the Pituitary of Interim and Terminal Sacrifice Male Rats: Stop-Dose BPA^{a, b, c}**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Hyperplasia, pars distalis	Interim	Incidence	8/20 (40%)	9/20 (45%)	3/20 (15%)	4/19 (21%)	4/20 (20%)	7/22 (32%)
		Severity Profile	8 0 0 0 (1.0)	7 1 0 1 (1.4)	0 3 0 0 (2.0)	4 0 0 0 (1.0)	4 0 0 0 (1.0)	6 1 0 0 (1.1)
	Terminal	Incidence	12/46 (26%)	16/48 (33%)	18/48 (38%)	15/49 (31%)	19/50 (38%)	19/43 (44%)
		Severity Profile	0 6 3 3 (2.8)	5 4 6 1 (2.2)	4 8 2 4 (2.3)	3 6 3 3 (2.4)	3 9 5 2 (2.3)	4 8 3 4 (2.7)
		Poly-3 Incidence	12/37.2* (32%)	16/38.2 (42%)	18/40.8 (44%)	15/37.3 (40%)	19/38.9 (49%)	19/32.7* (58%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.

3 ^bIn the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Statistical Methods), there was a significant dose
4 trend ($p = 0.049$) for pars distalis, cyst (not shown in Table). The p -value for the trend in the analysis including all animals was 0.056.

5 ^cAlso in the sensitivity analysis mentioned in footnote b, there was a statistically significant pairwise comparison ($p = 0.041$, Poly-3 test) between the 25,000 µg BPA/kg bw/day
6 dose group and the vehicle control for hypertrophy of the pars distalis (Poly-3 incidences 4/21.7 (18%) versus 0/24.3). In the analysis that included all animals, the Poly-3
7 incidences were 4/28.5 (14%) versus 1/35.1 (3%), $p = 0.118$. This lesion is not shown in the Table.

1 **Table 100. Non-Neoplastic Lesions in the Thyroid of Interim and Terminal Sacrifice Male Rats: Continuous-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Hyperplasia, C-cell	Interim	Incidence	10/22 (46%)	13/22 (59%)	9/20 (45%)	12/24 (50%)	7/18 (39%)	10/21 (48%)
		Severity Profile	3 4 3 0 (2.0)	7 4 2 0 (1.6)	6 2 1 0 (1.4)	5 4 3 0 (1.8)	2 4 0 1 (2.0)	6 3 1 0 (1.5)
	Terminal	Incidence	9/46 (20%)	13/40 (32%)	15/47 (32%)	15/44 (34%)	20/44 ^{^^} (46%)	11/44 (25%)
		Severity Profile	5 2 2 0 (1.7)	5 7 1 0 (1.7)	8 4 2 1 (1.7)	8 6 1 0 (1.5)	10 8 2 0 (1.6)	3 7 1 0 (1.8)
		Poly-3 Incidence	9/34.9* (26%)	13/32.8 (40%)	15/35.5 (42%)	15/34.1 (44%)	20/33.8** (59%)	11/30.5 (36%)
Hyperplasia, follicular cell	Interim	Incidence	1/22 (4%)	1/22 (4%)	2/20 (10%)	2/24 (8%)	2/18 (11%)	1/21 (5%)
		Severity profile	0 1 0 0 (2.0)	0 0 1 0 (3.0)	1 0 1 0 (2.0)	0 1 1 0 (2.5)	0 0 2 0 (3.0)	0 0 1 0 (3.0)
	Terminal	Incidence	3/46 (6%)	2/40 (5%)	9/47 [^] (19%)	6/44 (14%)	3/44 (7%)	3/44 (7%)
		Severity Profile	0 2 1 0 (2.3)	0 1 1 0 (2.5)	0 3 5 1 (2.8)	0 4 2 0 (2.3)	0 1 1 1 (3.0)	0 1 2 0 (2.7)
		Poly-3 Incidence	3/32.5 (9%)	2/31.2 (6%)	9/35.1 (26%)	6/32.0 (19%)	3/31.5 (10%)	3/28.6 (10%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.

1 **Table 101. Non-Neoplastic Lesions in the Thyroid of Interim and Terminal Sacrifice Male Rats: Continuous-Dose EE₂^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle ^b	0.05 EE ₂	0.5 EE ₂
Hyperplasia, C-cell	Interim	Incidence	10/22 (46%)	7/25 (28%)	9/24 (38%)
		Severity Profile	3 4 3 0 (2.0)	4 2 1 0 (1.6)	4 5 0 0 (1.6)
	Terminal	Incidence	9/46 (20%)	12/25 ^{^^} (48%)	7/25 (28%)
		Severity Profile	5 2 2 0 (1.7)	4 8 0 0 (1.7)	5 1 1 0 (1.4)
		Poly-3 Incidence	9/34.9 (26%)	12/20.3 ^{**} (59%)	7/20.2 (35%)
Hyperplasia, follicular cell	Interim	Incidence	1/22 (4%)	4/25 (16%)	2/24 (8%)
		Severity Profile	0 1 0 0 (2.0)	0 0 4 0 (3.0)	0 0 2 0 (3.0)
	Terminal	Incidence	3/46 (6%)	2/25 (8%)	3/25 (12%)
		Severity Profile	0 2 1 0	0 1 0 1	0 1 2 0
		Poly-3 Incidence	3/32.5 (9%)	2/17.7 (11%)	3/19.9 (15%)

2 ^aEE₂ doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bThe continuous vehicle control group data are the same as those shown for the continuous-dose BPA data in Table 100.

1 **Table 102. Non-Neoplastic Lesions in the Thyroid of Interim and Terminal Sacrifice Male Rats: Stop-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Hyperplasia, C-cell	Interim	Incidence	13/20 (65%)	9/20 (45%)	10/20 (50%)	11/19 (58%)	10/20 (50%)	12/22 (54%)
		Severity Profile	5 7 1 0 (1.7)	1 4 4 0 (2.3)	6 2 2 0 (1.6)	3 7 1 0 (1.8)	7 2 1 0 (1.4)	5 5 2 0 (1.8)
	Terminal	Incidence	12/43 (28%)	18/45 (40%)	11/44 (25%)	19/45 (42%)	18/48 (37.5%)	13/42 (31%)
		Severity Profile	4 7 1 0 (1.8)	10 6 2 0 (1.6)	4 5 1 1 (1.9)	11 6 2 0 (1.4)	10 7 1 0 (1.5)	5 6 1 1 (1.8)
		Poly-3	12/36.4	18/35.2	11/33.8	19/35.2	18/39.3	13/31.0
		Incidence	(33%)	(51%)	(33%)	(54%)	(46%)	(42%)
Hyperplasia, follicular cell	Interim	Incidence	1/20 (5%)	1/20 (5%)	4/20 (20%)	1/19 (5%)	0/20 (0%)	3/22 (14%)
		Severity Profile	0 0 1 0 (3.0)	0 0 1 0 (3.0)	0 1 3 0 (2.8)	0 0 1 0 (3.0)	-	0 0 3 0 (3.0)
	Terminal	Incidence	6/43 (14%)	6/45 (13%)	9/44 (20%)	10/45 (22%)	6/48 (12%)	7/42 (17%)
		Severity Profile	0 3 3 0	0 2 4 0	0 2 6 1	0 3 7 0	0 3 3 0	0 3 4 0
		Poly-3	6/34.7	6/34.0	9/35.5	10/32.3	6/36.6	7/28.9
		Incidence	(17%)	(18%)	(25%)	(31%)	(16%)	(24%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.

1 **Table 103. Non-Neoplastic Lesions in the Parathyroid Gland of Interim and Terminal Sacrifice Male Rats: Continuous BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Hyperplasia	Interim	Incidence	7/22 ^{*, #, ^N} (32%)	5/21 (24%)	7/19 (37%)	5/24 (21%)	2/19 (10%)	2/21 ^{^N} (10%)
		Severity Profile	3 4 0 0 (1.6)	2 3 0 0 (1.6)	3 3 1 0 (1.7)	1 4 0 0 (1.8)	0 2 0 0 (2.0)	1 1 0 0 (1.5)
	Terminal	Incidence	11/49 (22%)	11/46 (24%)	23/47 ^{^^^} (49%)	18/50 [^] (36%)	18/50 (36%)	12/46 (26%)
		Severity Profile	3 7 0 1 (1.9)	7 3 0 1 (1.5)	1 13 6 3 (2.5)	2 9 3 4 (2.3)	9 5 2 2 (1.8)	4 5 3 0 (1.9)
		Poly-3 Incidence	11/36.7 (30%)	11/33.9 (32%)	23/37.5 ^{**} (61%)	18/38.4 (47%)	18/39.0 (46%)	12/32.3 (37%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 **Table 104. Non-Neoplastic Lesions in the Parathyroid Gland of Interim and Terminal Sacrifice Male Rats: Continuous-Dose EE₂^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle ^b	0.05 EE ₂	0.5 EE ₂
Hyperplasia	Interim	Incidence	7/22 (32%)	6/26 (23%)	4/26 (15%)
		Severity Profile	3 4 0 0 (1.6)	0 6 0 0 (2.0)	1 2 1 0 (2.0)
	Terminal	Incidence	11/49 ^{#, ^} (22%)	7/25 (28%)	11/25 ^{#, ^} (44%)
		Severity Profile	3 7 0 1 (1.9)	2 3 1 1 (2.1)	3 5 1 2 (1.8)
		Poly-3 Incidence	11/36.7 ^c (30%)	7/18.2 (38%)	11/20.9 (53%)

4 ^aEE₂ doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.5 ^bThe continuous vehicle control group data are the same as those shown for the continuous-dose BPA data in Table 103.6 ^cIn the sensitivity analysis that excluded all animals that overlapped with animals treated with 250,000 µg BPA/kg bw/day (see Statistical Methods), there was a significant EE₂
7 dose trend ($p = 0.046$). The p -value for the trend in the analysis that included all animals was 0.051.

1 **Table 105. Non-Neoplastic Lesions in the Parathyroid Gland of Interim and Terminal Sacrifice Male Rats: Stop-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Hyperplasia	Interim	Incidence	4/20 (20%)	9/20 (45%)	3/19 (16%)	7/19 (37%)	4/19 (21%)	8/22 (36%)
		Severity Profile	1 2 1 0 (2.0)	7 1 1 0 (1.7)	1 2 0 0 (1.7)	5 2 0 0 (1.3)	4 0 0 0 (1.0)	1 6 1 0 (2.0)
	Terminal	Incidence	22/49 (45%)	17/46 (37%)	27/46 (59%)	23/49 (47%)	30/50 (60%)	23/43 (54%)
		Severity Profile	1 8 7 6 (2.8)	2 10 0 5 (2.5)	4 15 5 3 (2.3)	8 8 5 2 (2.0)	3 12 6 9 (2.7)	7 7 5 4 (2.3)
		Poly-3 Incidence	22/41.9* (52%)	17/36.6 (46%)	27/39.4 (69%)	23/38.0 (60%)	30/44.1 (68%)	23/34.1 (67%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 **Table 106. Non-Neoplastic Lesions in the Kidney of Interim and Terminal Sacrifice Male Rats: Continuous-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Hyperplasia, transitional epithelium	Terminal	Incidence	3/50 (6%)	4/48 (8%)	12/48 ^{^^} (25%)	7/50 (14%)	5/50 (10%)	4/45 (9%)
		Severity Profile	1 1 1 0 (2.0)	1 3 0 0 (1.8)	5 6 1 0 (1.7)	5 1 0 1 (1.6)	2 2 1 0 (1.8)	1 1 1 1 (2.5)
		Poly-3 Incidence	3/34.6 (9%)	4/34.5 (12%)	12/34.1 ^{**} (35%)	7/34.8 (20%)	5/34.1 (15%)	4/28.9 (14%)

4 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.5 **Table 107. Non-Neoplastic Lesions in the Kidney of Interim and Terminal Sacrifice Male Rats: Continuous-Dose EE₂^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle ^b	0.05 EE ₂	0.5 EE ₂
Hyperplasia, transitional epithelium	Terminal	Incidence	3/50 (6%)	2/26 (8%)	1/26 (4%)
		Severity Profile	1 1 1 0 (2.0)	1 1 0 0 (1.5)	0 0 1 0 (3.0)
		Poly-3 Incidence	3/34.6 (9%)	2/17.8 (11%)	1/19.7 (5%)

6 ^aEE₂ doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.7 ^bThe continuous vehicle control group data are the same as those shown for the continuous-dose BPA data in Table 106.

1 **Table 108. Non-Neoplastic Lesions in the Kidney of Interim and Terminal Sacrifice Male Rats: Stop-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Hyperplasia, transitional epithelium	Terminal	Incidence	12/50 (24%)	9/48 (19%)	12/48 (25%)	12/50 (24%)	20/50 (40%)	10/45 (22%)
		Severity Profile	3 8 0 1 (1.9)	4 2 3 0 (1.9)	5 5 1 1 (1.8)	4 7 0 1 (1.8)	8 11 1 0 (1.6)	3 5 2 0 (1.9)
		Poly-3 Incidence	12/40.0* (30%)	9/36.7 (24%)	12/37.2 (32%)	12/34.9 (34%)	20/40.6 (49%)	10/29.4 (34%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.

CLARITY-BPA Core Study, NTP RR 9

1 **Table 109. Non-Neoplastic Lesions in the Liver of Interim and Terminal Sacrifice Male Rats: Continuous-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Fatty change	Interim	Incidence	0/22 (0%)	0/22 (0%)	2/20 [^] (10%)	0/24 (0%)	0/19 (0%)	0/22 (0%)
		Severity Profile	-	-	0 2 0 0 (2.0)	-	-	-
	Terminal	Incidence	4/50 (8%)	8/47 (17%)	5/48 (10%)	5/50 (10%)	4/50 (8%)	2/45 (4%)
		Severity Profile	0 1 1 2 (2.2)	1 3 1 3 (2.8)	2 1 1 1 (2.2)	0 4 0 1 (2.4)	0 3 1 0 (2.2)	0 1 0 1 (3.0)
Hepatodiaphragmatic Nodule	Interim	Incidence	0/22 (0%)	2/22 (9%)	2/20 (10%)	3/24 (12%)	4/19* (21%)	1/22 (4%)
		Severity Profile	- _b	-	-	-	-	-
	Terminal	Incidence	6/50 (12.0%)	2/47 (4%)	4/48 (8%)	3/50 (6%)	7/50 (14%)	5/45 (11%)
		Severity Profile	6/34.6 (17.3%)	2/34.2 (6%)	4/32.8 (12%)	3/34.6 (9%)	7/35.4 (20%)	5/30.9 (16%)
Infiltration, cellular, mononuclear cells	Interim	Incidence	5/22 (23%)	11/22 [^] (50%)	9/20 (45%)	13/24 ^{*, #, ^} (54%)	11/19 ^{*, #, ^} (58%)	8/22 [#] (36%)
		Severity Profile	5 0 0 0 (1.0)	11 0 0 0 (1.0)	9 0 0 0 (1.0)	12 1 0 0 (1.1)	11 0 0 0 (1.0)	8 0 0 0 (1.0)
	Terminal	Incidence	35/50 (70%)	29/47 (62%)	37/48 (77%)	36/50 (72%)	34/50 (68%)	28/45 (62%)
		Severity Profile	21 14 0 0 (1.4)	16 13 0 0 (1.4)	22 15 0 0 (1.4)	26 10 0 0 (1.3)	21 13 0 0 (1.4)	19 9 0 0 (1.3)
		Poly-3 incidence	35/42.3 (83%)	29/40.1 (72%)	37/42.6 (87%)	36/42.3 (85%)	34/40.5 (84%)	28/35.4 (79%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.

3 ^bSeverity scores were not assigned for this lesion.

1 **Table 110. Non-Neoplastic Lesions in the Liver of Interim and Terminal Sacrifice Male Rats: Continuous-Dose EE₂^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle ^b	0.05 EE ₂	0.5 EE ₂
Fatty change	Interim	Incidence	0/22 ^{*, #, ^} (0%)	1/26 (4%)	4/26 ^{#, ^} (15%)
		Severity Profile	-	0 0 1 0 (3.0)	0 1 3 0 (2.8)
	Terminal	Incidence	4/50 (8.0%)	0/26 (0.0%)	1/25 (4.0%)
		Severity Profile	0 1 1 2 (3.2)	-	0 0 0 1 (4.0)
		Poly-3 Incidence	4/35.1 (11%)	0/17.6 (0%)	1/19.9 (5%)
Hepatodiaphragmatic Nodule	Interim	Incidence	0/22 (0%)	4/26 (15%)	4/26 (15%)
		Severity Profile	- ^c	-	-
	Terminal	Incidence	6/50 (12%)	3/26 (12%)	1/25 (4%)
		Severity Profile	- ^c	-	-
		Poly-3 Incidence	6/34.6 (17%)	3/17.8 (17%)	1/19.5 (5%)
Infiltration, cellular, mononuclear cells	Interim	Incidence	5/22 (23%)	13/26 (50%)	5/26 (19%)
		Severity Profile	5 0 0 0 (1.0)	13 0 0 0 (1.0)	5 0 0 0 (1.0)
	Terminal	Incidence	35/50 (70%)	22/26 (85%)	20/25 (80%)
		Severity Profile	21 14 0 0 (1.4)	16 6 0 0 (1.3)	12 8 0 0 (1.4)
		Poly-3 Incidence	35/42.3 (83%)	22/23.5* (94%)	20/23.1 (87%)

2 ^aEE₂ doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bThe continuous vehicle control group data are the same as those shown for the continuous-dose BPA data in Table 109.4 ^cSeverity scores were not assigned for this lesion.

1 **Table 111. Non-Neoplastic Lesions in the Liver of Interim and Terminal Sacrifice Male Rats: Stop-Dose BPA^a**

Lesion	Study Phase (Interim/Terminal)	Statistic	Vehicle	2.5 BPA	25 BPA	250 BPA	2500 BPA	25000 BPA
Fatty change	Interim	Incidence	0/20 (0%)	1/20 (5%)	1/20 (5%)	0/19 (0%)	2/20 (10%)	1/22 (4%)
		Severity Profile	-	0 1 0 0 (2.0)	0 0 1 0 (3.0)	-	0 0 2 0 (3.0)	0 0 1 0 (3.0)
	Terminal	Incidence	5/50 (10%)	2/48 (4%)	7/48 (15%)	6/50 (12%)	1/50 (2%)	1/46 (2%)
		Severity Profile	1 3 1 0 (2.0)	0 0 0 2 (4.0)	2 2 1 2 (2.4)	2 1 1 2 (2.5)	0 0 0 1 (4.0)	0 0 0 1 (4.0)
		Poly-3 incidence	5/38.9 (13%)	2/34.4 (6%)	7/36.2 (19%)	6/33.4 (18%)	1/36.2 (3%)	1/28.1 (4%)
Hepatodiaphragmatic Nodule	Interim	Incidence	1/20 (5%)	2/20 (10%)	3/20 (15%)	3/19 (16%)	2/20 (10%)	1/22 (4%)
		Severity Profile	- ^b	-	-	-	-	-
	Terminal	Incidence	3/50 (6%)	3/48 (6%)	1/48 (2%)	5/50 (10%)	4/50 (8%)	5/46 (11%)
		Severity Profile	- ^b	-	-	-	-	-
		Poly-3 incidence	3/37.6 (8%)	3/34.3 (9%)	1/35.2 (3%)	5/33.1 (15%)	4/37.7 (11%)	5/28.8 (17%)
Infiltration, cellular, mononuclear cells	Interim	Incidence	11/20 (55%)	13/20 (65%)	9/20 (45%)	13/19 (68%)	11/20 (55%)	15/22 (68%)
		Severity Profile	11 0 0 0 (1.0)	13 0 0 0 (1.0)	9 0 0 0 (1.0)	13 0 0 0 (1.0)	11 0 0 0 (1.0)	15 0 0 0 (1.0)
	Terminal	Incidence	34/50 (68%)	40/48 (83%)	37/48 (77%)	33/50 (66%)	33/50 (66%)	29/46 (63%)
		Severity Profile	19 15 0 0 (1.4)	27 13 0 0 (1.3)	19 18 0 0 (1.5)	26 7 0 0 (1.2)	23 10 0 0 (1.3)	15 13 1 0 (1.5)
		Poly-3 incidence	34/43.3 (79%)	40/44.0 (91%)	37/43.7 (85%)	33/41.6 (79%)	33/42.3 (78%)	29/37.0 (78%)

2 ^aBPA doses are µg/kg bw/day. See legend to Table 55 for description of data presentation.3 ^bSeverity scores were not assigned for this lesion.

1 **Appendix A List of Supplemental Appendices^a**

Supplemental Appendix	Title and Description
I	<p>Protocol and Amendments*</p> <p>Approved NCTR study protocol (E0219001), which includes description of study sponsor, testing facility and responsible personnel, study objectives, background of the scientific problem being addressed, and a detailed description of the study design. Follow-up amendments to the approved study protocol and rationale for the changes, as well as a copy of the study protocol with all amendment changes incorporated, are also included.</p>
II	<p>Protocol Deviations*</p> <p>Documentation generated by Priority One (Animal Care contractor), Toxicologic Pathology Associates (Pathology services contractor), or the Study Director to report noted deviations from the procedures defined in the approved study protocol or follow-up amendments. It includes description of deviations, the corrective measurements taken to prevent re-occurrence, and the assessment by the Study Director on the impact of the deviation on study integrity. A summary table with all deviations is also included.</p>
III	<p>Notes to Study File*</p> <p>Documentation on various events related to the study conduct and not covered in the study protocol deviations documentation.</p>
IV	<p>Study Startup Memo and Study Definition E0219002 (F₀ and F₁ Prewaning)*</p> <p>Documentation generated by the Computer Support Group to describe the programming of the in-life tracking system used to support the study and its validation, animal allocation and breeding schemes, treatment group definitions, rack configurations used for animals of the F₀ generation and F₁ animals prior to weaning on postnatal day 21. Definitions of disposition and reasons for removal terms are also included.</p>
V	<p>Study Startup Memo and Study Definition E0219003 (F₁ Postweaning)*</p> <p>Documentation generated by the Computer Support Group to describe the programming of the in-life tracking system used to support the study and its validation, animal allocation scheme, treatment group definitions, and rack configurations used for F₁ animals after weaning on postnatal day 21.</p>
VI	<p>Breeder Weight Ranking, Treatment Randomization, and Pairing Schedule*</p> <p>Documentation to define the treatment randomization and weight ranking of the F₀ breeders, the breeding pair randomization, and to report the breeder pairings conducted in the study.</p>
VII	<p>Chemistry Support Report</p> <p>Report by the Chemistry Support Group on the analyses of the study test articles, dose preparations, BPA levels in study materials, and phyto/mycoestrogens in diet. The standard operating procedures followed to perform these analyses are also included</p>
VIII	<p>Microbiology Support Report</p> <p>Report by the Surveillance/Diagnostic Program Support Group on the microbiological findings on sentinel animals, animal rooms, and animal husbandry supplies.</p>
IX	<p>Diet Preparation Services Report</p> <p>Report by the Diet Preparation Support Group describing the inventory and storage conditions of the study diet and test articles, dose preparations, and the standard operating procedures followed.</p>
X	<p>Animal Rooms Temperature and Humidity Reports*</p> <p>Report of the temperature and relative humidity recorded in the rooms used to house the animals over the course of the study.</p>

^a Supplemental Appendices are available at http://tools.niehs.nih.gov/cebs3/views/?action=main.dataReview&bin_id=3856

XI	<p>Dosing Pump Volume Delivery Accuracy Determinations* Documentation on the accuracy tests performed of the volumes dispensed by the Hamilton Microlab 500 Series Diluter/Dispenser instruments used in the oral dosing of the study animals over the course of the study.</p>
XII	<p>5K96 Diet Nutrient and Contaminant Analyses from Diet Manufacturer Certificates of analysis from the diet manufacturer of the nutrient and contaminants on each lot of study diet.</p>
XIII	<p>Summary Statistics for Food Consumption a. Interim Sacrifice b. Terminal Sacrifice Report by the Statistical Support Group on the analysis of feed consumption data collected after weaning from F₁ animals assigned to the interim (1-year) or terminal (2-year) sacrifice study arms. The analyses reported were limited to means and standard errors.</p>
XIV	<p>Estimate of BPA Background Ingestion from Diet Documentation on the calculations conducted to estimate the BPA background exposure of animals due to ingestion of study diet.</p>
XV	<p>Animals Transferred to Cellulose (Alpha Dri) Bedding* Documentation on the animals transferred from hardwood bedding to AlphaDri cellulose bedding over the course of the study. These transfers were recommended by Veterinary Services due to foot lesions or ventral masses that could be further irritated by the hardwood chips.</p>
XVI	<p>Rationale for Sensitivity Analyses in Statistical Reports* Background on the rationale to conduct a sensitivity statistical analysis that excluded any animal that was co-housed in the same room as animals treated with 250,000 µg BPA/kg body weight/day, and list of animals excluded in the sensitivity analysis.</p>
XVII	<p>Gestational Body Weight Statistical Analysis Report by the Statistical Support Group on the analysis of gestational body weight data collected from F₀ dams. The report includes a description of statistical methods used, tables of results of analyses conducted on the full set of study animals, and a summary of the results of the sensitivity analyses.</p>
XVIII	<p>Implantation Site Statistical Analysis Report by the Statistical Support Group on the analysis of uterine implantation data collected from F₀ dams. The report includes a description of statistical methods used, tables of results of analyses conducted on the full set of study animals, and a summary of the results of the sensitivity analyses.</p>
XIX	<p>Litter Parameters Statistical Analysis Report by the Statistical Support Group on the analysis of litter data collected, including litter counts, sex proportions, and body weights. The report includes a description of statistical methods used, tables of results of analyses conducted on the full set of study animals, and a summary of the results of the sensitivity analyses.</p>
XX	<p>Preweaning Animal Survival Analysis Report by the Statistical Support Group on the analysis of survival data collected from F₁ animals prior to weaning. The report includes a description of statistical methods used, tables of results of analyses conducted on the full set of study animals, and a summary of the results of the sensitivity analyses.</p>
XXI	<p>Interim Sacrifice Survival Analysis Report by the Statistical Support Group on the analysis of survival data collected after weaning from F₁ animals assigned to the interim (1-year) sacrifice study arm. The report includes a description of statistical methods used, tables of results of analyses conducted on the full set of study animals, and a summary of the results of the sensitivity analyses.</p>
XXII	<p>Terminal Sacrifice Survival Analysis Report by the Statistical Support Group on the analysis of survival data collected after weaning from F₁ animals assigned to the terminal (2-year) sacrifice study arm. The report includes a</p>

-
- description of statistical methods used, tables of results of analyses conducted on the full set of study animals, and a summary of the results of the sensitivity analyses.
- XXIII **Preweaning Body Weight Statistical Analysis**
Report by the Statistical Support Group on the analysis of body weight data collected from F₁ animals prior to weaning. The report includes a description of statistical methods used, tables of results of analyses conducted on the full set of study animals, and a summary of the results of the sensitivity analyses.
- XXIV **Postweaning Body Weight Statistical Analysis, Interim Sacrifice Animals**
Report by the Statistical Support Group on the analysis of the body weight data collected after weaning from F₁ animals assigned to the interim (1-year) sacrifice study arm. The report includes a description of statistical methods used, tables of results of analyses conducted on the full set of study animals, and a summary of the results of the sensitivity analyses.
- XXV **Postweaning Body Weight Statistical Analysis, Terminal Sacrifice Animals**
Report by the Statistical Support Group on the analysis of body weight data collected after weaning from F₁ animals assigned to the terminal (2-year) sacrifice study arm. The report includes a description of statistical methods used, tables of results of analyses conducted on the full set of study animals, and a summary of the results of the sensitivity analyses.
- XXVI **Vaginal Opening Time and Body Weight Statistical Analysis**
Report by the Statistical Support Group on the analysis of vaginal opening and body weight data collected from a subset of F₁ animals assigned to the terminal (2-year) sacrifice study arm. The report includes a description of statistical methods used, tables of results of analyses conducted on the full set of study animals, and a summary of the results of the sensitivity analyses.
- XXVII **Estrous Cycle Statistical Analysis**
Report by the Statistical Support Group on the analysis of vaginal cytology data collected from a subset of F₁ animals assigned to the terminal (2-year) sacrifice study arm to determine estrous cyclicity. The report includes a description of statistical methods used, tables of results of analyses conducted on the full set of study animals, and a summary of the results of the sensitivity analyses.
- XXVIII **Time to Onset of Aberrant Cycling Statistical Analysis**
Report by the Statistical Support Group on the analysis of vaginal cytology data collected from a subset of F₁ animals assigned to the terminal (2-year) sacrifice study arm to determine onset of abnormal estrous cycling. The report includes a description of statistical methods used, tables of results of analyses conducted on the full set of study animals, and a summary of the results of the sensitivity analyses.
- XXIX **Hematology and Clinical Chemistry Statistical Analysis, Interim Sacrifice Animals**
Report by the Statistical Support Group on the analysis of hematology and clinical chemistry data collected from F₁ animals assigned to the interim (1-year) sacrifice study arm. The report includes a description of statistical methods used, tables of results of analyses conducted on the full set of study animals, and a summary of the results of the sensitivity analyses.
- XXX **Organ Weight Statistical Analysis, Interim Sacrifice Animals**
Report by the Statistical Support Group on the analysis of organ weight data collected from F₁ animals assigned to the interim (1-year) sacrifice study arm. The report includes a description of statistical methods used, tables of results of analyses conducted on the full set of study animals, and a summary of the results of the sensitivity analyses.
- XXXI **Sperm Parameter Statistical Analysis, Interim Sacrifice Animals**
Report by the Statistical Support Group on the analysis of sperm parameter data collected from F₁ animals assigned to the interim (1-year) sacrifice study arm. The report includes a description of statistical methods used, tables of results of analyses conducted on the full set of study animals, and a summary of the results of the sensitivity analyses.
- XXXII **Pathology Report, Interim and Terminal Sacrifice Animals**
Report by Toxicologic Pathology Associates (Pathology services contractor) on the gross and microscopic lesions found in tissues collected from F₁ animals assigned to the interim (1-year) and terminal (2-year) sacrifice study arms. The incidence rates of neoplasms and non-neoplasms by
-

anatomic site and by individual animal, severity scores for some non-neoplasms, the cause of death, and the mammary gland fibroadenoma/adenoma/ adenocarcinoma counts are also included.

XXXIII **Neoplastic and Non-neoplastic Lesions Statistical Analysis, Interim Sacrifice Animals**
Report by the Statistical Support Group on the analysis of neoplastic and non-neoplastic lesions data collected from F₁ animals assigned to the interim (1-year) sacrifice study arm. The report includes a description of statistical methods used, tables of results of analyses conducted on the full set of study animals, and a summary of the results of the sensitivity analyses.

XXXIV **Neoplastic and Non-neoplastic Lesions Statistical Analysis, Terminal Sacrifice Animals**
Report by the Statistical Support Group on the analysis of neoplastic and non-neoplastic lesions data collected from F₁ animals assigned to the terminal (2-year) sacrifice study arm. The report includes a description of statistical methods used, tables of results of analyses conducted on the full set of study animals, and a summary of the results of the sensitivity analyses.

1 *Available upon request: cdm@niehs.nih.gov